prednisone

Research Excerpts

Overview

Prednisone (PRED) is a synthetic glucocorticoid (GC) widely used in immune-mediated diseases for its immunosuppressive and anti-inflammatory properties. Prednisone is an old and very valuable drug in clinical use for over 60 years by now.

Excerpt	Reference	Relevance
"Prednisone (PRED) is a synthetic glucocorticoid (GC) widely used in immune-mediated diseases for its immunosuppressive and anti-inflammatory properties. "	( Integrative Analysis of Gut Microbiota and Fecal Metabolites in Rats after Prednisone Treatment. Feng, D; Huang, WY; Kang, Y; Law, HK; Wu, Y; Zhang, J; Zhu, GH, 2021)	2.29
"Prednisone is a corticosteroid-derived drug which is widely used for its role in immunosuppression and treatment of lung disorders. "	( Prednisone stimulates white adipocyte browning via β3-AR/p38 MAPK/ERK signaling pathway. Mukherjee, S; Yun, JW, 2022)	3.61
"Prednisone is a mainstay of treatment for patients with focal segmental glomerulosclerosis (FSGS), a disease characterized by reduced podocyte number and glomerulosclerosis. "	( Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Krofft, RD; Liu, ZH; Naito, S; Pippin, JW; Shankland, SJ; Zhang, J, 2013)	1.83
"Prednisone is a well-established treatment option in rheumatoid arthritis. "	( Modified-release prednisone: in patients with rheumatoid arthritis. Henness, S; Yang, LP, 2013)	2.17
"Prednisone is an old and very valuable drug in clinical use for over 60 years by now. "	( The current relevance and use of prednisone in rheumatoid arthritis. Baerwald, C; Krasselt, M, 2014)	2.13
"Prednisone (PDN) is a well-known steroid clinically used in the treatment of hearing loss."	( Prednisone inhibits the IL-1β-induced expression of COX-2 in HEI-OC1 murine auditory cells through the inhibition of ERK-1/2, JNK-1 and AP-1 activity. Hong, H; Jang, BC, 2014)	2.57
"Prednisone is a widely used anti-inflammatory for a variety of conditions. "	( Palatability of a novel oral formulation of prednisone in healthy young adults. Bai, S; Dormer, N; Kearns, GL; Meyer, A; Neville, KA; Pierce, CD; Shoults, C, 2017)	2.16
"Prednisone therapy is a safe and effective adjunctive treatment for epilepsy."	( Prednisone therapy in pediatric epilepsy. Sinclair, DB, 2003)	2.48
"Prednisone is an alternative form of treatment for ELS, although the mechanism for its action is unclear."	( Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Rothner, AD; Streib, EW, 1981)	1.21
"Prednisone is an active drug in the treatment of multiple myeloma. "	( Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors. A Southwest Oncology Group study. Beckford, J; Bonnet, JD; Chilton, D; Gupta, V; Pierce, HI; Salmon, SE; Stock-Novack, D; Thompson, EB, 1994)	2.11
"Prednisone is a major factor of bone loss after kidney transplantation. "	( Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Casez, JP; Horber, FF; Jaeger, P; Lippuner, K; Montandon, A, 2002)	1.97
"Prednisone seems to be an important component of the MOPP combination in the management of stage IV Hodgkin's disease."	( Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Report from the British National Lymphoma Investigation. , 1975)	1.39
"Prednisone is a widely used medication in dermatology, particularly in pemphigus patients. "	( Estimation of prednisone intake in pemphigus vulgaris patients with the use of simple laboratory methods. Feuerman, EJ; Kaufman, H; Maayan, R; Segal, R, 1987)	2.08
"Prednisone is a glucocorticoid that must be converted in vivo to prednisolone for pharmacologic activity. "	( Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Eshelman, FN; Ferguson, RK; Rocci, ML; Sirgo, MA; Vlasses, PH, 1985)	1.96

Effects

Prednisone acetate (PA) has many adverse side effects despite the fact that oral administration of PA is widely administrated in the clinic. Oral prednisone has been the mainstay of therapy since its release for clinical use in 1948.

Excerpt	Reference	Relevance
"Prednisone acetate (PA) has many adverse side effects despite the fact that oral administration of PA is widely administrated in the clinic. "	( Intragastric administration of prednisone acetate induced impairment of hippocampal long-term potentiation. Ding, X; Wang, Y; Xiang, S; Zhang, J; Zhang, M, 2023)	2.64
"Oral prednisone has been the mainstay of therapy in JDM, and prednisone was reduced faster in patients diagnosed after 1997 when there was also an increase in other medications. "	( Medications received by patients with juvenile dermatomyositis. Bayat, N; Huber, AM; Kishi, T; Mamyrova, G; Miller, FW; Rider, LG; Targoff, IN; Ward, MM; Warren-Hicks, WJ; Wu, L, 2018)	0.99
"Prednisone response has been confirmed to be still great prognostic value and PPR children patients have poor outcomes generally. "	( [Prognostic Value of Prednisone Response in CCLG-ALL 2008]. An, WB; Chang, LX; Liu, TF; Ren, YY; Wan, Y; Zhang, JL; Zhu, XF; Zou, Y, 2015)	2.18
"DR prednisone has been approved in 16 European countries as well as Australia and Israel."	( A fresh look at glucocorticoids how to use an old ally more effectively. Buttgereit, F, 2012)	0.89
"Prednisone has been demonstrated to have a beneficial effect on muscle strength and function in boys with Duchenne dystrophy and should be offered (at a dose of 0.75 mg/kg/day) as treatment. "	( Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Ashwal, S; Baumbach, L; Connolly, A; Florence, J; Mathews, K; McDonald, C; Moxley, RT; Pandya, S; Sussman, M; Wade, C, 2005)	1.77
"Prednisone has been the mainstay of therapy since its release for clinical use in 1948."	( Current perspectives on the treatment of idiopathic pulmonary fibrosis. Collard, HR; King, TE; Walter, N, 2006)	1.06
"Prednisone has been used in this setting; however, limited data is available for this monotherapy in the asymptomatic HRPC population."	( Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Chi, KN; Heng, DY, 2006)	2.5
"Thus prednisone liquid has comparable bioavailability to the tablet, with an earlier peak plasma prednisolone concentration and significantly higher plasma prednisolone concentrations within the first hour of administration."	( Bioavailability assessment of a liquid prednisone preparation. Flesher, KA; Georgitis, JW; Szefler, SJ, 1982)	0.99
"Prednisone has been shown to decrease IFN-alpha-related toxicity without reducing the response rate."	( Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. Fosså, SD; Haarstad, H; Jacobsen, AB; Risberg, T; Schjølseth, SA, 1994)	1.31
"Prednisone therapy has improved hematologic function in some patients, but has not resulted in a reduction in bone mass."	( Osteopetrosis. The pharmaco-physiologic basis of therapy. Key, LL; Ries, WL, 1993)	1.01
"Prednisone has been shown to improve strength in Duchenne dystrophy. "	( Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Brooke, MH; Cwik, VA; Fenichel, GM; Griggs, RC; Mendell, JR; Miller, JP; Moxley, RT; Pandya, S; Pestronk, A; Robison, J, 1993)	1.98
"Prednisone tapering has become more common in the management of transplant recipients. "	( Quality of life outcomes associated with variable posttransplant prednisone dosing regimens. Gaber, AO; Hathaway, DK; Milstead, J; Wicks, MN; Winsett, RP, 1996)	1.97
"Prednisone has been commonly considered the mainstay of immunosuppressive therapy after liver transplantation. "	( Immunosuppression without prednisone after liver transplantion is safe and associated with normal early graft function: preliminary results of a randomized study. Angelico, M; Anselmo, A; Baiocchi, L; Casciani, CU; Negrini, S; Orlando, G; Palmieri, G; Pisani, F; Tisone, G; Vennarecci, G, 1998)	2.04
"Prednisone has to be continued over a large period of time creating adverse effects in elderly people unless minimal doses are used."	( [Polymyalgia rheumatica and temporal arteritis. Observations on prognosis and treatment]. Auquier, L; Paolaggi, JB, 1990)	1

Actions

Prednisone alone or a lower dose of prednisone in combination with azathioprine induces remission and enhances survival in autoimmune hepatitis. Prednisone therapy might enhance earlier recovery but does not improve the long-term prognosis of VN.

Excerpt	Reference	Relevance
"The prednisone-mediated increase in α7 integrin was associated with increased laminin-α2 in prednisone-treated dystrophin-deficient muscle."	( Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy. Burkin, DJ; Kornegay, JN; Sarathy, A; Wuebbles, RD, 2013)	1.11
"A prednisone increase led to remission in 35 patients (80%)."	( Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Brunetta, P; Ding, L; Fervenza, FC; Hoffman, GS; Iklé, D; Kallenberg, CG; Langford, CA; Lim, N; Merkel, PA; Miloslavsky, EM; Monach, PA; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stone, JH; Tchao, NK; Villareal, M, 2015)	0.98
"Prednisone might inhibit lymphoproliferation and valganciclovir might prevent complications related to HHV-6 reactivation."	( Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir--a hypothesis. Mian, P; Moling, O; Pagani, E; Piccin, A; Rimenti, G; Rossi, P; Tappeiner, L; Vedovelli, C, 2012)	1.34
"Prednisone alone or a lower dose of prednisone in combination with azathioprine induces remission and enhances survival in autoimmune hepatitis. "	( Emerging treatments for autoimmune hepatitis. Czaja, AJ, 2002)	1.76
"Prednisone therapy might enhance earlier recovery but does not improve the long-term prognosis of VN. "	( Prednisone treatment for vestibular neuritis. Braverman, I; Golz, A; Issa, A; Shupak, A, 2008)	3.23
"Prednisone levels were lower than prednisolone levels."	( Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Barberis, L; Frigo, GM; Gatti, G; Martini, A; Notarangelo, LD; Perucca, E, 1984)	1.31
"Prednisone was shown to cause a small but significant improvement over no treatment in scored neurological disability, some measures of computer-assisted sensory detection threshold, graded muscle strength, and some attributes of nerve conduction."	( Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Bartleson, JD; Daube, JR; Dinapoli, RP; Dyck, PJ; Low, PA; Mokri, B; O'Brien, PC; Oviatt, KF; Swift, T; Windebank, AJ, 1982)	2.43
"Prednisone dosage was lower in diabetics with EOD at 6 months, but did not differ among the three groups at 12 months."	( Heart transplantation in patients with diabetic end-organ damage before transplantation. Aleksic, I; Blanche, C; Czer, LS; Dalichau, H; Freimark, D; Nessim, S; Nusser, P; Takkenberg, JJ; Trento, A, 1996)	1.02
"Prednisone did not produce an immediate change in gastric secretion--there being a latent period lasting 1 to 2 days before marked changes were observed."	( Effects of prednisone on gastric secretion and development of stomach lesions in swine. Grummer, RH; Hoekstra, WG; Kowalczyk, T; Will, JA; Zamora, CS, 1975)	1.37
"Prednisone may also suppress cartilage breakdown by either acting at the level of the synthesis or by acting on the release/action of the stimulating factors."	( Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis. Ghandur-Mnaymneh, L; Howell, DS; Martel-Pelletier, J; Pelletier, JP; Woessner, JF, 1985)	0.99

Treatment

Prednisone or vitamin E treatment reduced urinary protein from 14 days to 28 days after ADR injection. Prednisone treatment, even at moderate doses, increases the risk, whilst antimalarials have a protective effect.

Excerpt	Reference	Relevance
"The prednisone treatment group was given progesterone (20 ∼ 40 mg daily injection) + prednisone (5 mg/d) for four weeks."	( Clinical Research into Treating Unexplained Recurrent Spontaneous Abortion during Early Pregnancy with the Qing Yi Tiao Mian Formula. Du, L; Jiang, GJ; Pan, DC; Shen, MJ, )	0.61
"Prednisone treatment was significantly associated with a higher risk of adverse events (24.2% vs."	( Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration. Álvarez-Navascúes, C; Arencibía, A; Barreira-Díaz, A; Conde, I; Crespo, J; Del Barrio, M; Díaz-González, Á; El Hajra, I; Escudé, L; Estévez, P; Fernández, A; Ferre-Aracil, C; García-Retortillo, M; Gómez, E; Gómez, J; Hernández-Guerra, M; Horta, D; Londoño, MC; López, C; Mateos, B; Molina, E; Morillas, RM; Pérez-Medrano, I; Riveiro-Barciela, M; Salcedo, M; Sapena, V; Soria, A; Zamora, J, 2023)	1.63
"Both prednisone treatment and targeting Pebp1 pathway are promising strategies to alleviate inflammation and necroptosis that occurred in AAV gene therapy or related diseases."	( AAV induces hepatic necroptosis and carcinoma in diabetic and obese mice dependent on Pebp1 pathway. Cheng, Y; Dong, J; Feng, N; Gao, P; Han, Y; He, Z; Huang, R; Lai, H; Yang, Y; Yu, H; Zhai, Q; Zhang, Y; Zhang, Z; Zhong, W, 2023)	1.37
"Oral prednisone treatment does not appear to significantly reduce the incidence of AVB requiring acute PPM implantation after TAVI."	( Effect of acute CORticosteroids on conduction defects after Transcatheter Aortic Valve Implantation: the CORTAVI study. Barillà, F; Barone, L; Belli, M; Di Luozzo, M; Marchei, M; Muscoli, S; Prandi, FR; Romeo, F; Sergi, D; Uccello, G, 2023)	1.42
"Prednisone treatment (3 mg/kg from 8 weeks of age) relieved the decrease of NAA but further increased the accumulation of pyruvate in the frontal cortex, additionally affected eight enriched pathways in the hypothalamus, and led to significant imbalances between the excitation and inhibition in both the frontal cortex and hypothalamus."	( Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice. Li, S; Lu, F; Lu, H; Wang, S; Wen, C; Wu, D; Xie, M; Xie, Z; Xu, ZH; Zhou, J, 2020)	1.49
"Prednisone pre-treatment was associated with a numerically higher rate of recurrence and colchicine treatment with a numerically lower rate, but the differences were non-significant."	( Do Colchicine and Prednisone Affect the Rate of Recurrence of Post-Pericardiotomy Syndrome. Aravot, D; Freidkin, L; Iakobishvili, Z; Kornowski, R; Landes, U; Mager, A; Schamroth Pravda, N, 2020)	1.61
"Prednisone treatment duration at diagnosis was also significantly reduced (13.1 versus 5.8 days, p = 0.004)."	( Using a standardised protocol was effective in reducing hospitalisation and treatment use in children with newly diagnosed immune thrombocytopenia. Chartrand, C; Di Liddo, L; Labrosse, R; Nguyen, UP; Pastore, Y; Vincent, M, 2017)	1.18
"Oral prednisone treatment resulted in complete clinical remission."	( [Sarcoid-like granulomatosis associated with eosinophilic fasciitis]. Bagot, M; Battistella, M; Bouaziz, JD; Guibal, F; Hefez, L; Leonard-Louis, S; Sallé de Chou, C; Vignon-Pennamen, MD; Zuelgaray, E, 2018)	0.94
"Prednisone treatment for 30 and 90 days improved articular structure and decelerated the degeneration of the femur in CIA rats, but did not improve BMD and bone biomechanics."	( Effect of prednisone treatment for 30 and 90 days on bone metabolism in collagen-induced arthritis (CIA) rats. Chen, W; Cui, L; Lu, J; Lv, X; Min, Y; Wu, X; Xu, B; Zhang, X; Zou, L, 2018)	1.6
"Prednisone treatment modified circulatory NET levels and was associated with beneficial outcome.CAP is accompanied by pronounced NET formation."	( Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. Baumgartner, C; Blum, CA; Christ-Crain, M; Ebrahimi, F; Giaglis, S; Hahn, S; Hasler, P; Kutz, A; Mueller, B; Schuetz, P; van Breda, SV, 2018)	1.2
"Prednisone treatment during the first 4 weeks after the initiation of ART for HIV infection resulted in a lower incidence of tuberculosis-associated IRIS than placebo, without evidence of an increased risk of severe infections or cancers. "	( Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. Blumenthal, L; Buyze, J; Colebunders, R; Jackson, A; Lynen, L; Maartens, G; Meintjes, G; Nair, A; Ravinetto, R; Schutz, C; Stek, C; Thienemann, F; van Loen, H; Wilkinson, RJ, 2018)	3.37
"Prednisone-treated patients had higher levels of depressive symptoms and subjective and objective cognitive deficits than those not taking prednisone."	( A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders. Brown, ES; Frol, AB; Getahun, Y; Khan, DA; Pacheco, M; Vasquez, A, )	0.85
"Prednisone-treated patients did not develop new treatment-related clinical problems."	( Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Re Boccuzzi, G; De Luca, G; Ferrero, V; Ghini, AS; Marino, P; Pesarini, G; Presbitero, P; Ribichini, F; Rognoni, A; Tomai, F; Vassanelli, C; Zivelonghi, C, 2013)	1.32
"All prednisone-treated patients had normal plasma creatinine (PCr) after 1 month of treatment (median 59.1 [45-85] μmol/l) whereas only 50 % of patients in the non-treatment group had normal creatinine (median 81.0 [42-123] μmol/l) at the same time point (p = 0.025). "	( Prednisone in the treatment of tubulointerstitial nephritis in children. Ala-Houhala, M; Arikoski, P; Jahnukainen, T; Nuutinen, M; Rönnholm, K; Saarela, V; Ylinen, E, 2013)	2.39
"A prednisone-treated systemic flare occurred during the first trimester without later complication."	( Adult-onset Still's disease and pregnancy: about ten cases and review of the literature. Broussolle, C; Durieu, I; Gerfaud-Valentin, M; Hot, A; Huissoud, C; Seve, P, 2014)	0.96
"Prednisone treatment is often used as the first-line treatment and studies suggest response to treatment in 50-66% of cases."	( Common variable immunodeficiency-associated granulomatous and interstitial lung disease. Kayser, G; Prasse, A; Warnatz, K, 2013)	1.11
"Prednisone treatment promoted nephrin expression in the kidney (P<0.05)."	( [Effects of prednisone on renal FAK and Pyk2 expressions in rats with adriamycin- induced nephritis]. Chen, X; Lin, X; Liu, C; Wang, J; Wu, X; Zheng, J, 2014)	1.5
"Prednisone treatment for 7 days in patients with community-acquired pneumonia admitted to hospital shortens time to clinical stability without an increase in complications. "	( Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Arici, B; Baumgartner, C; Bingisser, R; Blum, CA; Briel, M; Burki, D; Christ-Crain, M; Drozdov, D; Duplain, H; Elsaesser, H; Mueller, B; Nigro, N; Refardt, J; Rodondi, N; Schuetz, P; Suter-Widmer, I; Tarr, P; Thomann, R; Ullmer, E; Urwyler, SA; Winzeler, B; Wirz, S; Zimmerli, W, 2015)	2.29
"The prednisone-treated group showed an adjusted mean 6.4-point (95% CI, 1.9-10.9; P = .006) greater improvement in ODI scores at 3 weeks than the placebo group and a mean 7.4-point (95% CI, 2.2-12.5; P = .005) greater improvement at 52 weeks."	( Oral steroids for acute radiculopathy due to a herniated lumbar disk: a randomized clinical trial. Ackerson, L; Avins, AL; Carragee, E; Carver, R; Firtch, W; Goldberg, H; Hamilton, L; Maratukulam, A; Pressman, A; Smith, W; Tyburski, M; Won, LA, 2015)	0.9
"Prednisone treatment dose-dependently attenuated the lupus symptoms in MRL/lpr mice with decreased proteinuria levels, prolonged survival times, decreased serum anti-nuclear antibody levels, and reduced spleen and thymus indices. "	( Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. Deng, XM; Sun, XJ; Wang, QT; Wei, W; Yan, SX, 2015)	3.3
"Prednisone treatment restricts B lymphocyte differentiation into plasma cells in MRL/lpr mice, which may be correlated with the inhibition of IL-21 production and the restoration of the balance between Blimp-1 and Bcl-6."	( Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. Deng, XM; Sun, XJ; Wang, QT; Wei, W; Yan, SX, 2015)	3.3
"Prednisone-treated dogs were more likely to develop polyuria, polydipsia, and polyphagia than were cyclosporine-treated dogs."	( Comparison of the efficacy of prednisone and cyclosporine for treatment of dogs with primary immune-mediated polyarthritis. Herrera, MA; Kass, PH; Rhoades, AC; Sykes, JE; Vernau, W, 2016)	1.44
"Prednisone treatment significantly increased serum cystatin C concentration from 1.24 +/- 0.40 mg/L at baseline to 1.61 +/- 0.80 mg/L at the end of study (p < 0.05). "	( Corticosteroids Significantly Increase Serum Cystatin C Concentration without Affecting Renal Function in Symptomatic Heart Failure. Ge, N; Liu, C; Zhai, JL; Zhao, Q; Zhen, Y, 2016)	1.88
"Prednisone treatment did not significantly modify the function and expression of MDR1 in T and NK cells of ITP patients."	( Multidrug resistance-1 in T lymphocytes and natural killer cells of adults with idiopathic thrombocytopenic purpura: effect of prednisone treatment. Crespo-Solís, E; Graue, G; López-Karpovitch, X; Piedras, J, 2008)	1.27
"Prednisone or vitamin E treatment reduced urinary protein from 14 days to 28 days after ADR injection. "	( [Relationship between glomerular nephrin expression and oxidative stress reaction in rats with adriamycin-induced nephrosis]. Lu, L; Zhu, Y, 2009)	1.8
"Prednisone treatment, even at moderate doses, increases the risk, whilst antimalarials have a protective effect."	( Predictors of major infections in systemic lupus erythematosus. Aguirre, C; Egurbide, MV; Martinez-Berriotxoa, A; Olivares, N; Ruiz-Arruza, I; Ruiz-Irastorza, G, 2009)	1.07
"In prednisone-treated dogs, serum chloride and corrected chloride concentrations were significantly lower on days 7, 14, 21, and 28 and serum bicarbonate concentrations were significantly higher on days 14, 21, and 28, compared with baseline values."	( Effect of glucocorticoid administration on serum aldosterone concentration in clinically normal dogs. Behrend, EN; Corrigan, AM; Kemppainen, RJ; Martin, LG, 2010)	0.87
"Prednisone treatment in mdx mice resulted in decreased CTSB activity and increased grip strength in forelimbs and hindlimbs."	( Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged near-infrared imaging. Baudy, AR; Hoffman, EP; Johnston, HK; Jordan, S; Kesari, A; Nagaraju, K; Sali, A, 2011)	1.09
"Prednisone treatment delays the progressive course of Duchenne muscular dystrophy. "	( Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen. de Groot, IJ; Hendriks, JC; Noordam, C; Sie, LT; ten Dam, K; van Alfen, N, 2012)	2.03
"MR prednisone plus DMARD treatment produced higher response rates for ACR20 (48% vs 29%, p<0.001) and ACR50 (22% vs 10%, p<0.006) and a greater median relative reduction from baseline in morning stiffness (55% vs 35%, p<0.002) at week 12 than placebo plus DMARD treatment. "	( Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Alten, RE; Boers, M; Buttgereit, F; Kirwan, J; Mehta, D; Romer, U; Saag, KG; Supronik, J; Szechinski, J; Szombati, I; Witte, S, 2013)	1.43
"Prednisone treatment significantly normalized the intensities of peaks 9069 and 15005 (which correspond to cortexin-1 and interleukin-17A, respectively, according to Swiss Prot database) by increasing the expression of 9069 but reducing expression of 15005."	( Proteomic analysis indicates altered expression of plasma proteins in a rat nephropathy model. Ai, S; Chen, R; Lin, Q; Zheng, J, 2013)	1.11
"Prednisone treatment induced a decrease in Bcl-2 and Bcl-xl levels in 17 and 16 of the 28 patients, respectively, while Bax protein increased in 14 of the 21 patients."	( Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Addeo, R; Casale, F; Crisci, S; D'Angelo, V; Di Tullio, MT; Indolfi, P; Morgera, C; Poggi, V, 2003)	1.31
"The prednisone treatment group had a marked increase in the median CD4 cell count in the first 2 weeks, which stabilized at a level similar to that in the nonprednisone treatment group."	( Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)	1.04
"Prednisone treatment with hemodialysis improved the situation."	( Renal failure in a patient with autosomal dominant polycystic kidney disease and coexisting dermato-polymyositis: first report in the literature. Atik, E; Bahceci, F; Karincaoglu, Y; Sari, R; Sarikaya, M; Sevinc, A, 2004)	1.04
"Prednisone treatment is used to prolong ambulation in patients with Duchenne muscular dystrophy (DMD). "	( Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Beenakker, EA; Brouwer, OF; Fock, JM; Koopman, HM; Maurits, NM; Van der Hoeven, JH; Van Tol, MJ, 2005)	2.14
"Prednisone-treated patients manifested a significant reduction in tinnitus."	( Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study. Cornejo-Suarez, A; Gonzalez-Perez, O; Morales-Luckie, E; Zaragoza-Contreras, MA, 2005)	1.36
"Prednisone treatment may lead to a shortened course of chorea (4.0 weeks in prednisone-treated [n = 32] vs 9.0 weeks in untreated [n = 14]; P < .0001)."	( Rheumatic chorea: relationship to systemic manifestations and response to corticosteroids. Bale, JF; Firth, SD; Tani, LY; Thompson, JA; Veasy, LG; Walker, AR, 2007)	1.06
"Prednisone treatment 1) did not affect leucine Ra or leucine oxidation; 2) increased plasma glutamine Ra, mostly owing to enhanced glutamine de novo synthesis (medians +/- interquartiles, 412 +/- 61 vs."	( Corticosteroids increase glutamine utilization in human splanchnic bed. Altomare, A; Darmaun, D; Haymond, M; Mauras, N; Sager, B; Thibault, R; Welch, S, 2008)	1.07
"Prednisone treatment tended to accelerate the conversion, but not significantly."	( Conversion of micronodular cirrhosis into macronodular cirrhosis. Christensen, E; Fauerholdt, L; Juhl, E; Poulsen, H; Schlichting, P; Tygstrup, N, )	0.85
"Prednisone treatment also resulted in significantly more thyroid cytoplasmic colloid droplets per follicular cell (3.19 vs 0.57 in treated and control dogs)."	( Effect of prednisone on thyroid gland morphology and plasma thyroxine and triiodothyronine concentrations in the dog. Kemppainen, RJ; Lorenz, MD; Munnell, JF; Thompson, FN; Woltz, HH, 1983)	1.39
"Prednisone treatment appears to have improved the survival, but it is probable that treatment with prednisone alone may be less effective than a regimen in which it is combined with cyclophosphamide or nitrogen mustard."	( Evaluation of treatment in lupus nephritis: effects of prednisone. Dosekun, AK; Pollak, VE, 1982)	1.23
"The prednisone-treated groups had a reduction in serum IgG concentrations (1 mg/kg vs placebo, p < 0.007; 2 mg/kg vs placebo, p < 0.003)."	( A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. Eigen, H; FitzSimmons, S; Rosenstein, BJ; Schidlow, DV, 1995)	1.05
"Prednisone treatment was not associated with any significant change in the concentrations of albumin or mucin-like glycoprotein."	( Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. Boushey, HA; Claman, DM; Fahy, JV; Liu, J; Wong, H, 1994)	1.26
"Prednisone treatment resulted in symptom resolution and lesion regression."	( Endoscopic findings in arytenoid sarcoidosis. Bisetti, A; Guidi, L; Mariotta, S; Valeri, B, 1994)	1.01
"Prednisone-treated dogs were hyperglycemic during treatment but returned to normoglycemia after steroid withdrawal."	( Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone. Carroll, PB; Demetris, J; Fontes, P; Ricordi, C; Rilo, HL; Zeng, YJ, 1994)	1.23
"Prednisone-treated dogs lost 13.2% of their initial bone mass by 48 wk."	( Salmon calcitonin reduces vertebral bone loss in glucocorticoid-treated beagles. Jackson, TW; Lyles, KW; Nesbitt, T; Quarles, LD, 1993)	1.01
"Prednisone treatment during the first month on the drug prevented the interferon-gamma-secreting cell surge."	( Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Arnason, BG; Dayal, AS; Jensen, MA; Lledo, A, 1995)	1.01
"Prednisone-treated men with preoperative antisperm antibodies showed improved fertilization rates (40% vs."	( Indications for corticosteroids prior to epididymal sperm retrieval. Goldstein, M; Palermo, GD; Rosenwaks, Z; Schlegel, PN; Shin, D, )	0.85
"Prednisone-treated dogs had significant (P < 0.05) decreases in all SIg levels, all lymphocyte subpopulations and erythrocyte numbers, and had an increase in neutrophil counts."	( The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Kaushik, A; Kruth, SA; Rinkardt, NE, 1999)	1.38
"CyA-prednisone treatment caused a marked shift in the carbohydrate disposal from a meal, enhancing the hepatic glucose uptake and decreasing peripheral glucose disposal."	( Disposition of a mixed meal by conscious dogs after seven days of treatment with cyclosporine A and prednisone. Cherrington, AD; Goldstein, RE; Lacy, DB; Moore, MC; Palmer, B, )	0.91
"Prednisone-treated patients had a significant increase in HCV RNA from baseline during steroid treatment (400 +/- 60% increase vs."	( Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial. Anguiano, A; Bylund, DL; McHutchison, JG; Mondala, T; Pockros, PJ; Ponnudurai, R; Wilkes, LB, 2001)	2.47
"Prednisone treatment significantly reduced the level of TGF-beta1 and HYP in diaphragm from mdx mice to values similar to control mice, but resulted in a higher level of the HP cross-link compared with untreated mdx mice."	( Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. Gosselin, LE; Granchelli, JA; Hartel, JV; Hudecki, MS; Pollina, CM, 2001)	1.43
"Prednisone treatment inhibited the appearance of mRNA, protein, or both for T(H)2 cytokines (IL-4 and IL-5), as well as for IL-2 and transforming growth factor alpha, but did not inhibit increases of immunoreactive GM-CSF in bronchoalveolar lavage fluid."	( Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects. Bochner, BS; Breslin, L; Freidhoff, LR; Hubbard, WC; Lichtenstein, LM; Liu, MC; Proud, D; Schleimer, RP; Schroeder, JT; Stealey, BA; Xiao, H, 2001)	1.42
"Prednisone treatment started within the first week of the disease can restore better function to the paralyzed face than is achieved without such therapy, and facial nerve decompression has been unnecessary."	( The true nature of Bell's palsy: analysis of 1,000 consecutive patients. Adour, KK; Byl, FM; Hilsinger, RL; Kahn, ZM; Sheldon, MI, 1978)	0.98
"Prednisone treatment for infertility and subsequent pregnancy maintenance in humans resulted in a significant decrease in the birth weight of full-term infants and a marked increase in the percentage of newborn infants weighing 2500 grams or less, that is, "light for dates" in comparison to control offspring. "	( Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Gandelman, R; Karow, WG; Reinisch, JM; Simon, NG, 1978)	2.02
"Prednisone treatment of patients with chronic active hepatitis inhibited both spontaneous and concanavalin A-stimulated lymphocyte cytotoxicity to human Chang liver cells."	( Lymphocyte cytotoxicity to autologous liver cells in chronic active hepatitis. Isselbacher, KJ; Wands, KR, 1975)	0.98
"The prednisone treated patients showed significantly lower values of all sex hormones with respect to deflazacort treated patients."	( Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. Caporali, R; Caprotti, M; Caprotti, P; Montecucco, C; Notario, A, 1992)	0.76
"Prednisone pretreatment did not seem to improve the efficacy of interferon therapy."	( [Treatment of chronic hepatitis B with interferon alpha (Wellferon) with and without previous corticosteroid therapy -- results of a multicenter, double blind study]. Cianciara, J; Gładysz, A; Juszczyk, J; Laskus, T; Loch, T; Mach, G; Machaj, A; Simon, K, 1992)	1
"Prednisone treatment appeared to reduce the patient's antibody titers to normal levels."	( Management and monitoring of cancer-associated retinopathy. Keltner, JL; Roth, AM; Thirkill, CE; Tyler, NK, 1992)	1
"Prednisone treatment did not significantly alter the cardiovascular responses."	( Interaction between corticosteroid and beta-agonist drugs. Biochemical and cardiovascular effects in normal subjects. Flannery, EM; Herbison, GP; Taylor, DR; Wilkins, GT, 1992)	1
"Prednisone treatment led to 10 of 41 (24%) patients improving, while secondary therapy with ATG led to four of 21 (19%) improving."	( Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Blazar, BR; Filipovich, AH; Kersey, JH; McGlave, PB; Miller, WJ; Ramsay, NK; Roy, J; Weisdorf, DJ, 1992)	1
"The prednisone-treated group had a mean reduction in adrenocortical function (mean +/- SEM change in stimulated plasma cortisol of -19.8 +/- 1.77 micrograms/dl) that was significant (p less than 0.0001) compared with that of the placebo-treated group."	( A comparative study of the effects of intranasal triamcinolone acetonide aerosol (ITAA) and prednisone on adrenocortical function. Dockhorn, R; Ellis, E; Feiss, G; Mansfield, L; Morris, R; Rom, D; Smith, JA; Tobey, RE, 1992)	0.98
"Prednisone treatment resulted in diminished bone formation rates (15 +/- 3.4 vs."	( Prednisone-induced osteopenia in beagles: variable effects mediated by differential suppression of bone formation. Quarles, LD, 1992)	2.45
"Prednisone pretreatment did not alter the immediate skin erythema or release of histamine but ablated the late secondary erythema and rise in histamine."	( Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. Charlesworth, EN; Kagey-Sobotka, A; Lichtenstein, LM; Norman, PS; Schleimer, RP, 1991)	2.45
"Prednisone treatment did not influence the prevalence of revertants."	( Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Bulman, DE; Burghes, AH; Burrow, KL; Coovert, DD; Kissel, JT; Klein, CJ; Mendell, JR; Rammohan, KW, 1991)	1.26
"Prednisone pretreatment does not seem to have any additional benefit to using interferon alone in these patients, while the effect in patients with elevated aminotransferase levels remains to be proven."	( Alpha-interferon treatment in Chinese patients with chronic hepatitis B. Fung, YL; Lai, CL; Lau, JY; Leung, EK; Lok, AS; Wong, LS; Wu, PC, 1990)	1
"Prednisone treatment causes protein wasting and adds additional risks to a patient, whereas human growth hormone (hGH) treatment causes positive nitrogen balance. "	( Human growth hormone prevents the protein catabolic side effects of prednisone in humans. Haymond, MW; Horber, FF, 1990)	1.96
"Prednisone is the first treatment we employ."	( Cluster headaches. Ryan, RE, 1989)	1
"Prednisone treatment at dose levels frequently effective in polymyositis failed to prevent disease progression in those patients observed for 2 or more years."	( Inclusion body myositis. Observations in 40 patients. Engel, AG; Litchy, WJ; Lotz, BP; Nishino, H; Stevens, JC, 1989)	1
"Prednisone treatment led to a decrease in the concentration of serum testosterone in seven of nine patients where it was not initially suppressed below 2 nmol/L, and caused a decrease in serum levels of androstenedione and dehydroepiandrosterone sulfate in more than 50% of patients."	( Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989)	1.25
"Oral prednisone pretreatment significantly reduced the mean of each subject's peak late-phase concentration of both MBP (30.7 +/- 5.8 ng/ml versus 13.3 +/- 4.3 ng/ml; p = 0.005) and EDN (885 +/- 659 ng/ml versus 71 +/- 41 ng/ml; p less than 0.05)."	( Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. Bascom, R; Dunnette, S; Gleich, GJ; Lichtenstein, LM; Naclerio, RM; Pipkorn, U; Proud, D, 1989)	0.73
"The prednisone-treated group required 9 admissions to hospital for CF-related pulmonary disease compared with 35 for the placebo group."	( Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Auerbach, HS; Colten, HR; Kirkpatrick, JA; Williams, M, 1985)	1.11
"Prednisone treatment can sometimes reverse this condition when combined with parenteral nutrition."	( [Acute manifestations in Crohn disease and ulcerative colitis. Conservative treatment of acute situations]. Goebell, H, 1988)	1
"Prednisone remains the treatment of choice and, in many cases, its use can be intermittent."	( Allergic bronchopulmonary aspergillosis and fungoses. Greenberger, PA, 1988)	1
"The prednisone-treated group had higher mean plasma levels of triglyceride [2.06 +/- 1.3 (+/- SD) vs."	( Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. Ettinger, WH; Hazzard, WR, 1988)	0.76
"prednisone treatment of chronic aggressive hepatitis and/or nonalcoholic cirrhosis, 20 were HBsAg positive on entry."	( Immunosuppressive treatment of HBsAg-positive chronic liver disease: significance of HBeAg. Aldershvile, J; Schlichting, P; Tage-Jensen, U, )	0.85
"The treatment of prednisone plus HCQ may improve implantation rate, biochemical pregnancy rate, and clinical pregnancy rate, and reduce pregnancy loss rate in frozen embryo transfer outcomes for ANA-positive women."	( Combined treatment of prednisone and hydroxychloroquine may improve outcomes of frozen embryo transfer in antinuclear antibody-positive patients undergoing IVF/ICSI treatment. Cheng, K; Deng, W; Gao, R; Meng, C; Qin, L; Zeng, X, 2021)	1.26
"Treatment with prednisone 10 mg/day was maintained."	( [Diagnostic difficulties of IgG4-related disease - a case report]. Gładyś, A; Lenczewska, K; Leśniak, K; Niemczyk, S; Żelek, K, 2022)	1.06
"Treatment with prednisone plus levothyroxine may present a novel approach in these patients."	( Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. Feng, R; Fu, H; Huang, X; Jiang, H; Jiang, Q; Liu, H; Liu, K; Lu, J; Niu, T; Wang, H; Wang, J; Wang, X; Xie, Y; Xu, L; Xue, J; Zhang, X, 2018)	1.24
"Treatment with prednisone, azathioprine, and ursodeoxycholic acid led to a good response."	( Type 2 autoimmune hepatitis overlapping with primary sclerosing cholangitis in a 10-year-old boy. Bahri, I; Boudawara, T; Gargouri, L; Maalej, B; Mahfoudh, A; Majdoub, I; Mnif, H; Mnif, L; Safi, F; Tahri, N; Turki, F, 2013)	0.73
"Treatment with prednisone significantly reduced the frequency of CD4(+)CXCR5(+) and CD4(+)CXCR5(+)PD-1(+) TFH cells and the levels of serum IL-21, but increased IL-4 and IL-10 in those patients."	( A higher frequency of CD4⁺CXCR5⁺ T follicular helper cells in patients with newly diagnosed IgA nephropathy. Jiang, Y; Shi, X; Wang, Y; Zhang, L; Zou, H, )	0.47
"Treatment with prednisone, methotrexate, and acyclovir induced the complete remission of mucosal and joint symptoms, which then relapsed after interruption of antiviral therapy or immunosuppressive therapy."	( Pemphigus vulgaris in a patient with arthritis and uveitis: successful treatment with immunosuppressive therapy and acyclovir. Bottoni, U; Carlesimo, M; Cordiali, P; Di Carlo, A; Di Napoli, A; Laganà, B; Muscianese, M; Pimpinelli, F; Pranteda, G, )	0.47
"Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients."	( Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy. Ayana, DA; Jiang, Y; Liu, Y; Qu, Z; Zhao, P, 2014)	0.74
"post-treatment with prednisone); and evaluating parameters before and after prednisone use, including values for sputum eosinophils, sputum eosinophil cationic protein (ECP), and sputum IL-5-with or without values for post-bronchodilator FEV1-with corresponding 95% CIs or with sufficient data for calculation."	( Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis. Maurici, R; Pizzichini, E; Pizzichini, MM; Sakae, TM; Trevisol, DJ, 2014)	1.11
"Treatment with prednisone alone was associated with more frequent relapses (odds ratio [OR] 2.90), while large vessel involvement (OR 6.14) and cerebral infarcts at the time of diagnosis (OR 3.32) were associated with a poor response to treatment."	( Adult primary central nervous system vasculitis treatment and course: analysis of one hundred sixty-three patients. Brown, RD; Christianson, TJ; Giannini, C; Hunder, GG; Huston, J; Miller, DV; Salvarani, C, 2015)	0.76
"The treatment with prednisone resulted in a rapid resolution of clinical symptoms."	( Polymyalgia rheumatica in a patient with splenic marginal zone lymphoma - a case report. Gawroński, K; Kisiel, B; Rzepecki, P; Tłustochowicz, W, 2015)	0.74
"A treatment with prednisone was introduced, and the patient's condition significantly improved."	( [Neuralgic amyotrophy--a case report]. Banach, M; Miller, M, 2015)	0.75
"Treatment with prednisone was associated with greater weight gain (β = 0.072 kg/m(2) , 95% CI 0.042, 0.10; P < 0.001)."	( Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, L; Ibrahim, S; Jorgenson, E; Michaud, K; Mikuls, TR; Sauer, BC; Teng, CC, 2016)	0.77
"Treatment with prednisone 60 mg daily resulted in significant improvement by the next day."	( Neutrophilic dermatosis of the dorsal hands in an elderly man. Brandt, JC; Gonzalez, A; Perbtani, Y; Steffes, W; Vaziri, S, 2016)	0.77
"Treatment with prednisone resulted in decreased CD86 expression in marrow (P=0.02) and PB (P=0.04) monocytes."	( Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. Arpinati, M; Baccarani, M; Chirumbolo, G; Marzocchi, G; Rondelli, D, 2008)	0.69
"Cats treated with prednisone had a significantly longer survival time than those receiving other treatments."	( Feline gastrointestinal eosinophilic sclerosing fibroplasia. Craig, LE; Flatland, B; Hardam, EE; Hertzke, DM; Moore, RR; Rohrbach, BW, 2009)	0.68
"The treatment with prednisone (1 mg/kg) brought the rapid improvement of muscle weakness and CPK value as well as mouth dryness and cholestatic liver dysfunction like in primary biliary cirrhosis."	( [A case of chronic graft-versus-host disease presenting with polymyositis]. Inoue, M; Kitazono, T; Maeda, A; Okazaki, T; Ozaki, S; Shibata, T, 2009)	0.67
"Dogs treated with prednisone experience statistically significant increases in blood lactate concentrations, which can result in type B hyperlactatemia. "	( Effects of prednisone on blood lactate concentrations in healthy dogs. Boysen, SR; Bozzetti, M; Dunn, M; Pang, DS; Rose, L, )	0.86
"Treatment with prednisone and methotrexate resulted in complete remission of symptoms."	( Dermatomyositis with inclusion body myositis pathology. Iverson, D; Layzer, R; Lee, HS; Margeta, M, 2009)	0.69
"Treatment with prednisone successfully resolved the lesions in this patient."	( A case of linear immunoglobulin A bullous dermatosis in a patient exposed to sun and an analgesic. Caldarola, G; Cozzani, E; Parodi, A; Pellicano, R, 2009)	0.69
"Treatment with prednisone and cyclosporine was initiated based on a presumptive diagnosis of granulomatous meningoencephalitis."	( Detection of Neospora caninum tachyzoites in cerebrospinal fluid of a dog following prednisone and cyclosporine therapy. Galgut, BI; Grondin, TM; Harkin, KR; Janardhan, KS; Wight-Carter, MT, 2010)	0.92
"Treatment with prednisone and azathioprine resulted in a dramatically improved outcome."	( De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis: a case report. Wang, B; Wang, T; Zhang, Y, 2010)	0.7
"Upon treatment with prednisone, the pain quickly decreased and 3 months later the inflammatory changes visible on MRI were clearly reduced."	( [Low back pain and MRI-abnormalities: atypical polymyalgia rheumatica]. Bravenboer, B; de Rijk, MC; Pijpers, R; Wlazlo, N, 2011)	0.68
"Treatment with prednisone and azathioprine, plus, in three children, cyclosporine, resulted in complete remission in eight, partial remission in six, and failure in two."	( Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. Bernard, O; Choulot, JJ; Fabre, M; Gori, L; Jacquemin, E; Maggiore, G; Pacifico, L; Resti, M; Sciveres, M, 2011)	0.71
"Treatment with prednisone and ursodeoxycholic acid led to a good response."	( Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin. Murashima, N; Nakayama, S, 2011)	0.71
"Treatment with prednisone and chlorambucil was initiated, and the dog had a good response."	( Waldenström's macroglobulinemia in a dog with a bleeding diathesis. Fournel-Fleury, C; Jaillardon, L, 2011)	0.71
"Treatment with prednisone resulted in normal values after only 3 days."	( Asymptomatic macrothrombocytopenia in a young pure-bred beagle dog: a case report. Abel, SJ; Bodié, K; Desmond, DJ; Fagerland, JA; Gagne, GD; Sramek, MK, 2011)	0.71
"Treatment with prednisone 10 mg daily, colchicine 0.6 mg twice daily, and pentoxifylline 400 mg three times daily resulted in significant improvement in this case of idiopathic neutrophilic dermatosis of the hands."	( A rare case of idiopathic neutrophilic dermatosis of the hands. Cook, E; Epstein, R; Miller, R, 2011)	0.71
"Treatment with prednisone is initiated with a clinical and laboratory improvement in the patient's condition."	( [Kikuchi-Fujimoto disease]. Alianak, M; Corral, M; Fainberg, A; Huergo, I; Staffieri, F, 2012)	0.72
"Treatment with prednisone and gamma interferon normalised the thickness of the gastric wall and gastric outlet function."	( [Gastric outlet obstruction in chronic granulomatous disease]. Born, M; Hassan, C; Willinek, WA, 2002)	0.65
"Treatment of prednisone is more beneficial to reversion of atrial fibrillation into sinus rhythm among patients with HARGD."	( [Treatment of hyperthyroid atrial fibrillation associated with Graves disease by prednisone]. Li, M; Qiu, M; Wei, H, 2002)	0.91
"Treatment with prednisone induced clinical improvement and normalization of the laboratory data."	( Pfeifer-Weber-Christian's panniculitis in an obese patient with antinuclear antibody-positive leukocytoclastic vasculitis. De Capite, C; Foccillo, G; Giunta, R; Lucivero, G; Mordente, S, )	0.47
"Treatment with prednisone and/or cyclophosphamide controlled mucocutaneous and nail manifestations in all cases."	( Nail manifestations in pemphigus vulgaris. Cahali, JB; Kakuda, EY; Maruta, CW; Santi, CG, )	0.47
"Treatment with prednisone resulted in a significant decrease in the L/M ratio."	( The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Bitton, A; Thomson, AB; Waschke, KA; Wild, GE, 2003)	0.99
"Treatment with prednisone (50 mg/day) and blood transfusion was started before delivery."	( Pregnancy complicated with pure red cell aplasia: a case report. Kawarabayashi, T; Makino, Y; Nagano, M; Tamura, K, 2003)	0.66
"Treatment with prednisone and hydroxychloroquine led to complete control of the cutaneous and muscular involvement, which was maintained during prednisone tapering."	( Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis. Bellosta, M; Bogliolo, L; Caporali, R; Cavagna, L; Montecucco, C, 2004)	0.66
"Treatment with prednisone did not influence the levels of IL-8."	( Decreased levels of myeloperoxidase in induced sputum of patients with COPD after treatment with oral glucocorticoids. Barczyk, A; Pierzchala, W; Sozañska, E; Trzaska, M, 2004)	0.66
"The treatment with prednisone at the dose of 40 mg/d during 6 weeks was introduced, and the dose was decreased gradually to 10 mg/d within 6 months."	( [Outcome of immunosuppressive treatment of a patient with renal failure due to retroperitoneal fibrosis]. Kurzawska-Firlej, D; Oko, A; Piernik, T; Suchanek-Krawiec, A, 2004)	0.64
"Treatment with prednisone alone as first line, then combined prednisone with cyclophosphamide if NR to prednisone seemed equally effective when compared with using combined prednisone and cyclophosphamide initially."	( Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases. Huang, YW; Philipp, C; Saidi, P, 2004)	0.66
"Treatment with prednisone is preferable, followed by immunosuppressive therapy or tamoxifen in case of resistance to steroids."	( [Fatigue, loss of appetite and anuria due to retroperitoneal fibrosis]. de Beus, E; Rensma, PL, 2007)	0.68
"Oral treatment with prednisone has demonstrated efficacy in reducing restenosis after percutaneous coronary interventions (PCI). "	( Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions. Brunelleschi, S; Feola, M; Ferrero, V; Ribichini, F; Rognoni, A; Vacca, G; Vassanelli, C, 2007)	0.9
"Treatment with prednisone showed good response in a majority of both adults and childhood PRCA."	( Thirty-nine cases of pure red cell aplasia: a single center experience from India. Mahapatra, M; Pati, HP; Saxena, R; Srinivas, U, 2007)	0.68
"Treatment with prednisone and azathioprine may lead to a rapid improvement in aminotransferase levels."	( Development of autoimmune hepatitis in primary biliary cirrhosis. Gossard, AA; Lindor, KD, 2007)	0.68
"Treatment with prednisone with gradual tapering yielded a good response."	( Chronic idiopathic granulomatous mastitis. Ablin, J; Ben-David, D; Gutman, M; Katz, U; Langevitz, P; Molad, Y; Paran, D, 2007)	0.68
"Treatment with prednisone 40 mg led to complete improvement of his pulmonary disease."	( Pulmonary sarcoidosis associated with etanercept therapy. Farah, RE; Shay, MD, 2007)	0.68
"Treatment with prednisone and cyclophosphamide failed to induce remission."	( Plasmapheresis-immunoadsorption for treatment of systemic lupus erythematosus in a dog. Gordon, BR; Hurvitz, AI; Matus, RE; Saal, S; Scott, RC, 1983)	0.61
"Pretreatment with prednisone plus diphenhydramine or prednisone and diphenhydramine plus ephedrine decreased the reaction rate to 9.0% and 3.1%, respectively, during 657 procedures in 563 patients."	( Two pretreatment regimens for high-risk patients receiving radiographic contrast media. Greenberger, PA; Patterson, R; Radin, RC, 1984)	0.59
"Pretreatment with prednisone and diphenhydramine has been demonstrated to reduce this reaction rate to 9% in 465 procedures."	( Contrast media reactions. Greenberger, PA, 1984)	0.59
"Treatment with prednisone resulted in a dramatic improvement in both symptoms and respiratory values."	( Sarcoidosis. Reversal of respiratory failure 21 years after onset of disease. Hunt, KK; Matthews, JI, 1984)	0.61
"Treatment with prednisone corrected hypoventilation, improved symptoms, increased lung volumes, returned respiratory muscle strength to normal range, but did not change the degree of lung stiffness."	( Reversible hypercapnic respiratory insufficiency in scleroderma caused by respiratory muscle weakness. Chausow, AM; Kane, T; Levinson, D; Szidon, JP, 1984)	0.61
"Treatment with prednisone and azathioprine resulted in the disappearance of vetetating lesions and in healing, with postinflammatory hyperpigmentation."	( Pyodermite végétante of Hallopeau. Immunofluorescence studies performed in an early disease stage. Faber, WR; Neumann, HA, 1980)	0.6
"Treatment with prednisone administered on alternate days was accompanied by decreasing proteinuria and increasing serum levels of albumin in all the patients."	( Membranous nephropathy: high-dose alternate-day therapy with prednisone. Biava, CG; Hopper, J; Tu, WH, 1981)	0.84
"Treatment with prednisone, immunosuppressants, and aspirin was unsuccessful."	( Bilateral acute retinal necrosis. Price, FW; Schlaegel, TF, 1980)	0.6
"Pigs treated with prednisone had hemorrhages in the proper gastric (fundic) gland area of the stomach."	( Effect of prednisone on gastric blood flow in swine. Frandle, KA; Reddy, VK; Samson, MD; Zamora, CS, 1980)	0.99
"Treatment by prednisone made it possible to maintain the percentages of binding to the three tracers for two weeks at the levels reached after the fourth plasma exchange."	( Reduction of anti-thyroid hormone autoantibodies through plasma exchange and corticosteroid therapy. Attali, JR; Perret, G; Sebaoun, J; Valensi, P, 1994)	0.64
"Treatment with prednisone as soon as a significant rise in anti-dsDNA occurs prevents relapse in most cases, without increasing the cumulative dose of prednisdone given."	( Prevention of relapses in systemic lupus erythematosus. Bootsma, H; de Boer, G; Derksen, R; Gmelig-Meyling, F; Hermans, J; Kallenberg, C; Kater, L; Limburg, P; Spronk, P; Wolters-Dicke, H, 1995)	0.63
"Treatment with prednisone and cyclophosphamide produced total remission after a follow-up of 22 months."	( [Idiopathic granulomatous angiitis of the central nervous system]. Alonso de Leciñana, M; Arpa, J; Barreiro, P; Gutiérrez Molina, M; Morales, C; Palomo, F, 1994)	0.63
"Treatment with prednisone was found to induce disturbances of the lipid metabolism at the level of total cholesterol and of triglycerides."	( Lipid peroxidation in autoimmune systemic vasculitides. Effect of corticoid treatment on lipid peroxidation. Antioxidant protection with vitamin E. Serban, MG; Tănăseanu, S, )	0.47
"The treatment with prednisone did not change the level of peroxides neither the activity of the antioxidant enzymes studied."	( Lipid peroxidation and the activity of some antioxidant enzymes in patients with systemic vasculitides treated with corticoids. Niţă, V; Serban, MG; Tănăseanu, S, )	0.45
"Treatment with prednisone (2 mg/kg daily for 8 weeks) and vincristine (1 mg/m2 once weekly for 4 weeks) brought about partial remission of the angioimmunoblastic lymphadenopathy with normalization of the clinical and laboratory findings, the splenohepatomegaly regressed, and there was only a small amount of ascites."	( [Reversible myelofibrosis in angioimmunoblastic lymphadenopathy]. Mayet, WJ; Meyer zum Büschenfelde, KH; Orth, T; Störkel, S; Treichel, U, 1994)	0.63
"Treatment with prednisone and azathioprine did not give any improvement of the neurological symptoms."	( Hemiparkinsonism in a patient with primary Sjögren's syndrome. A case report and a review of the literature. Koudstaal, PJ; van de Merwe, JP; Visser, LH, 1993)	0.63
"Treatment with prednisone resulted in relief of lumbar and flank pain a well as in prevention of further digestive tract hemorrhage."	( [Retroperitoneal fibrosis and portal hypertension]. Bernasconi, S; Pedrinis, E; Realini, S; Reiner, M, 1993)	0.63
"Treatment with prednisone and cyclophosphamide was started with a good clinical response, stabilization of renal insufficiency and disappearance of P-ANCA (MPO)."	( Microscopic polyangiitis. A systemic vasculitis with a positive P-ANCA. Bernis, C; Daudén, E; Fraga, J; Peñas, PF; Porras, JI; Sarriá, C, 1996)	0.63
"Treatment with prednisone rather than placebo resulted in a more rapid improvement in arterial PO2 (PaO2) (1.12 mm Hg/d versus -0.03 mm Hg/day; p = 0.002), alveolar-arterial oxygen gradient (A-aDO2) (-1.16 mm Hg/d versus -0.03 mm Hg/day; p = 0.04), FEV1 (0.05 L/d versus 0.00 L/d; p = 0.006), and peak expiratory flow (PEF) (0.15 L/s/d versus 0.04 L/s/d; p = 0.009)."	( Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Carvalho, P; Charan, NB; Crowley, JJ; Nielson, CP; Thompson, WH, 1996)	0.94
"Treatment with prednisone (2 mg/kg/day) resulted in regression of her dyspnoea with a decrease of systolic pulmonary artery pressure to 65 mmHg, and of the arterio-capillary gradient to 15 mmHg; the lupus serology became negative with a clinical follow-up of 37 months."	( [Precapillary pulmonary arterial hypertension disclosing systemic lupus erythematosus]. Babuty, D; Cosnay, P; Fauchier, JP; Fauchier, L; Goupille, P; Marchal, C; Valat, JP, 1996)	0.63
"Treatment with prednisone, a 3-week tapering dose (60, 40, 20 mg), cleared the dermatitis."	( Wrist dermatitis: contact allergy to neoprene in a keyboard wrist rest. Elston, DM; Johnson, RC, 1997)	0.64
"Treatment with prednisone resulted in normalization of calcium levels in all patients."	( Idiopathic calcitriol-induced hypercalcemia. A new disease entity? Evron, E; Goland, S; Schattner, A; Sthoeger, ZM; von der Walde, J, 1997)	0.64
"Treatment with prednisone (40 mg/day) and PTU resulted in a prompt normalization of T3."	( [Treatment of amiodarone-induced hyperthyroidism: corticosteroids or potassium perchlorate? What value do interleukin-6 levels have?]. Konfino, O; Martin-Du Pan, R; Zimmermann, M, 1997)	0.64
"Treatment with prednisone and isotonic saline (0.9% NaCl) solution led to prompt clinical response."	( Adrenal insufficiency in a neonatal foal. Couëtil, LL; Hoffman, AM, 1998)	0.64
"Treatment with prednisone and vitamin E resulted in complete resolution of the nephrotic syndrome and slow improvement of the yellow nails, respectively."	( Yellow nails and minimal change nephrotic syndrome. Fernández-Llaca, H; Val-Bernal, JF; Yáñez, S, 1999)	0.64
"Treatment with prednisone of 0.5 to 2 mg/kg/day should be considered in all patients and continued for six months before declaring the patient resistant to therapy."	( Management of focal segmental glomerulosclerosis: evidence-based recommendations. Burgess, E, 1999)	0.64
"Treatment with prednisone suppressed median sputum eosinophilia (from 16.3 to 0%, p<0.001), decreased sputum ECP (from 7,480 to 700 microg x L(-1), p = 0.01), but did not improve neutrophil numbers, fibrinogen or IL-5."	( Prednisone-dependent asthma: inflammatory indices in induced sputum. Clelland, L; Dolovich, J; Efthimiadis, A; Hargreave, FE; Pavord, I; Pizzichini, E; Pizzichini, MM, 1999)	2.09
"Treatment with prednisone, furosemide and theophylline was started, which led to a gradual improvement in 2 weeks and a persistent remission after 9 months."	( Chronic systemic capillary leak syndrome. Report of a case and review of the literature. Airaghi, L; Miadonna, A; Montori, D; Santambrogio, L; Tedeschi, A, 2000)	0.65
"A treatment of prednisone was started together with methotrexate."	( [Takayasu's arteritis--case report and review of the literature]. Gerster, JC; Schurch, MA, 2000)	0.65
"Treatment with prednisone resulted in complete resolution of hypercalcemia in 4 cats."	( Idiopathic hypercalcemia in cats. Center, SA; Chew, DJ; DiBartola, SP; Midkiff, AM; Randolph, JF, )	0.47
"Treatment with prednisone was successful."	( [Pulmonary sarcoidosis diagnosed in 2 cases suspected to be neoplasms]. Bernard, J; Burakowska, B; Langfort, R; Wiatr, E, 2000)	0.65
"Treatment with prednisone improved clinical symptoms and MRI findings concomitant with reduction of RF titer."	( Rheumatoid factor positive hypertrophic cranial pachymeningitis in association with hypopituitarism and multiple cranial nerve palsies. Abe, K; Hayashi, T; Manabe, Y; Narai, H; Sakai, K; Warita, H, 2001)	0.65
"Treatment with prednisone, laser or plastic surgery operation are all effective to body surface hemangioma and proper treatment method should be selected according to different period and different type of hemangioma to improve the therapeutic effectiveness."	( [Treatment methods of body surface hemangioma]. Chen, JM; Huang, HB; Liang, J, 2002)	0.67
"Treatment with prednisone, carnitine, vitamins and food containing carnitine rich is very effective."	( [Studies of the clinicopathological changes of eight patients with lipid storage myopathy]. Wang, C; Xu, X; Yin, J, 2001)	0.65
"Treatment with prednisone or gamma rays inhibits partially and delays the appearance of arthritis in LEW, acting essentially on ConA-stimulable subpopulation."	( [Lymphocyte subpopulations in adjuvant arthritis of rats. Effects of corticoids and gamma irradiation]. Delbarre, F; Kahan, A; Le Gô, A; Piatier, D, 1978)	0.6
"Treatment with prednisone resulted in clinical improvement but no change in muscle histology."	( Hereditary carnitine deficiency of muscle. Dimauro, S; Griggs, RC; Markesbery, W; VanDyke, DH, 1975)	0.59
"Treatment with prednisone improved the condition, and the CT abnormality disappeared."	( Computed tomography changes in neurosarcoidosis clearing with steroid treatment. Brooks, J; Fowler, HL; Strickland, MC; Vulpe, M; Williams, JP, 1979)	0.6
"Treatment with prednisone, cyclophosphamide, and plasmapheresis was associated with rapid disappearance of the serum anti-GMB antibody and temporary stabilization of renal function."	( Treatment of Goodpasture's syndrome with immunosuppression and plasmapheresis. Finch, RA; McGowan, E; Rutsky, EA; Wilson, CB, 1979)	0.6
"On treatment with prednisone, the patient's strength and reading skill improved, symptoms resolved, and muscle enzymes returned to normal."	( Reversible alexia, mitochondrial myopathy, and lactic acidemia. Skoglund, RR, 1979)	0.58
"Treatment with prednisone followed by beclomethasone resulted in a marked improvement in her condition."	( Idiopathic bronchial stenosis in a young woman. Hooper, RG; Matthews, JI, 1978)	0.6
"Treatment with prednisone was associated with improvement in the clinical disease and the histologic picture on repeat biopsy."	( Renal failure as a presenting sign of diffuse sarcoidosis in an adolescent girl. Ruley, EJ; Shin, ML; Turner, MC, 1977)	0.6
"Treatment with prednisone produced impressive amelioration of the pericarditis with no recurrence of the lupus erythematosis syndrome during a prolonged period of observation following cessation of corticosteroid therapy."	( Pericardial tamponade. A presenting manifestation of procainamide-induced lupus erythematosus. Ghose, MK, 1975)	0.59
"Treatment with prednisone was followed by an improvement in bleeding time, although in vitro platelet function deteriorated."	( Prednisone-induced hemostasis in a platelet function abnormality. Hathaway, WE; Hutter, JJ, 1975)	2.04
"Treatment with prednisone and penicillin over a three-month period resulted in return of good cochlear function in one ear."	( Hearing loss of acquired syphilis: diagnosis confirmed by incudectomy. Nadol, JB, 1975)	0.59
"Treatment with prednisone and sulfasalazine was continued. "	( Dietary supplementation with fish oil in ulcerative colitis. Beeken, W; Burakoff, R; Cort, D; DeSchryver-Kecskemeti, K; Gramlich, TL; Rodgers, J; Stenson, WF, 1992)	0.64
"Treatment with prednisone and aspirin appears to be efficacious, safe, and economic in the prevention of pregnancy loss and fetal growth retardation in patients with aCL."	( Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992)	0.87
"Treatment with prednisone and plasma exchange resulted in some improvement."	( Case-of-the-month: perineuritis presenting as mononeuritis multiplex. Albers, JW; Sima, AA; Simmons, Z, 1992)	0.62
"Boys treated with prednisone had stronger average muscle strength scores, than did boys treated with placebo as early as 10 days after starting therapy."	( Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Brooke, MH; Fenichel, GM; Griggs, RC; Mendell, JR; Miller, JP; Moxley, RT; Pestronk, A, 1991)	2.05
"Treatment with prednisone or 5-aminosalicylic acid reduced TXB2 levels in the chronic stage of the inflammatory disease and improved the morphological damage as assessed macroscopically and histologically."	( Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Guarner, F; Malagelada, JR; Rodriguez, R; Salas, A; Vilaseca, J, 1990)	0.62
"Treatment with prednisone was accompanied by resolution of hypoglycemic episodes and disappearance of the antireceptor antibodies."	( Hypoglycemia due to antiinsulin receptor antibodies in systemic lupus erythematosus. Boden, G; Lopatin, M; Varga, J, 1990)	0.62
"Treatment with prednisone again resulted in resolution of all symptoms and normalization of radiographic and hepatic function abnormalities."	( Pulmonary fibrosis after bone marrow transplantation responsive to treatment with prednisone and cyclosporine. Abbondanzo, SL; Cottler-Fox, M; Deeg, HJ; Raschko, JW; Spitzer, TR; Torrisi, JR, 1989)	0.84
"Treatment with prednisone alone results in fewer infections and better survival than prednisone and azathioprine in standard-risk chronic GVHD."	( Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Appelbaum, FR; Dahlberg, S; Deeg, HJ; Doney, KC; Flournoy, N; Sanders, JE; Storb, R; Sullivan, KM; Weiden, P; Witherspoon, RP, 1988)	2.06
"Treatment with prednisone resulted in almost complete recovery of renal function."	( Renal failure due to granulomatous interstitial nephritis after pulmonary sarcoidosis. Jie, K; Lobatto, S; Valentijn, RM; van Dorp, WT; Weening, JJ, 1987)	0.61
"Treatment with prednisone and cyclophosphamide did not improve the hearing loss."	( Sensorineural hearing loss in lupus erythematosus. Caldarelli, DD; Corey, JP; Rejowski, JE, 1986)	0.61
"Treatment with prednisone (3 X 30 mg daily) led to complete cure of the hemiparesis within 6 weeks."	( Cerebral vasculitis as presenting symptom of systemic lupus erythematosus. Hogenhuis, LA; Sanders, EA, 1986)	0.61
"Treatment with prednisone and azathioprine improved the liver condition in 16 of the 18 patients given treatment."	( Liver disease associated with anti-liver-kidney microsome antibody in children. Alagille, D; Alvarez, F; Bernard, O; Hadchouel, M; Hadchouel, P; Homberg, JC; Maggiore, G; Odièvre, M, 1986)	0.61
"Treatment with prednisone and vincristine led to a rise in the platelet count to 100,000/mm3 after two months with no change in the splenomegaly."	( Autoimmune thrombocytopenia in sarcoidosis. Greenberg, BR; Lawrence, HJ, 1985)	0.61

Toxicity

Low-dose prednisone for OMG has an acceptable side-effect profile. Tripterygium glycosides enhances the effect of thiamazole andprednisone in the treatment of hyperthyroidism.

Excerpt	Reference	Relevance
" In DCA-saline pretreated rats the LD50 of isoproterenol was determined to be 14."	( Potentiation of isoproterenol cardiotoxicity by corticoids. Green, M; Guideri, G; Lehr, D, 1978)	0.26
" This case suggests that disseminated intravascular coagulation, and its rare association with hepatotoxicity, is a potentially fatal side effect of aspirin therapy."	( Aspirin hepatotoxicity and disseminated intravascular coagulation. Bennett, RM; Sbarbaro, JA, 1977)	0.26
" Vindesine was more toxic than Vincristine."	( A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study. Beardsley, GP; Buchanan, G; Hvizdale, E; Krischer, J; Link, M; Maybee, D; Mehta, P; Nitschke, R; Ragab, A; Vats, T, 1992)	0.52
" Clinicians should not fear using high dose ACTH/corticosteroids to treat severe Crohn's disease with an abdominal mass, if indicated, as it is both safe and effective whether an abscess cavity is present or not."	( The safety of corticosteroid therapy in Crohn's disease with an abdominal mass. Adler, DJ; Felder, JB; Korelitz, BI, 1991)	0.28
" The publication of cases of overdoses may provide useful information on the causes of the mistakes, on drug-induced toxic effects, and on salvage therapy."	( Overdose of vinblastine in a child with Langerhans' cell histiocytosis: toxicity and salvage therapy. Conter, V; Corbetta, A; D'Angelo, P; Fraschini, D; Jankovic, M; Masera, G; Pacheco, C; Rabbone, ML, )	0.13
"5 mg/kg daily from the first postoperative day is a safe practice after heart-lung transplantation."	( The safety of low-dose prednisone before and immediately after heart-lung transplantation. Ahmad, D; Kostuk, WJ; McKenzie, FN; Menkis, AH; Novick, RJ; Pflugfelder, PW; Reid, KR, 1991)	0.59
"Pulmonary toxicity is a well recognised side effect of anticancer agents particularly bleomycin, cyclophosphamide, methotrexate, and busulphan."	( Pulmonary toxicity following MOPP chemotherapy. Byrne, MJ; Cohney, SJ; Millward, MJ; Ryan, GF, 1990)	0.28
" From June 1988 to December 1989, 27 previously untreated patients with early-staged Hodgkin's disease with adverse features for disease-free survival received combined-modality therapy."	( NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Cabanillas, F; Hagemeister, FB; Liang, JC; McLaughlin, P; Meistrich, ML; Redman, JR; Rodríguez, MA; Romaguera, JE; Swan, F; Velásquez, WS, 1990)	0.28
" There were three fatal toxic events, two due to viral infection and one to a second malignant tumor (NHL)."	( Hodgkin's disease in children: treatment with MOPP and low-dose, extended field irradiation without laparotomy. Late results and toxicity. Berry, M; Blanchette, V; Chan, H; Doherty, M; Doyle, J; Freedman, M; Greenberg, M; Jenkin, D; Panzarella, T; Saunders, F, 1990)	0.28
" Home nebulizer therapy for children with asthma appears safe and reduces the need for hospital care and short courses of prednisone therapy."	( The efficacy and safety of home nebulizer therapy for children with asthma. Akhter, J; Gaspar, M; Zimo, DA, 1989)	0.48
"Eighty-five corticosteroid dependent patients with respiratory diseases requiring alternate day prednisone were studied for certain adverse effects that have been reported to be associated with corticosteroid therapy."	( Prevalence of adverse effects in corticosteroid dependent asthmatics. Aksamit, T; Fitzsimons, R; Grammer, LC; Halwig, JM; Patterson, R, )	0.35
"The morbidity and mortality due to short-term adverse effects of antileukemic chemotherapy were studied in a follow-up of 100 children with ALL on a conventional regimen."	( Toxicity of conventional ALL chemotherapy: incidence of short-term adverse effects in 100 children. Saarinen, UM, 1987)	0.27
" That preuremic transplantation is safe and efficacious in patients with immanent end-stage renal disease has not been established."	( Renal transplantation done safely without prior chronic dialysis therapy. Ascher, NL; Fryd, D; Migliori, RJ; Najarian, JS; Payne, WD; Simmons, RL; Sutherland, DE, 1987)	0.27
" In the 101 patients prospectively studied, the benefits from prednisone treatment far outweighed the adverse side effects, which occurred in 61 patients."	( Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases. Lozada, F; Migliorati, C; Silverman, S, 1984)	0.78
" In terms of reproductive and developmental toxicity, cyclosporine produces some adverse effects in both experimental animals and humans."	( International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosp Mattison, DR; Olshan, AF; Zwanenburg, TS, 1994)	0.29
" Adverse events occurred frequently (80."	( A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis. Carotti, M; Cervini, C; Salaffi, F; Sartini, A, )	0.13
"During a one month followup period, adverse reactions occurred with equal frequency among patients with RA and healthy controls."	( Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. Chalmers, A; Patterson, C; Scheifele, D; Shuckett, R; Teufel, A; Weber, J; Williams, D, 1994)	0.29
" For CS, charts were abstracted from the date of prednisone start for predefined adverse events (AEs)."	( Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Brasington, R; Burmeister, LF; Caldwell, JR; Furst, DE; Koehnke, R; Kohler, JA; Saag, KG; Zimmerman, B, 1994)	0.54
"Although disease severity is an important confounding factor, low dose long-term prednisone use equal to or greater than 5 mg/d is correlated with the development of specific adverse events in a dose-dependent fashion."	( Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Brasington, R; Burmeister, LF; Caldwell, JR; Furst, DE; Koehnke, R; Kohler, JA; Saag, KG; Zimmerman, B, 1994)	0.51
"In equally favorable cases, RP without diversion is not as safe as RP with diversion, especially in patients taking > or = 20 mg of prednisone/day."	( Omission of temporary diversion in restorative proctocolectomy--is it safe? Fabre, JM; Fazio, VW; Lavery, IC; Milsom, JW; Oakley, JR; Tjandra, JJ, 1993)	0.49
"Cardiotoxicity is a well recognized side effect of anthracyclines (doxorubicin and epirubicin) or antracenadiones (mitoxantrone) at cumulative or high doses."	( Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Arévila, N; Avilés, A; Díaz Maqueo, JC; García, R; Gómez, T; Nambo, MJ, 1993)	0.29
" Gastrointestinal morbidity was less in the cohort treated without Ara-C; however, infectious morbidity persisted at unacceptable levels and this program was terminated as too toxic to administer."	( Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Berman, E; Gaynor, J; Gee, T; Kempin, S; Kritz, A; Little, C; Scheinberg, D; Sogoloff, H; Telford, P; Weiss, M, 1993)	0.29
"The authors reviewed the clinical records of 602 patients with ocular inflammatory disease treated with immunosuppressive drug therapy and/or systemic corticosteroids for adverse systemic effects while undergoing therapy."	( Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Akova, YA; Christen, WG; Foster, CS; Messmer, E; Rodriguez, A; Tamesis, RR, 1996)	0.29
"Immunosuppressive drug treatment was more likely to result in discontinuation of therapy because of toxic side effects than was corticosteroid treatment."	( Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Akova, YA; Christen, WG; Foster, CS; Messmer, E; Rodriguez, A; Tamesis, RR, 1996)	0.29
"These findings suggest that when properly administered and monitored for adverse effects, most immunosuppressive agents used in the current study have similar risk profiles with relatively few serious therapeutic mishaps and largely reversible side effects."	( Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Akova, YA; Christen, WG; Foster, CS; Messmer, E; Rodriguez, A; Tamesis, RR, 1996)	0.29
" the primary side effect of sirolimus was a reversible decrease in platelet (PLT) and white blood cell (WBC) counts."	( The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Jordan, S; Kahan, BD; Murgia, MG, 1996)	0.52
"5 mg/d within 1 year, was effective and less toxic in this patient population, than the two higher dose regimens."	( Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Nesher, G; Rubinow, A; Sonnenblick, M, )	0.13
" Data were collected at each treatment cycle via a 75-item self-report questionnaire, with severity of each side effect graded on a 5-point scale."	( Side effects of CHOP in the treatment of non-hodgkin's lymphoma. North, C; Sitzia, J; Stanley, J; Winterberg, N, 1997)	0.3
" These data, though preliminary, indicate that early immunosuppression without the use of prednisone is safe and tends to be associated with improved liver and renal functions compared to conventional triple therapy."	( Immunosuppression without prednisone after liver transplantion is safe and associated with normal early graft function: preliminary results of a randomized study. Angelico, M; Anselmo, A; Baiocchi, L; Casciani, CU; Negrini, S; Orlando, G; Palmieri, G; Pisani, F; Tisone, G; Vennarecci, G, 1998)	0.82
" Toxicity information for IFN had been collected using patient-completed diaries so the actual duration of each adverse event could be determined."	( Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. Browman, G; Cole, B; James, K; Johnston, D; Li, T; Pater, J; Sugano, D; Zee, B, 1998)	0.3
" The aim of this study was to assess whether conversion from Sandimmune to Neoral provides safe and effective oral immunosuppression in stable liver transplant recipients."	( An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral. Dahlke, LM; Krom, RA; Pasha, TM; Porayko, MK; Wiesner, RH, 1998)	0.3
" Medical files were reviewed for adverse side effects: fever, pancreatitis, infections, gastrointestinal intolerance, aminotransferase level increase, leukopenia, and thrombocytopenia."	( Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Kirschner, BS, 1998)	0.3
"AZA or 6-MP was tolerated in 51 of 95 patients (54%) without adverse reaction; 27 of 95 (28%) experienced side effects that responded to dose reduction (23 patients) or spontaneously (4 patients), most commonly increased aminotransferase level (13."	( Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Kirschner, BS, 1998)	0.3
" The incidences of premature withdrawal from the study due to adverse events in the three groups were 4 of 51 (7."	( A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. de Fijter, JW; Hale, MD; Hené, RJ; Hilbrands, LB; Navarro, MT; Nicholls, AJ; Squifflet, JP; van Gelder, T; Vanrenterghem, Y; Verpooten, GA; Weimar, W, 1999)	0.3
"MPA Cpredose and MPA AUC are significantly related to the incidence of biopsy-proven rejection after kidney transplantation, whereas MMF dose is significantly related to the occurrence of adverse events."	( A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. de Fijter, JW; Hale, MD; Hené, RJ; Hilbrands, LB; Navarro, MT; Nicholls, AJ; Squifflet, JP; van Gelder, T; Vanrenterghem, Y; Verpooten, GA; Weimar, W, 1999)	0.3
" Many of these adverse side effects can be greatly reduced or prevented with close monitoring of patients."	( Ocular toxicity of systemic medications: a case series. To, TQ; Townsend, JC, 2000)	0.31
" Clinical cases illustrating possible adverse ocular side effects are presented, which include INH-induced optic neuropathy, phenothiazine-induced retinopathy, steroid-induced glaucoma, and vortex epitheliopathy secondary to amiodarone."	( Ocular toxicity of systemic medications: a case series. To, TQ; Townsend, JC, 2000)	0.31
" No toxic deaths have occurred."	( Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M, 2000)	0.6
" Despite increased hematotoxicity, moderate dose escalation is safe for the majority of the patients with G-CSF assistance and standard supportive treatment."	( Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Diehl, V; Engel, C; Loeffler, M; Schmitz, S; Tesch, H, 2000)	0.31
" Clinical response, remission, corticosteroid tapering, and adverse event data were collected."	( Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Cohen, RD, 2001)	0.31
" The distribution of adverse prognostic factors was comparable in the two-induction arm."	( Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Bernard, M; Casassus, P; Delain, M; Desablens, B; Guilhot, F; Hunault-Berger, M; Ifrah, N; Jouet, JP; Milpied, N; Sadoun, A, 2001)	0.31
" The long-term effectiveness and side-effect profiles of pulse immunosuppressive regimens warrant further study."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
"Rates of treatment failure (defined as need for supplemental immunosuppressive therapy or doubling of serum creatinine concentration, or death) and adverse events."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
" Combination therapy and cyclophosphamide therapy alone did not differ statistically in terms of effectiveness or adverse events."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
" The combination of pulse cyclophosphamide and methylprednisolone appears to provide additional benefit over pulse cyclophosphamide alone and does not confer additional risk for adverse events."	( Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001)	0.31
"Sputum induction is a safe and effective technique to study airway inflammation in stable asthma."	( Safety of sputum induction with isotonic saline in adults with acute severe asthma. Gibson, PG; Hensley, MJ; Simpson, JL; Wark, PA, 2001)	0.31
" Adverse effects were documented every 3 months."	( Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Bijlsma, JW; Jacobs, JW; Siewertsz Van Reesema, DR; van Everdingen, AA, 2002)	0.73
" No clinically relevant adverse effects were observed, except for a higher incidence of osteoporotic fractures in the prednisone group."	( Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Bijlsma, JW; Jacobs, JW; Siewertsz Van Reesema, DR; van Everdingen, AA, 2002)	0.94
"Data from 185 patients were retrospectively evaluated for adverse events, duration of exposure (person-days), and the mean atorvastatin dose exposure."	( Safety and efficacy of atorvastatin in heart transplant recipients. Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN, 2002)	0.31
"Data from 185 patients were retrospectively evaluated for adverse events, duration of exposure (person-days), and the mean atorvastatin dose exposure."	( Safety and efficacy of atorvastatin in heart transplant recipients. Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN, 2002)	0.31
"Atorvastatin, when used at moderate doses and with close biochemical and clinical monitoring, appears to be safe and is effective in aggressively lowering LDL in heart transplant recipients when treatment with other statins has failed to achieve LDL goals."	( Safety and efficacy of atorvastatin in heart transplant recipients. Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN, 2002)	0.31
"In this study we aimed to discuss whether the gonadal suppression is effective or not in preventing the gonadal toxic effects of some chemotherapeutics."	( The effects of GnRH analogues and antiandrogenes in preventing the gonadotoxic effects of COPP chemotherapy. Akay, AF; Bircan, MK; Deniz, M; Göçmen, M; Nergiz, Y; Sahin, H, 2001)	0.31
"As a conclusion we think that gonadal suppression applied during chemotherapy regimen could decrease the testicular toxic effects of chemotherapeutic but more clinical investigations needed for routine application."	( The effects of GnRH analogues and antiandrogenes in preventing the gonadotoxic effects of COPP chemotherapy. Akay, AF; Bircan, MK; Deniz, M; Göçmen, M; Nergiz, Y; Sahin, H, 2001)	0.31
" All the chemicals have been tested to evaluate their toxic effects on freshwater organisms from different trophic levels."	( Identification of phototransformation products of prednisone by sunlight: toxicity of the drug and its derivatives on aquatic organisms. DellaGreca, M; Fiorentino, A; Iesce, MR; Isidori, M; Nardelli, A; Previtera, L; Temussi, F, 2003)	0.57
" Although arthroplasty is safe in the general population, its safety in liver transplant recipients is unclear."	( The safety and outcome of joint replacement surgery in liver transplant recipients. Cohen, SM; Levitsky, J; Te, HS, 2003)	0.32
"CHOP-14 with the addition of rhG-CSF is safe and practicable in a large multicentre setting in patients aged 18-75 years."	( Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A, 2003)	0.32
" After completion of study drug administration, the patients were monitored until day 56 by serial laboratory tests, clinical examinations, and recording of adverse events."	( Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Chodoff, L; Ferguson, RM; Gonwa, TA; Kahan, BD; Karlix, JL; Leichtman, AB; Mulgaonkar, S; Schmouder, RL; Skerjanec, A, 2003)	0.32
" Compared with placebo-treated patients, FTY720 subjects did not show a major increase in adverse events or a change in renal function."	( Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Chodoff, L; Ferguson, RM; Gonwa, TA; Kahan, BD; Karlix, JL; Leichtman, AB; Mulgaonkar, S; Schmouder, RL; Skerjanec, A, 2003)	0.32
" The safety of pegfilgrastim in this patient population was determined by reports of adverse events."	( Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Case, D; George, S; Hackett, J; Liang, BC; Meza, LA; Neumann, TA; Shogan, JE; Yang, BB; Yunus, F, 2003)	0.32
"A retrospective cohort analysis of clinical data regarding adverse events of azathioprine in Crohn's disease."	( Side effects of azathioprine in patients with Crohn's disease. de Jong, DJ; Goullet, M; Naber, TH, 2004)	0.32
"In 15 of the 50 patients azathioprine was preliminary discontinued due to adverse events and in 11 of these patients (22%) adverse events were probably related to azathioprine."	( Side effects of azathioprine in patients with Crohn's disease. de Jong, DJ; Goullet, M; Naber, TH, 2004)	0.32
"Twenty-two per cent of patients discontinued azathioprine prematurely probably as a result of related adverse events."	( Side effects of azathioprine in patients with Crohn's disease. de Jong, DJ; Goullet, M; Naber, TH, 2004)	0.32
" Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab."	( Safety of rituximab therapy during the first trimester of pregnancy: a case history. Elinder, G; Kimby, E; Sverrisdottir, A, 2004)	0.32
" Hyperlipidemia was the only adverse event more frequent among SRL patients (49% vs."	( An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Alfieri, F; Felipe, CR; Franco, M; Garcia, R; Hanzawa, NM; Machado, PG; Medina-Pestana, JO; Park, SI; Silva, HT, 2004)	0.52
"Corticosteroid therapy after renal transplantation is associated with many adverse effects."	( Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Applegate, M; Dagher, F; Dayton, M; Guzowski, H; Kohli, R; Laftavi, MR; Leca, N; O'Keefe, J; Pankewycz, O; Pierce, D; Rubino, A; Stefanick, B; Stephan, R, 2005)	0.33
" Graft function, incidence of acute rejection (AR), findings of protocol graft biopsy and adverse effects were compared."	( Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation. Fukuzawa, N; Harada, H; Hirano, T; Iwami, D; Miura, M; Ogawa, Y; Satoh, H; Seki, T; Taniguchi, A; Togashi, M, 2005)	0.55
" This regimen is safe and effective for application during the early period after renal transplantation."	( Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation. Fukuzawa, N; Harada, H; Hirano, T; Iwami, D; Miura, M; Ogawa, Y; Satoh, H; Seki, T; Taniguchi, A; Togashi, M, 2005)	0.55
" The purpose of this study was to explore the association between these polymorphisms and the occurrence of azathioprine adverse effects in 112 renal transplant recipients undergoing triple immunosuppressive therapy including azathioprine, cyclosporine, and prednisone."	( The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Domański, L; Droździk, M; Dziewanowski, K; Gawrońska-Szklarz, B; Kurzawski, M, 2005)	0.51
"Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls."	( Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Benne, CA; Bijl, M; De Vries, JJ; Holvast, A; Horst, G; Huckriede, A; Kallenberg, CG; Wilschut, J, 2006)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"Immunosuppression without steroids is safe and reduces infection and metabolic complications."	( Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. Baliellas, C; Castellote, J; Fabregat, J; Figueras, J; Garcia-Gil, A; Gonzalez-Pinto, I; Lladó, L; Memba, R; Rafecas, A; Ramos, E; Serrano, T; Torras, J; Xiol, X, 2006)	0.33
" Severe adverse events occurred on 12 occasions (4% of cycles), involving 11 patients (22% of total); the most frequent severe adverse event was interstitial pneumonia which occurred in seven patients (14% of total)."	( Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Brusamolino, E; Fava, S; Gargantini, L; Lazzarino, M; Montalbetti, L; Morra, E; Pagnucco, G; Pascutto, C; Pinotti, G; Rigacci, L; Rusconi, C; Uziel, L, 2006)	0.33
" Adverse events were higher in everolimus-treated patients especially at the 4-mg/day dose, but there was no difference in the incidence of thrombocytopenia or leukopenia between all groups and renal function as determined by serum creatinine, and creatinine clearance remained stable to 36 months in everolimus-treated patients."	( Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Abecassis, M; Calmus, Y; Fischer, L; Freeman, R; Klempnauer, J; Langnas, A; Levy, G; Mayer, D; Nashan, B; Neuhaus, P; Punch, J; Roberts, J; Rogiers, X; Samuel, D; Schmidli, H; Sloof, M; Tuttle-Newhall, E, 2006)	0.33
" The main outcome measures were average time to clinical remission, average time to immunologic remission (non-detectable circulating pemphigus vulgaris antibodies), proportion of patients who remained free of clinical relapse within 5 years after discontinuation of therapy, time from treatment discontinuation until first relapse, and incidence of adverse effects."	( Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Blaszczyk, M; Cwikla, J; Kolacinska-Strasz, Z; Labecka, H; Natorska, U; Olszewska, M; Sulej, J, 2007)	0.34
"More than 50 years after the introduction of corticosteroids, few studies have focused on corticosteroid-induced adverse events after long-term systemic therapy."	( Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Cabane, J; Fardet, L; Flahault, A; Généreau, T; Kettaneh, A; Lebbé, C; Tiev, KP; Tolédano, C, 2007)	0.34
"To assess the frequency, risk factors and patient's opinion regarding clinical adverse events occurring early during prednisone therapy."	( Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Cabane, J; Fardet, L; Flahault, A; Généreau, T; Kettaneh, A; Lebbé, C; Tiev, KP; Tolédano, C, 2007)	0.55
" The main clinical adverse events attributable to corticosteroids were assessed after 3 months of therapy, by comparison with baseline status."	( Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Cabane, J; Fardet, L; Flahault, A; Généreau, T; Kettaneh, A; Lebbé, C; Tiev, KP; Tolédano, C, 2007)	0.34
" Lipodystrophy was the most frequent adverse event [63."	( Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Cabane, J; Fardet, L; Flahault, A; Généreau, T; Kettaneh, A; Lebbé, C; Tiev, KP; Tolédano, C, 2007)	0.34
"Lipodystrophy and neuropsychiatric disorders are common adverse events of long-term prednisone therapy and are particularly distressing for the patients concerned."	( Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Cabane, J; Fardet, L; Flahault, A; Généreau, T; Kettaneh, A; Lebbé, C; Tiev, KP; Tolédano, C, 2007)	0.56
"The dose-dense CHOP-14 regimen is efficient and safe in elderly patients with diffuse large B-cell lymphoma (DLBCL)."	( Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. de Nully Brown, P; Hansen, M; Jurlander, J; Tholstrup, D, 2007)	0.34
" The main adverse events were neutropenia (48% of cycles) and infections (10% of cycles), which were fatal in seven patients."	( Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Abella, E; García, M; Gardella, S; González-Barca, E; López, A; López-Guillermo, A; Miralles, P; Morgades, M; Oriol, A; Ribera, JM, 2008)	0.58
" Thirteen stopped infliximab because of loss of efficacy (n = 4), remission (n = 6) or non-compliance, chest tightness or side effect (1 each)."	( Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Cohen, P; Guaydier-Souquières, G; Guillevin, L; Hayem, G; Job-Deslandre, C; Josselin, L; Liferman, F; Mahr, A; Pagnoux, C; Pourrat, J, 2008)	0.35
"These observations highlight infliximab as a potentially useful and safe salvage treatment for patients with refractory SNV."	( Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Cohen, P; Guaydier-Souquières, G; Guillevin, L; Hayem, G; Job-Deslandre, C; Josselin, L; Liferman, F; Mahr, A; Pagnoux, C; Pourrat, J, 2008)	0.35
" Infliximab infusion can be complicated by clinically heterogeneous adverse reactions, potentially interfering with the course of treatment."	( Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Maggi, E; Matucci, A; Palandri, F; Parronchi, P; Romagnani, S; Rossi, O; Vultaggio, A, )	0.13
" The major adverse events in combination group were infusion-related responses which could be well tolerated in patients, and hematological toxicities which were similar to those in CHOP group."	( [Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma]. Li, JY; Lu, H; Qian, SX; Qiu, HX; Sheng, RL; Wu, HX; Xu, W; Zhang, ZH, 2008)	0.35
"IFN-alpha2a is efficient and safe for the long-term management of severe uveitis associated with Behçet disease."	( Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Bodaghi, B; Cassoux, N; Fardeau, C; Gendron, G; Gueudry, J; Lehoang, P; Piette, JC; Terrada, C; Wechsler, B, 2008)	0.35
" Most adverse events were transient and did not require change in therapy."	( The effectiveness and safety of mycophenolate mofetil in lupus nephritis. Ballou, S; Elyan, M, 2009)	0.35
"To report the adverse effects associated with prolonged high-dose prednisone for the treatment of autoimmune inner ear disease (AIED)."	( Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Alexander, TH; Brookhouser, PE; Derebery, JM; Espeland, MA; Gantz, BJ; Gulya, AJ; Hammerschlag, PE; Hannley, M; Harris, JP; Hughes, GB; Moscicki, R; Nelson, RA; Niparko, JK; Rauch, SD; Telian, SA; Weisman, MH, 2009)	0.59
" The present study suggests that with appropriate patient selection, monitoring, and patient education, high-dose corticosteroids are a safe and effective treatment of AIED."	( Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Alexander, TH; Brookhouser, PE; Derebery, JM; Espeland, MA; Gantz, BJ; Gulya, AJ; Hammerschlag, PE; Hannley, M; Harris, JP; Hughes, GB; Moscicki, R; Nelson, RA; Niparko, JK; Rauch, SD; Telian, SA; Weisman, MH, 2009)	0.35
"We sought to determine whether treatment with steroids, immunosuppressives (ISs), and anti-tumor necrosis factor (TNF) agents is associated with an increased risk of adverse events in patients with Crohn's disease (CD)."	( Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Arrighi, HM; Hass, S; Marehbian, J; Sandborn, WJ; Tian, H, 2009)	0.35
" Follow-up adverse events in patients with CD and controls were compared across different treatment categories and are presented as hazard ratios (HRs) and 95% confidence intervals (CIs)."	( Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Arrighi, HM; Hass, S; Marehbian, J; Sandborn, WJ; Tian, H, 2009)	0.35
" Most treatment-emergent adverse events (TEAEs) occurred in the 10-mg/kg intetumumab group."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.56
"Intetumumab was generally safe and well tolerated in combination with docetaxel, with a higher incidence of TEAEs in the 10 mg/kg dose cohort."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.56
"The severe pulmonary adverse events tended to occur more frequently with R-CHOP (18."	( Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Bang, SM; Kang, YA; Kim, JH; Lee, CT; Lee, JH; Lee, JS; Lee, KW; Lim, KH; Yoon, HI, 2010)	0.57
" Thalidomide, in combination with MP, is associated with adverse events (AEs) including peripheral neuropathy and venous thromboembolism."	( Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010)	0.56
" No patient developed vaccine-associated serious adverse events or disease flares."	( The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Farmaki, E; Kanakoudi-Tsakalidou, F; Pratsidou-Gertsi, P; Spoulou, V; Theodoridou, M; Trachana, M; Tritsoni, M, 2010)	0.36
" Secondary end-points were the rate of control of chronic cough at each step of therapy, the duration of treatment required, changes in cough symptom score, health-related quality of life and possible adverse effects."	( Efficacy and safety of modified sequential three-step empirical therapy for chronic cough. Li, X; Liang, S; Liu, B; Lü, H; Qiu, Z; Wang, L; Wang, Y; Wei, W; Yu, L, 2010)	0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ."	( Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010)	0.36
" Neutropenia (48%) was the most frequent grade 3 to 4 adverse event (AE); no grade 3 to 4 cardiac AEs were observed."	( Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Ardizzoni, A; Boggiani, D; Franciosi, V; Musolino, A; Panebianco, M; Salvagni, S; Vasini, G, 2011)	0.59
"DA-POCH-R was an active and safe combination therapy for patients aged ≥70 years with poor-prognostic untreated DLBCL."	( Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Ardizzoni, A; Boggiani, D; Franciosi, V; Musolino, A; Panebianco, M; Salvagni, S; Vasini, G, 2011)	0.59
"The majority of patients with Hodgkin's disease can be cured by combination of polychemotherapy and radiotherapy (RT) that can produce late toxic pulmonary and cardiac effects which often remain at a subclinical level."	( Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Viviani, S, 2010)	0.36
"These data confirm that the combination of mediastinal RT with the more commonly used polychemotherapy regimens produce late toxic effects."	( Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Viviani, S, 2010)	0.36
"The aim of the study is to characterize the pharmacokinetics and the gastrointestinal side effect profiles of enteric-coated mycophenolate sodium (EC-MPS) in de novo kidney transplant patients of Hispanic ethnicity."	( The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. Hutchinson, I; Min, DI; Qazi, Y; Shah, T; Tellez-Corrales, E; Wang, J; Wilson, J; Yang, JW, 2011)	0.37
" In conclusion, low-dose rATG induction therapy is safe and effective in patients older than 65."	( Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Alnimri, M; Kohli, R; Laftavi, MR; Pankewycz, O; Patel, S; Said, M; Soliman, MR, 2011)	0.37
" Though lack of difference may be attributed to the small sample size, suboptimal supportive care for intensive treatment would increase risk of toxic deaths."	( Outcome and haemato-toxicity of two chemotherapy regimens for childhood non-Hodgkin's lymphoma in a Kenyan hospital. Macharia, WM, 2009)	0.35
" Febrile neutropenia was rare (4%) and there were no toxic deaths."	( Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE, 2011)	0.37
" In both arms, greater rates of severe hematologic adverse events were associated with RI (eGFR < 50 mL/min), however, therapy discontinuation rates were unaffected."	( Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I, 2011)	0.63
" This case illustrates a unique side effect of INH that caused exudative EPEs and drug-induced lupus with positive anti-dsDNA."	( Isoniazid (INH)-induced eosinophilic exudative pleural effusion and lupus erythematosus. A clinical reminder of drug side effects. Dahal, K; Khattri, S; Kushawaha, A; Lee, M; Mobarakai, N, 2011)	0.37
"MTX treatment is safe and beneficial as a steroid-sparing agent in PV."	( Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Barzilai, A; Baum, S; Greenberger, S; Lyakhovitsky, A; Samuelov, L; Solomon, M; Trau, H, )	0.13
"In the largest adult case series in Burkitt-PTLD to date, sequential immunochemotherapy with rituximab followed by standard CHOP or R-CHOP was a both safe and effective treatment."	( Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis Anagnostopoulos, I; Atta, J; Gärtner, B; Lehmkuhl, H; Lenze, D; Neuhaus, R; Oertel, S; Planker, M; Reinke, P; Riess, H; Trappe, RU; Zimmermann, H, 2012)	0.57
"Treatment with chronic corticosteroids has been associated with frequent significant adverse effects."	( Safety of prednisone for ocular myasthenia gravis. Bruce, BB; Kupersmith, MJ, 2012)	0.78
"Low-dose prednisone for OMG has an acceptable side-effect profile and causes few serious complications (2-year risk, ∼1%)."	( Safety of prednisone for ocular myasthenia gravis. Bruce, BB; Kupersmith, MJ, 2012)	1.2
"Pregabalin is one of the first-line treatments for painful diabetic peripheral neuropathy in many countries, and we have administered it to relieve the neurotoxicity associated with adverse effects of VCR in a DLBCL patient treated with the R-CHOP regimen."	( [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012)	0.38
" A causality assessment of the adverse reaction identified the antibiotic as the most probable cause of the observation."	( A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012)	0.38
" The adverse events in R-CHOP group were similar with that in CHOP group."	( [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up]. Cao, JN; Chen, FY; Cheng, YF; Cheng, ZX; Li, F; Li, JM; Wang, C; Wang, JM; Wei, Z; Zou, SH, 2012)	0.38
"R-CHOP is a safe and effective regimen for management of newly diagnosed DLBCL, with a better remission rate, PFS and OS."	( [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up]. Cao, JN; Chen, FY; Cheng, YF; Cheng, ZX; Li, F; Li, JM; Wang, C; Wang, JM; Wei, Z; Zou, SH, 2012)	0.38
"To clarify whether increase of body weight in patients with early rheumatoid arthritis (RA) upon administration of prednisone is a side effect of prednisone or a result of better control of disease activity, we examined the association of prednisone and disease activity with a subsequent change in body mass index (BMI)."	( Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? Bakker, MF; Bijlsma, JW; Bossema, ER; Ehrlich, JC; Geenen, R; Jacobs, JW; Jurgens, MS; Lafeber, FP; van Albada-Kuipers, IA; Welsing, PM, 2013)	0.82
" Secondary endpoints include AIRs during the 24 h following their second infusion and any adverse events experienced during the 26-week study; efficacy measures were also followed as secondary endpoints."	( A safety analysis of oral prednisone as a pretreatment for rituximab in rheumatoid arthritis. Carter, JD; McNeil, A; Ricca, LR; Sebba, AI; Valeriano-Marcet, J; Vasey, FB; Zarabadi, SA, 2012)	0.68
" Only 1 patient experienced a grade 4 adverse event due to a nonsymptomatic pulmonary embolism."	( Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer. Arévalo, E; Carranza, OE; Castañón, E; Castillo, A; Collado-Gómez, V; Fusco, JP; Gil-Aldea, I; Gil-Bazo, I; López, I; Zudaire, ME, 2013)	0.39
" The most common grade 2-3 hematologic adverse event was neutropenia, which was observed in 47 patients (56 %)."	( Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Ciruelos, E; Cortés-Funes, H; Dorta, M; Ghanem, I; Manneh, R; Manso, L; Mendiola, C; Sepúlveda, J; Valdiviezo, N; Vega, E, 2013)	0.39
"NPLD-based metronomic regimen was effective and safe in pretreated advanced breast cancer patients."	( Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Ciruelos, E; Cortés-Funes, H; Dorta, M; Ghanem, I; Manneh, R; Manso, L; Mendiola, C; Sepúlveda, J; Valdiviezo, N; Vega, E, 2013)	0.39
" The two most frequent treatment-related adverse events (AEs) were fatigue and nausea."	( A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Advani, R; Bolejack, V; Foss, FM; Goy, A; Jacobsen, E; Komrokji, R; Pendergrass, K; Sjak-Shie, N; Smith, MR, 2013)	0.59
" No adverse events were recorded."	( Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Audard, V; Bouachi, K; Dahan, KY; Deschênes, G; Lang, P; Mojaat, R; Munyentwali, H; Plaisier, EM; Remy, P; Ronco, PM, 2013)	0.39
"Elderly kidney transplant recipients receiving rabbit antithymocyte globulin did not experience different short-term graft survival, graft function or rates of infection, malignancy or hematologic adverse reactions than did nonelderly patients; they experienced fewer episodes of delayed graft function, but had lower 3-year patient survival."	( Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients. Campos, S; Dinh, DB; Feyssa, EL; Jawa, P; Khanmoradi, K; Knorr, JP; Ortiz, JA; Parsikia, A; Zaki, RF, 2013)	0.39
" Two toxic deaths were observed."	( High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013)	0.6
" Severe adverse events occurred in only the control group (14."	( Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial. Chen, N; Chen, X; Chen, Y; Deng, W; Deng, Y; Ni, Z; Shi, W; Yuan, F; Zhan, Y; Zhong, Y, 2013)	0.39
" Grade 3-4 hematologic adverse events were: neutropenia in 28% of the courses, thrombocytopenia in 9%, and anemia in 3%."	( Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M, 2013)	0.63
" No serious adverse events were observed."	( Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. Lu, W; Xie, L; Xue, W; Yang, S; Yin, A, 2013)	0.7
" No grade 3-4 adverse events were observed."	( Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E, 2015)	0.42
"AA appears to be safe and well tolerated even in patients with cardiovascular comorbidities or with increased risk factors for cardiovascular diseases."	( Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E, 2015)	0.42
"Our study confirmed the weight of cardiac toxic effect of CHOP ± R regimen."	( Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. Brion, A; Cahn, JY; Daguindau, E; Deconinck, E; Limat, S; Nerich, V; Perrin, S; Woronoff-Lemsi, MC, 2014)	0.4
" Fifty-three patients withdrew after cycle 1; 10 for grade 3 or 4 IRRs and one for a grade 3 adverse event."	( Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Brewster, M; Chai, A; Dakhil, S; Gregory, SA; Hermann, R; Hurst, D; Monte, M; Richards, P; Schreeder, MT; Windsor, KS, 2014)	0.4
" Number of cabazitaxel cycles, dose reductions for any cause, dose delays possibly related to cabazitaxel adverse events, and tolerability were similar in the three age groups."	( Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014)	0.4
" All patients were evaluated for the occurrence of adverse drug reactions associated with prednisone at week 12."	( [The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis]. He, YJ; Liu, SY; Yang, L; Zhang, L; Zhang, X, 2013)	0.85
" No serious adverse event was observed during the study."	( [The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis]. He, YJ; Liu, SY; Yang, L; Zhang, L; Zhang, X, 2013)	0.63
" Adverse events were summarised descriptively."	( Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Beer, TM; Carles, J; de Bono, JS; de Souza, P; Efstathiou, E; Fizazi, K; Flaig, TW; Fradet, Y; Griffin, TW; Hainsworth, JD; Higano, CS; Kheoh, T; Logothetis, CJ; Mainwaring, P; Molina, A; Mulders, PF; North, S; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Shore, ND; Small, EJ; Smith, MR; Taplin, ME; Todd, MB; Van Poppel, H; Yu, EY; Yu, MK, 2014)	0.4
"In recent decades, numerous methods have been developed for data mining of large drug safety databases, such as Food and Drug Administration's (FDA's) Adverse Event Reporting System, where data matrices are formed by drugs such as columns and adverse events as rows."	( Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection. Huang, L; Tiwari, R; Zalkikar, J; Zheng, D, 2017)	0.46
"We conducted a phase III study to test the hypothesis that initial therapy with "lower dose" prednisone is effective and safe for patients with newly diagnosed acute graft-versus-host disease."	( Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Boeckh, M; Carpenter, PA; Flowers, ME; Furlong, T; Green, ML; Martin, PJ; McDonald, GB; Mielcarek, M; Storb, R; Storer, BE, 2015)	0.91
"Addition of abiraterone to LHRHa with radiation is safe and achieves effective prostatic androgen suppression."	( External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens. Cho, E; Dalkin, BL; Konodi, MA; Kurland, BF; Liao, JJ; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Russell, KJ, 2015)	0.42
" Five adverse events induced therapy termination: 2 myocardial infarctions, 2 pneumonias, and 1 reduced condition."	( Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases. Aurich, M; Ho, AD; Rohlfing, S; Schöning, T; Witzens-Harig, M, 2015)	0.42
" Adverse effects were more frequent among HD recipients (MD=43%, HD=66%, p=0."	( Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Les, I; Martínez-Berriotxoa, A; Pijoán, JI; Rodríguez-Álvarez, R; Ruiz-Irastorza, G, )	0.4
"MD prednisone regimen may be an effective and safe alternative to HD prednisone regimen in GCA."	( Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Les, I; Martínez-Berriotxoa, A; Pijoán, JI; Rodríguez-Álvarez, R; Ruiz-Irastorza, G, )	1.02
" Specific adverse events with abiraterone-prednisone were similar between the age subgroups."	( Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. Carles, J; Griffin, TW; Kheoh, T; Li, J; Molina, A; Mulders, PF; Rathkopf, DE; Ryan, CJ; Smith, MR; Van Poppel, H, 2015)	0.68
"Twice daily budesonide transnasal nebulization is an effective and safe treatment as evidenced by significant improvements in nasal symptoms and reduction in polyp size, coupled with an absence of hypothalamic-pituitary-adrenal axis suppression, which is safer than the systemic corticosteroids."	( [The efficacy and safety of budesonide inhalation suspension via transnasal nebulization compared with oral corticosteroids in chronic rhinosinusitis with nasal polyps]. Lou, H; Wang, C; Zhang, L, 2015)	0.42
"Both groups were followed for 24 months after transplantation for immunosuppressive regimen-associated and time-dependent occurrences of adverse events (AEs) and serious adverse events (SAEs)."	( Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. Felipe, CR; Felix, MJ; Osmar Medina-Pestana, J; Tedesco-Silva, H, 2016)	0.43
"Exploring the relationships among adverse events is important because those that arise from a common mechanism are amenable to a common intervention, which can improve symptom management, quality of life, and treatment adherence."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"The CTCAE data from a randomized clinical trial conducted by SWOG that compared docetaxel plus estramustine versus mitoxantrone plus predinsone in patients with advanced prostate cancer were used to identify severe adverse event clusters."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"A total of 109 adverse event types were captured using the CTCAE."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"Several severe adverse event clusters were identified in patients with advanced prostate cancer."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
" The therapeutic efficacy of patients in 2 groups was analyzed according to the peripheral hemogram indexes, symptom and sign disappeared time as well as adverse reaction incidence."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
"application of rituximab combined with fludarabine and cyclophosphamide in the treatment of CLL shows the higher curative effect, can effectively improve the symptoms and reduce the incidence of adverse reactions."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
" Conversion to MPS was associated with a higher incidence of adverse events."	( Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. Aguiar, W; Campos, E; Cristelli, M; Felipe, C; Ferreira, A; Franco, M; Gerbase de Lima, M; Hannun, P; Medina-Pestana, J; Sandes-Freitas, T; Tedesco-Silva, H, 2016)	0.43
"To investigate whether long-term use of low-dose P with or without AA leads to corticosteroid-associated adverse events (CA-AEs) in mCRPC patients."	( Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Charnas, R; Chi, KN; de Bono, JS; De Porre, P; Fizazi, K; Gomella, LG; Londhe, A; McGowan, T; Miller, K; Montgomery, B; Pelhivanov, N; Rathkopf, DE; Ryan, CJ; Scher, HI; Shore, ND; Todd, MB, 2016)	0.65
"We assessed adverse events in patients with metastatic castration-resistant prostate cancer during long-term treatment with a low dose of a corticosteroid."	( Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Charnas, R; Chi, KN; de Bono, JS; De Porre, P; Fizazi, K; Gomella, LG; Londhe, A; McGowan, T; Miller, K; Montgomery, B; Pelhivanov, N; Rathkopf, DE; Ryan, CJ; Scher, HI; Shore, ND; Todd, MB, 2016)	0.65
" Incidence of acute rejection, renal graft survival and SRL-related adverse effects of the immunosuppressive regimen were also observed."	( [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation]. Chen, G; Ding, T; Lin, ZB; Wang, XX; Zhu, L, 2016)	0.43
"The combination therapy of SRL and low dose of CsA is overall a safe and effective maintenance immunosuppressive regimen, but it is important to initiate at an appropriate stage."	( [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation]. Chen, G; Ding, T; Lin, ZB; Wang, XX; Zhu, L, 2016)	0.43
" These patients were followed up for 18 months, and the total effective rate, the survival rate and the adverse reaction rate were compared between these two groups."	( [Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL]. Li, ZH; Wang, Y; Xing, MT; Zhan, XR; Zhang, YP, 2016)	0.43
" The most common grade 3-4 adverse events were haematological; the most common of these was grade 4 neutropenia in 18 (75%) of 24 patients."	( Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; McPhail, E; Micallef, IN; Nowakowski, GS; Witzig, TE, 2016)	0.43
"Glucocorticoids (GCs), such as prednisone, are the standard of care for several inflammatory and immunologically mediated diseases, but their chronic systemic administration is severely limited by serious adverse effects that are both dose and time dependent."	( Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. Daniel, S; Fleishaker, DL; Mukherjee, A; Whaley, FS; Zeiher, BG, 2016)	0.97
" The incidence of adverse effects with prednisone was not dose related, and nervous system disorders, mainly headache, were the most frequently reported adverse effects."	( Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. Daniel, S; Fleishaker, DL; Mukherjee, A; Whaley, FS; Zeiher, BG, 2016)	0.95
" The overall incidence of adverse events was similar between the two treatment groups (p > ."	( Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K, 2017)	0.69
" The most frequent adverse events in all 3 active treatment arms were Cushingoid appearance, erythema, hirsutism, increased weight, headache, and nasopharyngitis."	( Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Cwik, V; Dubow, JS; Fehlings, DL; Florence, JM; Greenberg, CR; Griggs, RC; King, W; Kissel, JT; Mendell, JR; Meyer, JM; Miller, JP; Moxley, RT; Pandya, S; Pestronk, A; Vanasse, M, 2016)	0.71
" Clinical outcomes of induction and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated."	( Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Cha, JM; Chang, SK; Cho, YK; Choi, CH; Han, DS; Im, JP; Jang, BI; Jeen, YT; Jeon, SR; Jeon, TJ; Jung, SA; Kim, ES; Kim, HJ; Kim, HS; Kim, JH; Kim, JS; Kim, JW; Kim, N; Kim, TO; Kim, WH; Kim, YH; Kim, YS; Koo, JS; Lee, BI; Lee, CK; Lee, KM; Lee, SY; Park, DI; Park, SJ; Park, YS; Shin, SJ; Song, HJ; Song, ID; Yang, SK; Ye, BD, 2016)	0.43
"3%) experienced adverse events related to infliximab."	( Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Cha, JM; Chang, SK; Cho, YK; Choi, CH; Han, DS; Im, JP; Jang, BI; Jeen, YT; Jeon, SR; Jeon, TJ; Jung, SA; Kim, ES; Kim, HJ; Kim, HS; Kim, JH; Kim, JS; Kim, JW; Kim, N; Kim, TO; Kim, WH; Kim, YH; Kim, YS; Koo, JS; Lee, BI; Lee, CK; Lee, KM; Lee, SY; Park, DI; Park, SJ; Park, YS; Shin, SJ; Song, HJ; Song, ID; Yang, SK; Ye, BD, 2016)	0.43
" However, clinicians must be aware of the risk of rare yet critical adverse events."	( Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. Cha, JM; Chang, SK; Cho, YK; Choi, CH; Han, DS; Im, JP; Jang, BI; Jeen, YT; Jeon, SR; Jeon, TJ; Jung, SA; Kim, ES; Kim, HJ; Kim, HS; Kim, JH; Kim, JS; Kim, JW; Kim, N; Kim, TO; Kim, WH; Kim, YH; Kim, YS; Koo, JS; Lee, BI; Lee, CK; Lee, KM; Lee, SY; Park, DI; Park, SJ; Park, YS; Shin, SJ; Song, HJ; Song, ID; Yang, SK; Ye, BD, 2016)	0.43
" All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2."	( Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Díaz, MG; Dreyling, M; Dyer, MJ; Grigg, A; Knapp, A; Lei, G; Marlton, P; Rule, S; Wassner-Fritsch, E, 2017)	0.46
" Adverse events [AEs] in pre-specified categories and serious AEs were recorded at least every 6 months of the 5-year observation period."	( Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017)	0.46
" An effective and safe alternative induction regimen is needed."	( Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Babu, BG; Basu, B; Roy, B, 2017)	0.46
" In comparison with few minor adverse events in the other two cohorts, several serious adverse events occurred in the CYC group."	( Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Babu, BG; Basu, B; Roy, B, 2017)	0.46
" However, among patients with DLBCL toxic effects due to therapy treatment are still very frequent, as well as inter-individual differences in the outcomes of patients even having similar stage, histological grade and histopathological type of the tumor."	( How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. Allegra, A; Cimino, F; Falduto, A; Gangemi, S; Musolino, C; Saija, A; Speciale, A, 2017)	0.46
" The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP."	( A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Bae, SB; Bae, SH; Cho, DY; Choi, CW; Do, YR; Hyun, MS; Jeong, SH; Jo, DY; Joo, YD; Kim, BS; Kim, H; Kim, HG; Kim, HJ; Kim, JA; Kim, JS; Kim, K; Kim, KH; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, YS; Kwak, JY; Lee, HS; Lee, JH; Lee, JJ; Lee, JO; Lee, MH; Lee, SM; Lee, WS; Lim, SN; Min, CK; Moon, JH; Mun, YC; Nam, SH; Park, JS; Park, KW; Park, MR; Park, SK; Shin, HJ; Song, MK; Yi, HG; Yoon, SS, 2017)	0.66
" Adverse events or laboratory abnormalities requiring TCZ dose modification were reported for 66 (13."	( Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies. Bernasconi, C; Caporali, R; Casado, G; Czirják, L; Haraoui, B; Reiss, W; Taylor, A, )	0.13
" The main adverse effects in TAC treatment were glucose intolerance, diabetes and abnormal aminotransferase."	( The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Chen, J; Li, H; Li, X; Liang, Q; Qu, F; Xie, X, 2017)	0.46
" Haemocytopenia was the predominant adverse effect, and acute toxicity was moderate, tolerable and well managed in both arms."	( The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Chang, Y; Duan, W; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Wang, X; Wu, J; Yan, J; Young, KH; Zhang, L; Zhang, M; Zhang, X, 2017)	0.71
" The clinical efficacy, PFS (progression-free survival), OS and the adverse reactions in the 2 groups were compared."	( [Clinical Efficacy and Safety of CMOD Regimen as the First Treatment for Aged New-diagnosed Patients with Peripheral T-cell Lymphoma]. Cui, N; Gao, L; Liu, XL, 2017)	0.46
" The adverse reactions in 2 groups were as follows: myelosuppression, mucositis, gastrointestinal reactions, fever, liver dysfunction, neurotoxicity, and alopecia etc."	( [Clinical Efficacy and Safety of CMOD Regimen as the First Treatment for Aged New-diagnosed Patients with Peripheral T-cell Lymphoma]. Cui, N; Gao, L; Liu, XL, 2017)	0.46
"Chronic use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs)."	( Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. Bao, Y; Betts, KA; Camez, A; Joshi, A; Mittal, M; Suhler, EB; Tari, S; Thorne, JE, 2017)	0.46
"This trial shows that MR prednisone appears to be a safe and effective treatment for GCA with a similar outcome profile to standard IR prednisolone."	( A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis. Achilleos, K; Dasgupta, B; Gayford, D; Mackerness, C; Mapplebeck, S; Maw, WW; Merinopoulos, D; Raine, C; Schofield, P; Stapleton, PP, 2018)	1.01
"A 23-item questionnaire (SIDECORT: side effect of corticosteroids) was constructed to assess the perception of these benefits and side effects in a systematic manner."	( Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study. Biggar, WD; Hendriksen, JGM; Hendriksen, RGF; Lionarons, JM; McAdam, LC; Vles, JSH, )	0.13
" Using factor analyses on the side effect items as reported by parents, two underlying factors were found, with the first factor describing cognitive, behavioural and emotional functioning, and the second factor describing physical functioning."	( Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study. Biggar, WD; Hendriksen, JGM; Hendriksen, RGF; Lionarons, JM; McAdam, LC; Vles, JSH, )	0.13
" The most common treatment-emergent adverse events were fatigue (32%), decreased appetite (25%), asthenia (18%), back pain (17%), and arthralgia (16%)."	( Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. Baron, B; Chowdhury, S; de Bono, JS; Elliott, T; Feyerabend, S; Fizazi, K; Grande, E; Hirmand, M; Melhem-Bertrandt, A; Werbrouck, P, 2018)	0.68
"Due to enhanced T-cell activity, immune checkpoint inhibitors cause immune-related adverse effects."	( Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. Grauer, DW; Henry, DW; Rockey, ML; Williams, KJ, 2019)	0.51
" The primary objective was to evaluate corticosteroid use for immune-related adverse effects, including starting dose, taper strategy, total duration, and resumption of immunotherapy."	( Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. Grauer, DW; Henry, DW; Rockey, ML; Williams, KJ, 2019)	0.51
"One hundred and three patients met inclusion criteria and experienced 123 immune-related adverse effects."	( Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. Grauer, DW; Henry, DW; Rockey, ML; Williams, KJ, 2019)	0.51
"Utilization of steroids for immune-related adverse effect at our institution is highly variable."	( Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. Grauer, DW; Henry, DW; Rockey, ML; Williams, KJ, 2019)	0.51
" Adverse events included neutropenia (92/76%), thrombocytopenia (70/10%) and leukopenia (65/50%)."	( Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized Belch, A; Bosly, A; Bunworasate, U; Cavalli, F; Dascalescu, A; Drach, J; Farber, C; Huang, H; Masliak, Z; Novak, J; Pei, L; Robak, T; Rooney, B; Samoilova, O; van de Velde, H; Vilchevskaya, K; Zaucha, J, 2018)	0.71
" Despite differences in total belimumab exposure (24 weeks in the placebo-to-belimumab group versus 76 weeks in the belimumab group), the proportions of patients experiencing more than one adverse event (AE) or a serious AE in the open-label phase were similar between groups (placebo-to-belimumab: 51."	( A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Bass, D; Doria, A; Fox, NL; Gordon, D; Groark, J; Hammer, A; Kleoudis, C; Roth, D; Scheinberg, M; Schwarting, A; Stohl, W, 2018)	0.48
" We analyzed the main outcomes, including the overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) response, tumor response and severe adverse events (AEs)."	( The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. Huang, C; Song, P; Wang, Y, 2018)	0.48
" Outcomes were number of responders to treatment, remission rate of treatment responders, overall probability of 5-year remission, and the occurrence of adverse events."	( Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. Basta, I; Doneddu, PE; Eftimov, F; Gallia, F; Nikolic, A; Nobile-Orazio, E; Peric, S; van Lieverloo, GGA; van Schaik, IN; Verhamme, C; Wieske, L, 2018)	0.48
" Adverse events leading to a change in treatment occurred in ten patients (8%)."	( Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. Basta, I; Doneddu, PE; Eftimov, F; Gallia, F; Nikolic, A; Nobile-Orazio, E; Peric, S; van Lieverloo, GGA; van Schaik, IN; Verhamme, C; Wieske, L, 2018)	0.48
" Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions known collectively as immune-related adverse events (irAEs)."	( A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. Geskin, L; Lopez, AT, 2018)	0.48
"PD-1/PD-L1 inhibitor-induced bullous pemphigoid (BP) is a rare but potentially serious dermatologic toxicity associated with checkpoint inhibitorsIn patients with pruritus or rash that is refractory to topical steroids, physicians should have a greater index of suspicion for higher-grade cutaneous immune-related adverse events."	( A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. Geskin, L; Lopez, AT, 2018)	0.48
" The adverse drug effects of tacrolimus were monitored."	( Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis. Cao, M; Fang, XJ; Jiang, QL; Liang, Y; Liu, XM; She, SF; Wang, SS; Zhao, LN, 2018)	0.48
" Nineteen patients in the tacrolimus group had adverse drug reactions, but no severe adverse effects appeared."	( Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis. Cao, M; Fang, XJ; Jiang, QL; Liang, Y; Liu, XM; She, SF; Wang, SS; Zhao, LN, 2018)	0.48
"Our study suggested that tacrolimus could be an effective and safe treatment for Osserman grade III and Osserman grade IV MG patients."	( Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis. Cao, M; Fang, XJ; Jiang, QL; Liang, Y; Liu, XM; She, SF; Wang, SS; Zhao, LN, 2018)	0.48
" We hypothesized that sirolimus administration within the first postoperative month in selected lung transplant recipients is safe and may be associated with favorable short-term and long-term outcomes due to its anti-proliferative properties and minimal adverse side effects."	( Early Sirolimus-Based Immunosuppression is Safe for Lung Transplantation Patients: Retrospective, Single Arm, Exploratory Study. Karolak, W; Ochman, M; Wojarski, J; Żegleń, S, 2018)	0.48
" The major adverse effects were bone marrow suppression, reduction of fibrinogen level, liver dysfunction, and digestive tract toxicities."	( PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. Deng, L; Gao, Y; Ke, X; Lin, N; Liu, W; Ping, L; Ren, H; Song, Y; Su, L; Tu, M; Wang, X; Xie, Y; Ying, Z; Zhang, C; Zhang, W; Zheng, W; Zhu, J, 2018)	0.48
"PEG-L-CHOP chemotherapy in combination radiotherapy is safe and durably effective treatment for adult extranodal NK/T-cell lymphoma with fewer allergic reactions."	( PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. Deng, L; Gao, Y; Ke, X; Lin, N; Liu, W; Ping, L; Ren, H; Song, Y; Su, L; Tu, M; Wang, X; Xie, Y; Ying, Z; Zhang, C; Zhang, W; Zheng, W; Zhu, J, 2018)	0.48
" The most frequently reported adverse events (>20% in either group) in the Japanese subgroup were hypertension, nasopharyngitis, weight increased, hypokalemia, hot flush, back pain, hyperglycemia, ALT and AST elevation."	( Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. Enjo, K; Fizazi, K; Fukasawa, S; Kawaguchi, K; Matsubara, N; Noguchi, H; Suzuki, H; Todd, M; Tran, N, 2018)	0.74
"Advances in anti-lymphoma therapy prolong overall survival, making late adverse effects, like doxorubicin-related cardiotoxicity, an even more important clinical issue."	( Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. Długosz-Danecka, M; Gruszka, AM; Jaroszyński, A; Jurczak, W; Krawczyk, K; Ogórka, T; Olszanecka, A; Skotnicki, AB; Sobociński, M; Szmit, S, 2018)	0.48
" The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11."	( Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. Chi, C; Dong, B; Fan, L; Gong, Y; Huang, Y; Pan, J; Sha, J; Shangguan, X; Wang, Y; Xue, W; Zhou, L, 2018)	0.71
" Nevertheless, glucocorticoid administration, in long-term especially, is also seen critically because of its potential adverse conditions."	( New concepts to reduce glucocorticoid toxicity. Alten, R; Mischkewitz, M, 2019)	0.51
"Myalgia and arthralgia immune-related adverse events (irAEs) in patients treated with checkpoint inhibitors (CPIs) present a clinical challenge."	( Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Allman, KD; Calabrese, C; Calabrese, LH; Garcia, JA; Grivas, P; Kirchner, E; Kontzias, A; Martin, A; Ornstein, MC; Profusek, P; Rini, BI; Wood, LS, 2019)	0.51
" ICIs initate antitumor immunity; however, these agents are associated with immune-related adverse events (irAEs) that may affect a variety of organs."	( Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Reynolds, KL; Seethapathy, H; Sise, ME, 2019)	0.51
" Information evaluated included patient signalment, feline immunodeficiency virus/feline leukemia virus status, anatomic location(s) of lymphoma, prior protocols (type and number), MOPP doses, MOPP response, remission duration, hematologic and biochemical parameters, and owner-reported adverse effects."	( Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats. Brown, DC; Krick, EL; MaloneyHuss, MA; Mauldin, GE; Veluvolu, SM, 2020)	0.8
" The most common adverse effects were neutropenia and gastrointestinal upset, which were reported in 18."	( Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats. Brown, DC; Krick, EL; MaloneyHuss, MA; Mauldin, GE; Veluvolu, SM, 2020)	0.8
"MOPP is a safe protocol for the treatment of relapsed or refractory feline lymphoma, with a promising overall response rate and median remission time."	( Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats. Brown, DC; Krick, EL; MaloneyHuss, MA; Mauldin, GE; Veluvolu, SM, 2020)	0.8
" Remission rate, relapse rate, and adverse events in the two groups were assessed."	( Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study. Bai, DF; Fang, W; Hu, Z; Ji, CF; Wang, L; Yuan, JZ; Zhang, J; Zhang, XJ, 2019)	0.51
"There are limited data on treatment patterns, adverse events (AEs), and economic burden in younger, commercially insured patients treated for mantle cell lymphoma (MCL)."	( Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Burudpakdee, C; Kabadi, SM; Near, A; Wada, K, 2019)	0.51
" The administration of intratympanic infliximab is an effective and safe technique."	( Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss. García-Fernández, A; Mata-Castro, N; Sanz-López, L; Varillas-Delgado, D, 2020)	0.56
" This subpopulation analysis assessed the impact of lenalidomide maintenance and treatment-emergent adverse events (TEAEs) on health-related quality of life (HRQOL)."	( Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. Abraham, J; Bouabdallah, R; Bron, D; Caballero, D; Casadebaig, ML; Casasnovas, RO; Catalano, J; Cohen, AM; Coiffier, B; Costello, R; da Silva, MG; Daguindau, N; Deeren, D; Eisenmann, JC; Fitoussi, O; Fruchart, C; Gaulard, P; Gonzalez, H; Greil, R; Grosicki, S; Howlett, S; Le Du, K; Lionne-Huyghe, P; Morschhauser, F; Mounier, N; Nicolas-Virezelier, E; Obéric, L; Perrot, A; Pica, GM; Roulin, L; Snauwaert, S; Takeshita, K; Thieblemont, C; Tilly, H; Tricot, S; Trotman, J; van Eygen, K, 2020)	0.56
" Clinical manifestation, IgG4-RD responder index (IgG-RD RI), serological indexes, gland ultrasound findings, and adverse drug effect were recorded."	( Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. Bian, W; Chen, D; Chen, J; Fu, J; Li, Y; Li, Z; Liu, Y; Sun, X; Zhang, W; Zhang, Y; Zhao, X, 2020)	0.56
" Rituximab (R) was added 10 days later without incident, and the patient completed six cycles of the R-CHOP therapy without adverse events."	( Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction. Hara, T; Ikeda, Y; Matsumoto, R; Murayama, M; Ohno, A; Sobajima, T; Sugiyama, Y; Suzuki, R; Tsurumi, H; Yamada, R; Yamagishi, Y; Yamakawa, K, 2020)	0.56
" The most important reported side effect was weight gain, associated with increased appetite among prednisone users (as monotherapy as well as in combination with other drugs)."	( Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis. Bast, A; de Jong, SMG; Drent, M; Ebner, NM; Elfferich, MDP; Jessurun, NT; Lewis, EDO; Proesmans, VLJ, 2020)	0.77
" The strongest association between a reported side effect and drug use was that of weight gain associated with increased appetite among prednisone users."	( Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis. Bast, A; de Jong, SMG; Drent, M; Ebner, NM; Elfferich, MDP; Jessurun, NT; Lewis, EDO; Proesmans, VLJ, 2020)	0.76
" (iii) Evaluation of the relative risk (RR) and risk difference of serious toxicity defined as adverse events (AEs) with grade ≥ 3 specific AEs."	( Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M, 2020)	0.56
" We hypothesised that ex vivo expanded lymphokine-activated killer (LAK) cells administered to FL-remission patients are safe and improve anti-CD20 efficacy."	( Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. Andrade-Campos, M; Bandrés, E; Feliu, J; García-Muñoz, R; Giraldo, P; Grande, C; Inogés, S; López-Díaz de Cerio, A; Martínez-Calle, N; Núñez-Córdoba, JM; Olave, MT; Panizo, Á; Panizo, C; Pena, E; Rodríguez-Calvillo, M, 2020)	0.56
"Patients treated for non-Hodgkin lymphoma are at risk of cardiovascular adverse events, with the risk of heart failure being particularly high."	( Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Asselbergs, FW; Bosman, LP; Cramer, MJ; Doevendans, PA; Kamphuis, JAM; Linschoten, M; Teske, AJ; van Rhenen, A, 2020)	0.76
" Studies reporting on cardiovascular adverse events and treatment-related cardiovascular mortality were included."	( Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Asselbergs, FW; Bosman, LP; Cramer, MJ; Doevendans, PA; Kamphuis, JAM; Linschoten, M; Teske, AJ; van Rhenen, A, 2020)	0.76
" Grade 3/4 adverse events were reported in 24 (68."	( Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Fizazi, K; Fukasawa, S; Hashine, K; Kitani, S; Matsubara, N; Mundle, S; Ohtake, N; Shibayama, K; Shin, T; Suzuki, H; Tran, N, 2020)	0.81
" RTX-related adverse events were mostly mild (most infusion-related reactions) in nature and serious adverse events were rare."	( Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. Gong, S; Li, J; Lu, W; Luo, H; Wang, Y, 2020)	0.56
"RTX proved to be efficient, well-tolerated and a safe drug in the treatment of membranous nephropathy."	( Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. Gong, S; Li, J; Lu, W; Luo, H; Wang, Y, 2020)	0.56
" No increase in mineralocorticoid excess-related adverse events was observed."	( Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Abrams, C; Attard, G; Chi, KN; Chien, C; de Jonge, MJA; de Wit, R; Friedlander, TW; Hellemans, P; Jiao, JJ; Posadas, EM; Saad, F; Yu, MK, 2020)	0.78
"In this single-center, prospective, randomized study, adverse events (AEs), serious AEs (SAEs), viral infections, laboratory abnormalities, dose reductions, and temporary or permanent discontinuation of the immunosuppressant were compared among patients receiving r-ATG/EVR (n = 85), BAS/EVR (n = 102), and BAS/MPS (n = 101)."	( Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. Felipe, CR; Medina Pestana, JO; Miranda, TA; Santos, RHN; Tedesco-Silva Junior, H, 2020)	0.56
" Physician-reported incidences of adverse events (AEs) for Cushingoid appearance, hirsutism, weight gain, and behavior change were less for vamorolone than published incidences for prednisone and deflazacort."	( Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. Arrieta, A; Castro, D; Clemens, PR; Conklin, LS; Damsker, JM; Dang, UJ; Finkel, RS; Gordish-Dressman, H; Guglieri, M; Hagerty, L; Hoffman, EP; Jaros, M; Kerchner, L; Kuntz, NL; Mah, JK; McDonald, CM; Mengle-Gaw, LJ; Morgenroth, LP; Nevo, Y; Ryan, MM; Schwartz, BD; Shale, P; Shimony, M; Smith, EC; Tulinius, M; Webster, R, 2020)	0.75
"This study indicates that Tripterygium glycosides enhances the effect of thiamazole and prednisone in the treatment of hyperthyroidism and without increasing the risk of adverse events."	( Efficacy and safety of tripterygium glycosides in the treatment of hyperthyroidism: A systemic review and meta-analysis. Gao, J; He, C; Jia, S; Xie, C, 2020)	0.78
" Other adverse reactions such as fever, debilitation, and alopecia were also observed."	( Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience. Hu, YC; Jiang, JH; Ma, L; Ma, Q; Wang, KY; Zhang, LL, 2021)	0.62
" We hypothesized that outpatient administration of DA-EPOCH at a comprehensive cancer center is both safe and cost-effective."	( Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. Kubal, TE; Li, W; McCarthy, KT; Richter, KA; Tobon, KA, 2021)	0.62
" Additional safety endpoints included hospitalizations between cycles, infectious complications, extravasations, drug spills, pump-malfunctions, and drug-related adverse events."	( Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. Kubal, TE; Li, W; McCarthy, KT; Richter, KA; Tobon, KA, 2021)	0.62
"Routine outpatient administration of DA-EPOCH is both safe and feasible with a positive annual impact on margin of $1,444,548 at a comprehensive cancer center."	( Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. Kubal, TE; Li, W; McCarthy, KT; Richter, KA; Tobon, KA, 2021)	0.62
" Two serious adverse events occurred, both in the placebo group (inguinal hernia and severe deterioration of cluster headache)."	( Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. Böger, A; Diener, HC; Freilinger, T; Gaul, C; Holle, D; Jansen, JP; Jürgens, TP; Katsarava, Z; Kaube, H; Kleinschnitz, C; Kraya, T; Nägel, S; Obermann, M; Ose, C; Scherag, A; Sonuc, N; Storch, P; Straube, A, 2021)	0.93
"Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)."	( Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021)	0.62
" Oral corticosteroid dose, adverse events, exacerbations, symptom control, disease activity, blood markers, and lung function were evaluated before, during, and after 7 monthly reslizumab treatments."	( Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Denson, JL; Dollin, YT; Dunn, RM; Guntur, VP; Manka, LA; Strand, MJ; Wechsler, ME, 2021)	0.62
" One had a severe adverse event, requiring removal from the study."	( Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Denson, JL; Dollin, YT; Dunn, RM; Guntur, VP; Manka, LA; Strand, MJ; Wechsler, ME, 2021)	0.62
"Yielding similar results to other anti-interleukin 5 biologic medications, reslizumab is generally a safe and effective treatment for EGPA that warrants further study."	( Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Denson, JL; Dollin, YT; Dunn, RM; Guntur, VP; Manka, LA; Strand, MJ; Wechsler, ME, 2021)	0.62
"2%) had grade 3/4 treatment-emergent adverse events, the most common being thrombocytopenia (26."	( Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E, 2021)	0.62
"To describe the frequency and severity of parent-reported medication side effects (SEs) in children with juvenile idiopathic arthritis (JIA) relative to physician-reported actionable adverse events (AEs), and to assess their impact on health-related quality of life (HRQoL)."	( Parent-Reported Medication Side Effects and Their Impact on Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis. Batthish, M; Berard, RA; Bruns, A; Cabral, DA; Chédeville, G; Duffy, CM; Gerhold, K; Gerschman, T; Guzman, J; McGuire, K; Proulx-Gauthier, JP; Rumsey, DG; Schmeling, H; Shiff, NJ; Soon, G; Tucker, LB, 2022)	0.72
" Baseline characteristics, safety (treatment-emergent adverse events, treatment-emergent severe adverse events), and efficacy [progression-free survival (PFS) and overall survival (OS)] were analyzed."	( Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. Birtle, A; Bjartell, A; Chowdhury, S; Costa, L; Feyerabend, S; Gomez-Veiga, F; Kalinka, E; Kramer, G; Lefresne, F; Lukac, M; Lumen, N; Maroto, P; Matveev, V; Paiss, T; Spaëth, D; Wapenaar, R, 2021)	0.86
" There were no unexpected adverse events in any patient subgroup."	( Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. Birtle, A; Bjartell, A; Chowdhury, S; Costa, L; Feyerabend, S; Gomez-Veiga, F; Kalinka, E; Kramer, G; Lefresne, F; Lukac, M; Lumen, N; Maroto, P; Matveev, V; Paiss, T; Spaëth, D; Wapenaar, R, 2021)	0.86
"Dexamethasone is the glucocorticoid of choice in many human inflammatory and immune-mediated conditions, given its reported effectiveness and limited side effect profile."	( Dexamethasone Can Be Safely and Effectively Used for Treatment of Masticatory Muscle Myositis in Dogs. Cherubini, GB; Foreman, M, 2021)	0.62
"Most data on overall survival (OS) and adverse events (AEs) in patients with mantle cell lymphoma (MCL) are from controlled trials; therefore, in this population-based study, we retrospectively assessed treatment patterns, OS, and AEs in MCL patients initiating systemic treatment during 2013-2015 using the United States Medicare claims database."	( Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Davis, K; Du, XL; Goyal, RK; Jain, P; Kabadi, SM; Kaye, JA; Le, H; Nagar, SP; Wang, M, 2021)	0.62
" The most common adverse events during induction were anemia (91%), febrile neutropenia (64%; grade 4 in 46%), thrombocytopenia (39%), and mucositis (21%)."	( Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas. Abou Dalle, I; Al Chami, F; Bazarbachi, A; Charafeddine, M; El Cheikh, J; El Darsa, H; El Sayed, R; Ibrahim, A; Kort, J, 2021)	0.62
"The replacement of vindesine with vincristine in mR-ACVBP seems feasible, with manageable adverse events and excellent 2-year progression-free survival."	( Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas. Abou Dalle, I; Al Chami, F; Bazarbachi, A; Charafeddine, M; El Cheikh, J; El Darsa, H; El Sayed, R; Ibrahim, A; Kort, J, 2021)	0.62
" Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 58% versus 49% of older patients receiving cabazitaxel versus abiraterone/enzalutamide and 48% versus 42% of younger patients."	( Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C, 2021)	0.62
" Serious adverse events (SAEs) were similar between older and younger patients (21."	( Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old. Amato, AA; David, WS; Doughty, CT; Guidon, AC; Suh, J, 2021)	0.62
" The results showed that SCR is safe and feasible in terms of a high compliance rate and stable nutritional status."	( Safety, Feasibility, and Effects of Short-Term Calorie Reduction during Induction Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Pilot Study. Huang, TC; Lee, CY; Lin, JM; Tang, CC; Tien, FM; Yeh, YC, 2021)	0.62
" We evaluated adverse side effects (ASEs) of corticosteroid treatment in patients with gMG."	( Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis. Govindarajan, R; Johnson, S; Katyal, N; Narula, N, 2021)	0.62
" The primary endpoint was objective response rates (ORR), and secondary endpoints were duration of response and incidence of adverse events (AEs)."	( The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study. Bai, O; Feng, X; Guo, Q; Guo, W; Li, J; Qu, L; Wang, Y; Yan, X; Young, KH; Zhao, Y, 2022)	0.94
" Adverse events (AEs), including incidence and severity of febrile neutropenia (26% patients in the BV-CEP group and 30% in the CHOEP group), were similar between groups."	( The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study. Bai, O; Feng, X; Guo, Q; Guo, W; Li, J; Qu, L; Wang, Y; Yan, X; Young, KH; Zhao, Y, 2022)	0.94
" The frequency of severe adverse events from the two regimens was similar."	( Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma. Cai, R; Guan, J; Huang, H; Huang, J; Lu, S; Que, Y; Sun, F; Sun, X; Wang, J; Xia, Z; Zhang, Y; Zhen, Z; Zhu, J; Zhu, X, 2022)	0.72
"In this single center, open label pilot study, once-weekly prednisone was safe and well tolerated."	( An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy. Ajroud-Driss, S; Casey, P; Joslin, BC; McNally, EM; Zelikovich, AS, 2022)	1.19
" Treatment-emergent adverse events related to DCVAC/PCa or placebo occurred in 69 of 749 (9."	( Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. Bahl, A; Bartunkova, J; Beer, TM; Cheung, E; Csöszi, T; Feyerabend, S; Filipovic, Z; Fricke, H; Gerritsen, W; Goncalves, F; Hajek, J; Hussain, A; Hussain, S; Kadlecova, P; Khoo, V; Korolkiewicz, RP; Kukielka-Budny, B; Oudard, S; Prokhorov, A; Samal, V; Scheiner, T; Sousa, N; Spisek, R; Stenzl, A; Vogelzang, NJ; Wiechno, P, 2022)	0.95
" This study aimed to evaluate the response and the adverse events of treatment with imatinib mesylate (IM) compared to conventional therapy using vinblastine and prednisolone (VP) in canine cutaneous MCTs."	( Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. Alexandre, PA; Brandão, PE; Casagrande, TAC; Dagli, MLZ; de Queiroz, GF; Fukumasu, H; Macedo, TR; Matera, JM; Melo, SR; Pinto, ACBCF, 2022)	0.91
"To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective."	( Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey. Bartlett, SJ; Bykerk, V; Hazlewood, GS; Hull, PM; Mujaab, K; Proulx, L; Richards, D; Schieir, O; Tugwell, P; Wells, G, 2022)	0.72
"We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)."	( Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey. Bartlett, SJ; Bykerk, V; Hazlewood, GS; Hull, PM; Mujaab, K; Proulx, L; Richards, D; Schieir, O; Tugwell, P; Wells, G, 2022)	0.72
" Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles."	( Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey. Bartlett, SJ; Bykerk, V; Hazlewood, GS; Hull, PM; Mujaab, K; Proulx, L; Richards, D; Schieir, O; Tugwell, P; Wells, G, 2022)	0.72
" Adverse events occurred in 78."	( Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Blockmans, D; Brouwer, E; Cid, MC; Dagna, L; Dasgupta, B; Hellmich, B; Molloy, E; Paolini, JF; Pupim, L; Salvarani, C; Samant, M; Trapnell, BC; Unizony, SH; Warrington, KJ; Wicks, I; Zhou, T, 2022)	0.72
"7%) patients had adverse events (AEs), and 96/424 (22."	( Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. Bass, D; Chu, M; Curtis, P; DeRose, K; Gu, J; Kurrasch, R; Li, X; Li, Y; Lowe, J; Meizlik, P; Roth, DA; Su, Y; Wang, G; Wang, M; Zhang, F; Zheng, J, 2022)	0.72
"Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases SUMMARY Programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) have been widely used in lung cancer treatment, but their immune-related adverse events (irAEs) require intensive attention."	( [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases]. Cao, BS; Gu, YC; Liu, Y; Xie, C, 2022)	0.72
" This retrospective study shows that CARMEN is a safe and active regimen both in HIV-negative and -positive patients with MYC-rearranged lymphomas."	( Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. Allione, B; Angelillo, P; Cattaneo, C; Erbella, F; Facchetti, F; Ferreri, AJM; Flospergher, E; Foppoli, M; Lleshi, A; Pagani, C; Pecciarini, L; Ponzoni, M; Re, A; Rossi, G; Sassone, M; Spina, M; Steffanoni, S; Verga, L, 2022)	0.72
"Corticosteroidal anti-inflammatory drugs are widely prescribed but long-term use shows adverse effects that detract from patient quality of life."	( Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. Ahmet, A; Baranello, G; Castro, D; Childs, AM; Clemens, PR; Damsker, JM; Dang, UJ; de Groot, IJM; De Waele, L; Deconinck, N; Finkel, RS; Goemans, N; Guglieri, M; Haberlova, J; Harper, AD; Hoffman, EP; Horrocks, I; James, MK; Jaros, M; Katsalouli, M; Kuntz, NL; Mah, JK; McDonald, CM; McMillan, HJ; Mengle-Gaw, LJ; Monduy, M; Nascimento-Osorio, A; Nevo, Y; Niks, EH; Perlman, SJ; Rao, VK; Ryan, MM; Sbrocchi, AM; Schwartz, BD; Selby, KA; Shale, P; Shieh, PB; Smith, EC; Spinty, S; Straub, V; Tulinius, M; van den Anker, J; Vilchez-Padilla, JJ; Ward, LM; Webster, R; Yang, ML, 2022)	0.98
"In this pivotal randomized clinical trial, vamorolone was shown to be effective and safe in the treatment of boys with DMD over a 24-week treatment period."	( Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. Ahmet, A; Baranello, G; Castro, D; Childs, AM; Clemens, PR; Damsker, JM; Dang, UJ; de Groot, IJM; De Waele, L; Deconinck, N; Finkel, RS; Goemans, N; Guglieri, M; Haberlova, J; Harper, AD; Hoffman, EP; Horrocks, I; James, MK; Jaros, M; Katsalouli, M; Kuntz, NL; Mah, JK; McDonald, CM; McMillan, HJ; Mengle-Gaw, LJ; Monduy, M; Nascimento-Osorio, A; Nevo, Y; Niks, EH; Perlman, SJ; Rao, VK; Ryan, MM; Sbrocchi, AM; Schwartz, BD; Selby, KA; Shale, P; Shieh, PB; Smith, EC; Spinty, S; Straub, V; Tulinius, M; van den Anker, J; Vilchez-Padilla, JJ; Ward, LM; Webster, R; Yang, ML, 2022)	0.98
" Data about the immunogenicity and adverse effects of the vaccine on patients with systemic autoimmune rheumatic diseases (SARDs) is emerging."	( Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients. Gepstein, R; Halperin, T; Kimhi, O; Kivity, S; Levy, Y; Naser, R; Parikh, R; Pri-Paz Basson, Y; Tartakover Matalon, S; Tayer-Shifman, OE; Ziv, A; Ziv-Baran, T, 2022)	0.72
" An adverse effects questionnaire was given to the participants upon their first visit to the clinic after their BNT162b2 vaccination."	( Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients. Gepstein, R; Halperin, T; Kimhi, O; Kivity, S; Levy, Y; Naser, R; Parikh, R; Pri-Paz Basson, Y; Tartakover Matalon, S; Tayer-Shifman, OE; Ziv, A; Ziv-Baran, T, 2022)	0.72
" No fever was observed following the BNT162b2 vaccine in seronegative patients, and the frequency of musculoskeletal adverse effects upon the second dose of the BNT162b2 vaccine was significantly higher in seropositive compared to seronegative patients and in the control group compared to the SARDs patients (p = 0."	( Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients. Gepstein, R; Halperin, T; Kimhi, O; Kivity, S; Levy, Y; Naser, R; Parikh, R; Pri-Paz Basson, Y; Tartakover Matalon, S; Tayer-Shifman, OE; Ziv, A; Ziv-Baran, T, 2022)	0.72
" Adverse effects of the vaccine including fever and musculoskeletal symptoms might be a signal for the acquisition of immunity in those patients."	( Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients. Gepstein, R; Halperin, T; Kimhi, O; Kivity, S; Levy, Y; Naser, R; Parikh, R; Pri-Paz Basson, Y; Tartakover Matalon, S; Tayer-Shifman, OE; Ziv, A; Ziv-Baran, T, 2022)	0.72
" • There is a correlation between immunogenicity and adverse effects of the vaccine."	( Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients. Gepstein, R; Halperin, T; Kimhi, O; Kivity, S; Levy, Y; Naser, R; Parikh, R; Pri-Paz Basson, Y; Tartakover Matalon, S; Tayer-Shifman, OE; Ziv, A; Ziv-Baran, T, 2022)	0.72
" The two groups did not differ in severe adverse events."	( Efficacy and safety of methylprednisolone pulse followed by oral prednisone vs. oral prednisone alone in sarcoidosis tubulointerstitial nephritis: a randomized, open-label, controlled clinical trial. Audard, V; Boffa, JJ; Cez, A; Daugas, E; Delahousse, M; Guerrot, D; Hanrotel, C; Krastinova, E; Mahevas, M; Pillebout, E; Rousseau, A; Valeyre, D; Verhelst, D, 2023)	1.15
" All treated patients experienced ≥1 adverse event (AE; 32 patients [76."	( Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. Burke, JM; Cheson, BD; Diefenbach, CS; Ferrari, S; Hahn, UH; Hawkes, EA; Khan, C; Lossos, IS; Musuraca, G; Nielsen, TG; Raval, A; Sellam, G; Sharman, JP; Shivhare, M; Tani, M; Vitolo, U; Younes, A; Yuen, S, 2023)	0.91
" Overall, safety risks increased with increasing dose and/or duration, but evidence on which dose is safe was conflicting."	( Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Aletaha, D; Bergstra, SA; Caporali, R; de Souza, S; Edwards, CJ; Hyrich, KL; Kerschbaumer, A; Landewé, RBM; Pope, JE; Schoones, JW; Sepriano, A; Smolen, JS; Stamm, TA; Takeuchi, T; van der Heijde, D; Verschueren, P; Winthrop, KL, 2023)	0.91
" No moderate/severe adverse events attributable to the vaccine were observed."	( Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose. Aikawa, NE; Barbas, CV; Bonfa, E; Caparbo, VF; Dagostin, MA; Fusco, SRG; Kupa, LVK; Martins, CCMF; Martins, VAO; Medeiros-Ribeiro, AC; Pasoto, SG; Pereira, RMR; Saad, CGS; Sales, LP; Shinjo, SK; Silva, CA; Yuki, EFN, 2023)	0.91
" Here we characterise the safety of these agents in subpopulations and assess manageability of key adverse events (AEs)."	( Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Bracarda, S; Chen, G; Chi, KN; de Bono, J; Garcia, J; Harris, A; Hinton, H; Massard, C; Matsubara, N; Olmos, D; Sandhu, S; Sane, R; Schenkel, F; Sternberg, CN; Sweeney, C, 2023)	0.91
" The primary outcome investigated was adverse events (AEs)."	( Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis. Boers, M; Boyadzhieva, Z; Buttgereit, F; Christensen, R; Da Silva, JAP; Dejaco, C; Hartman, L; Kirwan, J; Nielsen, SM; Palmowski, A; Pankow, A; Schneider, A; Wassenberg, S, 2023)	0.91
"Hematologic toxicity (HT) is a joint adverse event after CAR-T cells infusion."	( Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy. Bai, X; Guo, R; Li, Q; Lu, W; Lyu, H; Meng, J; Pu, Y; Wang, J; Xiao, X; Yuan, T; Zhang, M; Zhao, M, 2023)	1.21
"First-line AZA plus prednisone realizes a better hematological response and relapse-free duration with acceptable adverse events compared to prednisone alone in ANA-positive ITP patients."	( Efficacy and safety of azathioprine plus prednisone versus prednisone alone as first-line treatment for antinuclear antibody-positive immune thrombocytopenia: a retrospective cohort study. Chen, X; Dong, Z; Ma, L; Su, J; Wang, Q; Xiao, P; Xu, M, 2023)	1.5
"No studies have examined the association between the Geriatric Nutritional Risk Index (GNRI) at the initiation of chemotherapy for malignant lymphoma and the occurrence of adverse events."	( Influence of Geriatric Nutritional Risk Index on Occurrence of Adverse Events and Duration of Treatment in Patients With Lymphoma Receiving R-CHOP Therapy. Kikuchi, K; Sato, H; Sawada, M; Souma, T; Takeda, G; Watanabe, T, )	0.13
"To evaluate the incidence, diagnosis and treatment of immune-related adverse events (e-irAE) of checkpoint inhibition (ICI) in metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC)."	( Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors. Burger, M; Büttner, R; Oppolzer, IA; Riester, J; Schnabel, MJ, 2023)	0.91
"A course of tacrolimus of more than one year was effective and well-tolerated in young children with MG, and tacrolimus improved MG symptoms and reduced the dose and adverse events of oral prednisone."	( Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis. Li, W; Zhang, L; Zhang, M; Zhang, Y; Zhou, S, 2023)	1.1
"ICIs can cause rheumatic adverse events, resulting in decreased quality of life that may require immunesuppressive treatment."	( [Rheumatic adverse events due to immune checkpoint inhibitors]. Heslinga, SC; Labots, M; Lems, WF; Tsang-A-Sjoe, MWP; van Binsbergen, WH; van der Laken, J, 2023)	0.91

Pharmacokinetics

Twenty-eight days of SJW treatment resulted in no significant alterations in the pharmacokinetic parameters for prednisone or prednisolone. The aim of the present study was to assess the safety and pharmacodynamic interactions between EBR and GZR.

Excerpt	Reference	Relevance
" With increasing dose there is prolongation of the plasma half-life and increase in the volume of distribution and plasma clearance of prednisolone."	( Dose dependent pharmacokinetics of prednisolone. Downie, WW; Leatham, PA; Lowe, JR; Pickup, ME; Rhind, VM; Wright, V, 1977)	0.26
" However, the in vitro dissolution rates were not predictive of the overall bioavailability of the prednisone tablets tested in terms of peak concentration and area under the serum concentration-time curve."	( Bioavailability and pharmacokinetics of prednisone in humans. Desante, KA; Disanto, AR, 1975)	0.74
" Blood and urine samples were collected, and the pharmacokinetic parameters of prednisone and prednisolone were determined in each treatment period."	( Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. Blum, R; Garg, V; Jusko, WJ; Wilner, KD, 1992)	0.51
" The prednisolone pharmacokinetic parameters derived demonstrated an increased total clearance (by 60%), an increased volume of distribution (by 46%), a lower peak concentration (by 35%), and no difference in elimination half-life in patients with CF compared with those with asthma."	( Altered prednisolone pharmacokinetics in patients with cystic fibrosis. Accurso, FJ; Dove, AM; Hill, MR; Jusko, WJ; Larsen, GL; Szefler, SJ, 1992)	0.28
" Eleven blood samples were collected over 24 h for the pharmacokinetic studies on day 1 (first day of treatment) and on day Y (after the clinical evaluation)."	( Pharmacokinetics of prednisone and prednisolone in bullous pemphigoid patients. Chosidow, O; Diquet, B; Etienne, SD; Herson, S; Puech, AJ; Vandermeersch, V; Vu-Thi-My-Le, C, 1991)	0.6
" Thirdly, due to the short half-life of prednisolone no steady-state is achieved, and therefore area under the concentration-time curve needed to be determined in all studies."	( Clinical pharmacokinetics of prednisone and prednisolone. Frey, BM; Frey, FJ, 1990)	0.57
" All the pharmacokinetic parameters, including the conversion of prednisone to prednisolone were similar to the data already published in children with INS."	( Pharmacokinetics of prednisolone in children with the nephrotic syndrome. Alvinerie, M; Barthe, P; Bouissou, F; Houin, G; Rostin, M, 1990)	0.52
" These findings suggest a decreased systemic availability of prednisolone after prednisolone sodium metasulfobenzoate (Solupred) administration and show, from a strictly pharmacokinetic point of view, that equimolar doses of prednisone and prednisolone sodium metasulfobenzoate are not equivalent therapies."	( [Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers]. Chosidow, O; Diquet, B; Etienne, SD; Godeau, P; Herson, S; Vandermeersch, V; Vu-Thi-My-Le, C, 1990)	0.75
" The same parasitic burden provoked only a slight decrease in the elimination half-life of methylprednisolone alcohol when its hemisuccinate ester was administered."	( Comparative incidence of experimental fascioliasis on corticosteroid pharmacokinetics in sheep. Alvinerie, M; Galtier, P; Houin, G; Toutain, PL; Tufenkji, AE, 1989)	0.28
" For total prednisolone, the mean elimination half-life was relatively short (1."	( Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. Blackburn, M; Choonara, I; Lewis, I; Rayner, P; Wheeldon, J, 1989)	0.28
" The results of the three experiments support the use of a non-linear reversible metabolism model to describe the pharmacokinetic relationship between prednisone and prednisolone."	( The non-linear pharmacokinetics of prednisone and prednisolone. III. Experiments using the rabbit as an animal model. Ferry, JJ; Wagner, JG, )	0.61
"In order to assess the impact of demographic factors on serum levels of cyclosporine (CsA) estimated by radioimmunoassay (RIA) in renal allograft recipients, 493 pharmacokinetic studies were performed in 212 patients."	( Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Flechner, SM; Kahan, BD; Kramer, WG; Lorber, MI; Van Buren, CT; Wideman, C, 1986)	0.27
"Three simple linear and three simple non-linear pharmacokinetic models are presented which incorporate the reversible metabolism that occurs between prednisone and prednisolone."	( The non-linear pharmacokinetics of prednisone and prednisolone. I. Theoretical. Ferry, JJ; Wagner, JG, )	0.61
" Half-life values were similar on both occasions."	( Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Barberis, L; Frigo, GM; Gatti, G; Martini, A; Notarangelo, LD; Perucca, E, 1984)	0.59
"Clinical and pharmacokinetic observations suggest that azathioprine may diminish the plasma level of prednisolone."	( A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Frey, BM; Frey, FJ; Guentert, T; Lozada, F, 1981)	0.48
"The simplest three pharmacokinetic models which apply in cases of reversible metabolism are described."	( Reversible metabolism and pharmacokinetics: application to prednisone-prednisolone. Albert, KS; DiSanto, AR; Gillespie, WR; Wagner, JG, 1981)	0.51
" Changes in prednisone half-life were insignificant, but increases in the half-life of its metabolite were dose-dependent."	( Dose dependent pharmacokinetics of prednisone and prednisolone in man. Jusko, WJ; Rose, JQ; Yurchak, AM, 1981)	0.92
"Standard pharmacokinetic measures were performed in 35 patients beginning MTX therapy and 15 patients who had received the drug for a mean of 81 months."	( Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. Hamilton, RA; Kremer, JM; Petrillo, GF, 1995)	0.29
"No significant differences in area under the serum concentration versus time curve (AUC), maximal methotrexate concentration following dosing (Cmax), time to Cmax (Tmax), bioavailability (F), urinary MTX, renal clearance of MTX or creatinine clearance were observed between the 2 cohorts."	( Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. Hamilton, RA; Kremer, JM; Petrillo, GF, 1995)	0.29
" The mean values of half-life and apparent volume of distribution at steady-state in each group were similar."	( Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. Garg, V; Hon, YY; Jusko, WJ, 1994)	0.29
"The pharmacokinetics and the pharmacodynamic profile of subcutaneously administered recombinant human non-glycosylated interleukin-3 (rhIL-3) was studied in lymphoma patients after standard CHOP chemotherapy."	( Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. Hovgaard, DJ; Mortensen, BT; Nissen, NI, 1995)	0.29
" Eighteen volunteers entered the study; pharmacokinetic data were evaluable for 15 participants."	( Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone. Cavanaugh, JH; Karol, MD, 1996)	0.51
" Peak concentration was significantly higher with liquid prednisolone (mean +/- SD 430."	( A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. Kamada, AK; LaVallee, NM; Scott, MB; Selner, JC; Szefler, SJ; Wiener, MB, )	0.13
"In this 2-week, ascending dose study, the pharmacokinetic activity of sirolimus was examined in 40 stable renal transplant patients treated with cyclosporine and prednisone."	( Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. Kahan, BD; Zimmerman, JJ, 1997)	0.49
"We prospectively assessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide levels in a homogenous population of children with lower risk acute lymphoblastic leukemia and correlated pharmacokinetic parameters with disease outcome."	( Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Ames, MM; Balis, FM; Bleyer, WA; Ge, J; Gilchrist, GS; Holcenberg, JS; Murphy, RF; Poplack, DG; Sather, HN; Tubergen, DG; Waskerwitz, MJ; Zimm, S, 1998)	0.3
"The pharmacokinetic and adrenal interactions of recombinant human interleukin-10 and prednisolone were examined in this open-label, randomized, four-way crossover study in 12 healthy adult male volunteers."	( Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. Blum, RA; Chakraborty, A; Cutler, DL; Jusko, WJ; Mis, SM, 1999)	0.55
" This study also describes the application of the ELISA method to a pharmacokinetic study in a homogeneous group of patients with follicular lymphoma who received 4 weekly doses of MAb at the standard dose of 375 mg/m2 as consolidation of chemotherapy."	( Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Arcaini, L; Astori, C; Avanzini, MA; Iacona, I; Lazzarino, M; Lunghi, F; Morra, E; Orlandi, E; Regazzi, MB; Rupolo, M; Zagonel, V, 2000)	0.31
" The aim of this study was to compare the mycophenolic acid (MPA) pharmacokinetic profile and its pharmacodynamic effect on patients receiving either standard (2 g) or low (1."	( Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Brunet, M; Carrillo, M; Corbella, J; Martorell, J; Millán, O; Oppenheimer, F; Rojo, I; Vilardell, J, 2000)	0.31
" Pharmacokinetic parameters of prednisolone as assessed by Cmax, t 1/2, AUC, or serum protein binding were not affected by prasterone."	( Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. Blum, RA; Jusko, WJ; Meno-Tetang, GM; Schwartz, KE, 2001)	0.53
"Although renal allograft outcome correlates more closely with area under the concentration time curve (AUC) for cyclosporin (CsA) compared with the 12-h trough level (C0), few studies have prospectively evaluated pharmacokinetic monitoring in kidney transplantation."	( Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? Browne, BJ; Emovon, OE; Op't Holt, C, 2002)	0.31
" This paper describes the outcome of 32 A-A recipients of de novo renal allograft who received CsA-based triple immunotherapy according to individual pharmacokinetic profiles."	( Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. Browne, BJ; Emovon, OE; Holt, CO; Howell, D; King, JA; Singleton, B, 2003)	0.32
" Pharmacokinetic measurements revealed that FTY720 displayed linear relations of doses and concentrations over a wide range, but had no effect on CsA exposure."	( Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Chodoff, L; Ferguson, RM; Gonwa, TA; Kahan, BD; Karlix, JL; Leichtman, AB; Mulgaonkar, S; Schmouder, RL; Skerjanec, A, 2003)	0.32
" The coadministration of daclizumab did not result in a pharmacokinetic interaction with MPA, the active metabolite of MMF."	( Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Bumgardner, G; Gaston, RS; Kirkman, RL; Light, S; Nieforth, K; Patel, IH; Pescovitz, MD; Vincenti, F, 2003)	0.32
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
"To characterize the pharmacokinetic behavior of oral cyclosporin (CsA) in renal transplant patient, based on through blood concentration (C0) value, and to develop and to evaluate a Bayesian method for the individualized adjustment of CsA daily dose (DD)."	( [Cyclosporin pharmacokinetic modeling in renal transplant patients]. Jiménez Torres, NV; Pallardó Mateu, L; Pérez Ruixo, JJ; Porta Oltra, B, )	0.13
" Group A (N=48) was used to characterize CsA pharmacokinetic behavior and Group B (N=19) to evaluate Bayesian predictive performance for the model developed."	( [Cyclosporin pharmacokinetic modeling in renal transplant patients]. Jiménez Torres, NV; Pallardó Mateu, L; Pérez Ruixo, JJ; Porta Oltra, B, )	0.13
" In the final model, the Dmax parameter is affected by plasmatic urea values and shows a half-life stabilization time of 90."	( [Cyclosporin pharmacokinetic modeling in renal transplant patients]. Jiménez Torres, NV; Pallardó Mateu, L; Pérez Ruixo, JJ; Porta Oltra, B, )	0.13
"The characterization of the pharmacokinetic behavior of CsA requires us to consider parameters such as Dmax and Km as non lineal functions of time, while the first order autoregressive terms DD and C0 must also be incorporated into the model."	( [Cyclosporin pharmacokinetic modeling in renal transplant patients]. Jiménez Torres, NV; Pallardó Mateu, L; Pérez Ruixo, JJ; Porta Oltra, B, )	0.13
" We compared three groups of children according to the growth kinetics during the study year (catch-up, stable, or decline) for clinical and pharmacokinetic parameters."	( Glucocorticoid pharmacokinetics and growth retardation in children with renal transplants. Bresson, JL; Broyer, M; Chavatte, C; Gimenez, F; Guest, G; Hankard, R; Le Bihan, C; Loirat, C; Maisin, A; Mogenet, A; Niaudet, P; Proust, V; Singlas, E, 2004)	0.32
"Complete pharmacokinetics and pharmacodynamic analysis was determined in 19 patients during 38 cycles of chemotherapy: 19 cycles with CHOP and 19 CHOP + HAART in a crossover-designed study."	( Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Boiocchi, M; Cattarossi, G; Corona, G; Di Gennaro, G; Tirelli, U; Toffoli, G; Vaccher, E, 2004)	0.32
" Therefore, pharmacodynamic interactions between HAART and DOX should be considered."	( Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Boiocchi, M; Cattarossi, G; Corona, G; Di Gennaro, G; Tirelli, U; Toffoli, G; Vaccher, E, 2004)	0.32
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."	( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. Jolivette, LJ; Ward, KW, 2005)	0.33
" The purpose of this study was to detect interpatient pharmacokinetic variability of tacrolimus and to assess the predictability of individual tacrolimus concentrations at various times for the area under the curve (AUC) seeking to find the best sampling time for an abbreviated AUC to predict the total body exposure of tacrolimus after the first oral dose in Chinese renal transplantation recipients."	( Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. Chen, LZ; Chen, YH; Dai, YP; Fei, JG; Li, J; Qiu, J; Zheng, KL, 2005)	0.54
"5, and 3 hours as an abbreviated AUC were as good as a full pharmacokinetic study (r = ."	( Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. Chen, LZ; Chen, YH; Dai, YP; Fei, JG; Li, J; Qiu, J; Zheng, KL, 2005)	0.54
" Therefore, we tested the pharmacokinetic profile of microemulsion CsA as a superior approach to guide clinical immunosuppression after de novo simultaneous pancreas-kidney transplantations."	( Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. Drewelow, B; Gock, M; Klar, E; Kundt, G; Schareck, W; Wacke, R, 2006)	0.33
" Based on literature datasets, a linear two-compartment pharmacokinetic model was developed to adequately describe the reversible metabolism between free prednisone and prednisolone."	( A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. Derendorf, H; Winkler, J; Xu, J, 2007)	0.54
"Three plasma samples and a 24-hour urine collection for day 1 of the first three cycles of chemotherapy were analysed in 30 patients, and the pharmacokinetic parameters of the respective drugs were estimated by population pharmacokinetic methods (nonlinear mixed-effects model [NONMEM] software)."	( Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. Busse, D; Diehl, V; Engert, A; Fuhr, U; Hempel, G; Jaehde, U; Jetter, A; Josting, A; Kasel, D; Klimm, B; Merkel, U; Reif, S; Rietbrock, S; Schwab, M; Wilde, S, 2007)	0.34
"The pharmacokinetic parameters and respective covariates were similar to the published data."	( Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. Busse, D; Diehl, V; Engert, A; Fuhr, U; Hempel, G; Jaehde, U; Jetter, A; Josting, A; Kasel, D; Klimm, B; Merkel, U; Reif, S; Rietbrock, S; Schwab, M; Wilde, S, 2007)	0.34
" Antibiotic peak concentration in blood decreased by 55%, doxorubicin circulated several times longer, and the area under the concentration-time curve increased 5 times if compared with standard doxorubicin administration."	( Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes. Ataullakhanov, FI; Galkina, NM; Kulikova, EV; Medvedev, PV; Pivnik, AV; Skorokhod, O; Vitvitsky, VM; Zybunova, EE, 2007)	0.34
"Twenty-eight days of SJW treatment resulted in no significant alterations in the pharmacokinetic parameters for prednisone or prednisolone."	( Lack of pharmacokinetic interaction between St. John's wort and prednisone. Bell, EC; Chan, HM; Lin, YJ; Ravis, WR, 2007)	0.79
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"This study was conducted to evaluate time-dependent pharmacokinetic changes and drug interactions over the first 6 months after transplantation in kidney transplant recipients receiving tacrolimus (TAC), prednisone (PRED) and mycophenolate mofetil (MMF) or sirolimus (SRL)."	( Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Casarini, DE; Felipe, CR; Fernandes, FB; Garcia, R; Medina-Pestana, JO; Park, SI; Pinheiro-Machado, PG; Tedesco-Silva, H, 2009)	0.79
" Mycophenolic acid area under the time concentration curve from 0 to 12 hours and apparent mycophenolic acid plasma clearance (CL/f) were measured for each patient."	( Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant. Abtahi, B; Mohammadpur, AH; Naghibi, M; Nazemian, F, 2008)	0.35
"Mycophenolic acid area under the time-concentration curve (0-12 h), mycophenolic acid area under the time-concentration curve (6-10 h), first peak concentration (Cmax1), and secondary peak concentration (Cmax2) were higher in the impaired group, while mycophenolic acid plasma clearance was higher in the control group (P < ."	( Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant. Abtahi, B; Mohammadpur, AH; Naghibi, M; Nazemian, F, 2008)	0.35
" We carried out a pilot pharmacokinetic study in 10 patients with B-cell non-Hodgkin lymphoma treated with rituximab associated with chemotherapy on a three-weekly basis."	( Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Blasco, H; Chatelut, E; Congy-Jolivet, N; de Bretagne, IB; Le Guellec, C, 2009)	0.35
"To determine the pharmacokinetic (PK) profile of manganese (Mn) after a 2-hour intravenous infusion of mangafodipir at 5 micromol/kg body weight and to correlate Mn concentrations with oxidative stress, early decrease in serum total bilirubin concentration, and prothrombin time (PT) in chronic alcoholic patients with acute alcoholic hepatitis."	( Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. Batteux, F; Debray, M; Hirt, D; Laurent, A; Pavlovic, S; Poupon, J; Richardet, JP; Sogni, P; Treluyer, JM; Urien, S; Weill, B, 2009)	0.35
" The elimination half-life at steady state of rituximab in all patients was estimated to be 19."	( Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L, 2010)	0.36
" The pharmacokinetic comparability of Prolastin-C to Prolastin was assessed in subjects with AAT deficiency."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
" Pharmacokinetic plasma samples were drawn over 7 days following last dose in the first treatment period and over 10 days following the last dose in the second period."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
"09, demonstrating pharmacokinetic equivalence between the 2 products."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
"Prolastin-C demonstrated pharmacokinetic equivalence and a comparable safety profile to Prolastin."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
" At 3 days, there was a strong correlation between AUC0-24 and Cmin both for tacrolimus QD (r=."	( Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Burgos, D; Cabello, M; Díez de los Rios, MJ; García, P; García-Sáiz, M; González-Molina, M; Gutiérrez, C; Hernández, D; López, V; Sola, E, 2010)	0.36
"The pharmacokinetic study of EC-MPS was conducted in 11 de novo kidney transplant patients of Hispanic ethnicity."	( The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. Hutchinson, I; Min, DI; Qazi, Y; Shah, T; Tellez-Corrales, E; Wang, J; Wilson, J; Yang, JW, 2011)	0.37
" The mean daily dose of EC-MPS at the time of the pharmacokinetic study was 1408 ± 108 mg."	( The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. Hutchinson, I; Min, DI; Qazi, Y; Shah, T; Tellez-Corrales, E; Wang, J; Wilson, J; Yang, JW, 2011)	0.37
" The MPA exposure expressed by the AUC appears to be higher in Hispanic patients than those reported in other ethnic groups, which may be the result of various factors such as difference of the uridine diphosphate glucuronosyltransferase enzyme genotypes, but gastrointestinal side effects were acceptable and the Cmax or AUC of MPAG showed correlations with gastrointestinal symptoms."	( The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. Hutchinson, I; Min, DI; Qazi, Y; Shah, T; Tellez-Corrales, E; Wang, J; Wilson, J; Yang, JW, 2011)	0.37
"To investigate the pharmacodynamic and pharmacokinetic parameters of pegylated liposomal doxorubicin (PLD) combined with cyclophosphamide, vincristine, and prednisolone in patients with peripheral T-cell lymphomas (PTCL)."	( Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. Fan, Y; Fang, L; Huang, ZY; Lin, NM; Luo, LH; Wu, FQ; Yu, HF, 2011)	0.37
" The pharmacokinetics (PKs) software was used to estimate the pharmacokinetic parameters of PLD."	( Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. Fan, Y; Fang, L; Huang, ZY; Lin, NM; Luo, LH; Wu, FQ; Yu, HF, 2011)	0.37
" The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910."	( Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. Fan, Y; Fang, L; Huang, ZY; Lin, NM; Luo, LH; Wu, FQ; Yu, HF, 2011)	0.37
" The results of the pharmacokinetic parameters showed that PLD had long retention time in blood circulation."	( Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. Fan, Y; Fang, L; Huang, ZY; Lin, NM; Luo, LH; Wu, FQ; Yu, HF, 2011)	0.37
"The purpose of this study was to characterize the pharmacokinetic (PK) properties of prednisolone, the metabolite of the prodrug prednisone, in cSLE patients and explore the relationship between PK properties and cSLE disease activity."	( Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Brunner, HI; Rieder, MJ; Sagcal-Gironella, AC; Sherwin, CM; Tirona, RG; Vinks, AA, 2011)	0.79
" Population pharmacokinetic modeling was performed with nonlinear mixed-effect modeling software (NONMEM VI)."	( The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Held, G; Lengfelder, E; Metzner, B; Müller, C; Murawski, N; Nickenig, C; Peter, N; Pfreundschuh, M; Poeschel, V; Reiser, M; Rixecker, T; Wenger, M; Wiesen, MH; Zeynalova, S; Zwick, C, 2012)	0.38
" Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel, which may enable tailored dosing in metastatic castration-resistant prostate cancer (mCRPC)."	( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012)	0.38
"For patients with mCRPC who received docetaxel, ≥grade 3 neutropenia on day 8 was prognostic for improved OS, which suggests its utility as a pharmacodynamic marker, in this hypothesis-generating analysis."	( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012)	0.38
" Altered organ function, changing biochemistry and use of a number of concomitant medicines in transplantation appear to lead to pharmacokinetic differences in transplant recipients compared with other patient groups."	( Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Barraclough, KA; Bergmann, TK; Lee, KJ; Staatz, CE, 2012)	0.62
" There was no substantial difference in pharmacokinetic parameters of the formulations apart from the programmed delay in release of glucocorticoid from the modified-release tablets (C(max) 97%, AUC(0-∞) 101%, 90% confidence intervals within the requisite range for bioequivalence)."	( Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. Clarke, L; Derendorf, H; Kirwan, JR; Ruebsamen, K; Schaeffler, A, 2013)	0.66
" The aims of this study were to evaluate the correlation between free serum and salivary PLN levels and to quantify this relationship within a population pharmacokinetic model."	( Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ackermans, MT; Freijer, J; Guan, Z; Kist-van Holthe, JE; Nauta, J; Ruiter, AF; Teeninga, N; van Gelder, T, 2013)	0.68
" Population pharmacokinetic analysis was performed with nonlinear mixed effect modeling using NONMEM."	( Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ackermans, MT; Freijer, J; Guan, Z; Kist-van Holthe, JE; Nauta, J; Ruiter, AF; Teeninga, N; van Gelder, T, 2013)	0.68
"This study is the first to describe the relationship between salivary and (free) serum PLN using a population pharmacokinetic model."	( Monitoring prednisolone and prednisone in saliva: a population pharmacokinetic approach in healthy volunteers. Ackermans, MT; Freijer, J; Guan, Z; Kist-van Holthe, JE; Nauta, J; Ruiter, AF; Teeninga, N; van Gelder, T, 2013)	0.68
" Pharmacokinetic parameters were determined using noncompartmental methods and geometric least-square mean ratios, and 90% confidence intervals were generated."	( Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Borland, J; Chen, S; Peppercorn, AF; Piscitelli, S; Savina, P; Song, IH, 2013)	0.79
"Cyclosporine exhibits pharmacokinetic and pharmacodynamic variability in renal transplant recipients (RTR) attributed to P-glycoprotein (P-gp), an ABCB1 efflux transporter that influences bioavailability and intracellular distribution."	( Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients. Brazeau, D; Danison, R; DiFrancesco, R; Dole, K; Gillis, K; Gundroo, A; Leca, N; Tornatore, KM; Venuto, RC; Wilding, G; Zack, J, 2013)	0.39
" Our objective was to evaluate the influence of the sources of infliximab pharmacokinetic variability in RA."	( Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Corondan, A; Devauchelle-Pensec, V; Ducourau, E; Goupille, P; Le Goff, B; Mulleman, D; Paintaud, G; Perdriger, A; Solau-Gervais, E; Ternant, D; Watier, H, 2014)	0.4
" Infliximab concentrations were described using a two-compartment population pharmacokinetic model."	( Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Corondan, A; Devauchelle-Pensec, V; Ducourau, E; Goupille, P; Le Goff, B; Mulleman, D; Paintaud, G; Perdriger, A; Solau-Gervais, E; Ternant, D; Watier, H, 2014)	0.4
" Pharmacokinetic parameters of prednisone or its pharmacologically active metabolite, prednisolone, are not well characterized in transplant recipients."	( Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus. Akhlaghi, F; Gohh, RY; Ionita, IA; Ogasawara, K, 2014)	0.96
" This review summarizes its efficacy and toxicity, and focuses on the pharmacokinetic features of vincristine that affect clinical outcomes."	( Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. Said, R; Tsimberidou, AM, 2014)	0.4
" A physiologically-based pharmacokinetic (PBPK) model was also built."	( Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib. Ballard, J; Evers, R; Gibson, CR; Hreniuk, D; Kassahun, K; Liu, C; Mahon, C; Marcantonio, EE; Mehta, A; Morris, D; Mostoller, K; Palamanda, J; Stoch, SA; Tang, C; Wagner, JA; Zajic, S, 2014)	1.85
" Population pharmacokinetic parameters were estimated by the NLME software."	( [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Chen, Y; Gao, P; He, X; Li, J; Niu, C; Wang, C; Wang, Y; Zhang, H, 2014)	0.4
" Pharmacokinetic sampling was performed at pre-dose, post-infusion, 24, 48 h, 7 and 21 days."	( Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Gota, V; Karanam, A; Menon, H; Nair, R; Rath, S; Sengar, M; Subramanian, P; Tembhare, P; Yadav, A, 2016)	0.43
"The pharmacokinetic profile and B-cell response to Reditux™ are comparable with those reported for MabThera™."	( Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Gota, V; Karanam, A; Menon, H; Nair, R; Rath, S; Sengar, M; Subramanian, P; Tembhare, P; Yadav, A, 2016)	0.43
" This study was conducted to characterize the safety and pharmacodynamic (PD) dose-response of a 7-day course of oral prednisone on biomarkers of GC receptor agonism."	( Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. Daniel, S; Fleishaker, DL; Mukherjee, A; Whaley, FS; Zeiher, BG, 2016)	0.89
" In addition, Cmax was associated with a progression-free survival advantage."	( Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017)	0.46
" The aim of the present study was to assess the safety and pharmacokinetic interactions between EBR and GZR and single doses of cyclosporine, tacrolimus, mycophenolate mofetil (MMF), and prednisone."	( Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Guo, Z; Iwamoto, M; Panebianco, D; Talaty, J; Wolford, D; Yeh, WW, 2018)	0.67
" Prednisone and its metabolite, prednisolone, steady-state noncompartmental pharmacokinetic parameters were estimated."	( Prednisone Pharmacokinetics During Pregnancy and Lactation. Ahmed, MS; Bennett, B; Caritis, SN; Clark, S; Easterling, TR; Hays, K; Hebert, MF; Honaker, MT; Kantrowitz-Gordon, I; Ryu, RJ; Shen, DD; Thummel, KE; Umans, JG; Venkataramanan, R, 2018)	2.83
" To take advantage of the predictive power of machine learning and the explanatory power of pharmacokinetics, we propose a latent variable mixture model for learning clusters of pharmacokinetic models demonstrated on a clinical data set investigating 11β-hydroxysteroid dehydrogenase enzymes (11β-HSD) activity in healthy adults."	( Learning pharmacokinetic models for in vivo glucocorticoid activation. Arlt, W; Bunte, K; Chappell, MJ; Hassan-Smith, ZK; Smith, DJ; Tiňo, P; Tomlinson, JW, 2018)	0.48
" Pharmacokinetic evaluation was performed at two consecutive visits at least 4 weeks apart."	( Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP, 2019)	0.51
" Serial blood samples for pharmacokinetic analysis were collected on C1D7 and C2D8."	( Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Abrams, C; Attard, G; Chi, KN; Chien, C; de Jonge, MJA; de Wit, R; Friedlander, TW; Hellemans, P; Jiao, JJ; Posadas, EM; Saad, F; Yu, MK, 2020)	0.78
" No clinically significant pharmacokinetic interaction was observed between abiraterone and apalutamide; however, apalutamide decreased exposure to prednisone."	( Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Abrams, C; Attard, G; Chi, KN; Chien, C; de Jonge, MJA; de Wit, R; Friedlander, TW; Hellemans, P; Jiao, JJ; Posadas, EM; Saad, F; Yu, MK, 2020)	0.98
"Mycophenolic acid (MPA) is an effective oral immunosuppressive drug used to treat lupus nephritis (LN), which exhibits large pharmacokinetic variability."	( Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. Abud-Mendoza, C; Martínez-Martínez, MU; Medellín-Garibay, SE; Milán-Segovia, RDC; Reséndiz-Galván, JE; Romano-Aguilar, M; Romano-Moreno, S, 2020)	0.56
"This is the first MPA population pharmacokinetic model to have found that co-administration of prednisone results in a considerable increase on clearance."	( Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. Abud-Mendoza, C; Martínez-Martínez, MU; Medellín-Garibay, SE; Milán-Segovia, RDC; Reséndiz-Galván, JE; Romano-Aguilar, M; Romano-Moreno, S, 2020)	0.78
"A human mechanistic physiology-based pharmacokinetic (PBPK) model of vincristine following intravenous dosing was developed to predict potential DDI interactions with combination therapy."	( Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. Chen, B; Fretland, AJ; McGinnity, DF; Pilla Reddy, V; Sharma, S; Vishwanathan, K; Ware, JA; Xu, Y; Zhou, D, 2021)	0.62
" The physiologically based pharmacokinetic (PBPK) modeling is a well-established method that permits extrapolation from adult to juvenile populations."	( Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease. Ahmad, T; Alqahtani, F; Alqahtani, NS; Alshammari, FA; Imran, I; Khalid, S; Masood, I; Rasool, MF; Saeed, H, 2023)	0.91

Compound-Compound Interactions

Prednisone in combination with an antibiotic can effectively relieve pain and voiding symptoms, improve QOL and reduce WBC in the EPS of CNP patients, and therefore well deserves to be recommended in clinical application.

Excerpt	Reference	Relevance
"The patients were randomly assigned to a regimen of cyclophosphamide, vincristine, prednisone, and doxorubicin or to this regimen combined with recombinant interferon alfa."	( Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. Andersen, JW; Bhide, V; Borden, EC; Hawkins, MJ; O'Connell, MJ; Oken, MM; Smalley, RV, 1992)	0.51
" All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and decarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis."	( Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Banfi, A; Bonadonna, G; Bonfante, V; Devizzi, L; Santoro, A; Tesoro Tess, JD; Valagussa, P; Viviani, S; Zanini, M; Zucali, R, 1992)	0.28
" A randomized double-blind study evaluated a polyethylene glycol (PEG) conjugate L-asparaginase combined with chemotherapy (vincristine, cyclophosphamide, doxorubicin, and prednisone)."	( Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma. Fox, LE; Kurzman, ID; Loar, AS; MacEwen, EG; Rosenthal, RC, )	0.33
" Therapy should be given with a great deal of caution in patients with decompensated liver disease, as one may precipitate the untimely demise of the patient even though viral replication is decreased."	( Alpha-interferon combined with immunomodulation in the treatment of chronic hepatitis B. Peters, M, 1991)	0.28
" We have characterized PCN or macrolides induced cytochromes P-450 by their specific ability to interact with macrolide derivatives and, using the cytochrome P-450 spectral binding assays, we have shown that some compounds, implicated in drug interaction with macrolides, interact preferentially with the same cytochromes."	( Specific drug binding to rat liver cytochrome P-450 isozymes induced by pregnenolone-16 alpha-carbonitrile and macrolide antibiotics. Implications for drug interactions. Delaforge, M; Sartori, E, 1990)	0.28
"Five responses (lung metastases, three; lymph node metastases, two) were observed in 23 patients with metastatic renal cell carcinoma who received recombinant interferon-alpha-2A (IFN) 18 X 10(6) U in three intramuscular doses each week combined with oral prednisone (10 to 20 mg daily)."	( Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study. Fosså, SD; Gunderson, R; Moe, B, 1990)	0.72
" It is noteworthy that in all subsets, ABVD (Adriamycin + bleomycin + vinblastine + dacarbazine), either combined with irradiation or alternated with MOPP (mechlorethamine + vincristine + procarbazine + prednisone), yielded superior results compared with MOPP with or without irradiation."	( Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Bonadonna, G; Santoro, A; Valagussa, P, 1985)	0.46
" There was little evidence that either form of treatment was superior in prolonging survival, for in one study the patients treated with a drug combination lived significantly longer than those treated with MP, while in another the reverse was true, and there was no difference in the survival of the two groups in the remaining 11 studies."	( Melphalan/prednisone versus drug combinations for plasma cell myeloma. Bergsagel, DE, 1989)	0.68
"Primary brain lymphomas are usually treated with surgery in combination with radiotherapy, whereas only a few cases have been treated with chemotherapy."	( Primary brain malignant non-Hodgkin lymphoma: report of a case treated with chemotherapy in combination with radiotherapy. Büchi, G; Ferrari, G; Geda, C; Grosso, E; Termine, G, 1986)	0.27
"From 1976 to 1981, 335 patients with untreated Hodgkin's disease, clinical stages I, II, and IIIA, have been treated by MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) chemotherapy, three to six cycles according to the prognostic factors, combined with radiotherapy."	( Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. Audebert, A; Bernadou, A; Diebold, J; Eghbali, H; Hoerni, B; Krulik, M; Merle-Béral, H; Parlier, Y; Rojouan, J; Zittoun, R, 1985)	0.46
"One hundred recipients of first cadaveric kidney transplants were treated with three different immunosuppressive regimens: (1) conventional immunosuppression, (2) CsA alone, and (3) low-dose CsA in combination with low-dose prednisone, with rapid adjustment to give CsA whole blood trough levels of 300 to 800 ng/mL."	( Cyclosporine alone or in combination with prednisone in cadaveric renal transplantation. Brünisholz, M; Brunner, F; Follat, F; Harder, F; Landmann, J; Loertscher, R; Mihatsch, M; Thiel, G; Wenk, M, 1984)	0.72
"One hundred and seventy-nine previously treated children with acute lymphoblastic leukemia in relapse considered not "resistant" to vincristine (VCR) were randomly allocated to receive reinduction therapy with either vindesine (VND) or VCR, in combination with prednisone and L-asparaginase."	( Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial. Anderson, J; Chard, R; Chilcote, R; Hammond, D; Krivit, W; Pyesmany, A, )	0.51
"20 patients with myasthenia gravis (MG), refractory to anticholinesterase and steroid therapy, underwent plasma exchange therapy combined with immunosuppressive drugs and lymphocytapheresis."	( Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis. Cornelio, F; Forlani, G; Garelli, S; Pelucchetti, D; Valbonesi, M; Zerbi, D, 1982)	0.26
"In a twelve-month period, 56 consecutive patients with acute leukemia, aged 15-50, were treated by administration of a 10-day continuous infusion of Ara-C in combination with adriamycin, oncovin and prednisone (10 day ADOAP)."	( Adriamycin combined with 10-day Ara-C, vincristine, and prednisone (10-day ADOAP) in the treatment of adult acute leukemia patients under fifty years of age. A Southwest Oncology Group Study. Amare, M; Morrison, FS; Oishi, N; Pendleton, O; Saiki, JH; Schreiter, SL; Stuckey, WJ; Vial, R, 1982)	0.7
"In an 18-month period, 340 consecutive adult patients with acute leukemia were treated using a 7-day continuous infusion of Ara-C in combination with rubidazone, vincristine and prednisone (ROAP)."	( Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group Study. Amare, M; Balcerzak, S; Benjamin, R; Costanzi, JJ; Hussein, K; Morrison, FS; Pendleton, OJ; Ryan, DH, 1982)	0.71
"The clinical efficacy of COP-BLAM chemotherapy combined with human recombinant granulocyte colony-stimulating factor (G-CSF) was evaluated in 104 previously untreated patients with non-Hodgkin's lymphoma (NHL)."	( COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma. Niitsu, N; Umeda, M, 1995)	0.29
" This pilot study examines the effect of donor bone marrow (DBM) infusion and antithymocyte serum (ATS) in combination with immunosuppressive drug therapy in prolonging renal allograft survival in dogs."	( Renal allograft survival in outbred mongrel dogs using rabbit anti-dog thymocyte serum in combination with immunosuppressive drug therapy with or without donor bone marrow. Atilola, M; Binnington, AG; Holmberg, DL; Johnston, K; Mathews, KA; Maxie, G; Miller, CM; Smith, G, )	0.13
"18 patients with acute promyelocytic leukemia (APL) were treated with HATP (Harringtonine, Adriamycin, Thioguanine, Prednisone) chemotherapy combined with chinese traditional medications."	( [HATP chemotherapy combined with Chinese traditional medications in treating acute promyelocytic leukemia]. Guo, AX; Huang, SL; Wang, QE, 1993)	0.5
"Three hundred thirty-five previously untreated patients with multiple myeloma in clinical stages II and III entered a randomized trial comparing intermittent oral melphalan and prednisone (MP) therapy (n = 171) with MP in combination with natural (leukocyte-derived) alpha-interferon (MP/IFN) (n = 164)."	( Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Björeman, M; Björkholm, M; Brenning, G; Carlson, K; Celsing, F; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Osterborg, A, 1993)	0.73
"We evaluated the efficacy and adverse effects of biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) therapy combined with granulocyte colony-stimulating factor (G-CSF) for treating non-Hodgkin's lymphoma (NHL)."	( Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma. Niitsu, N; Umeda, M, 1996)	0.76
"To determine response rate and remission as well as survival times for dogs with multicentric lymphoma treated first with doxorubicin alone or in combination with asparaginase and then with cyclophosphamide, vincristine sulfate, and prednisone (CVP) and to identify prevalence of toxicoses associated with this protocol and factors associated with prognosis."	( Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). Getzy, DM; Mallinckrodt, CH; Ogilvie, GK; Valerius, KD, 1997)	0.7
"For dogs with multicentric lymphoma, treatment with doxorubicin alone or in combination with asparaginase and then with CVP resulted in an acceptable response rate and low prevalence of toxicoses."	( Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). Getzy, DM; Mallinckrodt, CH; Ogilvie, GK; Valerius, KD, 1997)	0.51
" In conclusion, intensive therapy using high-dose CSA combined with VP16 and prednisone might be a therapeutic option for patients with otherwise refractory LCH."	( Treatment of relapsed Langerhans cell histiocytosis by cyclosporin A combined with etoposide and prednisone. Göbel, U; Janssen, G; Körholz, D, )	0.58
"Mycophenolate mofetil (MMF) combined with conventional cyclosporine and steroids doses efficiently prevents acute rejection in kidney transplants."	( Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Andrés, A; Cruzado, JM; Fulladosa, X; Gil-Vernet, S; Grinyó, JM; Morales, JM; Moreso, F; Pérez, JL; Serón, D, 1998)	0.3
"One hundred and sixty seven patients with non-Hodgkin's lymphoma were randomly divided into two groups, the treatment group, which consisted of 112 cases using Chinese herbs combined with chemotherapy and 55 cases of control group were treated by chemotherapy only."	( [Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy]. Guo, XM; Li, JX; Yang, XF, 1997)	0.3
" These showed that Chinese herbs combined with chemotherapy was a safe and effective method for treating NHL and deserve to be recommended."	( [Clinical observation on 112 cases with non-Hodgkin's lymphoma treated by Chinese herbs combined with chemotherapy]. Guo, XM; Li, JX; Yang, XF, 1997)	0.3
"IVIg combined with prednisone for a 3-month period was not effective in IBM."	( A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Cupler, E; Dalakas, MC; Fujii, M; Koffman, B; Sivakumar, K; Spector, S, 2001)	0.88
"Thirty-three patients with previously untreated advanced aggressive B-cell NHL received six infusions of Rituxan (375 mg/m2 per dose) on day 1 of each cycle in combination with six doses of CHOP chemotherapy given on day 3 of each cycle."	( Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Czuczman, M; Fisher, RI; Gilman, P; Grillo-Lopez, A; Grossbard, ML; Kunkel, LA; Link, BK; Lowe, A; Vose, JM, 2001)	0.31
"This is the first report to demonstrate the safety and efficacy of the Rituxan chimeric anti-CD20 antibody in combination with standard-dose CHOP in the treatment of aggressive B-cell lymphoma."	( Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Czuczman, M; Fisher, RI; Gilman, P; Grillo-Lopez, A; Grossbard, ML; Kunkel, LA; Link, BK; Lowe, A; Vose, JM, 2001)	0.31
"Patients who were PCR-positive for B-cell leukemia-lymphoma 2 (bcl-2) gene rearrangement [t(14;18)] were evaluated for responses to rituximab alone or combined with CHOP."	( Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Alkuzweny, B; Czuczman, MS; Gordon, L; Grillo-López, AJ; LoBuglio, AF; Maloney, D; McLaughlin, P; Rosenberg, J; Saleh, M; White, CA, 2001)	0.31
"Rituximab, alone or combined with CHOP, eradicated bcl-2 positive cells from PB and BM in over half of the patients treated and was associated with a high overall clinical response rate."	( Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Alkuzweny, B; Czuczman, MS; Gordon, L; Grillo-López, AJ; LoBuglio, AF; Maloney, D; McLaughlin, P; Rosenberg, J; Saleh, M; White, CA, 2001)	0.31
" In addition, the effects on viral load, CD4 counts, and opportunistic infections were examined with the use of combination chemotherapy combined with HAART."	( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001)	0.31
" The first 40 patients entered onto the study received reduced doses of cyclophosphamide and doxorubicin, combined with vincristine and prednisone (modified CHOP [mCHOP]), whereas the subsequent 25 patients entered onto the study received full doses of CHOP combined with granulocyte colony-stimulating factor (G-CSF)."	( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001)	0.51
"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively."	( Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S, 2001)	0.31
"To investigate the effects of Tiaojining recipe (TJNR) combined with corticosterone (CS) in treating infantile primary nephrotic syndrome (IPNS)."	( [Clinical observation of tiaojining recipe in combination with corticosterone in infantile primary nephrotic syndrome]. Li, R; Peng, Z; Wei, Y, 2000)	0.31
"Sixty inpatients with IPNS were divided into two groups, which consisted of 30 cases as the treated group treated by TJNR combined with CS and 30 cases of the control group were treated by CS alone for 8 weeks."	( [Clinical observation of tiaojining recipe in combination with corticosterone in infantile primary nephrotic syndrome]. Li, R; Peng, Z; Wei, Y, 2000)	0.31
"Alternating COPP/ABVD and rapid alternating COPP/ABV/IMEP in combination with extended-field radiotherapy are equally effective in intermediate-stage Hodgkin's lymphoma and produce excellent long-term treatment results."	( Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Anselmo, AP; Brosteanu, O; Diehl, V; Doelken, G; Duehmke, E; Engert, A; Franklin, J; Georgii, A; Greil, R; Hasenclever, D; Herrmann, R; Josting, A; Kirchner, H; Koch, P; Koch, T; Lathan, B; Loeffler, M; Munker, R; Paulus, U; Pfistner, B; Pfreundschuh, M; Rueffer, U; Schalk, KP; Sieber, M; Tesch, H; Wolf, J, 2002)	0.31
"Low-dose cyclosporin(CsA) therapy combined with prednisolone was performed in 10 adult patients with frequently relapsing minimal change nephrotic syndrome(MCNS)."	( [Low-dose cyclosporin therapy combined with prednisolone for relapsing minimal change nephrotic syndrome in adults]. Honda, K; Itabashi, M; Koike, M; Nihei, H; Nitta, K; Suzuki, K; Tsukada, M; Uchida, K; Yumura, W, 2002)	0.31
" We report the case of a 49 year-old female with advanced mantle cell lymphoma (MCL), who successfully underwent auto-peripheral blood stem cell transplant (auto-PBSCT) in combination with in vivo purging of tumor cells using rituximab."	( [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab]. Hino, N; Ishibashi, K; Kanaji, N; Uno, H, 2002)	0.31
"To explore the clinical effect of recombinant roasted licorice decoction (RRLD) combined with low-dose glucocorticoids (GC) in treating idiopathic thrombocytopenic purpura (ITP)."	( [Clinical study on effect of recombinant roasted licorice decoction combined with low-dose glucocorticoids in treating idiopathic thrombocytopenic purpura]. Hu, J; Liu, YQ; Luo, YG, 2001)	0.31
"To explore the clinical effect of Tripterygiitotorum (T II) combined with prednisone in treating patients with myasthenia gravis (MG) and the changes of immune function after treatment."	( [Clinical effect of Tripterygiitotorum combined with prednisone and its effect on serum IL-6 level in treating patients with myasthenia gravis]. Li, ZX; Tan, H; Xiong, XJ, 2002)	0.8
" However, the optimal dose of granulocyte colony-stimulating factor (G-CSF) for PBSC mobilization in combination with chemotherapy for autograft remains unknown."	( A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Chou, T; Kasai, M; Kawano, F; Kiyama, Y; Masaki, Y; Mitsuya, H; Morishima, Y; Ogura, M; Ohnishi, K; Sasaki, T; Takeyama, K; Tobinai, K; Yokozawa, T, 2003)	0.32
"To find the optimal dose of glycosylated G-CSF (lenograstim) for PBSC mobilization in combination with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL), we conducted a dose-finding study on 43 newly diagnosed patients who had unfavorable prognostic factors."	( A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Chou, T; Kasai, M; Kawano, F; Kiyama, Y; Masaki, Y; Mitsuya, H; Morishima, Y; Ogura, M; Ohnishi, K; Sasaki, T; Takeyama, K; Tobinai, K; Yokozawa, T, 2003)	0.32
"Liposomal doxorubicin at doses of 40, 50, 60, and 80 mg/m(2) was given with fixed doses of cyclophosphamide, vincristine, and prednisone every 21 days."	( Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. Boswell, WD; Espina, B; Levine, AM; Lieberman, RD; Nathwani, BN; Sherrod, A; Tulpule, A; Welles, L, 2004)	0.74
"Liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is active in AIDS-NHL, with complete remissions achieved in 75% independent of HIV viral control or tissue MDR-1 expression."	( Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. Boswell, WD; Espina, B; Levine, AM; Lieberman, RD; Nathwani, BN; Sherrod, A; Tulpule, A; Welles, L, 2004)	0.77
"Records of 75 patients with aggressive B-NHL,received infusions of 375 mg/m(2) of rituximab combined with or without chemotherapy in our center,have been retrospectively analyzed."	( [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Lin, TY; Sun, XF; Xia, ZJ; Zhang, HY; Zhang, L, 2004)	0.32
"Docetaxel, a taxane previously approved for the treatment of breast cancer and non-small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatment of metastatic androgen-independent (hormone-refractory) prostate cancer."	( Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R, 2004)	0.77
" Diagnosis was based on the very typical ocular feature combined with a positive blood or vitreous culture."	( [Endogenous Candida endophthalmitis combined with severe general diseases]. Stoffelns, BM, 2005)	0.33
" When given with prednisone, docetaxel was also shown to reduce pain and serum prostate specific antigen levels and improve quality of life compared with mitoxantrone/prednisone."	( Which drug combination for hormone-refractory prostate cancer? Doggrell, SA, 2005)	0.67
"The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL)."	( Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Czuczman, M; Fisher, RI; Grillo-Lopez, A; Grossbard, ML; Link, BK; Vose, JM, 2005)	0.51
"Data on tacrolimus pharmacokinetics in combination with mycophenolate mofetil and prednisone are scarce in Chinese renal transplantation recipients."	( Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. Chen, LZ; Chen, YH; Dai, YP; Fei, JG; Li, J; Qiu, J; Zheng, KL, 2005)	0.76
"Tacrolimus AUC12 show remarkable interindividual variations after the first oral dose in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients."	( Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. Chen, LZ; Chen, YH; Dai, YP; Fei, JG; Li, J; Qiu, J; Zheng, KL, 2005)	0.74
" The treatment group (n=22) were treated with acupoint-injection of Chinese medicine combined with prednisone, and the control group (n=19) with prednisone."	( [Observation on clinical therapeutic effect of acupoint-injection therapy combined with prednisone on nephrotic syndrome and effect on immunologic function]. Cao, Y; Zhang, YM, 2005)	0.77
"Acupoint-injection of Chinese medicine combined with prednisone can significantly increase therapeutic effect on nephrotic syndrome and strengthen immunologic function."	( [Observation on clinical therapeutic effect of acupoint-injection therapy combined with prednisone on nephrotic syndrome and effect on immunologic function]. Cao, Y; Zhang, YM, 2005)	0.8
" In this study, the antitumor activity of A in combination with ADR (AHOP) was investigated in comparison with the standard CHOP regimen."	( NSC 290205-based therapy in murine pancreatic adenocarcinoma PAN02 in combination with adriamycin (ADR). Andreadis, C; Boutis, A; Lialiaris, TS; Mouratidou, D; Papageorgiou, A, )	0.13
"It is very likely that the D-lactamic steroid (androstan) alkylator forA, containing the amide group -NH-CO-, combined with ADR which intercalates between DNA base-pairs, is the explanation for the higher activity of AHOP as compared to CHOP."	( NSC 290205-based therapy in murine pancreatic adenocarcinoma PAN02 in combination with adriamycin (ADR). Andreadis, C; Boutis, A; Lialiaris, TS; Mouratidou, D; Papageorgiou, A, )	0.13
" It is possible that lamivudine combined with chemotherapy may have had a therapeutic effect on ATL in this case."	( [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy]. Hasegawa, H; Miyagi, T; Nagasaki, A; Nakachi, S; Shinzato, O; Taira, N; Takasu, N; Tomoyose, T, 2006)	0.33
" We conclude that both sirolimus monotherapy and sirolimus in combination with prednisone and/or MMF are efficacious and safe in liver transplant recipients."	( Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Maheshwari, A; Thuluvath, PJ; Torbenson, MS, 2006)	0.56
"To study the effect of Shenbing Mistura (SM) combined with glucocorticoid on recurrent nephrotic syndrome (RNS) in children and levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in blood and urine."	( [Clinical effect of shenbing mistura combined with glucocorticoid on recurrent nephrotic syndrome in children and levels of interleukin-6 and tumor necrosis factor-alpha in blood and urine]. Dang, XQ; Hu, GH; Wang, JH, 2006)	0.33
"SM combined with glucocorticoid could significantly reduce the recurrence rate and elevate the clinical effect in children with RNS, it could also lower the levels of IL-6 and TNF-alpha in patients' blood and urine."	( [Clinical effect of shenbing mistura combined with glucocorticoid on recurrent nephrotic syndrome in children and levels of interleukin-6 and tumor necrosis factor-alpha in blood and urine]. Dang, XQ; Hu, GH; Wang, JH, 2006)	0.33
"A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere, Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC)."	( A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Perard, R; Riemsma, R; Trowman, R, 2007)	0.74
"To observe the curative effect of Qingjin Runfei Decoction (QRD) combined with hormone and antibiotic in treating radiation pneumonia (RP)."	( [Clinical observation on treatment of radiation pneumonia by Qingjin Runfei Decoction combined with hormone and antibiotic]. Ma, SL; Yue, JH; Zhang, T, 2007)	0.34
"The objective of this study is to evaluate the long-term efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in Chinese patients with newly diagnosed diffuse large B cell lymphoma (DLBCL)."	( Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Chen, QS; Chen, Y; Li, JM; Qian, Y; Shen, Y; Shen, ZX; Wang, L; Xia, ZG; You, JH; Zeng, XY, 2007)	0.54
"Sixty-one patients with PMR were randomly assigned to two groups, the 32 patients in the treatment group treated with YHD two doses per day combined with prednisone and the 29 patients in the control group treated with prednisone alone."	( [Clinical observation on effect of modified Yanghe Decoction combined with glycocorticoid for treatment of polymyalgia rheumatica]. Fu, HZ, 2007)	0.54
"EA warming therapy combined with western medicine has a significant therapeutic effect on myasthenia gravis."	( [Electroacupuncture warming therapy combined with western medicine for treatment of myasthenia gravis and effect on IL-4 level in the patients]. Cui, X; Feng, J; Wang, SH, 2007)	0.34
"To evaluate the preliminary efficacy, safety, and impact on quality of life (QoL) of high-dose calcitriol (DN-101) combined with mitoxantrone and glucocorticoids in androgen-independent prostate cancer (AIPC)."	( A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. Beer, TM; Chan, JS; Dehaze, DR; Garzotto, M; Pinski, JK; Quinn, DI; Ryan, CW; Sokoloff, M, 2008)	0.58
"To evaluate the efficacy and safety of corticoid in combination with an antibiotic in the treatment of chronic nonbacterial prostatitis (CNP)."	( [Corticoid combined with an antibiotic for chronic nonbacterial prostatitis]. Hou, Y; Lü, C; Wu, ZP; Xiao, N; Yang, MG; Zhao, XK, 2009)	0.35
"Prednisone in combination with an antibiotic can effectively relieve pain and voiding symptoms, improve QOL and reduce WBC in the EPS of CNP patients, and therefore well deserves to be recommended in clinical application."	( [Corticoid combined with an antibiotic for chronic nonbacterial prostatitis]. Hou, Y; Lü, C; Wu, ZP; Xiao, N; Yang, MG; Zhao, XK, 2009)	1.8
" The treated group was administered with GTC and prednisone, while the control group with prednisone alone."	( [Clinical observation on treatment of 10 patients with chronic inflammatory demyelinating polyneuropathy by gullong tongluo capsule combined with prednisone]. Chen, JL; Hu, JY; Zhang, ZH, 2009)	0.81
"The curative effect of GTC combined with prednisone in treating CIDP was better than that of prednisone alone."	( [Clinical observation on treatment of 10 patients with chronic inflammatory demyelinating polyneuropathy by gullong tongluo capsule combined with prednisone]. Chen, JL; Hu, JY; Zhang, ZH, 2009)	0.82
"Third-generation regimens (MACOP-B [methotrexate/leucovorin (LV)/doxorubicin/cyclophosphamide/vincristine/ prednisone/bleomycin] or VACOP-B [etoposide/LV/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin]) in combination with local radiation therapy seem to improve lymphoma-free survival of primary mediastinal large B-cell lymphoma (PMLBCL)."	( Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Broccoli, A; Brusamolino, E; Cabras, MG; Chiappella, A; Finolezzi, E; Martelli, M; Rossi, A; Salvi, F; Stefoni, V; Zinzani, PL, 2009)	0.57
"To retrospectively analyze and compare the treatment efficiency of CHOP-based regimens with or without high-dose consolidation treatment combined with hematopoietic stem cell transplantation (HDT-HSCT) in the patients with lymphoblastic lymphoma (LBL)."	( [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. Dong, M; Feng, FY; Han, XH; He, XH; Liu, P; Qin, Y; Shi, YK; Sun, Y; Wang, JW; Yang, JL; Yang, S; Zhang, CG; Zhou, LQ; Zhou, SY, 2009)	0.35
"To investigate the feasibility and efficacy of rituximab combined with high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation (ASCT) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL)."	( [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma]. Cen, XN; Chen, H; Han, MZ; Han, XH; He, XH; Huang, H; Huang, HQ; Jiang, WQ; Liu, P; Ma, J; Ren, HY; Shen, XM; Shi, YK; Wang, C; Wang, JM; Yang, S; Zhou, SY; Zhu, J, 2009)	0.35
"We evaluated the safety and efficacy of intetumumab in combination with docetaxel in patients with castrate-resistant metastatic prostate cancer."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.56
"Intetumumab was generally safe and well tolerated in combination with docetaxel, with a higher incidence of TEAEs in the 10 mg/kg dose cohort."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.56
" The results of five phase III trials assessing thalidomide in combination with melphalan and prednisone (MPT) have demonstrated significantly improved response rates compared with melphalan and prednisone (MP) alone."	( Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S, 2010)	0.78
"CHOP-like regimen combined with rituximab is a standard chemotherapy for diffuse large B-cell lymphoma (DLBCL)."	( Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Dan, K; Gomi, S; Hirakawa, T; Inokuchi, K; Yamaguchi, H; Yokose, N, 2010)	0.36
"To observe the effects of ginsenosides combined with prednisone in SLE patients."	( [Efficacy of ginsenosides combined with prednisone in patients with systemic lupus erythematosus: a prospective, randomized, double-blind, placebo-controlled trial]. Cai, Q; Feng, YL; Guan, JL; Ling, CQ; Xu, MJ; Xu, X; You, YL; Zhang, LL, 2010)	0.88
"Prednisone combined with ginsenosides can increase the clinical effective rate and improve the clinical symptoms of SLE patients."	( [Efficacy of ginsenosides combined with prednisone in patients with systemic lupus erythematosus: a prospective, randomized, double-blind, placebo-controlled trial]. Cai, Q; Feng, YL; Guan, JL; Ling, CQ; Xu, MJ; Xu, X; You, YL; Zhang, LL, 2010)	2.07
"The prognosis and management of acute exacerbations of hepatitis-B in patients with lymphoma after chemotherapy in combination with rituximab remain unclear."	( Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Chen, ZH; Dong, M; Li, X; Lin, Q; Ma, XK; Wei, L; Wen, JY; Wu, XY, 2010)	0.36
"This randomized trial was performed to investigate the efficacy of low-dose rituximab in combination with glucocorticoids for treatment of patients with immune thrombocytopenia (ITP)."	( Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Cao, J; He, X; Li, Z; Lu, G; Mou, W; Pan, X; Xu, K, 2011)	0.37
" All patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for varying durations."	( Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma. Dogan, A; Galardy, PJ; Khan, SP; Kumar, R; Rodriguez, V, 2011)	0.59
"To investigate the therapeutic effects and mechanisms of using artemisinin (Art) combined with glucocorticoid (GC) to treat lupus nephritis (LN) mice."	( Effect of artemisinin combined with glucocorticoid on the expressions of glucocorticoid receptor α mRNA, glucocorticoid receptor β mRNA and P300/CBP protein in lupus nephritis mice. An, P; Qiao, CL; Shi, XM; Sun, WS; Wang, Z; Wu, XL; Zhang, WG, 2011)	0.37
"As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed by autologous stem-cell transplantation has also been advocated for high-risk patients."	( Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Anglaret, B; Belhadj, K; Brechignac, S; Casasnovas, O; Ferme, C; Feugier, P; Fitoussi, O; Gabarre, J; Ghesquieres, H; Gisselbrecht, C; Haioun, C; Herbrecht, R; Janvier, M; Morschhauser, F; Mounier, N; Parrens, M; Salles, G; Tilly, H; Van Den Neste, E; Ysebaert, L, 2011)	0.37
" We conducted a phase I trial to establish the maximum tolerated dose of lenalidomide that could be combined with R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone)."	( Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE, 2011)	0.56
"This study was purposed to investigate the changes of serum immunoglobulin (Ig) level during treatment of diffuse large B cell lymphoma by using rituximab (RTX) combined with CHOP."	( [Change of serum immunoglobulin level in patients with diffuse large B cell lymphoma after rituximab combined with chemotherapy]. Gao, CJ; Huang, WR; Li, HH; Wang, QS; Wang, SH; Yu, L; Zhao, Y, 2011)	0.37
"This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients."	( Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ, 2012)	0.87
"To study the treatment effects of cultured Cordyceps sinensis combined with glucocorticosteroid on experimental pulmonary fibrosis in rats induced by bleomycin."	( [Effectiveness of cultured Cordyceps sinensis combined with glucocorticosteroid on pulmonary fibrosis induced by bleomycin in rats]. Gu, Y; Li, S; Liao, D; Lin, Y; Liu, R; Xu, H, 2011)	0.37
" sinensis combined with prednisone group."	( [Effectiveness of cultured Cordyceps sinensis combined with glucocorticosteroid on pulmonary fibrosis induced by bleomycin in rats]. Gu, Y; Li, S; Liao, D; Lin, Y; Liu, R; Xu, H, 2011)	0.68
"AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)."	( Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012)	0.84
"AT-101 was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high-risk patients."	( Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012)	0.64
" In preclinical and clinical studies, panobinostat showed good anti-myeloma activity in combination with several agents."	( Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012)	0.64
"An international, Phase II trial was conducted to assess two doses of ofatumumab, a human CD20 monoclonal antibody, combined with cyclophosphamide (750 mg/m(2) ), doxorubicin (50 mg/m(2) ), prednisone (100 mg days 3-7) and vincristine (1·4 mg/m(2) ) (O-CHOP), as frontline treatment for follicular lymphoma (FL)."	( Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Czuczman, MS; Gadeberg, OV; Goldstein, N; Gupta, I; Hess, G; Jewell, RC; Lin, TS; Lisby, S; Pedersen, LM; Strange, C; Viardot, A; Windfeld, K, 2012)	0.57
"Bortezomib has demonstrated efficacy in patients with relapsed B-cell non-Hodgkin lymphoma (NHL) both alone and in combination with other agents; however, limited data exist regarding its toxicity in combination with common frontline therapies for indolent NHL."	( A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M, 2012)	0.58
"Bortezomib combined with modified R-CHOP produced high response rates without substantial increases in toxicity."	( A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Bumpers, K; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; Kaufman, JL; Khoury, HJ; King, N; Lechowicz, MJ; Lewis, C; Lonial, S; Shenoy, PJ; Sinha, R; Tighiouart, M, 2012)	0.58
"The authors present the report of an ankylosing spondylitis combined with angioimmunoblastic T cell lymphoma after the anti-tumour necrosis factor treatment."	( Ankylosing spondylitis combined with angioimmunoblastic T cell lymphoma. Xu, L, 2011)	0.37
"We performed a dose-escalation study to investigate the safety of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)."	( Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012)	0.83
"Three-weekly docetaxel and prednisone could be combined with sorafenib at 400 mg BID on days 1-21 without reaching MTD."	( Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012)	0.92
"We performed a phase II study to evaluate the efficacy of bortezomib in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas (PTCLs) based on our phase I study results."	( Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Do, IG; Huh, J; Kang, HJ; Kim, HJ; Kim, HK; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, SS; Min, SK; Park, SK; Ryoo, BY; Suh, C; Yang, WI; Yoon, DH, 2012)	0.58
"To study the effectiveness of mycophenolate mofetil (MMF) as first-line therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease."	( The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar, AM; Al-Mezaine, HS; Al-Muammar, AM; Hemachandran, S; Kangave, D, 2012)	0.38
" Here, safety of LDE as carmustine carrier (50 mg m(-2) , intravenous) combined with vincristine and prednisone for the treatment of dogs with lymphoma was tested and compared with commercial carmustine with vincristine and prednisone."	( Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma. Barboza, R; Coelho, BM; Guerra, JL; Lucas, SR; Maranhão, RC; Pozzi, DH, 2015)	0.85
"To research the effects of Qingyang Toujie Mixture (QTM) in combination with prednisone tablet on the balance of Th1 and Th2 (Th1/Th2) of systemic lupus erythematosus (SLE) patients of yin deficiency syndrome (YDS)."	( [Effects of qingyang toujie mixture in combination with prednisone tablet on Th1/Th2 cytokines in patients suffering from systemic lupus erythematosus]. Chen, YH; Duan, HY; He, YP; Huang, GH; Linag, XF; Liu, Y; Wen, XM; Xu, QY; Zeng, ZL; Zhong, JX, 2013)	0.87
"QTM in combination with prednisone tablet was effective to improve the balance of Th1/Th2 cytokines, and alleviate the toxic and adverse reactions of hormone or immune inhibitors."	( [Effects of qingyang toujie mixture in combination with prednisone tablet on Th1/Th2 cytokines in patients suffering from systemic lupus erythematosus]. Chen, YH; Duan, HY; He, YP; Huang, GH; Linag, XF; Liu, Y; Wen, XM; Xu, QY; Zeng, ZL; Zhong, JX, 2013)	0.94
"Aflibercept in combination with docetaxel and prednisone given as first-line chemotherapy for men with metastatic castrate-resistant prostate cancer resulted in no improvement in overall survival and added toxicity compared with placebo."	( Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Arén, O; Bavbek, S; Birtle, A; Elliott, T; Fizazi, K; Fléchon, A; Gil, T; Gravis, G; Hatteville, L; Ivanov, S; Karlsson, CT; Karyakin, O; Magherini, E; Matveev, V; Orlandi, F; Petrylak, D; Rosenthal, M; Skoneczna, I; Tannock, IF; Tombal, B; Viana, L, 2013)	0.89
") in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)."	( Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Aziz, R; Ghosh, D; Ibrahim, A; Justice, R; Kluetz, PG; Maher, VE; Mehrotra, N; Ning, YM; Palmby, T; Pazdur, R; Pfuma, E; Sridhara, R; Tang, S; Tilley, A; Zhang, L; Zirkelbach, JF, 2013)	0.97
" In this study we assessed cytotoxicity of ONC in combination with currently used anticancer drugs on a human diffuse large B-cell lymphoma (DLBCL)-derived cell line (Toledo)."	( In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line. Bogusz, J; Cebula-Obrzut, B; Darzynkiewicz, Z; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P; Witkowska, M; Zwolińska, M, 2013)	0.39
"GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy."	( Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Chen, H; Cheng, L; Kang, Y; Li, L; Pan, C; Shu, X; Sun, M; Xu, X, 2014)	0.4
" In the present protocol, bortezomib was combined with bendamustine and prednisone, in order to assess the efficacy and safety of this combination therapy in patients with newly diagnosed/untreated MM."	( Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T, 2014)	0.97
"The aim of the present study was to evaluate the efficacy of cyclosporine A (CsA) combined with medium/low dose prednisone in the treatment of progressive immunoglobulin A nephropathy (IgAN)."	( Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy. Guan, GJ; Liu, ZC; Luo, Q; Lv, XA; Xu, L, 2014)	0.87
" We demonstrated that lenalidomide can be safely combined with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone); this new combination is known as R2CHOP."	( Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. Ansell, SM; Foran, JM; Gascoyne, RD; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; Macon, WR; Micallef, IN; Nelson, GD; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Thompson, CA; Witzig, TE, 2015)	0.62
"Low-dose THAL together with PRED appeared to be effective in the treatment of PMF-associated anemia, and the response duration would prolong significantly if combined with DANA."	( [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y, 2014)	0.67
" We aimed to explore the effectiveness and safety of low-dose prednisone or cyclosporine A (CsA) combined with nucleoside analog (NA) in patients with severe thrombocytopenia associated with HBV-related LC."	( Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. Feng, R; Fu, HX; Hu, JD; Huang, XJ; Jiang, H; Jiang, M; Jiang, Q; Liu, H; Ma, H; Niu, T; Wang, H; Wang, JW; Wang, X; Wang, Z; Wei, L; Xie, YD; Xu, LP; Zhang, XH; Zhu, XL, 2015)	0.66
"The CHOP-OR study is a prospective phase II study to evaluate the safety, feasibility and activity of a CHOP chemotherapy in combination with ofatumumab in induction and subsequent maintenance for patients with newly diagnosed RS."	( Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome. Boyle, L; Clifford, R; Dutton, SJ; Eyre, TA; Francis, A; Roberts, C; Schuh, A, 2015)	0.42
" Ofatumumab in combination with prednisone is safe and a phase II examination of efficacy is ongoing."	( Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Alsina, M; Anasetti, C; Ayala, E; Betts, BC; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Locke, FL; Mishra, A; Nishihori, T; Ochoa-Bayona, L; Perez, L; Pidala, J; Riches, M, 2015)	0.7
"We conducted an open-label, single-arm Phase I/II clinical trial in metastatic CRPC (mCRPC) patients eligible for docetaxel combined with treatment with autologous mature dendritic cells (DCs) pulsed with killed LNCaP prostate cancer cells (DCVAC/PCa)."	( Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Babjuk, M; Bartunkova, J; Becht, E; Bilkova, P; Fucikova, J; Gasova, Z; Horvath, R; Hromadkova, H; Jarolim, L; Kayserova, J; Kubackova, K; Lastovicka, J; Podrazil, M; Rozkova, D; Sochorova, K; Spisek, R; Vavrova, K; Vrabcova, P, 2015)	0.42
"To investigate the efficacy and safety of Rituximab combined with second line regimen for treatment of relapsed and refractory Hodgkin lymphoma."	( [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients]. Li, H; Liu, H; Qiu, L; Xiong, W; Yi, S; Zou, D, 2015)	0.42
"Seven patients with relapsed and refractory Hodgkin lymphoma were treated with Rituximab combined with second line regimen."	( [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients]. Li, H; Liu, H; Qiu, L; Xiong, W; Yi, S; Zou, D, 2015)	0.42
"These results indicate that the Rituximab combined with second line regimen is an effective therapy for relapsed and refractory Hodgkin lymphoma."	( [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients]. Li, H; Liu, H; Qiu, L; Xiong, W; Yi, S; Zou, D, 2015)	0.42
" This study aimed to assess the efficacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab (R-CHOP) by examining the stem cell mobilization in NHL patients."	( Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma. Gui, L; Han, X; He, X; Liu, P; Qin, Y; Shi, Y; Yang, J; Yang, S; Yao, J; Zhang, C; Zhang, S; Zhao, L; Zhou, P; Zhou, S, 2015)	0.42
"To evaluate the efficacy and safety of methotrexate (MTX) used alone or combined with low- to moderate-dose oral corticosteroids (OC) for treating severe AA (totalis, universalis and severe multifocal)."	( Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. Anuset, D; Bernard, P; Perceau, G; Reguiai, Z, 2016)	0.43
"MTX combined with low- to moderate-dose OC may be an efficient and well-tolerated treatment for severe AA."	( Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. Anuset, D; Bernard, P; Perceau, G; Reguiai, Z, 2016)	0.43
" These patients may benefit from rituximab combined with intensive chemotherapy."	( [Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement]. Li, H; Li, Z; Liu, H; Liu, W; Lü, R; Qiu, L; Xiong, W; Yi, S; Zou, D, 2015)	0.42
" We conducted a phase 1b trial to determine the maximum tolerated dose (MTD) of lenalidomide in combination with R-ESHAP (rituximab, etoposide, cisplatin, cytarabine, methylprednisolone) (LR-ESHAP) in patients with relapsed or refractory DLBCL."	( Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A, 2016)	0.43
"To compare the therapeutic effects of prednisone combined with mycophenolate mofetil (MMF) versus cyclosporin A (CsA) in children with steroid-resistant nephrotic syndrome (SRNS)."	( [Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome]. Ding, YF; Duan, CR; Li, ZH; Lin, Z; Wu, TH; Xun, M; Yin, Y; Zhang, L; Zhang, Y, 2016)	0.98
"The clinical data of 164 SRNS children who were treated with prednisone combined with MMF or CsA between January 2004 and December 2013 were collected, and the clinical effect of prednisone combined with MMF (MMF group, 112 children) or CsA (CsA group, 52 children) was analyzed retrospectively."	( [Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome]. Ding, YF; Duan, CR; Li, ZH; Lin, Z; Wu, TH; Xun, M; Yin, Y; Zhang, L; Zhang, Y, 2016)	0.95
"Prednisone combined with MMF or CsA is effective and safe for the treatment of SRNS in children, and within 3 months of treatment, CsA has a better effect than MMF."	( [Comparison of therapeutic effects of prednisone combined with mycophenolate mofetil versus cyclosporin A in children with steroid-resistant nephrotic syndrome]. Ding, YF; Duan, CR; Li, ZH; Lin, Z; Wu, TH; Xun, M; Yin, Y; Zhang, L; Zhang, Y, 2016)	2.15
"To explore the clinical efficacy and safety of rituximab combined with fludarabine and cyclophosphamide for the treatment of the chronic lymphocytic leukemia (CLL)."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
" The patients in control group were treated with CHOP chemotherapy, the patients in observation group were treated with rituximab combined with fludarabine, cyclophosphamide treatment."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
"application of rituximab combined with fludarabine and cyclophosphamide in the treatment of CLL shows the higher curative effect, can effectively improve the symptoms and reduce the incidence of adverse reactions."	( [Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia]. Han, HJ; Lu, YW; Xia, RX, 2016)	0.43
"To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma."	( [Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma]. Yang, YZ, 2016)	0.43
"Compared with CHOPE regimen alone, CHOPE regimen combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma can efficiently delay the disease progression, reduce tumor burden level, enhance the long-term survival rate, morever did not increase the risk of toxic side effects."	( [Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma]. Yang, YZ, 2016)	0.43
"Low-dose P given with or without AA is associated with low overall incidence of CA-AEs."	( Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Charnas, R; Chi, KN; de Bono, JS; De Porre, P; Fizazi, K; Gomella, LG; Londhe, A; McGowan, T; Miller, K; Montgomery, B; Pelhivanov, N; Rathkopf, DE; Ryan, CJ; Scher, HI; Shore, ND; Todd, MB, 2016)	0.65
"To evaluate the safety, preliminary efficacy, and pharmacokinetics of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in combination with the immunochemotherapeutic regimen, rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP), in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL)."	( Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. Ananthakrishnan, R; Boni, J; Crump, M; Davies, A; Hatake, K; Ishibashi, T; MacDonald, D; Ogura, M; Paccagnella, ML; Tobinai, K; Vandendries, E, 2016)	0.62
"To evaluate the efficacy and adverse effects of low dose thalidomide (TD) combined with modified VCMP (vincristine+cyclophosphamide+melphalan+prednisone) (TD+mVCMP) and VAD (vincristine+doxorubicin+dexamethsone) (TD+VAD) regimens for treating aged patients with MM."	( [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Liu, HB; Wang, W, 2016)	0.64
"Low dose TD combined with modified VCMP regimen for treatment of newly diagnosed aged patients with MM is safe and effective, which may be used as the first line treatment regimen for population in aged MM patients."	( [Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Liu, HB; Wang, W, 2016)	0.43
" The primary endpoint of the phase 1 portion of this study was to establish the maximum tolerated dose of everolimus that could be combined with R-CHOP-21."	( Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; McPhail, E; Micallef, IN; Nowakowski, GS; Witzig, TE, 2016)	0.43
"The mTORC1 inhibitor everolimus given for 14 days in combination with R-CHOP-21 for patients with DLBCL is safe."	( Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; McPhail, E; Micallef, IN; Nowakowski, GS; Witzig, TE, 2016)	0.43
" Bortezomib is the first product to be approved for the treatment of patients with previously untreated MCL, for whom haematopoietic stem cell transplantation is unsuitable, and is used in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP)."	( Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. Gairy, K; Lee, D; Seshagiri, D; Thilakarathne, P; van Keep, M, 2016)	0.82
"To evaluate the effectiveness and safety of mycophenolate mofetil (MMF) as first-line therapy combined with systemic corticosteroids in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease."	( Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar, AM; Al-Muammar, A; Dosari, M; Gikandi, PW; Hemachandran, S, 2017)	0.46
"Use of MMF as first-line therapy combined with systemic corticosteroids in patients with initial-onset acute VKH disease prevents progression to chronic recurrent granulomatous inflammation and development of 'sunset glow fundus'."	( Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Abu El-Asrar, AM; Al-Muammar, A; Dosari, M; Gikandi, PW; Hemachandran, S, 2017)	0.46
" We have previously shown in a retrospective analysis that lenalidomide combined with continuous low-dose cyclophosphamide and prednisone (REP) had remarkable activity in heavily pretreated, lenalidomide-refractory MM patients."	( Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S, 2016)	0.87
"We treated 4 with a diagnosis of diffuse large B cell lymphoma involving the gastrointestinal tract with rituximab combined with adjusted dose EPOCH (R-DA-EPOCH) scheme based on a comprehensive analysis of the onset process, clinical and pathological features, and prognosis of the patients, and evaluated their treatment response."	( [Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases]. Guo, YX; Hu, RH; Hui, WH; Su, L; Sun, WL; Wan, SG; Zhao, H, 2016)	0.43
" In both animal models the anti-lymphoma activity of selinexor is enhanced through combination with DEX or EVER."	( Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Aboukameel, A; Azmi, AS; Baloglu, E; Bhutani, D; Carlson, R; Elloul, S; Kauffman, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Zonder, J, 2016)	0.43
"The aim of this study was to evaluate the clinical efficacy of Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma."	( Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials. Fang, B; Jiang, J; Jiang, Y; Jin, W; Lan, Y; Liu, M; Liu, Y; Ma, G; Qu, Z; Wang, X; Zeng, Y, 2016)	0.43
" All the clinical studies related to Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma were screened and reviewed."	( Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials. Fang, B; Jiang, J; Jiang, Y; Jin, W; Lan, Y; Liu, M; Liu, Y; Ma, G; Qu, Z; Wang, X; Zeng, Y, 2016)	0.43
" The pooled results showed that Aidi injection combined with CHOP chemotherapy regimen can significantly improve the ORR (odds ratio [OR] =1."	( Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials. Fang, B; Jiang, J; Jiang, Y; Jin, W; Lan, Y; Liu, M; Liu, Y; Ma, G; Qu, Z; Wang, X; Zeng, Y, 2016)	0.43
"With the present evidence, Aidi injection combined with CHOP chemotherapy regimen can improve the treatment response and quality of life and decrease the risk of developing severe leukopenia or thrombocytopenia."	( Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials. Fang, B; Jiang, J; Jiang, Y; Jin, W; Lan, Y; Liu, M; Liu, Y; Ma, G; Qu, Z; Wang, X; Zeng, Y, 2016)	0.43
"LEF combined with prednisone has a certain efficacy on the RNS and displays few adverse reactions."	( Efficacy of leflunomide combined with prednisone in the treatment of refractory nephrotic syndrome. Chen, W; Liu, L; Liu, Y; Qu, X; Zhang, Y, 2016)	1.04
" The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients."	( The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M, 2017)	0.46
"This was a phase I/II trial to determine the safety and efficacy of alisertib when given in combination with abiraterone plus prednisone (AP)."	( A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z, 2016)	0.86
"A tolerable dose of alisertib in combination with AP in mCRPC was not established in this study."	( A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z, 2016)	0.65
" The aim of the SYNERGY trial was to investigate the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients with metastatic castration-resistant prostate cancer."	( Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Bergman, AM; Blumenstein, B; Chi, KN; de Bono, JS; Ferrero, JM; Feyerabend, S; Gleave, M; Gravis, G; Higano, CS; Jacobs, C; Merseburger, AS; Mukherjee, SD; Reeves, J; Saad, F; Stenzl, A; Zalewski, P, 2017)	0.93
" Drug-drug interactions (DDIs) may occur in prostate cancer patients due to inhibition by abiraterone of liver cytochrome P450 (CYP)-dependent enzymes CYP2C8 and 2D6, which are involved in the metabolism of approximately 25% of all drugs, and induction by enzalutamide of CYP3A4, 2C9 and 2C19, which metabolize up to 50% of medications."	( The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Bracarda, S; Crucitta, S; Danesi, R; De Souza, P; Del Re, M; Derosa, L; Fogli, S; Massari, F; Santini, D, 2017)	0.67
"We evaluated the efficacy and safety of tacrolimus (TAC) combined with corticosteroids in treating patients with idiopathic membranous nephropathy (IMN)."	( Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy. Cui, W; Dong, W; Guan, S; Li, Q; Li, W; Liu, M; Lu, X; Luo, M; Luo, P; Miao, L; Min, X; Wang, Y, 2017)	0.46
" The authors used appropriate linear regression univariate models and created 5 different multivariate models to examine individual drug-drug interactions (DDIs)."	( A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA. Alvarez-Elías, AC; Filler, G; Singh, RN; Todorova, EK; Yoo, EC, 2017)	0.69
" We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel."	( Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph Alekseev, B; Beer, TM; Blumenstein, B; Chi, KN; Fizazi, K; Fléchon, A; Gravis, G; Hotte, SJ; Jacobs, CA; Joly, F; Malik, Z; Matveev, V; Saad, F; Stewart, PS, 2017)	0.94
"To investigate the effectiveness, visual outcome, and prognostic factors of Vogt-Koyanagi-Harada (VKH) disease treatment with a reduced dose of corticosteroids combined with immunosuppressive agents."	( Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents. Du, L; Kijlstra, A; Liang, L; Qi, J; Wang, C; Wu, L; Yang, P; Ye, Z; Zhou, Q, 2018)	0.48
" Reduced doses of corticosteroids combined with immunosuppressive agents were used for 1-1."	( Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents. Du, L; Kijlstra, A; Liang, L; Qi, J; Wang, C; Wu, L; Yang, P; Ye, Z; Zhou, Q, 2018)	0.48
"A reduced dose of corticosteroids combined with immunosuppressive agents effectively controlled the intraocular inflammation and improved visual acuity in most Chinese VKH patients."	( Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents. Du, L; Kijlstra, A; Liang, L; Qi, J; Wang, C; Wu, L; Yang, P; Ye, Z; Zhou, Q, 2018)	0.48
"This study aimed to evaluate the efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treating patients with diffuse large B-cell lymphoma (DLBCL)."	( Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. Ding, SS; Guo, L; Hu, X; Li, S; Liang, X; Wen, SJ; Yang, SE; Zeng, M, 2017)	0.66
" S0806 was a single arm phase I/II trial of vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to days 1-5 due to toxicity), combined with R-CHOP given on day 3 of a 21-day cycle for 8 cycles, with primary phase II endpoint of 2-year progression free survival (PFS)."	( A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Bane, CL; Barr, PM; Fisher, RI; Friedberg, JW; LeBlanc, M; Li, H; Persky, DO; Popplewell, LL; Rimsza, LM; Smith, SM; Von Gehr, A, 2018)	0.48
" Case reports and small reviews have evaluated the addition of agents directed against plasma cell disorders in combination with traditional lymphoma-directed regimens."	( Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Dittus, C; Ellsworth, S; Grover, N; Park, SI; Tan, X, 2018)	0.72
"A pharmacotherapy combined with early HBO resulted in full recovery of hearing."	( Successful treatment of sudden sensorineural hearing loss by means of pharmacotherapy combined with early hyperbaric oxygen therapy: Case report. Olex-Zarychta, D, 2017)	0.46
" Previous data indicated that treatment with prednisone in combination with antibiotics results in significant acceleration of the healing phase."	( Corticosteroid Therapy in Combination with Antibiotics for Erysipelas. Barzilai, A; Baum, S; Elphasy, H; Solomon, M; Trau, H, 2018)	0.74
"To investigate the effectiveness of corticosteroids combined with antibiotics for the treatment of erysipelas."	( Corticosteroid Therapy in Combination with Antibiotics for Erysipelas. Barzilai, A; Baum, S; Elphasy, H; Solomon, M; Trau, H, 2018)	0.48
"We prospectively enrolled 215 newly diagnosed patients with IgG4-RD, who were initially treated with glucocorticoid (GC) alone or in combination with immunosuppressive agents (IM), and had at least 6 months of follow up."	( Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Fei, Y; Feng, R; Lai, Y; Peng, L; Wang, L; Wang, M; Zeng, X; Zhang, F; Zhang, P; Zhang, W; Zhang, X; Zhao, Y, 2018)	0.48
" To investigate the clinical efficacy of glucocorticoids in combination with ursodesoxycholic acid in the treatment of glucocorticoids in combination with ursodesoxycholic acid, one hundred and twenty patients with AH who were admitted to the hospital from February 2014 and February 2016 were selected and randomly divided into an observation group and a control group using random number table."	( Glucocorticoids in combination with ursodesoxycholic acid in the treatment of autoimmune hepatitis. Li, WY; Wang, YC; Yang, XS, )	0.13
"Lenalidomide in combination with R-CHOP had an acceptable safety profile and showed anti-cancer activity in patients with previously untreated high burden follicular lymphoma."	( Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Becker, S; Bouabdallah, R; Cabeçadas, J; Casasnovas, O; Feugier, P; Gabarre, J; Gouill, SL; Haioun, C; Jardin, F; Lamy, T; Molina, TJ; Morschhauser, F; Mounier, N; Salles, G; Tilly, H; Tournilhac, O, 2018)	0.48
"To assess the efficacy and safety of tacrolimus in combination with corticosteroids in patients with immune-mediated necrotising myopathy."	( Tacrolimus combined with corticosteroids effectively improved the outcome of a cohort of patients with immune-mediated necrotising myopathy. Bu, B; Feng, F; Ji, S; Li, Y; Wang, Q, )	0.13
"The medical records of 20 hospitalised patients with immune-mediated necrotising myopathy (IMNM) who had received tacrolimus combined with oral prednisone from January 2014 to August 2017 were retrospectively reviewed."	( Tacrolimus combined with corticosteroids effectively improved the outcome of a cohort of patients with immune-mediated necrotising myopathy. Bu, B; Feng, F; Ji, S; Li, Y; Wang, Q, )	0.33
" This review will cover the current use of abiraterone acetate in combination with prednisone for the treatment of castration-resistant prostate cancer."	( Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone. Duarte, C; Jimeno, A; Kessler, ER, 2019)	0.96
"The primary purpose of this study was to identify the most common drug-drug interactions (DDI'S) in patients prescribed medications upon discharge from the emergency department."	( Descriptive study of drug-drug interactions attributed to prescriptions written upon discharge from the emergency department. Bridgeman, PJ; Jawaro, T; Mele, J; Wei, G, 2019)	0.51
" The primary endpoint is the identification and characterization of drug-drug interactions caused by discharge prescriptions written by the treating physician."	( Descriptive study of drug-drug interactions attributed to prescriptions written upon discharge from the emergency department. Bridgeman, PJ; Jawaro, T; Mele, J; Wei, G, 2019)	0.51
" Here, we explore the therapeutic potential and possible mechanisms of SAA in combination with low-dose prednisone in adriamycin (ADR)-induced minimal change disease (MCD) rat model and mouse podocyte injury cell model."	( Therapeutic and antiproteinuric effects of salvianolic acid A in combined with low-dose prednisone in minimal change disease rats: Involvement of PPARγ/Angptl4 and Nrf2/HO-1 pathways. Fan, H; Fu, F; Gao, Z; Ji, K; Kong, L; Li, X; Liu, K; Liu, Y; Qi, D; Wang, X; Xie, H; Yu, C; Yue, G; Zhu, H, 2019)	0.95
" We observed the efficacy and safety of tocilizumab combined with methotrexate (MTX) in the treatment of refractory AOSD, and to explore the possibility of reducing the dosage of tocilizumab after disease control."	( Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article. Guo, SH; Shen, HL; Wang, CY; Wang, LP, 2019)	0.51
" We report the pharmacokinetics (PK) and drug-drug interaction (DDI) for pola."	( Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Agarwal, P; Dere, RC; Girish, S; Jin, JY; Lee, C; Li, C; Li, X; Lu, D; Lu, T; Miles, D; Shemesh, CS, 2020)	0.56
" Pola was evaluated as a potential victim and perpetrator of a PK drug-drug interaction with R/G-CHP."	( Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Agarwal, P; Dere, RC; Girish, S; Jin, JY; Lee, C; Li, C; Li, X; Lu, D; Lu, T; Miles, D; Shemesh, CS, 2020)	0.56
"We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas."	( Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Bair, SM; Ballard, H; Barta, SK; Bogusz, AM; Chong, E; Dwivedy Nasta, S; Filicko-O'Hara, J; Gaballa, S; Gerson, J; Hung, SS; Khan, N; King, C; Landsburg, DJ; Lim, M; Maity, A; Mitnick, S; Nagle, SJ; Nakamura, H; Nejati, R; Plastaras, JP; Ruella, M; Schuster, SJ; Steidl, C; Strelec, L; Svoboda, J; Waite, TS; Youngman, M, 2021)	1.04
" Abiraterone acetate in combination with prednisone was the first approved hormone therapy demonstrating survival benefit, and represents, to date, an alternative, or a second-line treatment after taxane-based chemotherapy, in addition to androgen-deprivation therapy, in hormone sensitive, and metastatic castration-resistant prostate cancer."	( Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. Manceau, C; Mourey, L; Ploussard, G; Pouessel, D, 2020)	1.09
" High-dose chemotherapy regimens such as DA-EPOCH should be administered to young patients in combination with rituximab."	( Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma. Chen, Z; Li, Y; Tian, C, 2020)	0.56
" In a monocentric cohort of 68 SMLZ patients, we showed that rituximab in monotherapy or in combination with bendamustine, compared with rituximab associated with the polychemotherapy cycle cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP), resulted in a higher 5-year progression-free survival (91."	( Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life. Cabras, MG; Caocci, G; Dessì, D; La Nasa, G; Mantovani, D; Moi, G; Mulas, O, 2021)	0.62
" We conducted a phase II study to investigate the efficacy and safety of dose-adjusted (DA)- EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) combined with high-dose methotrexate (HD-MTX) in newly diagnosed patients with CD5+ DLBCL."	( DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Asano, N; Igarashi, T; Izutsu, K; Katayama, N; Kato, K; Kinoshita, T; Miyawaki, K; Miyazaki, K; Nishikawa, M; Nishikori, M; Nishimura, Y; Ohata, K; Ohshima, K; Okamoto, M; Sakai, R; Sunami, K; Suzumiya, J; Takahashi, N; Tamaru, S; Yamada, T; Yamaguchi, M; Yamamoto, G; Yano, H; Yoshida, I, 2020)	0.77
" This study was designed to explore the effect of dexamethasone and gamma globulin combined with prednisone in the treatment of pediatric HSPN."	( Effects of dexamethasone and gamma globulin combined with prednisone on the therapeutic effect and immune function of Henoch-Schonlein purpura nephritis in children. Chen, L; Liu, X; Ma, K; Wang, X; Yin, L, 2021)	1.08
"According to the treatment plan, 60 children treated with dexamethasone and gamma globulin were included in the control group, and the rest 55 children treated with dexamethasone and gamma globulin combined with prednisone were selected as the research group."	( Effects of dexamethasone and gamma globulin combined with prednisone on the therapeutic effect and immune function of Henoch-Schonlein purpura nephritis in children. Chen, L; Liu, X; Ma, K; Wang, X; Yin, L, 2021)	1.05
"Dexamethasone and gamma globulin combined with prednisone can improve the immune function of children with HSPN and promote the recovery of renal function."	( Effects of dexamethasone and gamma globulin combined with prednisone on the therapeutic effect and immune function of Henoch-Schonlein purpura nephritis in children. Chen, L; Liu, X; Ma, K; Wang, X; Yin, L, 2021)	1.12
"To analyze the efficacy of rituximab combined with CHOP/EPOCH regimen for treatment of diffuse large B-cell lymphoma（DLBCL） patients, and to explore the high risk factors of refractory and relapsed patients."	( [Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen]. Chen, BA; Gao, C; Gu, Y; Wu, X; Zhang, J, 2020)	0.56
" The remission rate of DLBCL patients treated by rituximab combined with CHOP/EPOCH was analyzed, and survival analysis was conducted to explore the risk factors influencing refractory recurrence."	( [Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen]. Chen, BA; Gao, C; Gu, Y; Wu, X; Zhang, J, 2020)	0.56
"The remission rate of DLBCL patients treated by rituximab combined with CHOP/EPOCH regimen is high, but about one third of the patients still show refractory and relapsed."	( [Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen]. Chen, BA; Gao, C; Gu, Y; Wu, X; Zhang, J, 2020)	0.56
" Although the safety profile and efficacy of RW-CHOP was comparable with R-CHOP and its tolerability was acceptable, weekly rituximab in combination with CHOP during the early treatment period did not improve PFS in untreated patients with DLBCL."	( A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Ando, K; Dobashi, N; Fukuhara, N; Hotta, T; Iida, S; Imaizumi, Y; Ishizawa, K; Kinoshita, T; Kuroda, J; Maruyama, D; Masaki, Y; Miyazaki, K; Mizutani, T; Murayama, T; Nagai, H; Nosaka, K; Ogawa, G; Ogura, M; Ohmachi, K; Suehiro, Y; Takamatsu, Y; Tobinai, K; Tokunaga, T; Tsukamoto, N; Tsukasaki, K; Uchida, T; Utsumi, T; Yakushijin, Y; Yamamoto, K; Yamauchi, N; Yoshida, I; Yoshida, S; Yoshino, T, 2021)	0.62
" We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide)."	( A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. Albany, C; Dawson, NA; Higano, CS; Mehlhaff, BA; Nordquist, LT; Patel, KR; Petrylak, DP; Quinn, DI; Sartor, O; Siegel, J; Trandafir, L; Vaishampayan, UN; Wagner, VJ, 2021)	0.99
"Technetium-99m imaging BSLA may offer objective, quantifiable assessment of isotope uptake changes, and potentially treatment response, in patients with mCRPC and bone metastases treated with radium-223 alone or in combination with abiraterone/prednisone or enzalutamide."	( A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. Albany, C; Dawson, NA; Higano, CS; Mehlhaff, BA; Nordquist, LT; Patel, KR; Petrylak, DP; Quinn, DI; Sartor, O; Siegel, J; Trandafir, L; Vaishampayan, UN; Wagner, VJ, 2021)	0.99
"This study evaluated the clinical efficacy of leflunomide combined with low-dose prednisone (0."	( Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. Chen, J; Huang, X; Liu, W; Lu, Y; Ou, C; Qiu, L; Ran, H; Yang, W, 2023)	1.37
"Many clinical trials have assessed the effect and safety of monoclonal antibodies (MAbs) in combination with proteasome inhibitors or immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma (MM)."	( Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled tr Deng, J; Gong, Y; Liu, X; Wu, X; Ye, W; Zheng, X, 2021)	1.02
" In conclusion, MAbs targeting CD38 are the best, followed by those targeting SLAMF7; MAbs targeting PD-1/PD-L1 are the worst when in combination with bortezomib/immunomodulators plus dexamethasone/prednisone for the treatment of MM."	( Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled tr Deng, J; Gong, Y; Liu, X; Wu, X; Ye, W; Zheng, X, 2021)	1.01
" We present population pharmacokinetics (PopPK) and exposure-response (ER) analyses for venetoclax (a selective BCL-2 inhibitor) administered with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with relapsed/refractory (R/R) and previously untreated (1L) non-Hodgkin lymphoma (NHL) from the phase 1b/2 CAVALLI study, to confirm dose selection for future studies."	( Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R, 2022)	0.91
"Analyses included 216 patients with R/R or 1L NHL treated for eight 21-day cycles with 400-800 mg venetoclax (cycle 1: days 4-10; cycles 2-8: days 1-10) in combination with R for eight cycles and CHOP for 6-8 cycles."	( Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R, 2022)	0.72
"The PopPK and ER analyses, in addition to the positive benefit-risk observed in the clinical data, support the selection of 800 mg venetoclax given with R-CHOP for future studies in BCL-2-immunohistochemistry-positive patients with 1L DLBCL."	( Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R, 2022)	0.72
" The experimental group took oral cyclosporine A and prednisone tablets, while the control group received oral cyclosporine A combined with shock therapy."	( Clinical nephrotoxicity induced by cyclosporin A combined with hormone therapy for nephrotic syndrome. Huang, Y; Li, G; Liu, X; Song, Q; Wang, C; Wang, R; Xun, Z, 2021)	0.87
"Ribociclib, a CDK4/6 inhibitor, demonstrates preclinical antitumor activity in combination with taxanes."	( A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Aggarwal, R; Carneiro, BA; de Kouchkovsky, I; Fong, L; Friedlander, T; Lewis, C; Paris, PL; Phone, A; Rao, A; Ryan, CJ; Small, EJ; Szmulewitz, RZ; Zhang, L, 2022)	0.94
"Rituximab (R) or obinutuzumab (G) combined with CHOP chemotherapy are used in previously untreated follicular lymphoma (FL)."	( Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma. Boulanger, C; Claustre, G; Durot, E; Etienne-Selloum, N; Fornecker, LM; Graff, V; Maloisel, F; Slimano, F, 2023)	0.91
"This study retrospectively explored the effectiveness of electroacupuncture (EA) combined with Qianzhengsan decoction (QZSD) for the treatment of peripheral facial paralysis (PFP)."	( Electroacupuncture combined with Qianzhengsan decoction for the treatment of peripheral facial paralysis: A retrospective study. Chen, WQ; Li, Q, 2022)	0.72
"To investigate the efficacy of cyclophosphamide combined with prednisone in membranous nephropathy (MN) patients with different cytochrome P450 (CYP) 2B6 gene polymorphisms and explore the factors influencing the efficacy."	( The Efficacy of Cyclophosphamide Combined with Prednisone in Membranous Nephropathy Patients with Different Cytochrome P450 2B6 Gene Polymorphisms and Analysis of Factors Influencing the Efficacy. Liu, H; Lv, Y; Zhang, M, 2022)	1.22
"Cyclophosphamide combined with prednisone was effective in treating MN with different CYP2B6 gene polymorphisms."	( The Efficacy of Cyclophosphamide Combined with Prednisone in Membranous Nephropathy Patients with Different Cytochrome P450 2B6 Gene Polymorphisms and Analysis of Factors Influencing the Efficacy. Liu, H; Lv, Y; Zhang, M, 2022)	1.26
"To review the drug-drug interactions between tacrolimus and lopinavir/ritonavir in 23 patients who received solid organ transplant during the first wave of COVID-19 and to determine the efficacy as well as safety of prednisone monotherapy."	( Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir. Ambrosioni, J; Arranz, N; Bodro, M; Brunet, M; Castel, MÁ; Cofan, F; Crespo, G; Diekmann, F; Farrero, M; Forner, A; Gonzalez-García, R; LLigoña, A; Marcos, MÁ; Miró, JM; Moreno, A; Rodríguez-García, M; Roma, JR; Ruiz, P; Soy, D; Tuset, M, 2023)	1.1
"This is a retrospective, single-center PSM study evaluating the efficacy and safety of chidamide combined with the CHOEP (C-CHOEP) regimen versus the single CHOEP regimen in patients with untreated peripheral T cell lymphomas (PTCL)."	( Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study. Wang, W; Wei, C; Zhang, W; Zhang, Y; Zhao, D; Zhou, D, 2023)	1.11
" Aim: This study aimed to perform a retrospective analysis for analyzing the efficacy of treatment with oral steroids combined with postauricular steroid injection in patients with delaying effective treatment."	( Effects of Oral Steroids Combined with Postauricular Steroid Injection on Patients with Sudden Sensorineural Hearing Loss with Delaying Intervention: A Retrospective Analysis. Fei, B; Liu, ZB; Lv, LY; Zhu, WY, 2023)	0.91
"Oral steroids combined with postauricular steroid injection should be employed for treatment of SSNHL patients with delaying effective treatment over three weeks."	( Effects of Oral Steroids Combined with Postauricular Steroid Injection on Patients with Sudden Sensorineural Hearing Loss with Delaying Intervention: A Retrospective Analysis. Fei, B; Liu, ZB; Lv, LY; Zhu, WY, 2023)	0.91

Bioavailability

Oral dexamethason can be considered as a non-cytotoxic biomaterial with high potential to improve the mesalamine and prednisone bioavailability by sustaining the drug release and enhancing drug permeability.

Excerpt	Reference	Relevance
" Prednisone is effectively absorbed and converted to its active therapeutic derivative, prednisolone, in healthy volunteers and in patients with liver disease; the bioavailability of oral prednisone approximates 100% of an intravenous dose and is comparable after administration of either prednisone or prednisolone."	( Corticosteroid pharmacokinetics in liver disease. Go, VL; Uribe, M, )	1.04
" In patients, variability was similarly wide after both preparations, but overall bioavailability after both prednisone and prednisolone was similar to that found in controls, although three patients showed subnormal values after both preparations, possibly as a result of impaired intestinal absorption."	( Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Chakraborty, J; Davis, M; English, J; Ideo, G; Marks, V; Tempini, S; Williams, R, 1978)	1.91
" Factors that affect bioavailability among drugs of the same type (especially oral drugs) include not only disintegration and absorption rates but also the amount of food taken before or with the dose, interactions with other drugs, the physical state of the patient, and the "first-pass effect" upon drug with high liver clearance."	( Drug bioavailability studies. Wagner, JG, 1977)	0.26
"A three-way crossover bioavailability study was performed using nine adult male volunteers with three different commercial prednisone tablets."	( In vitro and in vivo availability of commercial prednisone tablets. Albert, KS; Blair, DC; Sakmar, E; Sullivan, TJ; Wagner, JG, 1975)	0.72
"In a clinical study involving 22 normal adult volunteers, the bioavailability and pharmacokinetics of prednisone tablets with varying dissolution rates were evaluated."	( Bioavailability and pharmacokinetics of prednisone in humans. Desante, KA; Disanto, AR, 1975)	0.74
"This presentation has attempted to provide a brief view of the importance of bioavailability and bioequivalence to those physicians who use corticosteroids."	( Corticosteroids and bioavailability. Stubbs, SS, 1975)	0.25
" A considerable inter-patient variation in bioavailability after a standard dose of prednisolone (20 mg) was noted."	( Measurement of plasma prednisolone in man. May, CS; Paterson, JW; Ssendagire, R; Wilson, CG, 1975)	0.25
"Several reports document an inverse correlation between bioavailability of maintenance chemotherapeutic agents and the likelihood of relapse in childhood."	( Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Blatt, J; Gula, MJ; Lucas, K, )	0.13
" Bioavailability averaged 88."	( Altered prednisolone pharmacokinetics in patients with cystic fibrosis. Accurso, FJ; Dove, AM; Hill, MR; Jusko, WJ; Larsen, GL; Szefler, SJ, 1992)	0.28
"A randomized, four-way cross-over study was conducted in eight healthy male volunteers to determine the relative and absolute bioavailability of prednisone (PN) and prednisolone (PL)."	( Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. Bekersky, I; Colburn, WA; Ferry, JJ; Heath, EC; Horvath, AM; Ryan, CF, 1988)	0.74
"The relative bioavailability of single oral doses of prednisone with and without sucralfate administration was determined in 12 healthy male volunteers."	( Lack of effect of sucralfate on prednisone bioavailability. Amend, WJ; Birnbaum, J; Gambertoglio, JG; Lizak, P; Romac, DR; Yong, CL, 1987)	0.81
" The bioavailability of prednisone in these patients exhibited a low intersubject variability, while the metabolic clearance rate of total and of unbound prednisolone varied considerably from patient to patient."	( Prednisolone clearance: a possible determinant for glucocorticoid efficacy in patients with oral vesiculo-erosive diseases. Benet, LZ; Frey, FJ; Lozada, F, 1983)	0.57
" The bioavailability of prednisone, the interconversion of prednisone into prednisolone, the total and unbound prednisolone clearances, the prednisolone binding capacity of albumin and transcortin, and the affinity of albumin for prednisolone were not different when the 14 patients without cushingoid side effects were compared with the 13 cushingoid patients."	( Endogenous and exogenous glucocorticoids in cushingoid patients. Amend, WJ; Benet, LZ; Frey, BM; Frey, FJ; Lozada, F, 1982)	0.57
"The pharmacokinetics and bioavailability of prednisolone after doses of oral prednisone and intravenous prednisolone were determined in seven patients receiving corticosteroids for treatment of inflammatory bowel disease in active disease and remission."	( Effect of inflammatory bowel disease on absorption and disposition of prednisolone. George, DE; Jusko, WJ; Lebenthal, E; Milsap, RL; Murray, KA; Szefler, SJ, 1983)	0.49
" Since the absorption rate is not clinically relevant in patients on long-term glycoside therapy, our results indicate that digitoxin is preferable to digoxin in such patients."	( Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion. Kuhlmann, J; Rietbrock, N; Wilke, J, 1982)	0.26
"Limited information is available on the pharmacokinetics and bioavailability of prednisone and prednisolone in patients with different disease states."	( Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. Amend, WJ; Benet, LZ; Gambertoglio, JG, 1980)	0.76
"Prednisone and prednisolone are drugs with the potential for therapeutic inequivalence due to bioavailability problems."	( Prednisone and prednisolone bioavailability in renal transplant patients. Amend, WJ; Birnbaum, JL; Feduska, NJ; Frey, FJ; Gambertoglio, JG; Holford, NH; Lizak, PS; Salvatierra, O; Vincenti, F, 1982)	3.15
"To assess the relative bioavailability of a recently developed liquid prednisone preparation, prednisolone pharmacokinetics were evaluated after the administration of three separate steroid preparations."	( Bioavailability assessment of a liquid prednisone preparation. Flesher, KA; Georgitis, JW; Szefler, SJ, 1982)	0.77
" Distribution, elimination and other bioavailability parameters were calculated from the obtained data."	( [Pharmacokinetics of prednisolone in adrenal insufficiency ]. Benker, G; Hackenberg, K; Reinwein, D; von Papen, C, 1982)	0.26
"The pharmacokinetics and bioavailability of prednisolone and prednisone after doses of 60 mg/m2 oral prednisone and 50 mg/m2 intravenous prednisolone were determined in six children receiving corticosteroids for treatment of nephrotic syndrome during active disease and in remission."	( Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. Appiani, AC; Assael, BM; Edefonti, A; Jusko, WJ; Rocci, ML, 1982)	0.51
" Renal graft impairment together with decreased IGF bioavailability may, in addition to the presumed direct effects of PDN on cartilage, contribute to the growth retardation after RTx."	( Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation. Blum, WF; de Muinck Keizer-Schrama, SM; Drop, SL; Hokken-Koelega, AC; Stijnen, T, 1993)	0.49
"No significant differences in area under the serum concentration versus time curve (AUC), maximal methotrexate concentration following dosing (Cmax), time to Cmax (Tmax), bioavailability (F), urinary MTX, renal clearance of MTX or creatinine clearance were observed between the 2 cohorts."	( Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. Hamilton, RA; Kremer, JM; Petrillo, GF, 1995)	0.29
"The pharmacokinetics of prednisone and prednisolone was examined in 12 healthy male subjects to assess the bioavailability and the parameters of reversible metabolism between the two steroids."	( Bioavailability and reversible metabolism of prednisone and prednisolone in man. Garg, V; Jusko, WJ, 1994)	0.86
"), the bioavailability (0."	( Metabolism of prednisone in kidney transplanted patients with necrosis of the femoral head. Egfjord, M; Lausten, GS; Olgaard, K, 1993)	0.65
" The bioavailability of both IGF-I and IGF-II is regulated by specific IGF-binding proteins (IGFBPs)."	( Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Aumann, V; Blum, WF; Kluba, U; Mittler, U; Mohnike, KL; Vorwerk, P, 1996)	0.29
" This study suggests that variable oral bioavailability of CsA represents a biopharmaceutical risk factor for the occurrence of chronic rejection."	( Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Kahan, BD; Katz, SM; Rutzky, LP; Schoenberg, L; Urbauer, DL; Van Buren, CT; Welsh, M, 1996)	0.29
"01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%."	( A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. Kamada, AK; LaVallee, NM; Scott, MB; Selner, JC; Szefler, SJ; Wiener, MB, )	0.36
"Fluticasone propionate is a glucocorticoid with negligible oral bioavailability and very low intranasal bioavailability that is used as an intranasal spray for the treatment of rhinitis."	( Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. Dockhorn, RJ; Field, EA; Findlay, SR; Korenblat, PE; Kral, KM; Vargas, R, 1998)	0.54
" No correlation was found between the degree of gastrointestinal damage and the presumed bioavailability of co-trimoxazole as estimated from serum levels of trimethoprim and sulphamethoxazole."	( Gastrointestinal damage induced by cytostatic treatment does not affect the bioavailability of co-trimoxazole. Höglund, P; Johnsson, A; Ljungberg, B; Nilsson-Ehle, I; Nyhlén, A, )	0.13
"Prednisone and methylprednisolone are well absorbed orally and have lower treatment costs than IV methylprednisolone, but concern that low-dose corticosteroid may cause increased disease activity and that high oral doses may cause gastric ulceration inhibits use of oral therapy for MS attacks."	( Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Enns, R; Hilsden, RJ; Meddings, JB; Metz, LM; Sabuda, D, 1999)	2.01
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
"Oral budesonide in adult studies is a potent corticosteroid with decreased systemic bioavailability and an improved adverse effect profile in comparison with prednisone."	( Benign intracranial hypertension associated with budesonide treatment in children with Crohn's disease. Ballin, A; Bujanover, Y; Hager, H; Lerman-Sagie, T; Levine, A; Watemberg, N, 2001)	0.51
"To quantify the influence of a high-fat meal on the oral bioavailability of the immunosuppressant everolimus in a single-dose study in healthy subjects and to confirm the results in a small food-effect screening assessment in patients with renal transplants who were receiving multiple-dose everolimus."	( Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Budde, K; Figueiredo, J; Golor, G; Hartmann, S; Kovarik, JM; Lison, A; Neumayer, HH; Rordorf, C, 2002)	0.31
" The results of these studies indicate that prednisone has poor efficacy for the treatment of heaves because it is poorly absorbed and the active metabolite prednisolone is rarely produced."	( Prednisone per os is likely to have limited efficacy in horses. Kollias-Baker, C; Peroni, DL; Robinson, NE; Stanley, S, 2002)	2.02
"As a part of a steroid-sparing clinical trial, we studied the effect of steroids on MPA bioavailability in 26 kidney transplant recipients."	( Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Cattaneo, D; Gaspari, F; Gotti, E; Perico, N; Remuzzi, G, 2002)	0.31
" Bioavailability of cyclosporin (CsA) has been implicated as a possible contributing factor."	( Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. Browne, BJ; Emovon, OE; Holt, CO; Howell, D; King, JA; Singleton, B, 2003)	0.32
" Interaction between copper and other stressors operating only in the field probably balance the higher bioavailability in spiked soil."	( Effect of a copper gradient on plant community structure. Attrill, MJ; Axelsen, JA; Jensen, J; Pedersen, MB; Strandberg, B, 2006)	0.33
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
"In the setting of a controlled clinical study, the co-administration of GFJ with FK506 increased the bioavailability of FK506."	( Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Liu, C; Liu, XM; Lv, Y; Ma, F; Shang, YF; Wang, B; Wu, Z; Yu, L; Zhang, XF; Zhang, XG, 2009)	0.35
"Sunitinib is an orally bioavailable small molecule that inhibits multiple receptor tyrosine kinases."	( Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor. Atrash, F; Bar-Sela, G; Hadad, S; Haim, N; Kedem, E; Pollack, S; Shahar, E, 2010)	0.36
"Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects."	( Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C, 2010)	0.75
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Hepatic biotransformation of 1α,25(OH)(2)D(3) by cytochrome P450 (P450) enzymes could be an important determinant of bioavailability in serum and tissues."	( Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism. Adomat, H; Deb, S; Guns, ES; Pandey, M, 2012)	0.38
" Administration after a full or light meal did not affect pharmacokinetic characteristics, but bioavailability was reduced under fasted conditions."	( Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. Clarke, L; Derendorf, H; Kirwan, JR; Ruebsamen, K; Schaeffler, A, 2013)	0.66
" Findings suggest low comparative bioavailability of oral prednisone compared to prednisolone in cats and consideration of lean body mass or ideal body weight for dosing practices."	( Influence of body condition on plasma prednisolone and prednisone concentrations in clinically healthy cats after single oral dose administration. Center, SA; Randolph, JF; Rishniw, M; Simpson, KW; Warner, KL, 2013)	0.88
"Cyclosporine exhibits pharmacokinetic and pharmacodynamic variability in renal transplant recipients (RTR) attributed to P-glycoprotein (P-gp), an ABCB1 efflux transporter that influences bioavailability and intracellular distribution."	( Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients. Brazeau, D; Danison, R; DiFrancesco, R; Dole, K; Gillis, K; Gundroo, A; Leca, N; Tornatore, KM; Venuto, RC; Wilding, G; Zack, J, 2013)	0.39
" Our results demonstrate that DSMs can be considered as a non-cytotoxic biomaterial with high potential to improve the mesalamine and prednisone bioavailability by sustaining the drug release and enhancing drug permeability."	( Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine. da Silva, TH; Hirvonen, JT; Mäkilä, EM; Reis, RL; Salonen, JJ; Santos, HA; Shahbazi, MA; Zhang, H, 2013)	0.81
"Oral dexamethasone demonstrates bioavailability similar to that of oral prednisone but has a longer half-life."	( A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma. Alter, HJ; Lam, J; Liu, B; Rehrer, MW; Rodriguez, M, 2016)	0.88
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Primary DLBCL of the central nervous system (CNS) (primary central nervous system lymphoma [PCNSL]) is an exception because of the low CNS bioavailability of related drugs."	( Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. Angelillo, P; Anzalone, N; Bordignon, C; Calimeri, T; Cattaneo, D; Ciceri, F; Citterio, G; Conte, GM; Corti, A; Curnis, F; De Lorenzo, D; Fallanca, F; Ferreri, AJM; Foppoli, M; Guggiari, E; Lopedote, P; Nonis, A; Politi, LS; Ponzoni, M; Rrapaj, E; Sassone, M; Scarano, E; Steffanoni, S; Tarantino, V, 2020)	0.56
" Predictably, the excretion trend of the analytes of interest were generally comparable with those obtained after oral administration, even if the excretion profile showed a broad interindividual variability, with the absorption rate and the systemic bioavailability after rectal administration being strongly influenced by the type of formulations (suppository or rectal cream, in our case) as well as the physiological conditions of the absorption area."	( Urinary excretion profile of prednisolone and prednisone after rectal administration: Significance in antidoping analysis. Botrè, F; Colamonici, C; Comunità, F; Curcio, D; de la Torre, X; Iannella, L; Mazzarino, M, 2022)	0.98

Dosage Studied

The mean daily dosage of prednisone (or its equivalent) was 8. The acyclovir dosage was 2400 mg (800 mg three times a da.

Excerpt	Relevance	Reference
" The common liquid dosage preservatives methylparaben, propylparaben, and sodium benzoate do not interfere with quantitative prednisolone, prednisone, and hydrocortisone determinations."	( High-pressure liquid chromatographic evaluation of aqueous vehicles for preparation of prednisolone and prednisone liquid dosage forms. Gupta, VD, 1979)	0.68
" Because of rapid progression of the amyloidosis and further infections, cytotoxic drug therapy was stopped, corticosteroid dosage was decreased, and supplementary immunoglobulin therapy was instituted."	( Amyloidosis associated with dermatomyositis and features of multiple myeloma. The progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy. Dawkins, RL; Zilko, PJ, 1975)	0.25
" The analysis of the maintaining therapy in 22 patients affected with an acute myelocytic leukemia and living for more than 6 months revealed that the interval therapy with a high dosage of cytostatic combinations in the sense of the COAP scheme is preferable compared with the daily administration of 6-mercaptopurin, in addition methotrexate twice a week."	( [Problems in maintenance therapy in acute myeloid leukemias in adults]. Gürtler, R; Raderecht, C, 1975)	0.25
" The development of interstitial pneumopathy after this low bleomycin dosage may have been favored by a previous thorax irradiation 22 years earler for round cell sarcoma."	( [Interstial pneumopathy after low dose bleomycin therapy]. Frey, F; Marone, C; Zimmermann, A, 1977)	0.26
" The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients."	( Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. Bodey, GP; Cabanillas, F; Freireich, EJ; Rodriguez, V, 1979)	0.26
" The test regimen differed from the standard prednisone relapse regimen used by the International Study of Kidney Disease in Children in that the total dosage was about double, and the duration of daily therapy (8 weeks vs."	( Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. , 1979)	0.76
" In fact, when the optimum dosage of 75 (mumol/kg)/day x 5 was used, the administration of ara-C alone was followed by an increased life span (ILS) of 45%."	( Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone. Hong, CI; Nechaev, A; West, CR, 1979)	0.46
" It is concluded that allopurinol should be used only in select patients, and the dosage should be modified if renal disease exists."	( Severe hypersensitivity reactions to allopurinol. Lang, PG, 1979)	0.26
" At the end of 2 years, the seven patients still taking prednisone were on maintenance dosage of this drug."	( Alternate-day prednisone: preliminary report of a double-blind controlled study. Daube, JR; Duane, DD; Howard, FM; Lambert, EH, 1976)	0.86
" A longitudinal study of serum ACE activity was found to be an effective way of judging the therapeutic efficacy of various steroid dosage levels."	( The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis. Lieberman, J, 1976)	0.26
" Dosage is initially high (60--100 mg daily, secondarily on alternate days), and should be reduced very slowly, once a definite improvement is achieved."	( [Long term administration of oral prednisone or prednisolone in treatment of myasthenia gravis. Report of five cases (author's transl)]. Contamin, F; Ecoffet, M; Mignot, B; Offenstadt, G; Singer, B, )	0.41
"A 63-year-old man, with a Waldenström's disease discovered by cryoglobulinemia (ischemic lesions of fingers) was quickly aggravating (hyperviscosity syndrome) under treatment by chlorambucil in a dosage of 8 mg daily."	( [Polychimiotherapy and Waldenström's macroglobulinemia (author's transl)]. Barrier, J; Bouret, O; Grolleau, JY; Ozanne, P; Renault, JJ, )	0.13
" 46% complete and 12% partial remissions were obtained in 37 patients treated with cytosine arabinoside and 6-thioguanine doubling the dosage of the above mentioned regimen followed by 3 cycles of TRAP (and COAP)."	( [Induction and maintenance treatment of acute myelogenous leukemia in adults by sequential use of combination chemotherapy (author's transl)]. Fülle, HH, 1977)	0.26
" CA and CYT were each given in the dosage of 120 mg/m2 intravenously, daily in 3 divided doses, for 4 days."	( Improved survival in young children with acute granulocytic leukemia treated with combination therapy using cyclophosphamide, oncovin, cytosine arabinoside, and prednisone. Madanat, FF; Sullivan, MP, 1979)	0.46
" The amount of improvement correlated linearly with beclomethasone dosage over the range 200 to 1,600 microng/day."	( A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. Baksh, L; Chuang, L; Errington, N; Haines, DS; Jennings, B; Lefcoe, NM; Toogood, JH, 1977)	0.26
" The duration of hemodialysis, the age of the patients, and daily dosage of prednisone did not seem to influence the development of cataracts."	( Ocular complications after renal transplantation. Gombos, GM; Kountz, SL; Pfefferman, R, 1977)	0.49
" Dose-response curves using six concentrations of PHA and five concentrations of cells over 0-5 days revealed a decrease in [(3)H]TdR by stimulated lymphocytes from some SLE patients."	( Phytohemagglutinin response in systemic lupus erythematosus. Reconstitution experiments using highly purified lymphocyte subpopulations and monocytes. Utsinger, PD; Yount, WJ, 1977)	0.26
" No significant correlations were found between the lipid levels and daily prednisone dosage or with the duration of the period following transplantation."	( Abnormal serum lipid patterns in primary renal allograft recipients. Azen, SP; Blankenhorn, DH; Boothe, S; Chatterjee, SN; Chin, HP; Massry, SG, 1977)	0.49
" Limited weight bearing and reduction in the dosage of prednisone failed to prevent the progressive destruction of five femoral heads in three patients."	( Aseptic necrosis after renal transplantation in children. Ettenger, RB; Fine, RN; Isaacson, AS; Malekzadeh, MH; Pennisi, AJ; Stanley, P; Uittenbogaart, CH, 1978)	0.51
" Present knowledge of mechanisms of action and dose-response relationships is complete, and it is difficult to prescribe therapy which will achieve a predictable therapeutic effect without inhibiting growth."	( Growth and glucocorticoids in children with kidney disease. Chesney, R; McEnery, P; Moel, D; Pennisi, A; Potter, D; Talwalkar, YB; Travis, LB; Wolff, E, 1978)	0.26
" A therapeutic program, which included high dose corticosteroids initially, the combinations of azathioprine with corticosteroids chronically, and the rapid reduction in corticosteroid dosage to an alternate day schedule, appears to contribute to improved survivorship."	( Longterm survival of lupus nephritis patients treated with azathioprine and prednisone. Barnett, EV; Dornfeld, L; Lee, DB; Liebling, MR, 1978)	0.49
" Haemodialysis was started, cytotoxic drugs were stopped, and steroid dosage was reduced."	( Haemodialysis and transplantation in Wegener's granulomatosis. Alexandre, GP; Pirson, Y; van Ypersele de Strihou, C; Vandenbroucke, JM, 1979)	0.26
" Dosage in such patients should be reduced in accordance with serum albumin concentration."	( Corticosteroid pharmacokinetics in liver disease. Go, VL; Uribe, M, )	0.13
" Our results suggest that high dosage of prednisone decreases the renal blood flow and this adverse effect has to be considered in the therapy."	( Effect of high-dose prednisone on renal hemodynamics of normal and transplanted dog kidneys. Althaus, P; Horpácsy, G; May, G; Mebel, M; Schuldt, HH, 1979)	0.85
" Group III (n = 4) dogs were not operated upon and received all drugs in full dosage in order to test any direct toxic effect on normal kidneys."	( Cimetidine for kidney transplantation: experimental observations. Toledo-Pereyra, LH; Zammit, M, 1979)	0.26
" Our data suggest that for optimal graft and patient survival the dosage of steroids should be less than 150 mg/day of methylprednisolone on days 1-3, less than 50 mg/day of prednisone on days 4-21, less than 30 mg/day on days 22-30, and less than 20 mg/day between one mo and one yr."	( Steroid treatment for routine immunosuppression in cadaver renal transplantation. A survey of hospitals. Gonzalez, FM; Kodlin, D; Kumar, P; Leech, SH, )	0.32
" steroid was required, but the steroid dosage requirement then rebounded in the 2 weeks after the end of the prescribed treatment period."	( Antithymocyte globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen. Brodie, JA; Morrell, RM; Rafi, M; Schultz, JR; Wechter, WJ, 1979)	0.26
" The lesion regressed over a four-month period with high dosage corticosteroid therapy, but he developed optic atrophy and visual acuity of no light perception."	( Ocular sarcoidosis occurring as a unilateral optic disk vascular lesion. Noble, KG, 1979)	0.26
" In four occasions, excessive dosage of vitamine D impaired the evolution of a previous nephropathy."	( [Hypervitaminosis D. Review of fifteen cases]. Callís, L; Castelló, F; Nieto, JL; Vilaplana, E, 1979)	0.26
"A novel computerized automated system is described which conforms to the basic requirements set forth in the compendia for testing the dissolution characteristics of solid dosage forms."	( ADS-12: an automated programmable 12-tablet dissolution testing system. Bendrot, H; Cioffi, FJ; Martynovych, S, 1979)	0.26
"A case is described of severe systemic lupus erythematosus, uncontrolled with moderate dosage of corticosteroid and cyclophosphamide, which responded quickly after 3 courses of plasmapheresis."	( Plasmapheresis combined with corticosteroids and cyclophosphamide in uncontrolled active systemic lupus erythematosus. Dequeker, J; Schildermans, F; Van de Putte, I, )	0.13
"The stability of liquid dosage forms of ethacrynic acid (1 mg/ml), indomethacin (2 mg/ml), methyldopate hydrochloride (25 mg/ml), prednisone (0."	( Stability of pediatric liquid dosage forms of ethacrynic acid, indomethacin, methyldopate hydrochloride, prednisone and spironolactone. Das Gupta, V; Ghanekar, AG; Gibbs, CW, 1978)	0.68
"Twenty-three children with idiopathic, relapsing minimal lesion nephrotic syndrome were divided according to their pattern of response to prednisone: (1) steroid dependent, if the relapse occurred while the dosage of prednisone was being decreased; and (2) frequent relapser, if the relapse occurred at variable periods of time (one week to two months) after discontinuing prednisone therapy."	( Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. Fennell, RS; Garin, EH; Pryor, ND; Richard, GA, 1978)	0.77
" The dosage of corticosteroids ingested during the initial period of therapy in patients with AN was tabulated and compared with that of 25 SLE control patients."	( Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Abeles, M; Rothfield, NF; Urman, JD, 1978)	0.26
"The utilization of ternary sugar solid dispersion systems and the incorporation of these systems into tablet dosage forms were investigated."	( Dissolution rates of hydrocortisone and prednisone utilizing sugar solid dispersion systems in tablet form. Allen, LV; Levinson, RS; Martono, DD, 1978)	0.53
" There appeared to be some correlation between dosage and degree of apparent atrophy."	( Steroids and apparent cerebral atrophy on computed tomography scans. Bentson, J; Reza, M; Wilson, G; Winter, J, 1978)	0.26
"The average prednisone dosage of 54 corticosteroid-dependent asthmatics was computed for one year prior to initiation of beclomethasone dipropionate."	( Long-term effects of beclomethasone dipropionate on prednisone dosage in the corticosteroid-dependent asthmatic. Bacal, E; Patterson, R, 1978)	0.89
" Following intensive round-the-clock therapy with theophylline (the dosage of which maintained serum levels of theophylline between 10 microgram/ml and 20 microgram/ml) and therapy with prednisone (20 mg twice daily for three weeks or more), there were improvements in spirometric and body plethysmographic measurements."	( Irreversibility of obstructive changes in severe asthma in childhood. Bell, TD; Buck, VM; Chai, H; Cooley, RL; Leung, PK; Loren, ML, 1978)	0.45
" Serial MEVs were not only useful for prognosis, but also helpful in regulating the dosage of prednisone."	( Prognostic value of minimal excitability of facial nerve in Bell's palsy. Challenor, Y; Devi, S; Duarte, N; Lovelace, RE, 1978)	0.48
" Thereafter, this therapy may need to be continued, often at an extremely low dosage level, sometimes intermittently, for many years before the hemoglobin value maintains itself without medication."	( Congenital hypoplastic anemia. Alter, BP; Diamond, LK; Wang, WC, 1976)	0.26
"A renal transplant service is described in which the pharmacist attends daily rounds, monitors drug dosage and conducts a medication instruction program aimed at improving patient compliance."	( Pharmacist involvement as a member of a renal transplant team. Mitchell, JF, 1976)	0.26
" in the same dosage in combination with heparin 5000 U/day."	( Treatment of acute allograft rejection with high doses of corticosteroids. Alarcon-Zurita, A; Ladefoged, J, 1976)	0.26
" Serum cholesterol and triglyceride levels could both be related to the dosage of prednisone these patients received."	( Hyperlipidemia following renal transplantation. Alfrey, AC; Ibels, LS; Subryan, V; Weil, R, 1976)	0.48
" Allergic nasal symptoms were disabling in many patients when the oral dosage of corticosteroids was tapered."	( Beclomethasone dipropionate aerosol in the treatment of steroid-dependent asthma. A 12-week double-blind study comparing beclomethasone dipropionate and a vehicle aerosol. Harvey, LL; Kass, I; Nair, SV, 1976)	0.26
" Serious complications and mortality could be related to high dosage of steroids and severe leukopenia."	( Influence of rejection on graft survival after renal transplantation. Black, HR; Finkelstein, FO; Lytton, B; Schiff, M, 1976)	0.26
" Serious complications and mortality could be related to high dosage of steroids and severe leukopenia."	( Influence of rejection on graft survival after renal transplantation. Black, HR; Finkelstein, FO; Lytton, B; Schiff, M, 1975)	0.25
" Depression of RES phagocytosis could be related to total steroid dosage in the previous year and to the patients liability to bacterial infections."	( Altered reticuloendothelial function in long-term renal allograft recipients. Drivas, G; Pulman, L; Uldall, PR; Wardle, N, 1976)	0.26
" As a consequence, shorter dosing intervals of these drugs seems to be advisable, rather than a reduction in the total daily dose."	( Drug protein binding and the nephrotic syndrome. Azarnoff, DL; Gugler, R, 1976)	0.26
" Mortality and morbidity closely correlated with the corticosteroid dosage used to attain control."	( Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Nelson, CT; Rosenberg, FR; Sanders, S, 1976)	0.26
" Collaborators were supplied with 4 composites of tablets of different dosage levels, 2 containing prednisolone and 2 containing prednisone."	( Collaborative study of a semiautomated method for the analysis of prednisolone and prednisone tablets. Brower, JF, 1977)	0.69
" Tolerable dosage levels of both regimens have been defined for future clincial trials."	( Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomas. Kiely, JM; O'Connell, MJ; Silverstein, MN; White, WL, )	0.13
" tcoherin has proven efficacious by three criteria: As a result of coherin treatment those patients receiving steroids could either eliminate them or reduce the dosage to safe levels."	( Long-term results in the treatment of regional ileitis with coherin. Goodman, I; Hiatt, RB, 1977)	0.26
"Twenty-three steroid-dependent severely asthmatic patients, ranging in age from 20 to 67 years, tolerated reduction in their oral dosage of steroids during a one-year trial of triamcinolone acetonide aerosol."	( A one-year trial of triamcinolone acetonide aerosol in severe steroid-dependent asthma. Chmelik, F; doPico, G; Kriz, RJ; Reed, CE, 1977)	0.26
" The corticosteroid dosage was proportional to each patient's weight."	( Reversibility of corticosteroid-associated cataracts in children with the nephrotic syndrome. Forman, AR; Loreto, JA; Tina, LU, 1977)	0.26
"Analysis of the response to corticosteroid therapy in a personal series of 8 consecutive cases of dermatomyositis in childhood shows that there are advantages in a moderate dosage, short-term treatment schedule, with gradual tapering of the dosage as soon as there is clinical improvement without waiting for full remission, and in trying to stop steroid therapy within six months rather than following the more prolonged regimen currently still in vogue."	( Treatment of dermatomyositis in childhood. Dubowitz, V, 1976)	0.26
"A patient with idiopathic thrombocytopenia purpura who was treated with high dosage corticosteroids for ten years, developed 18 separate lesions of avascular necrosis in 12 different bones."	( Steroid induced avascular necrosis of bones in eighteen sites: a case report. Milgram, JW; Riley, LH, 1976)	0.26
" The effect of treatment was to allow a reduction in corticosteroid dosage and a sustained remission of disease activity in patients."	( Rheumatoid arthritis treated with chlorambucil: a five-year follow-up. Thorpe, P, 1976)	0.26
" Ovarian over-stimulation was directly related to the dosage of clomiphene, and the increased levels of 17 alpha-hydroxyprogesterone thus produced persisted into the seventh week of pregnancy."	( Corpus luteum function during pregnancies of previously infertile women. Gentry, WC; Karow, WG, 1976)	0.26
" Prednisone at a dosage of approximately 1 mg/kg daily by the oral route produced significant reduction of this phenomenon only when commenced 2 weeks before inoculation."	( The peritoneal reaction to starch and its modification by prednisone. Cade, D; Ellis, H, 1976)	1.41
" She was treated with high dosage corticosteroids and incurred severe side effects, including bone marrow depression, renal magnesium stones, osteoporosis, depression of affect, convulsions with cerebral damage and adrenal suppression."	( Unwanted corticosteroid effects in childhood bone marrow failure, renal failure and brain damage: case report. Gillies, AH; Shellshear, ID, 1975)	0.25
" Although azathioprine does not confer dramatic benefit upon patients with chronic ulcerative colitis who require steroids, it does permit reduction of steroid dosage without apparent worsening of the disease."	( A controlled trial of azathioprine in the management of chronic ulcerative colitis. Binder, HJ; Kirsner, JB; Levin, B; Rosenberg, JL; Wall, AJ, 1975)	0.25
" The mean reduction in steriod dosage in the azathioprine group at the end of the trial (-15."	( A controlled trial of azathioprine in Crohn's disease. Kirsner, JB; Levin, B; Rosenberg, JL; Wall, AJ, 1975)	0.25
" The dosage of prednisone during the first posttransplant year corrected for patient weight showed a significant correlation with the development of PSC during the first posttransplant year."	( Posterior subcapsular cataracts: posttransplantation in children. Fine, RN; Malekzadeh, MH; Mickey, MR; Offner, G; Pennisi, AF; Wilson, WA, 1975)	0.61
"001--and with a variety of other measurements of bronchial dynamics and lung volumes, suggesting that the total eosinophil count reflects asthmatic activity and is useful for regulating steroid dosage and for early detection of exacerbations."	( Total eosinophil counts in the management of bronchial asthma. Horn, BR; Robin, ED; Theodore, J; Van Kessel, A, 1975)	0.25
" Functional psychosis was usually preciptated by corticsoteroid therapy and respond to a reduction in steroid dosage and administration of psychotropic drugs."	( Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. Klempner, MS; Lipsky, BA; Lockshin, MD; Sergent, JS, 1975)	0.25
" Prednisone in high dosage was associated in this series with 9 deaths and in 6 patients, with renal failure or an extra-renal complication."	( [Lupus nephropathy. Treatment with the indomethacin-hydroxychloroquine combination and comparison with corticoids]. Conte, JJ; Fournie, GJ; Mignon-Conte, MA, 1975)	1.16
" Dosage adjustments were often necessary during the initial phases of therapy."	( A controlled study in the use of combined drug therapy for metastatic breast cancer. Alberto, P; Brunner, KW; Martz, G; Obrecht, P; Senn, HJ; Sonntag, RW, 1975)	0.25
" Methodology and dosage schemes are discussed."	( Towards curative treatment of advanced Hodgkin's disease. Falkson, G; Falkson, HC, 1975)	0.25
" Addition of pg quantities of [3H]-prednisolone following oral dosage with prednisone or prednisolone."	( Measurement of plasma prednisolone in man. May, CS; Paterson, JW; Ssendagire, R; Wilson, CG, 1975)	0.48
" Radical excision of the tumor, if possible, and the remaining thymus, high dosage alternate day prednisone, and radiation therapy, if indicated, seem the treatments of choice."	( Myasthenia gravis and invasive thymoma: a 20-year experience. Brown, WJ; Goldman, AJ; Herrmann, C; Keesey, JC; Mulder, DG, 1975)	0.47
" A dose of 10-15 mg per day may be considered marginal for the development of cataract; dosage has no basic effect on the development of glaucoma."	( [Ophthalmic complications in general corticoid therapy]. Cepilová, Z; Krchnavá, B; Porubská, M; Slámová, J, 1991)	0.28
" Initial dosage was 500 mg, and the dose was escalated provided the total white blood cell count remained > 3,000 cells per cubic millimeter."	( Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Baughman, RP; Lower, EE, 1992)	0.28
" This was associated with a significant fall in the average prednisone dosage from 32 +/- 13."	( Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Baughman, RP; Lower, EE, 1992)	0.53
"Intermittent, intravenous cyclophosphamide therapy was associated with improved pulmonary function and reduced corticosteroid dosage in patients with idiopathic pulmonary fibrosis who survived at least six months after institution of therapy."	( Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Baughman, RP; Lower, EE, 1992)	0.28
" coli L-asparaginase (L-ase) in the induction phase at a dosage of 6000 U/m2/day x 7 d starting on d 15, as well as vincristine, prednisone, daunorubicin and cyclophosphamide, the last-named by random 1:1."	( Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Annino, L; Defazio, D; Gugliotta, L; Leone, G; Mandelli, F; Mattioli-Belmonte, M; Mazzucconi, MG; Tura, S, 1992)	0.49
" Patients received prednisone, at a dosage of 40 mg/d, for 4 weeks."	( Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992)	0.85
" In 11 of the 12, the prednisone dosage could eventually be tapered to < or = 5 mg/day."	( Methotrexate treatment of recalcitrant childhood dermatomyositis. DeNardo, BA; Miller, LC; Schaller, JG; Sisson, BA; Tucker, LB, 1992)	0.6
" Both disease remission and a reduction in corticosteroid dosage were obtained in four patients."	( Treatment of idiopathic inflammatory myopathies with cyclophosphamide pulses: clinical experience and a review of the literature. De Vita, S; Fossaluzza, V, 1992)	0.28
" Also this result differs from what most authors have observed: they maintain that Horton's arteritis has become rather resistant to the cortisone therapy and required high dosage for a very long time."	( [Horton's bitemporal arteritis. A case report]. Carmenini, G; Di Maio, F; Martusciello, S; Meloni, F; Nicoletti, M; Scioli, A, 1992)	0.28
" Three months previously (having symptoms of polymyalgia rheumatica) she had started treatment with a low dosage of prednison."	( [Temporal arteritis without histological changes]. Bomholt, C; Dietrichson, O; Prause, JU, 1992)	0.28
" In protocol ALL VIII/87 the only modification was the reduction of the MTX dosage from 5 g/m2 to 1 g/m2 with an infusion time of 24 hours (leucovorin rescue 15 mg/m2 after 48 and 54 hours)."	( [Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991]. Domula, M; Dörffel, W; Eggers, G; Exadaktylos, P; Hermann, J; Hilgenfeld, E; Kotte, W; Malke, H; Reimann, M; Zintl, F, )	0.13
" Larger numbers of patients will be needed to ascertain whether specific guidelines for dosage modifications can be made on the basis of serial WBC."	( Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Blatt, J; Gula, MJ; Lucas, K, )	0.13
" After each period, dose-response curves were measured on 4 study days with doubling doses of salbutamol, ipratropium, a combination of salbutamol and ipratropium, and placebo until a plateau in FEV1 was reached."	( Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. Alting-Hebing, D; Breederveld, N; Koëter, GH; Postma, DS; van der Mark, TW; Wempe, JB, 1992)	0.28
" Long-term use of alternate-day prednisone in high dosage appears to be the most efficacious regimen in both controlled and uncontrolled studies."	( Idiopathic membranoproliferative glomerulonephritis in childhood. West, CD, 1992)	0.57
" Works carried out by the Canadian research worker Toogood have addressed the question of the equivalent clinical dosing potency of inhaled and oral steroids."	( [Oral and inhaled corticoid therapy. Rivals or partners?]. Lacronique, J, 1992)	0.28
" Prednisone was used in 17 cases, high dosage of methylprednisolone in 8 (in one case twice), azathioprine in 11 and cyclophosphamide in 10."	( Immunosuppressive treatment for juvenile myasthenia gravis. Badurska, B; Ryniewicz, B; Strugalska, H, 1992)	1.19
" The results of this study indicate that 6 weeks of treatment with 220 micrograms/day or 440 micrograms/day of ITAA has no effect on adrenocortical function, but prednisone, at a dosage of 10 mg/day for 6 weeks, produces partial adrenocortical suppression."	( A comparative study of the effects of intranasal triamcinolone acetonide aerosol (ITAA) and prednisone on adrenocortical function. Dockhorn, R; Ellis, E; Feiss, G; Mansfield, L; Morris, R; Rom, D; Smith, JA; Tobey, RE, 1992)	0.7
" The latency period between the steroid therapy and the occurrence of AON ranged from 12 to 60 months; steroid therapy lasted for 12 to 16 days with a total dosage equivalent to 2370-7180 mg prednisolone."	( [Craniocerebral trauma and aseptic osteonecrosis. Steroid-induced sequelae after therapy of brain edema]. Griss, P; Pfeiffer, M, 1992)	0.28
" In those treated for two months or longer, the mean total serum IgE level fell from 2,462 U/ml (CI, 752 to 4,202 U/ml) to 502 U/ml (CI, 123 to 880 U/ml) during each course, and the mean daily steroid dosage was decreased to a mean of 24 mg/day (CI, 11 to 37 mg/day)."	( Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Denning, DW; Lewiston, NJ; Stevens, DA; Van Wye, JE, 1991)	0.28
"Two hundred dogs with pituitary dependent hyperadrenocorticism (PDH) were treated with mitotane at an initial daily dosage of 21 to 69 mg/kg (mean = 45."	( Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. Kintzer, PP; Peterson, ME, )	0.13
" In a multivariate analysis where both disease-related and treatment-related factors were taken into account drug dosage remained a significant prognostic factor."	( Treatment of Hodgkin's disease with MOPP chemotherapy: effect of dose and schedule modification on treatment outcome. Bezwoda, MA; Bezwoda, WR; Dansey, R, 1990)	0.28
" The results failed to show that prednisone at this dosage and frequency was of any benefit either in the short-term clinical response or in the long-term follow-up with regard to later requirement of valvular surgery (using the 5% level of significance)."	( A double-blind placebo-controlled trial of prednisone in active rheumatic carditis. Haffejee, IE; Moosa, A, 1990)	0.82
" EPVP II is given every 21 days with increased dosage and increased intensity of epirubicin."	( Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease. Early results in 100 consecutive patients. Pierre-et-Marie-Curie Group. Blanc, CM; David, B; Eghbali, H; Hoerni, B; Orgerie, MB; Rojouan, J; Zittoun, R, 1991)	0.52
"5 micrograms/kg/day, sc), which significantly shortened the duration of neutropenia and decreased the number of days with episodes of fever when compared with those not given rhG-CSF, consequently facilitating the treatment without prolonging the dosing intervals."	( [The COP-BLAM III therapy of non-Hodgkin's lymphoma]. Arai, N; Hara, A; Shirai, T; Umeda, M, 1991)	0.28
" Postoperatively, all received daily doses of cyclosporine (15 mg/kg) and azathioprine (1 mg/kg) and were subdivided into three steroid dosage groups."	( Normal bronchial healing without bronchial wrapping in canine lung transplantation. Auteri, JS; Jeevanandam, V; Kirby, TJ; Marboe, CC; Sanchez, JA; Smith, CR, 1992)	0.28
" Twelve patients remained in the study at the 84-month visit; the mean weekly dosage of MTX was 10."	( Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Coblyn, JS; Falchuk, KR; Fraser, PA; Holdsworth, DE; Maier, AL; Weinblatt, ME; Weissman, BN, 1992)	0.28
" The progressive reduction of corticosteroid dosage led rapidly to a distinct improvement, but not to a remission, of symptoms."	( Steroid myopathy: clinical and immunohistochemical study of a case. Camporeale, FS; Carandente, M; Cioffi, M; Gentile, A; Marolda, M; Orsini, AV; Palma, V, 1991)	0.28
" In a separate group of ten patients whose previous reactions to RCM were life threatening (shock), pretreatment was accompanied by a provocative dosing regimen."	( Comparison of three pretreatment protocols to prevent anaphylactoid reactions to radiocontrast media. Lieberman, PL; Marshall, GD, 1991)	0.28
" Our results suggest that CsA at normal dosage has no clinically important effect on beta-cell function."	( Cyclosporine's effect on insulin secretion in patients with kidney transplants. Casamitjana, R; Esmatjes, E; Ferrer, JP; Oppenhaimer, F; Ricart, MJ; Vilardell, J, 1991)	0.28
" 15% of previously untreated myeloma patients achieve a clinical response to IFN alpha alone with a possible dose-response relationship."	( Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Grimfors, G; Gyllenhammar, H; Hast, R; Juliusson, G; Mellstedt, H; Osterborg, A, 1991)	0.28
" We also found that neither patient assessment of severity of symptoms nor corticosteroid dosage correlate with objective spirometric measurements."	( Variability of pulmonary function tests in stable corticosteroid dependent asthma patients. Garb, KS; Kinney, JL; Klaustermeyer, WB; Santiago, SM, )	0.13
" Pulmonary function was assessed and dosage of prednisone and BDP (or P) were adjusted every 15 days according to a clinical score."	( High-dose beclomethasone: oral steroid-sparing effect in severe asthmatic patients. Georges, D; Henry-Amar, M; Lacronique, J; Marsac, J; Renon, D, 1991)	0.54
" Newly diagnosed patients with ITP received the usual prednisone therapy, 1 mg/kg/day, for 3 weeks, after which period the dosage was tapered off."	( Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP). Dubbeld, P; Hillen, HF; van der Heul, C, 1991)	0.8
" The long-term administration of small dosage of corticosteroid is effective in treating this disease in its active stage."	( Clinical studies in 500 patients with aortoarteritis. Fan, DJ; Liu, LS; Zheng, DY, 1990)	0.28
" A decrease in or cessation of cyclosporine dosage frequently is used in an attempt to minimize nephrotoxicity."	( Highly sensitized patients with delayed graft function: a management protocol. Hakala, TR; Hickey, DP; Hrebinko, R; Jordan, ML; Lopatin, WB; O'Donovan, R; Vivas, CA, 1991)	0.28
" In addition to the excellent graft survival obtained through 4 years, lower prednisone and CyA dosage levels are achieved with significantly decreased infection rates during the posttransplant period."	( Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol. Amend, W; Garovoy, M; Husing, R; McVicar, J; Melzer, J; Rabkin, J; Salvatierra, O; Tomlanovich, S; Vincenti, F, 1991)	0.51
" Higher dosage of prednisolone or prednisone more than 120 mg/day has never been used."	( Treatment of pemphigus. Ophaswongse, S; Piamphongsant, T, 1991)	0.56
" Fifty-six patients received an oral dosage of 50 mg/kg of aminocaproic acid every 4 hours for 5 days, up to a maximum of 30 g daily, and 56 patients received an oral dosage of 40 mg of prednisone daily (adjusted for weight) in two divided doses."	( Aminocaproic acid versus prednisone for the treatment of traumatic hyphema. A randomized clinical trial. Farber, MD; Fiscella, R; Goldberg, MF, 1991)	0.78
" To compare alternate-day and daily dosing of prednisone with respect to benefits and adverse side effects, the placebo group was started on alternate-day prednisone therapy, and the treatment group regimens were changed to equivalent doses of alternate-day prednisone without breaking the double-blind nature."	( A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Brooke, MH; Fenichel, GM; Griggs, RC; King, W; Mendell, JR; Miller, JP; Moxley, RT; Pestronk, A; Robison, J; Signore, L, 1991)	0.81
" We conclude that prednisone in moderate dosage has no significant effect on respiratory muscle function in humans, at least in the short term."	( Corticosteroid therapy and respiratory muscle function in humans. Gallagher, CG; Vasquez, A; Wang, YM; Zintel, T, 1991)	0.62
" After the surgical excision of the mediastinal mass (January, 1989) until now, Behcet's syndrome is in complete remission with a low dosage of prednisone."	( Unicentric Castleman's lymphadenopathy presenting with Behçet's syndrome: a case report. Ambrosetti, A; Bambara, LM; Biasi, D; Frigo, A; Givanni, S; Lunardi, C; Pacor, ML; Peroli, P; Urbani, G, )	0.33
" Maintenance with the same drugs in a modified dosage schedule continued for approximately 2 years."	( Multiagent chemotherapy in relapsed acute lymphoblastic leukemia in children. Belasco, JB; Luery, N; Scher, C, 1990)	0.28
" After increasing the dosage of prednisone, she recovered almost completely from this episode."	( [Cerebral disseminated lupus erythematosus; brain-racking for patient and physician]. de Glas-Vos, JW; Prins, JM, 1990)	0.56
" Long-term follow-up studies did not disclose any recurrence of the pituitary granulomatous process nor objective evidence of underlying disease even after steroid dosage has been tapered."	( Pituitary granuloma and pyoderma gangrenosum. Chanson, P; Derome, PJ; Guillausseau, PJ; Kujas, M; Lubetzki, J; Timsit, J; Violante, A; Warnet, A, 1990)	0.28
" We concluded that SCE analysis did not reveal any evidence suggesting that the dosage of CY used in this study had induced a permanent genetic damage."	( Cyclophosphamide-induced sister chromatid exchanges in patients with nephrotic syndrome. Bogdanović, R; Cvorić, A; Guć-Sśekić, M; Pilić, G, 1990)	0.28
" Prednisone was administered according to the following dosage schedules: 1) long-term daily, 2) standard intermittent, 3) standard alternate-day, and 4) short-term daily."	( Comparison of different regimens of prednisone therapy in frequently relapsing nephrotic syndrome. Müller-Wiefel, DE; Schärer, K; Wingen, AM, 1990)	1.46
" ALG dosage modifications were made in order to maintain peripheral CD3+ cells between 10 and 20%."	( Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation. Alsina, J; Andres, E; Castelao, AM; Diaz, C; Gil-Vernet, S; Griño, JM; Mestre, M; Sabate, I; Sabater, R; Seron, D, 1990)	0.28
" Concerning other patients with TA and with PMR a starting dose of 10 to 30 mg depending on the clinical picture then a follow up dosage of 10 and even less, is suggested."	( [Polymyalgia rheumatica and temporal arteritis. Observations on prognosis and treatment]. Auquier, L; Paolaggi, JB, 1990)	0.28
" Therefore, the patients were given prednisone at an initial dosage of 50-100 mg which was subsequently reduced."	( [Persisting alveolitis after Legionella pneumonia]. Hürter, T; Lorenz, J; Rumpelt, HJ; Schlegel, J, 1990)	0.55
" The mean dosage of azathioprin and prednisone in patients with SLE did not significantly differ from the non-SLE group."	( [Reactivation of the alpha 1-fetoprotein synthesis in systemic lupus erythematosus]. Knopf, B; Schulze, M; Wollina, U, 1985)	0.54
" In addition, increasing the dosage of epirubicin did not result in an increase in the haematologic toxicity or percent of CR."	( Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial. Brandi, M; Calabrese, P; De Lena, M; Lorusso, V; Maiello, E; Marzullo, F; Mazzei, A; Romito, S, 1989)	0.28
" Prednisone dosage decreased from 21."	( Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ball, TJ; Botoman, VA; Gelfand, MD; Kozarek, RA; Patterson, DJ; Wilske, KR, 1989)	1.19
" Regulation of dosage has to be individualized, and when one reaches the lower dose such as 5 to 10 mg per day, the drug may have to be tapered more slowly, or even maintained at that level for a period of time to prevent further recurrence of symptoms."	( Cluster headaches. Ryan, RE, 1989)	0.28
" Such a reduction in the TH/S ratio and in the number of circulating suppressor cells was not found in esophagitis due to either HSV or Candida and was unrelated to the serum cyclosporine level or prednisone dosage prescribed."	( T-cell populations in liver and renal transplant recipients with infectious esophagitis. Alexander, J; Brouillette, DE; Chien, MC; Gavaler, J; Tarter, RE; Van Thiel, DH; Yoo, YK, 1989)	0.47
" The predictive value of mechlorethamine dosage with regard to OS was retained in an analysis restricted to the patients receiving greater than or equal to six cycles of chemotherapy."	( Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. de Meijer, AJ; Dekker, AW; Haanen, C; van Rijswijk, RE; Verbeek, J, 1989)	0.28
" Repeated hemoptysis in September 1988 prompted us to add cyclosporine A in a dosage providing whole blood levels of 250-350 ng/ml."	( [Rare vascular complications of Behçet's disease (so-called angiobehçet)]. Salvetti, M; Stricker, H, 1989)	0.28
" It seems possible, however, that high initial dosing of CsA might trigger this complication in the early posttransplant period when other predisposing factors are present."	( Allograft renal vascular thrombosis--lack of increase with cyclosporine immunosuppression. Canafax, DM; Chavers, B; Fryd, DS; Gruber, SA; Matas, A; Najarian, JS; Payne, WD; Simmons, RL, 1989)	0.28
" These data indicated that hypertension develops in almost all patients after heart transplantation despite the lower dosage of cyclosporine used with the triple-drug immunosuppressive therapy and the absence of significant renal impairment with this regimen, and probably it is not the result of activation of the sympathetic nervous system."	( Arterial hypertension in heart transplant recipients treated with triple-drug immunosuppressive therapy. Antolick, A; Olivari, MT; Ring, WS, )	0.13
" The first era (1974-1980) consisted of the prophylactic administration of prednisone, Imuran (AZA), and Minnesota antilymphocyte globulin (MAG) with high prednisone dosage used to treat rejection."	( Prednisone when used as treatment for rejection correlates with poor outcome. Bond, O; Callender, CO; Dunston, GM; Flores, J; Gear, JC; John, D; Thompson, C; Toussaint, RM; Walters, CS; Yeager, C, 1989)	1.95
" Four attempts at reducing this dosage to 1 mg every other day brought about the recurrence of a few bullae and of cutaneous fragility."	( [Value of colchicine in treating acquired epidermolysis bullosa]. Berbis, P; Privat, Y, 1989)	0.28
" The drugs proved equally effective, provided a sufficient dosage was administered."	( Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. Baskerville, J; Jennings, B; Johansson, SA; Lefcoe, NM; Toogood, JH, 1989)	0.55
" All of the patients had received preliminary treatment with oral NAC in a dosage of 1,200 mg daily (Mucomyst Retard) or a placebo for 22 weeks in a double-blind design."	( [Steroid response after long-term treatment with oral N-acetylcysteine in patients with chronic obstructive bronchitis]. Balsløv, S; Brorson-Riis, L; Evald, T; Hansen, M; Hansen, NC; Maltbaek, N; Thorshauge, H, 1989)	0.28
" Gradual steroid dosage tapering resulted in prompt clinical improvement and marked increases in respiratory muscle strength, maximal inspiratory pressure increasing by 33 percent in one patient and by 70 percent in the other."	( Corticosteroid-induced myopathy and the respiratory muscles. Report of two cases. Decramer, M; Janssens, S, 1989)	0.28
" The CVPP schedule gave: (1) a constant drug dosage for each patient independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance, since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 10(9) l-1."	( Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. Bonichon, F; Chauvergne, J; de Mascarel, I; Eghbali, H; Hoerni, B; Lagarde, P, 1989)	0.28
" Childhood dermatomyositis is almost uniformly responsive to steroid treatment; there is a good chance of remission with minimal risk of secondary complications with an initial low dosage of prednisone (1 mg/kg/day)."	( [Dermatomyositis in children]. Dumas, R, 1989)	0.47
" Twenty-five of 39 patients had normal complement levels within six months (Group 1), and immunosuppressive therapy was tapered but continuously readjusted to the lowest dosage that preserved normal CH50 and maintained clinical remission."	( Effect of long-term normalization of serum complement levels on the course of lupus nephritis. Bank, N; Barland, P; Glicklich, D; Grayzel, AI; Laitman, RS; Sablay, LB, 1989)	0.28
" Our failure to demonstrate the differences in stage II patients may be due to the narrow range of dose intensity in this study or to a difference in the dose-response curves depending on the stage of disease."	( Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. Ang, PT; Buzdar, AU; Hortobagyi, GN; Kau, S; Smith, TL, 1989)	0.28
" In a prospective randomized multicenter trial, 123 patients undergoing acute rejection of cadaveric renal transplants were treated either with OKT3 daily for a mean of 14 days, with concomitant lowering of the dosage of other immunosuppressive drugs (63 patients), or with conventional high-dose steroids (60 patients)."	( A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. , 1985)	0.27
" Bedtime dosing may prevent nocturnal shortness of breath."	( Pharmacologic approaches to obstructive airway disease. Beck, BW, 1985)	0.27
" We administered systemic cyclosporine but could not obtain a favorable effect without a concomitant low dosage of prednisone."	( Multicentric reticulohistiocytosis in a child with sclerosing lesion of the leg. Immunohistopathologic studies and therapeutic trial with systemic cyclosporine. Aiba, S; Iizawa, O; Kuramoto, Y; Makino, Y; Tagami, H, 1989)	0.49
" The low dosage utilized (8 mg/kg instead of the usual 14-17 mg/kg) avoided virtually all the extrarenal side-effects of cyclosporin A, but not its nephrotoxicity."	( [Prospective study of a triple immunosuppressive combination in renal transplantation: cyclosporin A-corticoids-azathioprine]. Bellamy, J; Benoit, G; Charpentier, B; Fries, D; Hammouche, M; Kechrid, C; Moulin, B; Neyrat, N; Rieu, P, 1985)	0.27
" Nineteen patients had ocular manifestations of giant cell arteritis always from the onset, except for a fall in visual acuity; 26 relapses were observed in 18 patients, either during reduction of steroid dosage (21 cases) or after withdrawal (5 cases)."	( [Prognosis of treated temporal arteritis. Retrospective study of 87 cases]. Alcalay, M; Becq-Giraudon, B; Boissonnot, L; Bontoux, D; Gil, R; Gouet, D; Le Berre, D; Lefevre, JP; Maréchaud, R; Risse, JF, 1986)	0.27
" The second group of six patients received DFC initially followed by the PDN dosing regimen."	( Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA). Imbimbo, B; Indiveri, F; Piccardo, C; Piovano, P; Scudeletti, M, 1987)	0.27
" The mean initial steroid dosage was 87 mg prednisone equivalent per day."	( [Therapy of pemphigus. Critical remarks based on 44 clinical cases]. Smolle, J, 1985)	0.53
" The data demonstrate that ATG has a deleterious influence on the incidence and severity of CMV infection in renal transplant patients, even when the dosage of other immunosuppressive drugs is decreased during ATG therapy."	( Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation. Andiman, W; Bia, MJ; Flye, W; Gaudio, K; Kliger, A; Siegel, N; Smith, D, 1985)	0.27
" One may hope that this dosage of mechlorethamine will not be gonadotoxic."	( [Value of chlormethine in children with corticoid-dependent or partially corticoid-sensitive nephrosis, in steroid poisoning]. Loirat, C; Macher, MA; Maisin, A; Mathieu, H; Pillion, G, )	0.13
" The first patient suffered from ulcerative colitis and developed Guillain-Barré syndrome when the steroid dosage was being tapered."	( Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment. Abramsky, O; Steiner, I; Wirguin, I, 1986)	0.27
" All patients received CyA in increasing dosage (3 mg/kg to 6-10 mg/kg) postoperatively according to renal function, obtaining a trough high-pressure liquid chromatographic whole-blood target level of 200 to 400 ng/ml at the end of the first week."	( Incidence and severity of acute cardiac allograft rejection with two different low-dose cyclosporine maintenance protocols. Kober, I; Laczkovics, A; Laufer, G; Schreiner, W; Wollenek, G; Wolner, E, 1988)	0.27
" The ability of intensive dosing with the glucocorticoid steroid methylprednisolone to beneficially affect post-traumatic ischemia and to promote chronic neurologic recovery in spinal cord injured animals has been correlated not with its glucocorticoid activity, but rather with the ability to inhibit post-traumatic spinal lipid peroxidation."	( New pharmacological treatment of acute spinal cord trauma. Braughler, JM; Hall, ED; McCall, JM, 1988)	0.27
" However, measurement of IgE may be helpful in CEP, as it has been in allergic bronchopulmonary aspergillosis, to guide the dosage and duration of corticosteroid therapy."	( Chronic eosinophilic pneumonia (Carrington's) with increased serum IgE levels. A distinct subset? Gonzalez, EB; Hayes, D; Weedn, VW, 1988)	0.27
" The subsequent radiotherapy was limited to the initially involved fields, the dosage of 35, 30 or 25 Gy depending on the extent of chemotherapy."	( [Significance of procarbazine in the chemotherapy of Hodgkin's disease--a report of the Cooperative Therapy Study DAL-HD-85]. Bökkerink, JP; Brämswig, J; Heinecke, H; Hörnig, I; Ludwig, R; Niethammer, D; Reiter, A; Schellong, G; Steinhoff, A; von Lengerke, HJ, )	0.13
" The corticosteroid dosage and the serum testosterone level were inversely related (r = -0."	( Reduction of serum testosterone levels during chronic glucocorticoid therapy. Chipps, BE; MacAdams, MR; White, RH, 1986)	0.27
" Our study suggests that HPN and bowel rest is a useful therapeutic approach to selected patients with active Crohn's disease, which permits a reduction in corticosteroid dosage and partial healing of mucosal lesions in most."	( Endoscopic, radiographic, and clinical response to prolonged bowel rest and home parenteral nutrition in Crohn's disease. Kushner, RF; Shapir, J; Sitrin, MD, )	0.13
" Group II received prednisone at a comparable dosage and ciclosporin."	( Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Beyer, J; Dennebaum, R; Kahaly, G; Krause, U; Meuer, S; Muller, W; Schrezenmeir, J; Schweikert, B, 1986)	0.95
" Increasing the Cs dosage induced a remission again."	( A patient with a spontaneous factor VIII:C autoantibody: successful treatment with cyclosporine. Freen, M; Hart, HC; Kerckhaert, JA; Kraaijenhagen, RJ; van de Wiel, A; Verdel, G, 1988)	0.27
" To clarify this apparent disparity and to determine if glucocorticoid stimulation can augment GH release in man after direct pituitary stimulation with GHRH, we administered 1 microgram/kg GHRH dosage to seven normal men before and after a 4-day course of prednisone (20 mg, orally, three times daily)."	( Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. Culler, FL; Jones, KL; Kaufmann, S; Wehrenberg, WB, 1988)	0.82
" We retrospectively examined the relationship between serum creatine kinase (CK), muscle strength and the dosage and method of administration of prednisone in 30 patients with PM-DM observed monthly for a minimum of one year."	( Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. Medsger, TA; Oddis, CV, 1988)	0.48
" This quantity appears minimal and supplemental dosing of prednisone or modification of administration time would seem to be unnecessary."	( [Removal of prednisone and prednisolone during plasma exchange]. Assogba, U; Baumelou, A; Durande, JP; Lenoir, G; Pecquinot, MA; Raymond, F; Rottembourg, J, 1988)	0.9
" In patients who received cyclosporine, the dosage was adjusted to achieve trough whole blood concentrations of 100 to 250 ng/ml measured by liquid chromatography."	( Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Anderson, CF; Moyer, TP; Post, GR; Sterioff, S, 1988)	0.27
"To test our previous observation that methotrexate reduces corticosteroid requirements of patients with severe asthma, we studied 14 patients with corticosteroid-dependent bronchial asthma in a 24-week randomized double-blind crossover trial comparing a low dosage of methotrexate (15 mg per week) with placebo."	( Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. Andrade, WP; Bailey, GA; Blumenstein, BA; Mullarkey, MF; Olason, I; Wetzel, CE, 1988)	0.27
" Chemotherapy consisted of two cycles of CF (cyclophosphamide at a dosage of 100 mg/m2 orally on days 1-14+5-fluorouracil at 600 mg/m2 iv on days 1 and 8) during concurrent radiotherapy, followed by six cycles of CMFP (same CF dosages+methotrexate at 40 mg/m2 iv on days 1 and 8+prednisone at 40 mg/m2 orally on days 1-14)."	( Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer: four-year update. Fowble, BL; Fox, KR; Glick, JH; Glover, DJ; Goodman, RL; Haller, DG; Hurwitz, S; Mackie, JA; Rosato, EF; Weiler, C, 1988)	0.45
" Anticholinesterase medication (nine patients) and corticosteroid dosage (six patients) had been kept constant for a 2-month period."	( Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Arsura, EL; Bick, A; Brunner, NG; Grob, D, 1988)	0.27
" Since then, a multitude of different combinations and variations in drug dosage and timing have been used."	( Adjuvant chemotherapy for breast cancer: 20 years experience using CVFMP chemotherapy. Cooper, RG, 1988)	0.27
" In four patients, including two of the patients in whom rapid test dosing of a sulfonamide had been unsuccessful, treatment of the sulfa reaction with corticosteroids and antihistamines permitted continued sulfa administration."	( The management of patients with sulfonamide allergy. Boxer, MB; Dykewicz, MS; Greenberger, PA; Kelly, JF; Patterson, R, )	0.13
" In patients without clinical remission immunosuppressive drugs were prescribed in different schedule; the greater percentage of pharmacological remissions with less adverse effects was obtained with administration of prednisone 50-75 mg/die initially, than gradually reduced to smaller dosage in alternate day, associated to azathioprine."	( Myasthenia gravis treatment: twelve years experience on 110 patients. Jann, S; Premoselli, S; Scarlato, G; Valli, G, 1987)	0.46
" Careful tailoring of dosage is important to avoid adrenal atrophy and signs of adrenocortical hypofunction."	( Corticosteroids for rheumatic disease. 1. Physiology, pharmacology, and therapeutic strategies. Jamieson, T, 1986)	0.27
" It consisted of hydrocortisone (mean dosage 26 mg/m2) or prednisone (8."	( Compensatory maturational deceleration of growth or "catch-down growth" in patients with congenital adrenal hyperplasia after delayed initiation of therapy. Hunziker, U; Largo, R; Prader, A; Zachmann, M, 1986)	0.52
" Neither the presence of diabetes mellitus nor the CsA dosing frequency affected the measured pharmacokinetic parameters."	( Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Flechner, SM; Kahan, BD; Kramer, WG; Lorber, MI; Van Buren, CT; Wideman, C, 1986)	0.27
"Severe cases of pemphigus vulgaris should be treated with prednisone in high dosage (180-360 mg daily)."	( [Therapy of pemphigus and pemphigoid]. Schaumburg-Lever, G, 1986)	0.52
"We report a young woman with systemic lupus erythematosus complicated by pseudotumor cerebri which resolved with high dosage corticosteroid therapy."	( Dural sinus thrombosis: a mechanism for pseudotumor cerebri in systemic lupus erythematosus. Goodwin, JA; Levinson, DJ; Parnass, SM; Patel, DV; Reinhard, JD, 1987)	0.27
" Basic treatment depends on systemic corticotherapy at a dosage of 30-80 mg of prednisone throughout several months."	( [Laryngeal manifestations of sarcoidosis]. Bertrand, B; Frederickx, Y; Pigeolet, Y; Remacle, M, 1986)	0.5
" Patients received a mean dosage of 12."	( The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Kremer, JM; Lee, JK, 1986)	0.27
" The use of these two drugs in combination does not result in an interaction requiring dosage regimen alteration."	( Lack of effect of sucralfate on prednisone bioavailability. Amend, WJ; Birnbaum, J; Gambertoglio, JG; Lizak, P; Romac, DR; Yong, CL, 1987)	0.56
" Danazol was given at a daily dosage of 600 mg for 4 months."	( Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). Ambríz, R; Avilés, A; Chávez, G; Guillén, C; Morales, M; Pizzuto, J, 1986)	0.27
" Demonstration of systemic signs, bioptically confirmed bone-marrow infiltration and suboptimal cytostatic dosage correlated significantly with a lower full-remission rate."	( [Chemotherapy of advanced lymphogranulomatosis. Results of MOPP/COPP treatment at the West German Tumor Center, Essen]. Becher, R; Höffken, K; Ippisch, A; Pfeiffer, R; Schmidt, CG; Seeber, S, 1985)	0.27
" We are uncertain about the pharmacologic basis of these results but suggest that the increased dosage and more frequent administration of VP-16, relative to that of VM-26, was sufficient to overcome apparent resistance to the latter compound."	( Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia. Abromowitch, M; Bowman, WP; Ochs, J; Rivera, G, 1985)	0.58
" All but one of the patients subsequently received steroid therapy, the dosage of which varied."	( Dense deposit disease in children: prognostic value of clinical and pathologic indicators. The Southwest Pediatric Nephrology Study Group. , 1985)	0.27
" The admission and survival data of 488 patients with cirrhosis who participated in a controlled clinical trial of prednisone in a dosage of 10-15 mg daily (251 patients) versus placebo (237 patients) and who were observed for up to 12 yr were analyzed using Cox's multiple regression model."	( A therapeutic index that predicts the individual effects of prednisone in patients with cirrhosis. Andersen, PK; Christensen, E; Fauerholdt, L; Juhl, E; Poulsen, H; Schlichting, P; Tygstrup, N, 1985)	0.72
" Initial prednisone dosage ranged from 20 mg every other day to 2 mg/kg/day (maximum 60 mg), with subsequent modifications based on improvement."	( Prednisone therapy of membranoproliferative glomerulonephritis in children. Guggenheim, SJ; Lum, GM; Sedman, A; Warady, BA, 1985)	2.13
" Thereafter, the steroid dosage was reduced to 0-10 mg every other day and the measurements were repeated between the 12th and 24th month."	( The pathophysiology and response to steroid therapy in sarcoidosis. Ploysongsang, Y; Roberts, RD, 1986)	0.27
" The minor alterations in prednisolone kinetics during concomitant cimetidine dosing are not likely to induce clinically significant alterations in steroid effect."	( Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Eshelman, FN; Ferguson, RK; Rocci, ML; Sirgo, MA; Vlasses, PH, 1985)	0.51
" Seventy-five patients were given a course of prednisone in an initial dosage of 60mg/24hr, tapering over the following 8-16 weeks."	( Adult-onset nephrotic syndrome with minimal changes: response to corticosteroids and cyclophosphamide. Cameron, JS; Hicks, J; Nolasco, F; Ogg, CS; Williams, DG, 1985)	0.53
", CAF (CPA + ADM + 5-FU), and AC (ADM + CPA) are well known, but the dosage and administration schedule differ somewhat with the researcher."	( [Chemotherapy for recurrent breast carcinoma]. Taguchi, T, 1985)	0.27
" Seventy-five patients received corticosteroids, with a mean prednisone dosage of 22."	( Polymyalgia rheumatica. Duration of therapy and long-term outcome. Ayoub, WT; Franklin, CM; Torretti, D, 1985)	0.51
"In an 18-month period seven children who were treated for a variety of neurological and non-neurological diseases, and in whom the corticosteroid or corticotrophin dosage was reduced, developed a syndrome indistinguishable from "benign intracranial hypertension."	( Benign intracranial hypertension following corticosteroid withdrawal in childhood. Neville, BG; Wilson, J, 1970)	0.25
"The rate of recovery of adrenocortical function seems mainly to be determined by the dosage of corticosteroids during the initial stages of treatment rather than by the nature of the disease."	( Recovery of adrenocortical function during long-term treatment with corticosteroids. Der Kinderen, PJ; Schwarz, F; Thijssen, JH; Van Ditmars, MJ; Westerhof, L, 1972)	0.25
"The requirement for insulin decreased in both patients during the period of renal insufficiency and increased following transplantation; this seemed to be related to the large dose of steroids given because now that a maintenance level of steroids has been established, both patients require the same dosage of insulin as they did before the onset of renal insufficiency."	( Treatment of renal failure from diabetic nephropathy with cadaveric homograft. Beaudry, C; Laplate, L, 1973)	0.25
" Treatment with increased dosage of prednisone was associated with a rapid reversion to normal of the migration index and improvement in renal function."	( Changes in leucocyte migration after renal transplantation. Bewick, M; Dominguez, JA; Eddleston, AL; Evans, DB; Smith, MG; Williams, R, 1969)	0.52
" In patients whose renal function was stable at the time of initiation of MPG therapy, prednisone dosage could be lowered to an average of 37% of the previous dose and the patient's Cushingoid appearance or aseptic necrosis of the hips either did not progress or improved."	( Allograft prolongation with synthetic progestins. Gikas, PW; Haines, RF; Niederhuber, JE; Turcotte, JG, 1971)	0.47
" Corticosteroid administration was continued concurrently with azathioprine, but the dosage could be reduced and in one case they were withdrawn."	( Treatment of ulcerative colitis with azathioprine. Gilon, E; Theodor, E; Waks, U, 1968)	0.25
" The importance of dosage schedule for remission maintenance chemotherapy is stressed."	( The management of acute leukemia. Freireich, EJ, 1967)	0.25
" Dose-response studies indicate that bradykinin is more potent than serotonin or histamine in respect of wealing."	( Responses of skin blood vessels to bradykinin, histamine and 5-hydroxytryptamine. Greaves, M; Shuster, S, 1967)	0.25
" The side effects of antihistamines are minor, and the dosage of corticosteroid used and length of time it is given are small enough to avoid major side effects."	( Chronic urticaria. Possible causes, suggested treatment alternatives. Kaplan, AP, 1983)	0.27
" Preliminary results seem to indicate, that the dosage used may be reduced slowly and therapy finally stopped after 3-4 years of treatment in most patients."	( [Therapy of chronic hepatitis (author's transl)]. Arnold, W; Meyer zum Büschenfelde, KH, 1981)	0.26
" From 1976 to 1979 patients with Stage IV disease were treated wither with MOPP or with MOPP plus bleomycin at low dosage (B-MOPP); the incidence of complete remission was not significantly different in the two groups of patients (52 vs."	( Combination chemotherapy for stage IV Hodgkin's disease (Report no 14). Goldman, JM, 1981)	0.26
" Dosage is 1 mg/kg/day."	( [Idiopathic thrombocytopenic purpura (ITP) in childhood (author's transl)]. Schaison, G; Tobelem, G, )	0.13
" Nephrotoxicity, hepatotoxicity and other side-effects of cyclosporin A could usually be dealt with by dosage adjustments, making feasible the chronic use of this agent."	( Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Fernandez-Bueno, C; Iwatsuki, S; Klintmalm, GB; MacHugh, N; Porter, KA; Schroter, GP; Starzl, TE; Weil, R, 1981)	0.26
" Reduction of prednisone led to deterioration in all 3 patients; strength was regained when the higher dosage of prednisone was resumed."	( Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Rothner, AD; Streib, EW, 1981)	0.85
" After tapering the steroid dosage retinal perivasculitis developed associated with a small but significant elevation of the serum angiotensin-converting enzyme level."	( Angiotensin-converting enzyme in sarcoid perivasculitis. Tang, RA; Unger, KM; Willis, DA, 1983)	0.27
" Forty out of 45 patients suffered one or more rejection episodes which were treated by raising the dosage of prednisone."	( Ratios of T lymphocyte subpopulations predict survival of cadaveric renal allografts in adult patients on low dose corticosteroid therapy. Baldwin, WM; Oljans, PJ; Ploem, JS; Tanke, HJ; Van Es, A; Vanes, LA, 1983)	0.48
" Flare-ups of autoimmune ear disease are best managed by increasing steroid dosage or adding cytotoxic medications."	( Practical versus theoretical management of autoimmune inner ear disease. Barna, BP; Calabrese, LH; Hughes, GB; Kinney, SE, 1984)	0.27
" It seems reasonable to formulate a specific goal of treatment, and then fit dosage to the individual needs and tolerances of the patient rather than to a conventionalized "safe" limit, based on averaged data from different and perhaps quite dissimilar subjects."	( Personal observations on the use of inhaled corticosteroid drugs for chronic asthma. Baskerville, J; Jennings, B; Lefcoe, NM; Toogood, JH, 1984)	0.27
" In conclusion, (1) the rapid reduction in the CsA dosage is beneficial and has no drawbacks, and (2) our guidelines for withdrawing prednisone (timing of withdrawal, rate of reduction in dosage) still need further refinement."	( Cyclosporine alone or in combination with prednisone in cadaveric renal transplantation. Brünisholz, M; Brunner, F; Follat, F; Harder, F; Landmann, J; Loertscher, R; Mihatsch, M; Thiel, G; Wenk, M, 1984)	0.74
" He did not improve until the prednisone dosage was increased to 4 mg per kg per day."	( Cicatricial pemphigoid in a 6-year-old child: report of a case and review of the literature. Esterly, NB; Gerson, CR; Greenwald, MJ; Rosenbaum, MM, 1984)	0.56
" There were no differences in dosage of these two agents between patients who remain alive in CR and those who relapsed and died."	( Simultaneous low-dose radiation and low-dose chemotherapy in the treatment of advanced Hodgkin's disease. Gomez, GA; Han, T; Henderson, ES; Ozer, H; Panahon, AM; Stutzman, L, 1984)	0.27
" Supplemental dosing of prednisone following plasma exchange appears unnecessary."	( Removal of prednisone and prednisolone by plasma exchange. Henry, DH; Stigelman, WH; Talbert, RL; Townsend, RJ, )	0.83
"Obesity is accompanied by altered secretion and disposition of sex and glucocorticoid hormones, including cortisol, and also confounds parameter normalization and drug dosage selection relative to body weight."	( Prednisolone disposition in obese men. Jusko, WJ; Milsap, RL; Plaisance, KI, 1984)	0.27
" The data showed no statistical difference in any of the pharmacokinetic parameters among tableted products, subjects, or dosing periods in the study."	( In vitro and in vivo bioequivalence of commercial prednisone tablets. Brown, WJ; Francisco, GE; Honigberg, IL; Kotzan, JA; Pelsor, FR; Schary, WL; Shah, VP; Stewart, JT, )	0.38
" There was no correlation between drug dosage and length of survival, whereas the disappearance of blast cells from the peripheral blood appeared to be directly correlated with a longer survival."	( Characterization and treatment of the non-lymphoblastic crisis of chronic myelogenous leukemia. Annino, L; Mandelli, F; Mariani, G; Solinas, S, 1983)	0.27
" The adverse effects, which could be minimized by reducing the dosage in most instances, were primarily related to treatment that persisted for more than two weeks."	( Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases. Lozada, F; Migliorati, C; Silverman, S, 1984)	0.54
" These findings lend support to other data which indicate a useful role for MTX in the induction chemotherapy of advanced high-grade NHL, though the optimum dosage and drug sequence have yet to be determined."	( A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL). Barnard, DL; Cartwright, SC; Child, JA; Lauder, I; Simmons, AV; Stone, J; Thorogood, J, 1983)	0.27
"A dose-response analysis of the results of MOPP chemotherapy in 132 patients with Hodgkin's disease was carried out."	( A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. Carde, P; MacKintosh, FR; Rosenberg, SA, 1983)	0.27
" However, the disease progressed despite relatively high dose steroid therapy, complications of which contraindicated increasing the dosage and even necessitated rapid withdrawal of steroids."	( [Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica]. Celton, H; Doury, P; Eulry, F; Fabresse, FX; Larroque, P; Pattin, S, 1984)	0.27
" In two patients the corticosteroid dosage could be tapered."	( Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. Bickers, DR; Callen, JP; Hanno, R; Hawkins, C; Voorhees, JJ; Woo, TY, 1984)	0.27
" The latter group, therefore, does not profit from cytotoxic drugs in the dosage used."	( The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN). Brodehl, J; Ehrich, JH; Krohn, HP, )	0.13
"Eighty percent of 26 steroid-dependent, chronically asthmatic adults eliminated oral steroid dosage after 12 weeks of treatment with triamcinolone acetonide aerosol (800 micrograms/day)."	( Long-term triamcinolone acetonide aerosol treatment in adult patients with chronic bronchial asthma. Golub, JR, 1980)	0.26
" Treatment was continued until reductions in corticosteroid dosage no longer resulted in clinical evidence of GCA."	( Duration of corticosteroid therapy in giant cell arteritis. Fernandez-Herlihy, L, )	0.13
" The intermediate form shows a transient steroid-induced complete remission giving place to widely fluctuating platelet counts above and below 100,000 microliters once the steroid dosage is reduced to maintenance levels."	( Childhood idiopathic thrombocytopenic purpura in Egypt and the neighboring Arab countries: a regional form with three different patterns of clinical expression. Adnan, M; Afifi, AM; Guindi, MM, 1981)	0.26
"A short course of prednisone suspension given in a decreasing dosage schedule for up to ten days was often effective (68%) in resolving mucoid otitis media with effusion (OME, middle ear effusion)."	( Otitis media with effusion: results of treatment with a short course of oral prednisone or intranasal beclomethasone aerosol. Schwartz, RH, )	0.69
" A comparison of drug dosage in the group receiving TPN and the group receiving standard nutrition is a measure of drug tolerance in these patients."	( A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance. Brennan, MF; Fisher, RI; Popp, MB; Simon, RM, 1981)	0.26
" The neurological toxicity was little and led to reduction of the dosage in only two adults with preexisting neuropathy."	( A phase II study of vindesine in patients with hematological malignancies. Bosly, A; Cornu, G; Delannoy, A; Ferránt, A; Hulhoven, R; Michaux, JL; Sokal, G, 1980)	0.26
" The administration of pharmacological doses of glucocorticoids increased the dosage of 1,25(OH)2D3 needed to maintain a normal serum calcium level 7- to 10-fold in 2 patients whose renal grafts failed to function, but there was no decrease in sensitivity to 1,25(OH)2D3 in 1 patient whose renal graft functioned normally."	( Interactions between treatment with 1,25(OH)2D3 and glucocorticoids in uremic patients after kidney transplantation. Coburn, JW; Siemsen, AW; Sugihara, JG; Wong, EG, 1980)	0.26
" Life-table analysis of two dosage schedules of chlorambucil at four years showed that 91 per cent of patients on low doses and 80 per cent of those on high doses were still in remission."	( Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. Grupe, WE; Ingelfinger, JR; Makker, SP; Williams, SA, 1980)	0.53
" During such outbreaks the use of flunisolide not only delayed the need for more prednisone but also reduced the dosage needed."	( Episodic asthma as a bronchial provocation test. Izu, AE; Leech, SH; Rolston, BS, 1980)	0.49
" Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents."	( A new therapy schedule for pediatric non-Hodgkin lymphoma toxicity with preliminary results. Anderson, J; Chilcote, R; Coccia, P; Exelby, P; Hammond, D; Jenkin, RD; Kushner, J; Leikin, S; Meadows, AT; Siegel, S; Wilson, JF, 1980)	0.26
" The major defect was depressed granulocyte adherence early postoperatively and at the time of rejection crises, when prednisone dosage was maximal."	( Granulocyte function in recipients of renal transplant from live related donors and from cadavers. Barker, CF; Golshan, N; MacGregor, RR, 1980)	0.47
" The findings suggest that the development of steroid diabetes can serve as a warning signal for excessive dosage of corticosteroids, and help to identify patients that are particularly sensitive to immunosuppressive therapy with large doses of steroids."	( Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient? Groth, CG; Gunnarsson, R; Lundgren, G; Magnusson, G; Ost, L, 1980)	0.26
" A reduction of more than 50% in corticosteroid dosage applied within three months after transplantation seems to be possible, with a sharp decrease of morbidity rate."	( Less aggressive rejection therapy and low-dose corticosteroids leading to satisfactory cadaveric kidney graft survival and low morbidity rate. de Graeff, J; Kalff, MW; Koolen, MI; van den Broek, PH; van Es, A; van Hooff, JP, 1980)	0.26
" The TDD patients were begun on half the dosage of steroids, and at 30 days were receiving approximately two-thirds the dose that the non-TDD patients received."	( Renal transplantation after thoracic duct drainage. Bell, JD; Fish, JC; Flye, MW; Remmers, A; Sarles, HE; Townsend, CM, 1981)	0.26
" Reduction of the steroid dosage was followed by regression of the tumor."	( Kaposi's sarcoma complicating corticosteroid therapy for temporal arteritis. Fam, AG; Leung, F; Osoba, D, 1981)	0.26
"On the basis of 15-years' experience with the allogeneic transplantation of the kidney, the authors present recommendations, concerning the dosage of azathioprine and prednisone (methylprednisolone) during the schematic immunosuppression."	( Schematic and controlled immunosupression after renal allotransplantation. Jirka, J; Kaslík, J; Kaslíková, J; Kocandrle, V, 1981)	0.46
" The COPP patients received 84% of the calculated ideal doses of cyclophosphamide and 78% of the ideal dosage of procarbazine."	( Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Barnes, JM; Bennett, JM; Berard, CW; Ezdinli, EZ; Glick, JH; Orlow, EL, 1981)	0.26
" Of the 34 children shows relapses had tended to occur after the prednisone dosage had been reduced or immediately after the drug was discontinued (the steroid-dependent group), 22 also had early relapses after cytotoxic-drug treatment."	( Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. , 1982)	0.5
" Total prednisone dosage was identical during the 6-mo study periods and only dose spacing differed."	( Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Curtis, JJ; Galla, JH; Luke, RG; Saykaly, RJ; Woodford, SY, 1981)	0.99
" All patients were given a 50 IU intravenous test dose followed in 30 min by the full dosage (10,000 IU/m2), if no reaction occurred to the test dose."	( Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Barker, LF; Crom, WR; Dahl, GV; Denison, M; Evans, WE; Mauer, AM; Murphy, SB; Rivera, G; Tsiatis, A, 1982)	0.26
" Early convalescence was highly variable, often necessitating adjustments of cyclosporin A and steroid dosage to accommodate the possibilities of rejection or cyclosporin A nephrotoxicity, or both, simultaneously."	( Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids. Hakala, TR; Iwatsuki, S; Rosenthal, JT; Shaw, BW; Starzl, TE, 1982)	0.26
" The efficacy of corticosteroids, immunosuppressive and cytotoxic agents remains uncertain due to variable drug and dosage schedules, lack of comparable patient populations, and retrospective nature of previous reports."	( Lymphomatoid granulomatosis. Clinicopathologic study of four cases and literature review. Lynch, JP; Patton, WF, 1982)	0.26
" Proper dosage and sufficient length of treatment are absolutely essential for such successful outcome."	( The treatment of subglottic hemangiomas of infants with prednisone. Grunebaum, M; Sadan, N; Sadé, J, 1982)	0.51
" Marrow from Patient 1 yielded linear increases in numbers of colonies in erythropoietin dose-response studies, and the magnitude of response was much greater while on prednisone compared to pretreatment."	( Diamond-Blackfan syndrome. I. Erythropoiesis in prednisone responsive and resistant disease. Chan, HS; Freedman, MH; Saunders, EF, 1982)	0.71
"The influence of various dosing regimens on the response of asthmatic patients to aerosol steroid was investigated."	( Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. Baskerville, JC; Jennings, B; Johansson, SA; Lefcoe, NM; Toogood, JH, 1982)	0.26
" Prednisone in a dosage of 100 mg daily successfully interrupted the neutrophil cycling and prevented infection."	( Acquired cyclic neutropenia: successful treatment with prednisone. Rodgers, GM; Shuman, MA, 1982)	1.42
" The phenomenon was dose related and markedly diminished in two patients as the dosage of corticosteroid was decreased, despite the fact that the alternate-day regimen was continued."	( Relationship between alternate-day corticosteroid therapy and behavioral abnormalities. Fauci, AS; Sack, DS; Sharfstein, SS, 1982)	0.26
"Frentizole, an immunosuppressive phenylurea agent, used in a dosage of 4 mg/kg per day, was found to produce quick elevation of platelet counts in three thrombocytopenic patients."	( Frentizole therapy of thrombocytopenia in systemic lupus erythematosus and refractory idiopathic thrombocytopenic purpura. Colgan, JP; Ferguson, RH; O'Duffy, JD; Phyliky, RL, 1980)	0.26
" Suppression of cortisol and estrogens was greater after dexamethasone (Dx) than after a glucocorticoid-equivalent dosage of prednisone (Pd)."	( Loss of diurnal rhythm in plasma estrone, estradiol, and estriol in women treated with synthetic glucocorticoids at 34 to 35 weeks' gestation. Challis, J; Patrick, J; Richardson, B; Tevaarwerk, G, 1981)	0.47
" Eighteen patients were in early stage (I or II) and 11 of them were also submitted to involved field radiotherapy (60Co), immediately before (stage I) or during (stage II) the chemotherapy, with a mean dosage of 4,500 rad."	( Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin's lymphomas with unfavorable histology: preliminary results. Abate, G; Bruni, GS; Comella, G; Comella, P; Pergola, M; Zarrilli, D, 1980)	0.49
" Gradual reduction in prednisone dosage to 5 mg daily has coincided with a period of clinical resolution and modest improvement in lymphocyte reactivity."	( Idiopathic pyoderma gangrenosum and impaired lymphocyte function: failure of azathioprine and corticosteroid therapy. Breathnach, SM; Valdimarsson, H; Wells, GC, 1981)	0.58
" While earlier results suggested that adjuvant chemotherapy is especially effective in premenopausal women, newer studies and analyses indicate that appropriate dosage and consistent administration of chemotherapy are of decisive importance."	( [Results of, and indications for adjuvant chemotherapy in breast cancer]. Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L, 1981)	0.26
" Based on the course in our patients and the cases presented in previous reports, a suggested program of treatment for immunoblastic lymphadenopathy includes administration of moderate doses of steroids initially, with a subsequent increase to a higher dosage if desired improvement does not occur."	( The lung in immunoblastic lymphadenopathy. Banks, PM; Bradley, SL; Dines, DE; Hill, RW, 1981)	0.26
" Three cases of vitamin D poisoning are described, in each of which the indication for treating the patients was reasonable but the dosage was not adapted as it should have been."	( [Vitamin D intoxication]. Courvoisier, B; Jung, A, 1980)	0.26
" Approximately half the patients were being treated with an alternate day regime of prednisone, receiving high dosage one day and low the next."	( Psychiatric effects of alternate day steroid therapy. Cordess, C; Drachman, D; Folstein, M, 1981)	0.49
" Although the degree of leukocytosis was related to the dosage administered, it did appear sooner with higher doses."	( Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis. Gallant, LA; Gurewich, Y; Pinkhas, J; Shoenfeld, Y, 1981)	1.71
" dosage range."	( Dose dependent pharmacokinetics of prednisone and prednisolone in man. Jusko, WJ; Rose, JQ; Yurchak, AM, 1981)	0.54
" Nevertheless, persistent use of steroids in high dosage resulted in normalization of both CSF and brain scan abnormalities."	( Temporal arteritis: cerebrospinal fluid and brain scan abnormalities (case report). Gordon, EP; Gordon, M, 1980)	0.26
" Maintenance steroid dosage at the time of study ranged from 20 to 50 mg on alternate days, averaging 31 +/- 8 mg."	( Long-term corticosteroid effect on lymphocyte and polymorphonuclear cell function in asthmatics. Chiang, JL; Harris, K; McGillen, JJ; Patterson, R; Phair, JP; Riesing, KS; Roberts, M, 1980)	0.26
" A general discussion is presented on the role of the peristaltic apparatus in selecting a suitable dosage form at the developmental stage."	( Peristaltic dissolution apparatus: prediction of relative in vivo performance of prednisone tablets in humans. Legore, AA; Picotte, P; Simmons, DL, 1980)	0.49
" After initial negative radiologic investigations, his corticosteroid dosage was tapered, and the recurrence of his symptoms and signs prompted repeat computed tomographic scans."	( Medulloblastoma causing a corticosteroid-responsive optic neuropathy. Hirst, LW; Kumar, AJ; Miller, NR; Udvarhelyi, GB, 1980)	0.26
" To establish an optimal dosage schedule, 15 healthy male volunteers entered a two-phased study to determine (1) the single dose of prednisone required to produce maximal suppression of histamine and basophil levels and (2) the effects of repeated prednisone doses."	( Dose-response studies of the suppression of whole blood histamine and basophil counts by prednisone. Kay, DR; Mathews, KP; Muilenberg, ML; Pan, PM; Saavedra-Delgado, AM, 1980)	0.69
" The first drug used, in 20 patients, was methysergide maleate in a dosage of 3--6 mg daily over a four weeks period."	( [Cluster headache: clinical and therapeutic aspects in 26 cases]. Sanvito, WL; Tilbery, CP, 1980)	0.26
" The recognition of high NAG enzymuria permits to reduce dosage or discontinue treatment with potentially nephrotoxic drug prior to irreversible renal insufficiency as shown in the case of a patient with psoriatic arthritis treated with simultaneously administered cyclosporin and diclofenac."	( N-acetyl-beta-D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. Szechiński, J; Wiland, P, 1994)	0.29
" No (inverse) correlation between serum osteocalcin and the daily dosage of prednisone was found."	( Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Bijlsma, JW; Jacobs, JW; Jahangier, ZN; Lems, WF, )	0.36
" There was no increase in concurrent immunosuppressives dosage after the conversion."	( Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. Kaplan, MM; Pedrosa, MC; Rohrer, RM, 1995)	0.65
" Their dosage of oral prednisone was adjusted weekly according to predetermined criteria."	( Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Boltansky, H; Busse, WW; Chervinsky, P; de Boisblanc, BP; Kellerman, D; Noonan, M; Pearlman, D; Pinnas, J; Repsher, L; Weisberg, SC, 1995)	0.88
" It is clear that new dosing arrangements need to be created and studied."	( Corticosteroids in the treatment of rheumatologic diseases. Weisman, MH, 1995)	0.29
" Corticosteroid treatment (prednisone at the starting dosage of 30 mg/day) produced the healing of the disease in 5 months."	( [Scleroderma induced by chemical agents. Description of a case and review of the literature]. Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A; Pacor, ML; Spinaci, E, 1995)	0.59
" When the glucocorticoid dosage was reduced or the drug discontinued, the nephrotic syndrome recurred."	( [T-cell lymphoma under immunosuppressive treatment in minimal change glomerulopathy with nephrotic syndrome]. Schollmeyer, P; Späth, M, 1995)	0.29
"These data suggest that long-term renal function in cyclosporine-treated kidney transplant patients is primarily influenced by the occurrence of early and late rejection episodes rather than by the dosage or duration of cyclosporine therapy."	( Long-term renal function in cyclosporine-treated renal allograft recipients. Hodge, E; Novick, AC; Streem, S; Tanabe, K, 1995)	0.29
"Prednisone dosage was successfully tapered to 10 to 20 mg/d without worsening symptoms in 10 (38%) of the 26 patients studied."	( Therapeutic considerations in patients with refractory neurosarcoidosis. Agbogu, BN; Sewell, C; Stern, BJ; Yang, G, 1995)	1.73
"No significant differences in area under the serum concentration versus time curve (AUC), maximal methotrexate concentration following dosing (Cmax), time to Cmax (Tmax), bioavailability (F), urinary MTX, renal clearance of MTX or creatinine clearance were observed between the 2 cohorts."	( Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. Hamilton, RA; Kremer, JM; Petrillo, GF, 1995)	0.29
" The present study was designed to evaluate the ability of specific inspiratory muscle training (SIMT) to prevent the effects of a therapeutic dosage of corticosteroids on inspiratory muscle function in patients receiving the drug for diseases other than pulmonary, with no underlying respiratory or muscular disease."	( Inspiratory muscle training during treatment with corticosteroids in humans. Azgad, Y; Weiner, M; Weiner, P, 1995)	0.29
"Iatrogenic osteoporosis is a very common secondary osteoporosis is found in patients treated with large dosage of glucocorticosteroid of long duration."	( [Iatrogenic osteoporsis: six case reports]. Wang, JZ; Zheng, LM, 1994)	0.29
"An inverse relationship between the ophthalmodynamometric retinal venous collapse pressure and systemic prednisone dosage was observed."	( Ophthalmodynamometry and corticosteroids in central retinal vein occlusion. Beaumont, PE; Kang, HK, 1994)	0.5
"A total of 121 patients with fewer than 50 x 10(9) platelets per liter received an initial treatment with prednisone (PDN) at a dosage of 1 mg/kg of body weight for 1 month."	( Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Adomo, G; Amadori, S; Cecconi, M; Masi, M; Oliva, F; Perrotti, AP; Sciarra, A; Scimò, MT; Stasi, R; Stipa, E, 1995)	0.5
" The lung cancer (without lymph node metastases) was resected, and the temporal arteritis treated with prednisone in the standard dosage regimen."	( Simultaneous clinical manifestations of malignancy and giant cell temporal arteritis in a young woman. Lie, JT, 1995)	0.51
" The introduction of cyclosporine has allowed us to reduce the dosage of oral steroids and to accept DM patients (pts) for HTx."	( Mid-term results of heart transplantation in diabetic patients. Bianco, R; Boffa, GM; Caforio, AL; Casarotto, D; Casula, R; Gambino, A; Grassi, G; Livi, U; Milano, A; Thiene, G, 1994)	0.29
" GCS dosage was increased in 2 patients: 1 with recurrent serositis, 1 with persistent vasculitis."	( A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. Abeles, M; Wilson, K, 1994)	0.29
" Trough levels of 400-600 ng/dl (measured by radioimmunoassay) were achieved, at which point oral cyclosporine was given and oral dosage was adjusted to similar levels."	( Cyclosporine as an alternative to surgery in children with inflammatory bowel disease. Benkov, KJ; Janowitz, HD; LeLeiko, NS; Rosh, JR; Schwersenz, AH, 1994)	0.29
" The efficacy was assessed on the daily dosage of prednisone and was also evaluated using the FEV1 (VEMS) (the variations expressed were a percentage of the variation from the predicted value)."	( [Methotrexate in the treatment of asthma. Open trial in 10 corticoid-dependent patients with severe asthma]. Becquart, LA; Guéné-Ribassin, C; Lassalle, P; Tonnel, AB; Wallaert, B, 1994)	0.54
" Prednisone dosage was also significantly less when comparing the time before methotrexate therapy to immediately after completion of methotrexate therapy (0."	( Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute cellular rejection. Bullock, EA; Hawkins, JA; McGough, EC; Olsen, SL; Orsmond, GS; Renlund, DG; Shaddy, RE; Tani, LY; Taylor, DO, )	1.04
"Patients with active RA diagnosed at age > or = 60 were randomized to receive prednisone (15 mg/day for 1 month, with the dosage tapered as low as possible thereafter) (n = 28) or chloroquine (n = 28)."	( Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Breedveld, FC; Dijkmans, BA; Han, KH; Papapoulos, S; Pauwels, EK; Valkema, R; van Schaardenburg, D; Zwinderman, AH, 1995)	1.96
"Data from published research were extracted and evaluated according to study design, sample size, dosing regimen, outcome measures, and treatment efficacy and safety."	( Treatment of infantile spasms. Casto, DT; Haines, ST, 1994)	0.29
" However, the form of drug used, dosing regimen, and route of administration are highly variable."	( The use of corticosteroids in croup: a survey. Connors, K; Gavula, D; Terndrup, T, 1994)	0.29
" When rifampin-prednisone treatment must be used in giant cell arteritis, we propose increasing the prednisone dosage to 2 mg/kg per day."	( Rifampin-induced nonresponsiveness of giant cell arteritis to prednisone treatment. Becq-Giraudon, B; Bouquet, S; Carrie, F; Delon, A; Roblot, F; Roblot, P, 1994)	0.88
" Steady state dosage between 1/2 and 3 tablets per day was individually adjusted according to the severity of the clinical symptoms."	( Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone. Eberhardt, R; Gross, W; Krüger, K; Reiter, W; Zwingers, T, 1994)	0.49
" Comparison of the dose-response relationships for humans and rats indicates that, under conditions of no depletion of O6-alkylguanine-DNA alkyltransferase (AGT), O6-meG accumulates in blood leukocyte DNA of humans at a rate which is only approximately 2-fold lower than in rats, implying that, to the extent to which O6-meG contributes to the genotoxic activity of procarbazine, human susceptibility to it is likely to be comparable to that of the rat."	( Comparative dosimetry of O6-methylguanine in humans and rodents treated with procarbazine. Boussiotis, VA; Kyrtopoulos, SA; Pangalis, GA; Souliotis, VL; Valavanis, C, 1994)	0.29
" Until day 14, all recipients received cytomegalovirus hyperimmunoglobulin at a dosage of 2 ml/kg/day."	( Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies. Auer, T; Halwachs-Baumann, G; Iberer, F; Müller, H; Petutschnigg, B; Pleisnitzer, A; Rödl, S; Tscheliessnigg, K; Wasler, A; Wilders-Truschnig, M, )	0.13
" The patient has been free of lesions with a maintenance dosage of 10 mg of prednisone every other day."	( Pemphigus vulgaris in adolescence. A case presentation and review of the literature. Gorsky, M; Raviv, E; Raviv, M, 1994)	0.52
" At the time of entry, the subjects' mean dosage of prednisone was 23."	( Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma. Diaz, JD; Ledford, DK; Lockey, RF; Seleznick, MJ; Stewart, GE; Trudeau, WL, 1994)	0.54
" We describe 3 such patients, and our experience in tapering their steroid dosage with the use of dapsone or methotrexate."	( Steroid-sparing medications in temporal arteritis--report of three cases and review of 174 reported patients. Nesher, G; Sonnenblick, M, 1994)	0.29
" This was associated with delivery of 100% of the planned dosage of vincristine, prednisone, and daunorubicin at induction."	( Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D, 1994)	0.51
" The latter were successfully treated with oral vancomycine, but in the last relapse an increased dosage of prednisone was required, too."	( [Clostridium difficile in early childhood ulcerative pancolitis]. Hoppen, T; Keller, KM; Rister, M; Stolte, M, 1993)	0.5
" Kaplan Meier survival curves for the development of the first AE showed a dose-response relationship between prednisone and AE occurrence, independent of rheumatoid nodules."	( Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Brasington, R; Burmeister, LF; Caldwell, JR; Furst, DE; Koehnke, R; Kohler, JA; Saag, KG; Zimmerman, B, 1994)	0.5
" Increased growth is a major benefit of decreased steroid dosing in these children."	( Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients. Billmire, DF; Dunn, SP; Falkenstein, K; Lawrence, JP; Meyers, R; Vinocur, CD; Weintraub, WH, 1994)	0.29
" If disease activity allows, a reduction in prednisone dosage may reduce the risk of bacterial superinfection during zoster episodes."	( Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. Kahl, LE, 1994)	0.55
" Further investigation and formal studies of the dose-response relationships and kinetics of steroid administration may lead to improvement in the management of acute GVHD."	( Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Blazar, BL; Filipovich, AH; Hings, IM; Kersey, JH; McGlave, PB; Miller, WJ; Ramsay, NK; Weisdorf, DJ, 1993)	1.73
" The close correlation of plasma IL-6 concentrations with clinical symptoms suggests a direct contribution of this cytokine to the disease manifestations and presents the possibility that monitoring IL-6 levels would be useful in making decisions on adjustment of corticosteroid dosage in individual patients."	( Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Fulbright, JW; Goronzy, JJ; Hunder, GG; Roche, NE; Wagner, AD; Weyand, CM, 1993)	0.29
" After randomization, 123 patients also received interferon alfa-2b at a dosage of 5 million units three times weekly for 18 months."	( Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Bosly, A; Brice, P; Brousse, N; Haioun, C; Lepage, E; Leporrier, M; Parlier, Y; Peuchmaur, M; Reyes, F; Solal-Celigny, P, 1993)	0.29
" The authors believe that increasing dosage of the immunosuppressants is an effective method for the management of chronic renal rejection and the earlier the treatment is given the better the results would be."	( Treatment of chronic allograft rejection. Fan, Y; Jin, WH; Wang, XH; Xie, T; Xu, D, 1993)	0.29
" In 27 other patients, the prednisone dosage has been tapered to 5 mg/day or less with the aim of discontinuing the drug."	( Prednisone withdrawal in HLA identical and one haplotype-matched live-related donor and cadaver renal transplant recipients. Alexander, JW; First, MR; Hariharan, S; Schroeder, TJ; Weiskittel, P, 1993)	2.03
" Dosage began at 60 mg/m2 for 3 month, was reduced to 30 mg/m2 by 1 year and 15 mg/m2 by 2 years."	( Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Benfield, MR; Herrera, GA; Kelly, DR; Kohaut, EC; Waldo, FB; Wyatt, RJ, 1993)	0.52
" Gradual steroid dosage tapering resulted in marked improvement in both strength and endurance; the inspiratory muscle strength rose significantly to 112."	( The effect of corticosteroids on inspiratory muscle performance in humans. Azgad, Y; Weiner, M; Weiner, P, 1993)	0.29
" Three children who were treated with adrenocorticotropic hormone dosage larger than recommended died."	( Risk of infection during adrenocorticotropic hormone treatment in infants with infantile spasms. Alpert, G; Garty, BZ; Kivity, S; Rachmel, A; Shamir, R, 1993)	0.29
" The onset of symptoms may occur after only some weeks or after up to several years with no dose-response relationship."	( Interstitial lung disease--an underdiagnosed side effect of chlorambucil? Huhn, D; Kingreen, D; Mohr, M; Rühl, H, 1993)	0.29
" All drugs but mafosfamide, tested in place of cyclophosphamide, were used at concentrations corresponding to the in vivo dosage employed in the CEOP regimen."	( In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to multidrug regimen (CEOP) compounds using the MTT colorimetric assay. Brugiatelli, M; Callea, V; Messina, G; Morabito, F; Nobile, F; Oliva, B; Ramirez, F, )	0.13
" ALG treatment should usually be limited to 14 days, but azathioprine dosage can safely be increased after ALG discontinuation."	( Bone marrow function during quadruple immunosuppressive therapy after renal transplantation. Heaf, J, 1993)	0.29
" Of the 13 case patients whose dosage was recorded, 7 received less than the equivalent of 2 mg/kg per day of prednisone."	( Severe varicella associated with steroid use. Bresee, JS; Dowell, SF, 1993)	0.5
" Prednisone was administered at immunosuppressive dosage (1 mg."	( Effects of a short prednisone regime at clinical onset of type 1 diabetes. Casamitjana, R; Fernandez, J; Goday, A; Gomis, R; Pujol-Borrell, R; Rios, M; Vilardell, E, 1993)	1.52
" Primary measures of efficacy were quantified strength testing, antihuman acetylcholine receptor antibody titer, and dosage of corticosteroid medication."	( A clinical therapeutic trial of cyclosporine in myasthenia gravis. Hall, K; Phillips, JT; Rollins, JA; Tindall, RS; Wells, L, 1993)	0.29
"To complete research in this type of coagulation and cancer, a multicentric randomized clinical trial was performed, including 303 patients with small cell lung cancer (SCLC), treated by the addition of aspirin at 1 g/day (a dosage at which aspirin is considered to be a platelet aggregation inhibitor) to combined chemotherapy."	( No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. Chastang, C; Fabre, C; Lebeau, B; Massin, F; Muir, JF; Vincent, J, 1993)	0.29
"Prednisone was given orally to 12 dogs daily for 35 days at an anti-inflammatory dosage (1."	( Effects of oral administration of anti-inflammatory doses of prednisone on thyroid hormone response to thyrotropin-releasing hormone and thyrotropin in clinically normal dogs. Ferguson, DC; Hoenig, M; Moore, GE, 1993)	1.97
"Forty-one heart transplant patients with 43 episodes of asymptomatic moderate cardiac rejection were randomized to receive 3 days of 1,000 mg of intravenous Solu-Medrol (20 episodes) or prednisone as a bolus dose of 100 mg orally for 3 days, tapering to the previous maintenance dosage over 14 days (23 episodes)."	( Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. Brownfield, E; Drinkwater, DC; Kawata, N; Kobashigawa, JA; Laks, H; Moriguchi, JD; Stevenson, LW, 1993)	0.48
"Inhaled steroid therapy is being emphasized in the treatment of asthma but requires patient adherence to regular dosing regimens and skilled inhalation techniques for treatment to be effective."	( Disappearance of eosinophils from bronchoalveolar lavage fluid after patient education and high-dose inhaled corticosteroids: a case report. Fahy, J; Geaghan, S; Golden, J; Janson-Bjerklie, S, )	0.13
" After treatment with Chai-Ling-Tang, relapse was markedly improved, time for negative conversion of proteinuria shortened, prednisone dosage significantly reduced, and side effects eased."	( Therapeutic effect of chai-ling-tang (sairei-to) on the steroid-dependent nephrotic syndrome in children. Liu, XY, 1995)	0.5
" The CSA-associated toxicity may be reduced by initiating therapy at very low initial doses, with incremental dosage escalation to the desired target range."	( Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Foster, CS; Rodriguez, A; Vitale, AT, 1996)	0.29
"Twenty eligible patients with NHL and chronic lymphatic leukemia (CLL), resistant to or relapsed after previous protocols of polychemotherapy were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle."	( Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia. Bairey, O; Blickstein, D; Hadar, H; Lahav, M; Prokocimer, M; Shaklai, M; Shaklai, S; Sulkes, J, 1996)	0.29
" All patients needed course shortening and dosage reduction."	( Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia. Bairey, O; Blickstein, D; Hadar, H; Lahav, M; Prokocimer, M; Shaklai, M; Shaklai, S; Sulkes, J, 1996)	0.29
" However, unlike many of the side effects of corticosteroid treatment, the side effects of immunosuppressive therapy were reversible with reduction in dosage or discontinuation of the drug."	( Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Akova, YA; Christen, WG; Foster, CS; Messmer, E; Rodriguez, A; Tamesis, RR, 1996)	0.29
" For patients receiving acyclovir, the dosage was 2,000 mg (400 mg 5 times daily) for 10 days."	( Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Adour, KK; Byl, FM; Hitchcock, T; Quesenberry, CP; Ruboyianes, JM; Trent, CS; Von Doersten, PG, 1996)	0.56
" rhGM-CSF was administered at a dosage of 5 micrograms/kg for 10 days or until neutrophils were > 1/nl following chemotherapy."	( Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study. Bergmann, L; Hoelzer, D; Karakas, T; Knuth, A; Lautenschläger, G; Mitrou, PS, 1995)	0.29
" The corticosteroid dosage was gradually tapered."	( Predominant tubulointerstitial lupus nephritis. Madias, NE; Singh, AK; Ucci, A, 1996)	0.29
" The most significant factor responsible for these metabolic complications was the total dosage of prednisone and cyclosporine."	( Metabolic problems in recipients of liver transplants. Filo, RS; Hughes, D; Jindal, RM; Leapman, SB; Lumeng, L; Milgrom, ML; Pescovitz, MD; Sidner, RA, 1996)	0.51
" For lymphoma, CHOP chemotherapy dosage costs are approximately half of those for CDE infusion related to the specific drug regimen and drug dosage used."	( Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges. Anderson, NR; Lokich, JJ; Moore, CL, 1996)	0.29
" The principle cost differences between bolus and infusional schedules relate to drug dosage and the toxicity profile."	( Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges. Anderson, NR; Lokich, JJ; Moore, CL, 1996)	0.29
" Six years after the start of corticosteroid therapy for her annoying skin lesion, we started to treat her with high-dose intravenous immunoglobulin (IVIG) infusion therapy because of the difficulty of reducing the dosage of oral prednisone, that had secondarily induced adverse effects."	( Successful treatment of a therapy-resistant severely pruritic skin eruption of malignancy-associated dermatomyositis with high-dose intravenous immunoglobulin. Kikuchi-Numagami, K; Sato, M; Tagami, H, 1996)	0.48
" Once the patient's liver function normalized, prednisone dosage was reduced by 5 mg weekly."	( Dapsone hypersensitivity syndrome. Prussick, R; Shear, NH, 1996)	0.55
"Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline."	( Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. Braat, MC; Jonkers, RE; Koopmans, RP; van Boxtel, CJ, 1995)	0.69
" This modest dosage was found to give an excellent result in three patients and a poor result in one whose treatment was started at a much later stage of the disease than in the others."	( Oral prednisone in the treatment of acne agminata. Aiba, S; Tagami, H; Uesugi, Y; Usuba, M, 1996)	0.81
" GC mini pulses are effective on early clinical and biological parameters of inflammation and requires a lower cumulative daily dosage than conventional oral GC treatment."	( 6-methylprednisolone 'mini-pulses': a new modality of glucocorticoid treatment in systemic onset juvenile chronic arthritis. Borrone, C; Buoncompagni, A; Gattorno, M; Picco, P; Pistoia, V, 1996)	0.29
" Prednisone therapy was continued until the patient was discharged on hospital day 5, at which time the dosage was tapered."	( Reversal of erythema multiforme major with cyclophosphamide and prednisone. Cole, GW; Eastham, JH; Gómez, MF; Segal, JL, 1996)	1.44
" The most common postoperative dosage (used by 62 percent) was 100 mg of hydrocortisone phosphate intravenously every eight hours, which was tapered to 50 mg intravenously every 8 to 12 hours."	( Perioperative steroid use in colorectal patients. Results of a survey. Beck, DE; Opelka, FG, 1996)	0.29
" Methotrexate was given weekly for 8 weeks beginning at the conclusion of OKT3 therapy (postoperative days 8 to 16), and dosed according to white blood cell count."	( Methotrexate for rejection prophylaxis after heart transplantation. Ensley, RD; Olsen, SL; Renlund, DG; Taylor, DO, )	0.13
" carinii pneumonia reported to date in methotrexate-treated rheumatoid arthritis patients demonstrated a number of characteristics: the rheumatoid arthritis was of recent onset in some cases (a few months in one patient); lymphopenia was present in two thirds of cases; one-third of patients were not receiving corticosteroid therapy; the dosage and duration of methotrexate therapy varied widely, from 5 to 30 mg per week and two to 48 months; and four patients died."	( Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. Cortet, B; Delcambre, B; Duquesnoy, B; Flipo, RM; Lafitte, JJ; Roux, N; Tonnel, AB, 1996)	0.29
" MP dosage based on BMI may be a reasonable alternative to a fixed-dose regimen with the advantage of limiting steroid exposure and the consequent side-effects."	( Treatment of renal allograft acute rejection with methylprednisolone: effect of fixed dose versus dose per body mass index. Carson, RW; Douzdjian, V; Fisch, JC; Gugliuzza, KK; Rice, JC, 1996)	0.29
"In the patients who were receiving DHEA, the SLEDAI score, patient's and physician's overall assessment of disease activity, and concurrent prednisone dosage decreased, while in the patients taking placebo, small increases were seen."	( Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Engleman, EG; McGuire, JL; van Vollenhoven, RF, 1995)	0.49
" The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects."	( Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Reitter, B, 1995)	0.64
" Two patients developed exacerbation of hepatitis when the dosage of prednisolone was reduced after they had ten weeks of high dose prednisolone."	( Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC, 1996)	0.29
" The mean daily dosage of prednisone was 10."	( Calcific degeneration of bioprosthetic aortic valves in patients receiving steroid therapy. Eishi, K; Ishibashi-Ueda, H; Kobayashi, J; Kosakai, Y; Nakano, K; Sasako, Y; Yutani, C, 1996)	0.59
" Prednisone dosage was lower in diabetics with EOD at 6 months, but did not differ among the three groups at 12 months."	( Heart transplantation in patients with diabetic end-organ damage before transplantation. Aleksic, I; Blanche, C; Czer, LS; Dalichau, H; Freimark, D; Nessim, S; Nusser, P; Takkenberg, JJ; Trento, A, 1996)	1.2
" A second daily dosage of 50 mg of prednisone was successful in 21 days."	( Cranial polyneuropathy--Ramsay Hunt's syndrome: case report and discussion. Geunes, PM; Schuman, NJ; Turner, JE, 1997)	0.57
"The better pregnancy outcome associated with lower prednisone dosage is probably related to the fact that the patients selected to receive the low-dose regimen have had a longer and less complicated post-transplantation course."	( Prednisone dosage and pregnancy outcome in renal allograft recipients. Bar, J; Boner, G; Fisch, B; Gelerenter, I; Hod, M; Wittenberg, C, 1997)	1.99
" One exception might be CBCC patients who were younger (median age 56 years) and who were usually in good general condition so that they might qualify for high dosage chemotherapy and stem cell support."	( Outcome of patients with low-grade B cell non-Hodgkin lymphoma and initial bone marrow involvement: data of a single institution. Heinz, R; Hopfinger, G; Tüchler, H, 1997)	0.3
"002) inhibited by dexamethasone (10 mol/L), reflecting a shift of the dose-response curve."	( Steroid-resistant asthma immunologic characteristics. Luo, W; Sun, Y, 1996)	0.29
"From each article, the following was abstracted: reference citation; type of control; whether study incorporated a run-in period in which the baseline level of prednisone was reduced to the lowest possible dose; dosage and length of methotrexate therapy; baseline dosage; and type of steroid."	( Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Marin, MG, 1997)	0.49
" The greatest effect was evident in patients in whom an effort was made to reduce baseline steroid dosage and in whom methotrexate was used for 24 weeks."	( Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Marin, MG, 1997)	0.3
"Daily dosage of oral CSA was 3 to 5 mg/kg and mean duration of treatment was 37 months (range, 22-48 months)."	( Systemic cyclosporine A in severe atopic keratoconjunctivitis. Hannouche, D; Hoang-Xuan, T; Prisant, O; Robin, H, 1997)	0.3
" In summary, G-CSF (filgrastim) will facilitate the shortening of the dosage interval between cycles of CHOP chemotherapy due to accelerated hematological recovery."	( A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Grou Bailey, NP; Barnard, D; Child, JA; Cullen, MH; Earl, H; Fletcher, J; Smith, GM; Woodruffe, CM, 1996)	0.29
" Three patients were treated with intravenous acyclovir with concomitant reduction of steroid dosage and recovered completely."	( Management of varicella infection during the course of inflammatory bowel disease. Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB, 1997)	0.3
" If varicella infection occurs, prompt diagnosis and treatment with acyclovir and concomitant reduction in immunosuppressive therapy (reduction in steroid dosage and discontinuation of azathioprine) should be initiated immediately to limit viremia and avoid fatal complications."	( Management of varicella infection during the course of inflammatory bowel disease. Balasubramanian, S; Giannadaki, E; Greenstein, AJ; Manousos, ON; Mouzas, IA; Sachar, DB, 1997)	0.3
" Prognostic factors other than age should be taken into account, particularly when doses and dosing intervals are determined."	( Prognostic factors in elderly patients with non-Hodgkin's lymphoma treated with cyclophosphamide, vincristine, prednisone, bleomycin, Adriamycin, procarbazine (COP-BLAM) therapy. Niitsu, N, 1997)	0.51
" All of them achieved acceptable platelet counts within the first 4 weeks of danazol therapy that allowed the prednisone dosage to be tapered."	( Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Blanco, R; González-Gay, MA; Martinez-Taboada, VM; Rodriguez-Valverde, V; Sanchez-Andrade, A, 1997)	0.51
" In case of failure of this treatment, a high dose of prednisone (1 mg/kg) could be tried or a lower dosage (40 mg/day) could be used in cases with high IL-6 levels (type II)."	( [Treatment of amiodarone-induced hyperthyroidism: corticosteroids or potassium perchlorate? What value do interleukin-6 levels have?]. Konfino, O; Martin-Du Pan, R; Zimmermann, M, 1997)	0.55
" Registered variables included demographic data, disease characteristics, prednisone dosage and duration, comorbidities, and clinical outcomes."	( Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. Bahlas, S; Davis, P; Ramos-Remus, C, 1998)	0.53
" Furthermore, no patients had evidence of adrenal suppression from either dosing regimen."	( A pilot study of steroid therapy after emergency department treatment of acute asthma: is a taper needed? Cydulka, RK; Emerman, CL, )	0.13
"The efficacy and safety of regular-strength beclomethasone dipropionate MDI prescribed within its recommended dosing range of 2 to 5 puffs three to four times daily has been well established in more than 25 years of worldwide use."	( A systemic bioactivity comparison of double-strength and regular-strength beclomethasone dipropionate MDI formulations. Affrime, MB; Brannan, MD; Herron, JM; Reidenberg, P, 1998)	0.3
"Beclomethasone dipropionate, administered either via a double-strength (84 microg/puff) or regular-strength (42 microg/puff) inhaler dosed at 840 microg/day showed no evidence of hypothalamic-pituitary-adrenocortical axis suppression in adults with moderate asthma."	( A systemic bioactivity comparison of double-strength and regular-strength beclomethasone dipropionate MDI formulations. Affrime, MB; Brannan, MD; Herron, JM; Reidenberg, P, 1998)	0.3
" These results suggest that increasing DNM dosage in induction is one of the possible approaches to improve the outcome of adult ALL by decreasing the relapse occurrence."	( Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. April, F; Meneghini, V; Perona, G; Pizzolo, G; Ricetti, MM; Solero, P; Tecchio, C; Todeschini, G; Veneri, D; Zanotti, R, 1998)	0.3
" The acyclovir dosage was 2400 mg (800 mg three times a day) for 10 days, and prednisone was given as a single daily dose of 1 mg/kg of body weight for 10 days and tapered to 0 over the next 6 days."	( Idiopathic facial paralysis: a randomized, prospective, and controlled study using single-dose prednisone versus acyclovir three times daily. De Diego, JI; De Sarriá, MJ; Gavilán, J; Madero, R; Prim, MP, 1998)	0.75
"5-3 times the upper limit of normal received prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks with a two-week period between finishing prednisone and starting interferon-alpha2b."	( Interferon-alpha2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial. Hann, HW; Maddrey, WC; Martin, P; Muñoz, SJ; Rubin, R; Westerberg, S, 1998)	0.56
" IFNalpha was withdrawn because of toxicity in 10% of the patients, and a dosage reduction or temporary suspension was required in 28%."	( Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. Bouabdallah, R; Brice, P; Brousse, N; Coiffier, B; Doyen, C; Gabarre, J; Haïoun, C; Lepage, E; Pignon, B; Rossi, JF; Solal-Céligny, P; Tendler, CL; Tertian, G, 1998)	0.3
" The IFN dosage was 5 x 10(6) U three times weekly for 18 months."	( Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. Cole, BF; Gelber, RD; Gisselbrecht, C; Goldhirsch, A; Lepage, E; Reyes, F; Sebban, C; Solal-Céligny, P; Sugano, D; Tendler, C, 1998)	0.3
" This new product has been well received due to convenient dosing and relatively few side effects."	( Churg-Strauss syndrome associated with zafirlukast. Allen, JN; Knoell, DL; Lucas, J, 1998)	0.3
" On the basis of comparisons with other data sets, we hypothesize a dose-response relationship between glucocorticoid dose and PSA decline."	( Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Figg, WD; Li, A; Moore, A; Sartor, O; Weinberger, M, 1998)	0.7
" After conversion, the Neoral dosage was adjusted on the basis of trough levels measured at weeks 1, 2, 3, 4, 6, 8, and 12."	( An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral. Dahlke, LM; Krom, RA; Pasha, TM; Porayko, MK; Wiesner, RH, 1998)	0.3
" These medications were continued during the episode and subsequently afterwards, with adjustment to the prednisone dosage only."	( Hypersensitivity syndrome reaction to oral terbinafine. Gupta, AK; Porges, AJ, 1998)	0.51
"The results of this study do not suggest the use of TXT at this dosage and schedule in advanced soft tissue sarcoma."	( [Phase II study of docetaxel in patients with advanced stage soft tissue sarcoma]. Amodio, A; Carpano, S; Foggi, P; Gionfra, T; Lopez, M; Manfredi, C; Paoletti, G; Rinaldi, M, )	0.13
" The initial dosage was 200 mg a day, which was increased to 400 mg a day after 4 months."	( Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. Koblenzer, PS; Lee, JB, 1998)	0.3
" Further follow-up is required to assess the effect of dosage and the effect on survival and late toxicities."	( BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Bischoff, H; Diehl, V; Duehmke, E; Engert, A; Franklin, J; Georgii, A; Glunz, A; Haedicke, C; Hasenclever, D; Hermann, R; Holmer, L; Krause, S; Lathan, B; Loeffler, M; Paulus, U; Pfreundschuh, M; Rueffer, JU; Sextro, M; Sieber, M; Stappert-Jahn, U; Tesch, H; von Kalle, K; Winnerlein-Trump, E; Wolf, J; Wulf, G, 1998)	0.3
" Oral steroid dosing requirements and acute episodes of ABPA for days with vs days without itraconazole were compared."	( Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Esrig, S; Moss, RB; Nepomuceno, IB, 1999)	0.3
" Dosing with interleukin-10 produced strong inhibition of ex vivo cytokine production for the 24-hour postdosing period, whereas prednisolone, the active form of prednisone, was partly inhibitory for only 3 hours."	( Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. Blum, RA; Chakraborty, A; Cutler, DL; Jusko, WJ, 1999)	0.74
"Both plasma and urine cortisol suppression showed a dose-response for the daily doses of budesonide."	( A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone. Edsbäcker, S; Larsson, P; Nilsson, M, 1999)	0.3
" Corticosteroid dosing involves six phases: (1) initial high doses to control inflammation; (2) tapering to a maintenance dose that will continue to suppress the inflammation but lessen the risk of corticosteroid toxic reactions; (3) continuing to receive the maintenance dose until a decision to taper off corticosteroids is made; (4) tapering off corticosteroid therapy; (5) observation for relapse; and (6) treatment if relapse occurs."	( An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Judson, MA, 1999)	0.3
" The average number of days before reduction of the prednisone dosage could begin was 16."	( Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Calebotta, A; Carvalho, M; Castillo, R; González, F; Sáenz, AM, 1999)	0.55
"Oral methotrexate, at an initial dosage of 5 mg/wk, was given to 11 consecutive patients older than 70 years of age who were not responding to potent topical steroids."	( Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. Albertioni, F; Heilborn, JD; Peterson, C; Ståhle-Bäckdahl, M; Stephansson, E; Vassilaki, I, 1999)	0.3
" Neither dosage nor glucocorticoid employed were modified during the study."	( An open comparison of the diabetogenic effect of deflazacort and prednisone at a dosage ratio of 1.5 mg:1 mg. Blanch Sancho, JJ; Carmona Martín, M; Navarro López, V; Puras Tellaeche, A; Sáez Barcelona, JA, 1999)	0.54
" A nonnephrotoxic and powerful immunosuppressant such as mycophenolate mofetil (MMF) could allow a reduction of cyclosporine dosage or its withdrawal and an improvement in renal function in these patients."	( Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Alvárez-Cienfuegos, J; Girala, M; Gómez-Manero, N; Herrero, JI; Pardo, F; Prieto, J; Quiroga, J; Sangro, B, 1999)	0.3
" There is no apparent reason to change the dosing regimen of prophylactic co-trimoxazole when there is clinical evidence of damage to the gastrointestinal mucosa induced by chemotherapy."	( Gastrointestinal damage induced by cytostatic treatment does not affect the bioavailability of co-trimoxazole. Höglund, P; Johnsson, A; Ljungberg, B; Nilsson-Ehle, I; Nyhlén, A, )	0.13
" They were seen monthly and prednisone dosage was tapered following a pre-determined schedule."	( Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Baughman, RP; Lower, EE; Winget, DB, 2000)	0.6
" All patients went into remission with a lower daily dosage of oral prednisone at 3 and 6 months postplasmapheresis."	( Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Egan, CA; Meadows, KP; Zone, JJ, 2000)	0.54
", the dosing interval-corrected area under the concentration-time curves, and >/=36% for the trough concentration (C(0))."	( Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. Beusterien, KM; Dicesare, J; Kahan, BD; Katz, SM; Mosheim, MB; Schoenberg, LP; Urbauer, DL; VAN Buren, CT; Welsh, M; Wood, MR, 2000)	0.31
" Because previous pharmacokinetic studies showed a correlation between Rituximab serum levels and tumor response, the ELISA method used in this study, which allows a precise control of serum concentrations, could be useful for predicting the final response to the MAb and for selecting patients able to benefit from higher dosage or repeated drug administration."	( Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Arcaini, L; Astori, C; Avanzini, MA; Iacona, I; Lazzarino, M; Lunghi, F; Morra, E; Orlandi, E; Regazzi, MB; Rupolo, M; Zagonel, V, 2000)	0.31
"Sixteen textbooks and chemotherapy reference books reviewed quoted only one prednisone dosage as part of the standard CHOP regimen; the prednisone dosages quoted as standard varied between publications."	( The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard? Colon-Otero, G; Moreno, A; Solberg, LA, 2000)	1.09
" The mobilization kinetics of circulating progenitor cells in patients with aggressive NHL is dependent on the dosage and schedule of CHOP."	( Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study G Chou, T; Ikeda, S; Itoh, K; Kasai, M; Mizorogi, F; Morishima, Y; Ogura, M; Ohno, T; Ohtsu, T; Sai, T; Sasaki, Y; Taniwaki, M; Tobinai, K; Uike, N; Yoshida, K, 2000)	0.31
"9 mg/m2/week (90% of ideal CHOP dosing for both drugs)."	( Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. Bertino, J; Donnelly, GB; Glassman, J; Long, C; Moskowitz, CH; O'Brien, JP; Portlock, CS; Straus, DJ; Torres, P; Zelenetz, AD, 2000)	0.31
" It is suggested that cyclosporine, together with the decrease of prednisone dosage but independent of renal function, PTH, and vitamin D status, contributes to a transient stimulation of bone remodeling at six months, which counterbalances the deleterious effect of prednisone on bone formation and BMD."	( Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Achard, JM; Brazier, M; El Esper, I; Ezaitouni, F; Fardellone, P; Fournier, A; Hottelart, C; Ivan, C; Mazouz, H; Petit, J; Pruna, A; Westeel, FP, 2000)	0.54
" Prednisone dosage adjustments were based on a defined schedule determined by the change in a subject's disease activity score, and steroid administration was discontinued as remission was achieved."	( A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Daum, F; Grancher, K; Kohn, N; Lesser, M; Markowitz, J, 2000)	1.48
" Remission, pharmacological remission, and marked improvement with reduction in drug dosage were considered good results."	( Clinical characteristics and prognosis of myasthenia gravis in older people. Batocchi, AP; Di Schino, C; Evoli, A; Minisci, C; Tonali, P, 2000)	0.31
" In severe ophthalmopathy steroids are effective in more than 60% of patients [1, 3], but to be effective high dosage is necessary [1, 4-6]."	( [Treatment of Grave's ophthalmopathy with high doses of corticosteroids]. Cirić, J; Drezgić, M; Gligorović, M; Nesović, M; Pepenezić, Z; Randjelović, G; Stojanović, M; Trbojević, B; Zarković, M, )	0.13
" In the multiple regression test, a linear coincidence was observed between apo A1, apo B and prednisone cumulative dosage after the 1st month, TG and cyclosporine in the 6th month and LDL and cyclosporine in the 12th month after transplantation."	( Does immunosuppressive regimen influence the lipid disturbances in kidney recipients? Kisielnicka, E; Kortas, B; Lysiak-Szydłowska, W; Rutkowski, B; Wróblewska, M; Zdrojewski, Z, )	0.35
" Plasma concentrations were near the lower limit of quantitation (50 pg/mL) at the MF DPI 400-microg qd dosage and approximately 250 pg/mL at the 1,200-microg qd dosage."	( Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Affrime, MB; Flannery, BE; Herron, JM; Kosoglou, T; Thonoor, CM, 2000)	0.31
"The MF 800-microg bid dosage (1,600 microg/d), which is twice the highest projected clinical dosage, represents the lower limit for consistently detectable systemic effects of MF."	( Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Affrime, MB; Flannery, BE; Herron, JM; Kosoglou, T; Thonoor, CM, 2000)	0.31
"Interferon seems to be an effective drug in the treatment of cryoglobulinaemic glomerulonephritis, but dosage and length of treatment still need to be addressed by large multicentre studies."	( Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Baracetti, S; Campanacci, L; Carniello, S; Crovatto, M; Faccini, L; Faelli, A; Mazzaro, C; Mazzi, G; Nascimben, F; Panarello, G; Pozzato, G; Zorat, F, 2000)	0.31
" They had been receiving oral prednisone treatment for a median of 30 months (range 6-74); mean daily dosage during the six-month study period was 12."	( Management of glucocorticoid-induced osteoporosis in male veterans. Binkley, NC; Carnes, ML; Elliott, ME; Farrah, RM; Gudmundsson, A, 2000)	0.6
" All four patients obtained no clinical benefit from the treatment; moreover, inflammation indices worsened and the prednisone dosage was increased during the trial, in spite of a significant fall in CD4+ T cells."	( Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis. Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A, 2000)	0.52
" Despite this, the pharmacokinetics of prednisolone have never been fully characterized in these patients, and consequently dosing remains empirical."	( Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. Akhlaghi, F; Holt, DW; Lee, T; Majid, O; Trull, A, 2001)	0.56
" The regimen of glucocorticoid therapy was oral prednisone, starting with 160 mg daily followed by reducing the dosage by 20 mg every three days until 40 mg per day was attained and then tapering the dosage at 70 mg every other day until stoppage of the drug."	( [Treatment of acute optic neuritis with high dose of prednisone]. Ai, F; Hu, T; Jiang, R; Liu, Q; Zhang, M, 1998)	0.81
"Reasonable therapeutic dosage regimen for pemphigus are analyzed to find the factors related to prognosis."	( [A clinical analysis of 64 cases of pemphigus]. He, Z; Wang, B; Yu, B, 1998)	0.3
"We recommend a moderate to high dosage of corticosteroids be the first choice to control pemphigus."	( [A clinical analysis of 64 cases of pemphigus]. He, Z; Wang, B; Yu, B, 1998)	0.3
" When prednisone dosage was tapered from 10 mg/d to 10 mg every other day, clinically significant improvements were seen in weight, systolic and diastolic blood pressure, blood pressure medications, glycosylated hemoglobin level, and diabetic medications."	( Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Landsberg, D; Nussbaumer, G; Sivaraman, P, 2001)	0.79
" The clinical remission in the CsA-treated group confirmed the therapeutic effectiveness of this therapy in antihistaminic unresponsive CIU and, at dosage used, side effects were rare, mild and reversible."	( Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Cavallo, E; D'Oronzio, L; Dambra, PP; Ferrannini, A; Loria, MP; Nettis, E; Pannofino, A; Tursi, A, 2001)	0.31
" A frequent problem is relapse of disease when corticosteroid dosage is tapered off."	( Successful treatment of bronchiolitis obliterans organizing pneumonia with low-dose methotrexate in a patient with Hodgkin's disease. Breitbart, A; Egerer, G; Goldschmidt, H; Ho, AD; Möller, P; Spaeth, A; Witzens, M, 2001)	0.31
" In order to obtain a corticosteroid-sparing effect, new studies are necessary to evaluate a reduced initial dosage of corticosteroids."	( [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose]. Barrier, JH; Chevalet, P; de Wazières, B; Duhamel, E; el Kouri, D; Glémarec, J; Hamidou, M; Jégo, P; Maugars, Y; Planchon, B; Rodat, O, 2001)	0.31
" This suggested that, although the adult 12-hour dosing interval was appropriate for pediatric patients, they would require reduced dosing based on body size compared with adults."	( Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Ettenger, RB; Grimm, EM, 2001)	0.31
"Clinical studies comparing the potency of inhaled corticosteroids require steep dose-response slopes (b) and minimal response variability (s), as statistical power is inversely related to the s/b ratio."	( Asthma stability after oral prednisone: a clinical model for comparing inhaled steroid potency. Ahrens, RC; Donnell, D; Han, SH; Lux, CR; Teresi, ME; Vanden Burgt, JA, 2001)	0.6
" Because of that, there was no need to increase dosage nor to switch systemic immunosuppressors."	( [Transeptal steroids in necrotizing scleritis]. Folch Ramos, J; Sainz De La Maza Serra, M, 2001)	0.31
"This study sought to determine effects of multiple dosing of prasterone (DHEA, dehydroepiandrosterone) on the pharmacokinetics of prednisolone and endogenous cortisol secretion."	( Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. Blum, RA; Jusko, WJ; Meno-Tetang, GM; Schwartz, KE, 2001)	0.53
" Steroid dosage significantly predicted aggressive, but not anxious/depressed, behavior."	( Daily reports and pooled time series analysis: pediatric psychology applications. Lande, MB; Moore, KJ; Soliday, E, )	0.13
" The following objective parameters were used to assess the clinical outcome pre- and post-IVIg therapy: number of side effects, frequencies of recurrences and relapses, duration and total dosage of prednisone therapy, and the quality of life."	( Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Bhol, KC; Razzaque Ahmed, A; Sami, N, 2002)	0.5
" Despite prompt initiation of antimycotic therapy the outcome was fatal; dosage of conventional and liposomal amphotericin B was limited due to treatment-related toxicities."	( A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K, 2001)	0.31
" Retarded FH was associated with higher average prednisone dosage and better FH was associated with good graft function."	( The contribution of renal transplantation to final adult height: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Fine, RN; Ho, M; Tejani, A, 2001)	0.57
" Corticosteroid treatment led to long-lasting renal and hematologic remission, maintained by a small dosage of prednisone."	( Glomerular involvement in myelodysplastic syndromes. Bogdanović, R; Bunjevacki, G; Kuzmanović, M; Marković-Lipkovski, J; Mićić, D; Nikolić, V; Ognjanović, M; Stajić, N; Stanković, I, 2001)	0.52
" The dosage of prednisone could be tapered smoothly among the steroid dependent patients."	( [Mycophenolate mofetil in the treatment of primary nephrotic syndrome]. Chen, X; Chen, Y; Liu, Y; Liu, Z; Lu, F; Wang, H; Zhang, Y; Zhao, M, 2001)	0.66
"8 months), total used dosage of steroids (G1= 20, G2= 28, G3= 16 grams) and time of drug use (G1= 20, G2= 26, G3= 14."	( [A comparative study of therapeutic complications in Systemic Lupus Erythematosus and in idiopathic glomerulopathy]. Almeida, DB; Balbi, AL; Barbosa, RA; Lima, MC, )	0.13
" These patients (n = 13) were treated again with GH at the same dosage (0."	( Linear growth in children suffering from juvenile idiopathic arthritis requiring steroid therapy: natural history and effects of growth hormone treatment on linear growth. Czernichow, P; Lucidarme, N; Prieur, AM; Ruiz, JC; Simon, D, 2001)	0.31
" On two occasions, a pharmacokinetic profile was obtained over the dosing interval after drug administration under fasting conditions and after a high-fat meal in a randomized sequence."	( Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Budde, K; Figueiredo, J; Golor, G; Hartmann, S; Kovarik, JM; Lison, A; Neumayer, HH; Rordorf, C, 2002)	0.31
" Infliximab was administered at the dosage of 3 mg/Kg at the weeks 0, 2 and 6 and then every 8 weeks."	( [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study]. Bambara, LM; Biasi, D; Canestrini, S; Caramaschi, P; Carletto, A; Scambi, C; Scarperi, A, 2002)	0.31
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Alvarez, MI; Ferreira, J; Salinas, RA, 2002)	0.31
"Leflunomide seems to possess substantial immune suppressive potency in renal and liver transplant recipients and may be safely dosed for more than 300 days."	( Experiences with leflunomide in solid organ transplantation. Brady, L; Chong, A; Huang, W; Jensik, S; Kottayil, A; Longstreth, J; Millis, M; Mital, D; Williams, JW, 2002)	0.31
" The dosage of prednisone used was reduced by routine in both groups but Chinese herbal treatment was added to the treated group in the period of prednisone reduction."	( [Assessment on application of Chinese herbs in process of corticosterone reduction in nephrotic syndrome]. Guo, M; Xiao, Q; Zhao, X, 2000)	0.66
" Alternative dosing regimens based on pharmacokinetic simulation and limited clinical trials are being investigated."	( A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant Alloway, RR; Hodge, E; Lo, A; Stratta, RJ, 2002)	0.31
" The mean daily prednisone dosage in the treated patients with sarcoidosis was 20 mg and the mean duration of prednisone therapy was 6 months."	( Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia. Argimón, JM; Hurtado, I; Mañá, J; Pintó, X; Pujol, R; Salazar, A, 2002)	0.66
"Adding oral prednisone or in vitro organ irradiation to an immunosuppressive regimen for laryngeal transplantation may allow cyclosporine dosage to be decreased without compromising organ rejection rates."	( Effects of adding steroids, in vitro irradiation, or both to cyclosporine immunosuppression in the murine laryngeal transplantation model. Dan, O; Haug, M; Lorenz, RR; Strome, M, 2002)	0.69
" Secondly, an extended release low dosage tablet was followed for 7 h resulting in a linear dissolution profile."	( Multiple fiber-optic dual-beam UV/Vis system with application to dissolution testing. Cauchi, M; Johansson, J; Sundgren, M, 2002)	0.31
"The mean starting dosage of MMF was (1."	( Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Li, L; Lin, S; Wang, H, 2002)	0.31
"The following information was documented in each of the 15 patients before and after the initiation of IVIg therapy: total dosage and total duration of prednisone therapy and number of relapses."	( Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Ahmed, AR; Qureshi, A; Ruocco, E; Sami, N, 2002)	0.51
" Thus the goal was first to reduce tumour burden using the CHOP regimen as induction treatment followed by consolidation with rituximab administered on a standard 4 wk schedule at a dosage of 375 mg m-2 body surface area."	( Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Brezinschek, R; Höfler, G; Jäeger, G; Linkesch, W; Neumeister, P; Quehenberger, F; Sill, H, 2002)	0.31
" These patients (n = 13) were treated again with GH at the same dosage (0."	( Treatment of growth failure in juvenile chronic arthritis. Czernichow, P; Lucidarme, N; Prieur, AM; Ruiz, JC; Simon, D, 2002)	0.31
" We used a different dosing regimen of prednisone to determine if benefit to boys with Duchenne muscular dystrophy might be maintained with fewer side effects."	( High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Connolly, AM; Florence, J; Renna, R; Schierbecker, J, 2002)	0.9
" Prednisone therapy in a daily dosage of 1 mg/kg induced a marked improvement."	( Idiopathic retroperitoneal fibrosis and ankylosing spondylitis. A new case report. Abbar, M; Abouzahir, A; Archane, MI; Bezza, A; El Maghraoui, A; Ghadouane, M; Ghafir, D; Ohayon, V; Tabache, F, 2002)	1.22
" During delayed intensification, all patients received a dexamethasone dosage of 10 mg/m(2)/d for 21 days, with taper."	( Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Bostrom, BC; Erdmann, GR; Gaynon, PS; Gold, S; Heerema, NA; Hutchinson, RJ; Johnston, K; La, MK; Provisor, AJ; Sather, HN; Sensel, MR; Trigg, ME, 2003)	0.64
"Forty-three patients were divided semi-randomly into the treated group (n = 21) and the control group (n = 22), the former was treated with RRLD plus low-dose GC, and the latter was treated mainly with normal dosage of GC."	( [Clinical study on effect of recombinant roasted licorice decoction combined with low-dose glucocorticoids in treating idiopathic thrombocytopenic purpura]. Hu, J; Liu, YQ; Luo, YG, 2001)	0.31
" Corticosteroid treatment led to long-lasting renal and haematologic remission, maintained by a small dosage of prednisone."	( [Corticoid-sensitive nephrotic syndrome in children with myelodysplastic syndromes]. Bogdanović, R; Bunjevacki, G; Kuzmanović, M; Marković-Lipkovski, J; Mićić, D; Nikolić, V; Ognjanović, M; Stajić, N; Stanković, I, )	0.34
" Unless contraindicated, patients with diplopia were recommended for therapy with prednisone, up to 40 to 60 mg/d, with the dosage tapered for 5 to 6 weeks."	( Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Homel, P; Kupersmith, MJ; Latkany, R, 2003)	0.54
" Until optimal dosing strategies and a more complete adverse effect profile are established, combination therapy should be utilized cautiously in these patients."	( Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. Cahill, BC; Crompton, JA; Karwande, SV; O'Rourke, MK; Parker, ST; Somerville, KT; Stringham, JC, 2003)	0.32
" All patients responded with complete remission of symptomatology and had a prednisone dosage reduction until 70%."	( Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Da Ponte, C; De Roia, D; Guerra, R; Mazzi, G; Orazi, BM; Raineri, A; Santarossa, L; Zanolli, FA, 2003)	0.55
" Prednisone dosage was reduced from a mean of 19."	( Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. France, R; Kinney, T; Kozarek, R; Patterson, D; Rawlins, M, 2003)	1.23
" The daily dosage of prednisolone and beclomethasone was progressively decreased while the gain in nasal comfort was being preserved."	( Corticosteroid treatment in nasal polyposis with a three-year follow-up period. Avan, P; Bonfils, P; Halimi, P; Norès, JM, 2003)	0.32
" There was also no difference in the survival between radiotherapy dosage 50 Gy."	( [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma]. Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Lin, TY; Xia, ZJ; Xu, RH, 2003)	0.32
" Whether additional local radiotherapy is necessary,and the optimal radiation dosage warrant prospective randomized trial."	( [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma]. Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Lin, TY; Xia, ZJ; Xu, RH, 2003)	0.32
"This paper proposes the use of neural networks for individualizing the dosage of cyclosporine A (CyA) in patients who have undergone kidney transplantation."	( Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks. Camps-Valls, G; Jiménez-Torres, NV; Martín-Guerrero, JD; Pérez-Ruixo, JJ; Porta-Oltra, B; Serrano-López, AJ; Soria-Olivas, E, 2003)	0.32
" Dosing of these agents was concentration-controlled and open-labeled."	( Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. Bäckman, L; Brattström, C; Calne, R; Campistol, JM; Charpentier, B; Claesson, K; Durand, D; Groth, CG; Kreis, H; Lang, P; Morales, JM; Touraine, JL; Wramner, L, 2003)	0.32
"Mycophenolate mofetil (MMF) has proven to be a very effective drug for the prevention of acute rejection following renal transplantation when dosed as prescribed at 2 or 3 g/d."	( The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Akin, B; Bumgardner, GL; Elkhammas, EA; Ferguson, RM; Henry, ML; Pelletier, RP; Rajab, A, 2003)	0.32
" Nevirapine was administered at the lead-in dosage of 200 mg once daily."	( Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)	0.56
" Psychosis was unpredictable by the routes and dosage of corticosteroid used."	( Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Chau, SY; Mok, CC, 2003)	0.32
" The phototests were performed on large skin areas of the forearm or trunk; the first dose was twice the minimal erythema dose and the dosage was increased according to the individual reactions of the patients at the test sites."	( Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Bruijnzeel-Koomen, CA; Kazzaz, GA; Sanders, CJ; Sigurdsson, V; Toonstra, J; Van Weelden, H, 2003)	0.32
"Thirty patients with active Crohn's disease were treated with a 10 week course of prednisone using a tapering dosing regimen."	( The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Bitton, A; Thomson, AB; Waschke, KA; Wild, GE, 2003)	0.88
" In addition, before the modification, patients with Stage IV disease received a cumulative dose of 15,600 mg/m(2) of cyclophosphamide for 3 years; after 1980, these patients received the same dosage as the other patients (i."	( Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Filippa, DA; Mora, J; Qin, J; Wollner, N, 2003)	0.32
" Inflammation was stabilized, and steroid dosage could be significantly reduced."	( Nonnecrotizing herpetic retinopathies masquerading as severe posterior uveitis. Bodaghi, B; Cassoux, N; Fardeau, C; LeHoang, P; Rozenberg, F, 2003)	0.32
" The size of dosage and individual susceptibility appeared to be important factors in the development of digestive disturbances from steroids."	( Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone. BOLAND, EW, 1958)	0.46
"All patients were treated with GCs and responded rapidly (median initial dosage 60 mg prednisone/day)."	( Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Gabriel, SE; Hunder, GG; O'Fallon, WM; Orces, C; Proven, A, 2003)	0.54
"GCs are therapeutically effective in GCA and the prednisone dosage was reduced to physiologic levels in three-fourths of the patients within 1 year."	( Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Gabriel, SE; Hunder, GG; O'Fallon, WM; Orces, C; Proven, A, 2003)	0.57
" Patients with carotid abnormalities were significantly older, had higher blood pressure and total serum cholesterol levels, and had taken a higher prednisone cumulative dosage than those without any lesions."	( Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Corbanese, S; Doria, A; Favaretto, E; Gambari, PF; Ghirardello, A; Gilburd, B; Iaccarino, L; Patnaik, M; Pauletto, P; Peter, JB; Puato, M; Sherer, Y; Shoenfeld, Y; Todesco, S; Wu, R; Zampieri, S, 2003)	0.52
" Ligustrazine with the dosage of 80 mg twice a day was given to 25 patients in the treatment group by intravenous perfusion besides the medicine used in the control group."	( [Effect of ligustrazine on proliferative glomerulonephritis]. Tang, X, 2003)	0.32
"In the Swedish National Care Programme for Hodgkin's lymphoma (HL) a less intensive chemotherapy regimen with individualized dosing (LVPP/OEPA) was introduced in 1989."	( Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. Enblad, G; Glimelius, B; Gustavsson, A; Sundström, C, 2002)	0.31
" Beginning from the second LDL-A course, a dosage of 1 mg/kg/d of prednisone was administered for 6 weeks, then tapered."	( A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Akioka, Y; Chikamoto, H; Fukazawa, A; Hattori, M; Ito, K; Kawaguchi, H; Khono, M; Matsunaga, A; Miyakawa, S; Nakakura, H; Ogino, D, 2003)	0.81
" Satisfactory compliance was defined as taking compliance or correct dosing > 80%, while unsatisfactory compliance was defined as taking compliance or correct dosing < or = 80%."	( The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. de Klerk, E; Landewé, R; van der Linden, S; van der Tempel, H; van der Heijde, D, 2003)	0.32
" CsA was given at a starting dosage of 5 mg x kg(-1) x d(-1) for 3 months, with a 1 mg x kg(-1) x d(-1) reduction every month and then maintained at a dosage of 2 mg x kg(-1) x d(-1)."	( Cyclosporine A in treatment of membranous lupus nephropathy. Chen, H; Hu, W; Li, L; Li, S; Liu, Z; Shen, S; Yao, X, 2003)	0.32
" Since a significant gain of therapeutic effects could not be observed as thalidomide dosage was escalated, the optimal dose of thalidomide remains to be determined."	( Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C, 2003)	0.32
" Levels of mycophenolic acid (MPA), its glucuronide metabolite, and daclizumab were measured after dosing on days 28 and 56."	( Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Bumgardner, G; Gaston, RS; Kirkman, RL; Light, S; Nieforth, K; Patel, IH; Pescovitz, MD; Vincenti, F, 2003)	0.32
" In case of steroid responsiveness, the risk is the relapse when the steroid dosage is tapered or stopped and the complications related to the treatment which is given to maintain remission."	( [Lipoid nephrosis in childhood]. Niaudet, P, 2003)	0.32
" The patients received PTX at the initiating dosage until complete clinical cure."	( [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. Achirafi, A; de Carsalade, GY; Flageul, B, 2003)	0.32
" The SRL was dosed to achieve defined target whole blood 12-h trough levels."	( Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Baluarte, J; Brayman, KL; Harmon, WE; Meyers, KE; Palmer, JA; Salmanullah, M; Schachter, AD; Spaneas, LD, 2004)	0.32
" This observation suggests a strategy of individualized dosing adapted to hematotoxicity."	( Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Brosteanu, O; Diehl, V; Hasenclever, D; Loeffler, M, 2004)	0.32
" These patients had a lower cumulative prednisolon dosage and a stable clinical course."	( [Bone metabolism in 53 children and adolescents with chronic inflammatory bowel disease]. Borte, G; Deutscher, J; Gelbrich, G; Kiess, W; Kratzsch, J; Scheer, K, )	0.13
" Cumulative steroid dosage early after OLT is shown to be important, presumably by decreasing bone formation rates."	( Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Clarke, BL; Guichelaar, MM; Hay, JE; Malinchoc, M; Sibonga, J, 2004)	0.32
" Cox multivariate analysis included: donor age, sex, and weight; recipient sex, age, pre-HT diagnosis, hypertension, diabetes and hyperlipidemia post-HT; number of treated rejections and RS; and immunosuppressive dosage at 3, 6, and 12 months."	( Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Angelini, A; Caforio, AL; Feltrin, G; Fortina, AB; Gambino, A; Gerosa, G; Iliceto, S; Piaserico, S; Ramondo, A; Thiene, G; Tona, F; Valente, M, 2004)	0.32
" If patients were receiving cytotoxic agents, the dosage was not increased."	( Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Brasington, RD; Hoffman, GS; Lenschow, DJ; Liang, P; Merkel, PA, 2004)	0.32
" In 9 of the 14 responders, an increase in the anti-TNF dosage was required to sustain remission."	( Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Brasington, RD; Hoffman, GS; Lenschow, DJ; Liang, P; Merkel, PA, 2004)	0.32
"Prednisone dosage (25 mg/d) was tapered to 0 mg/d within 24 weeks and was adjusted if flare-ups occurred."	( Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Caporali, R; Cimmino, MA; Ferraccioli, G; Gerli, R; Klersy, C; Montecucco, C; Salvarani, C, 2004)	3.21
"Follow-up was short, and a high dose of folinic acid and a relatively high starting dosage of prednisone were used."	( Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Caporali, R; Cimmino, MA; Ferraccioli, G; Gerli, R; Klersy, C; Montecucco, C; Salvarani, C, 2004)	1.99
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Ferreira, J; Salinas, RA, 2004)	0.32
" Anicteric survival with the native liver was statistically compared between groups categorized by steroid dosage using Kaplan-Meier analysis."	( Postoperative corticosteroid therapy for bile drainage in biliary atresia--a nationwide survey. Hashimoto, T; Iwanaka, T; Kato, T; Muraji, T; Nio, M; Ohhama, Y; Ohi, R; Ohnuma, N; Takamatsu, H, 2004)	0.32
" Only the 200 mg of thalidomide arm of this trial met our definition of a tolerable maintenance therapy, defined as no dose reductions or discontinuation due to toxicity in at least 65% of patients for a minimum of 6 months, thus establishing a dosing schedule for phase III trials."	( Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Belch, AR; Chen, CI; Ding, K; Howson-Jan, K; Kovacs, MJ; Meyer, RM; Roy, J; Sadura, A; Shepherd, L; Shustik, C; Stewart, AK; White, D, 2004)	0.56
" Future studies should focus on alternative dosing schedules with more aggressive use of adjuvant therapies, including GFs."	( Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Ascher, NA; Bollinger, K; Khalili, M; Roberts, JP; Shergill, AK; Straley, S; Terrault, NA, 2005)	0.33
" Two class I trials examined the effect of lower dosage of prednisone (0."	( Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Ashwal, S; Baumbach, L; Connolly, A; Florence, J; Mathews, K; McDonald, C; Moxley, RT; Pandya, S; Sussman, M; Wade, C, 2005)	0.57
" The severity of rejection events, as well as the CyA and prednisone dosing regimens used during rejection, were assessed using a comprehensive chart analysis."	( Paradoxical cyclosporine A requirements in pediatric renal transplants receiving high-dose steroids. Acott, PD; Crocker, JF; Goralski, KB; Hardy, KW; McLellan, H; Renton, KW, 2005)	0.57
" Particularly in patients aged over 80 years, to avoid side effects it is essential to adjust dosage and route of administration of chemotherapy."	( [Malignant lymphoma, multiple myeloma and myeloproliferative diseases in the elderly]. Umeda, M, 2004)	0.32
" Our findings revealed a dose-response relationship between 8-iso-PGF2alpha concentrations and the dosage of prednisone."	( 8-Isoprostaglandin F2 alpha: a potential index of lipid peroxidation in systemic lupus erythematosus. Abou-Raya, A; el-Hallous, D; Fayed, H, 2004)	0.54
"Although our prednisone dosing data could not be used as an accurate predictor of onset or joint distribution, there was a tendency for correlation between the average daily dosing and the ARCO score."	( Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Klingenstein, G; Kornbluth, A; Levy, RN; Present, DH; Shah, AK, 2005)	0.7
" The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy."	( Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin Hayama, M; Higashihara, M; Kajiwara, K; Khori, M; Niitsu, N; Tamaru, J, 2005)	0.33
" Seven patients received indinavir at a dosage of 800 mg three times daily and three patients received nelfinavir at a dosage of 750 mg three times daily."	( Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. Bassetti, D; Bassetti, M; Cinelli, R; Cruciani, M; Di Gennaro, G; Gatti, G; Tirelli, U; Vaccher, E, 2005)	0.33
"There is a paucity of data examining the efficacy of valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in kidney transplant patients, particularly with regard to utilization of a risk-stratified dosing regimen."	( Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Alangaden, GJ; Chandrasekar, P; El-Amm, JM; Garnick, J; Granger, DK; Gruber, SA; Haririan, A; Morawski, K; Sillix, DH; West, MS, 2005)	0.33
" Adding anti-TNF therapy (24%) or another DMARD (10%), increasing the methotrexate dosage (24%), and substituting leflunomide for methotrexate were the main recommended treatments."	( Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists. Bergé, C; Boissier, MC; Daurès, JP; Maravic, M, )	0.13
" Although the symptoms worsened when the prednisone dosage was gradually reduced, her growth retardation and increased weight decided us to stop prednisone treatment."	( [Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis]. Dompeling, E; Hendriks, JJ; Jöbsis, Q; van Hoorn, JH, 2005)	0.59
" In this multicenter study, THP (pirarubicin)-COP (cyclophosphamide, vincristine, and prednisolone) was compared to two thirds dosage of full CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen with regard to both adverse events and efficacy."	( Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Harada, M; Hotta, T; Kitamura, K; Masaoka, T; Masuda, M; Matsuda, T; Miura, AB; Miyazaki, T; Mizoguchi, H; Mori, M; Niho, Y; Saito, H; Shibata, A; Takaku, F, 2005)	0.33
" Dosage was split with 18 mg given at breakfast and 18 mg zinc with supper."	( Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation--a case history and hypothesis. Eby, GA, 2005)	0.33
" All patients were initiated with equivalent azathioprine dosage (50 mg qd)."	( Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Bajaj, JS; Binion, DG; Emmons, J; Franco, J; Knox, JF; Levy, M; Podoll, J; Saeian, K; Varma, RR, 2005)	0.33
"Modifications in the timing and dosage of immunosuppression can ameliorate the morbidity and mortality that has prevented widespread use of intestinal transplantation (ITx) in children."	( Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Abu-Elmagd, K; Bond, GJ; Macedo, C; Mazariegos, GV; Murase, N; Peters, J; Reyes, J; Sindhi, R; Starzl, TE, 2005)	0.33
" Gender, ALL-immunophenotype, steroid-type or ASP dosing schedule did not alter the risk but older age and HR-disease were factors predisposing to TE associated with DFCI-ALL protocols."	( Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Athale, UH; Barr, RD; Chan, AK; Crowther, M; Siciliano, SA, 2005)	0.33
" After week 2, prednisone and MMF were both tapered by 20% of the initial dosage per week."	( Donor leukocytes combine with immunosuppressive drug therapy to prolong limb allograft survival. Bishop, GA; Fujioka, H; Kanatani, T; Kurosaka, M; Lanzetta, M; Matsumoto, T; McCaughan, GW; Owen, E, 2005)	0.68
" The combination of IFN-alpha and hydroxyurea is very useful and allows dosage reduction of IFN-alpha and better control of hypereosinophilia than with either agent alone."	( Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Butterfield, JH, 2005)	0.33
" The employment of methotrexate attained decrease in the dosage of steroids temporarily."	( [Treatment with nebulized lidocaine in steroid-dependent asthma]. de Paz Arranz, S; Fernández Parra, B; Herrera Mozo, I; Pérez Pimiento, A; Rodríguez Mosquera, M; Santaolalla Montoya, M, )	0.13
" She had received several bouts of steroids and had been in clinical remission for 12 weeks under a dosage of 40 mg/d prednisone."	( [Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?]. Dienes, HP; Kruis, W; Lanyi, B, 2005)	0.54
" Since single daily dosing of cyclosporine is rarely used, the objective of this investigation was to evaluate the efficacy of a single daily dose versus twice daily dosing of cyclosporine in renal transplant recipients."	( Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report. Al-Mousawi, M; Al-Mozairai, I; Halim, MA; Hamid, MH; Johny, KV; Nair, MP; Nampoory, MR; Said, T, 2005)	0.33
"MDOL can obviously improve the effect of hormonotherapy in SLE, it has advantages in reducing the dosage used and antagonizing the adverse reactions of glucocorticoid."	( [Intervention of maiwei dihuang oral liquid on hormonotherapy in treating active systemic lupus erythematosus]. Xu, DH; Yang, XY, 2005)	0.33
" The mean starting dosage of MTX in the study group was 15 mg/m(2)/week."	( The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Cameron, B; Campbell-Webster, N; Feldman, BM; Laxer, RM; Ota, S; Parker, S; Ramanan, AV; Schneider, R; Silverman, ED; Spiegel, L; Tran, D; Tyrrell, PN, 2005)	0.33
" Prednisone at a dosage of 1 mg/kg twice a day decreased the platelet count within 45 days of its initiation."	( Reactive thrombocytosis: an early manifestation of Takayasu arteritis. Colón, E; Goñi, M; Peredo, R; Ríos-Solá, G; Vilá, S, 2005)	1.24
" The immunosuppression scheme and dosage of drugs used in pregnant women are vital to both the normal course of pregnancy and delivery of a healthy child."	( [Immunosuppressive drug therapy during pregnancy after kidney transplantation]. Gryboś, M; Kazimierczak, I; Kazimierczak, K; Klinger, M; Weyde, W; Zmonarski, S, 2005)	0.33
"4g of aciclovir tablets 3 times per day for 5 days and 50 mg of prednisone daily for 5 days, and the patients in P group were treated with 50 mg of prednisone daily for 5 days, and then the dosage of prednisone was reduced by 20 mg per two days for the next 10 days."	( [Outcome of treatment 46 patients with Bell's palsy with aciclovir and prednisone]. Chen, WL; Huang, ZQ; Yang, ZH, 2005)	0.8
"The groups were comparable at baseline in age, gender, daily dosage of prednisone, BMD at the spine and the hip and markers of bone turnover, while the number of patients with prevalent vertebral deformities was slightly higher in the alendronate-treated patients (54% versus 39%, not significant)."	( Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Bijlsma, JW; Dijkmans, BA; Geusens, P; Lems, WF; Lips, P; Lodder, MC; Schrameijer, N; van de Ven, CM, 2006)	0.76
" However, the most appropriate dosage regimen remains controversial, as the corticosteroid regimens used in these trials differed greatly, and no studies have directly compared medium-, high-, and low-dose regimens."	( Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic obstructive pulmonary disease? Hemstreet, BA; Vondracek, SF, 2006)	0.33
" Comparison of lipid levels at different prednisone dosages and disease activity levels revealed that changes in triglyceride levels were mainly associated with changes in disease activity, changes in both total cholesterol and LDL cholesterol levels were associated with changes in the prednisone dosage and not disease activity, and low levels of HDL cholesterol were associated with active SLE, whereas the prednisone dosage was associated with increased levels of HDL cholesterol."	( The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Adeli, K; Beyenne, J; Feldman, B; Sarkissian, T; Silverman, E, 2006)	0.6
" There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors."	( Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. Belkacémi, Y; Bolla, M; Castelain, B; Knobel, D; Landmann, C; Oner, FD; Ozsahin, M; Poortmans, P; Tsang, RW; Zouhair, A, 2006)	0.33
" In this case, once the dosage of oral prednisone was increased and methotrexate was added to the therapeutic scheme, inflammation was controlled within 1 month."	( Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Burnier, MN; Deschênes, J; Ozdal, PC; Vianna, RN, 2006)	0.6
" Unfortunately, high dosage prednisone can be used for only a month, because of steroid toxicity."	( An informative case of Graves' disease with implications for schizophrenia. Adams, DD; Knight, JG; Manning, P; Smith, G, )	0.43
"Temporal arteritis (TA) may offer major complications, whilst high dosage of prednisone may result in serious side effects."	( Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup. Haanen, HC; Seldenrijk, CA; ter Borg, EJ, 2007)	0.57
" The accentuated neutropenia may be related to the specific chemotherapy regimen or drug, eg, cyclophosphamate since same day Pf was safe with regimens in which a non alkylating agent (taxane, gemcitabine, navelbine, cisplatin) was used with a weekly chemotherapy dosing schema and did not generate accentuated neutropenia."	( Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Lokich, JJ, 2006)	0.33
" All errors were due to incorrect dosing or failure to administer an indicated medication."	( Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia. Geyer, LJ; Hawkins, DS; Taylor, JA; Winter, L, 2006)	0.33
" Questions remain concerning the optimal dosage and schedule of rituximab for DLBCL, as well as the optimal chemotherapy regimen partner for rituximab."	( Rituximab for the treatment of diffuse large B-cell lymphomas. Held, G; Pfreundschuh, M; Pöschel, V, 2006)	0.33
" MTX was given at an initial weekly dosage of 15 mg (n = 3), 20 mg (n = 9), or 25 mg (n = 10)."	( The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. Joly, P, 2006)	0.33
" A control group included 16 RA patients only with stable therapy (some dosage of prednisone and MTX)."	( [Are there any positive effects of TNF-alpha blockers on bone metabolism?]. Cutolo, M; Paolino, S; Seriolo, B; Sulli, A, )	0.36
"The purpose of this study was to examine the relationship between the specific types of medication, length of use, frequency of use, and dosing time of day on the dental caries of children diagnosed with asthma."	( A cross-sectional study of medication-related factors and caries experience in asthmatic children. Chen, JW; Donovan, K; Lee, JY; Milano, M, )	0.13
" PL-doxorubicin 30 mg/m2, was given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses."	( CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Battista, M; Battista, R; Cabras, MG; Fabbri, A; Fanin, R; Gallamini, A; Lenoci, M; Molinari, AL; Tomadini, V; Zaccaria, A; Zaja, F, 2006)	0.56
" A high daily dosage of prednisone relative to body weight was found to be neither a predictor of exacerbation nor a predictor of early improvement in bivariate correlation analysis."	( Clinical predictors of steroid-induced exacerbation in myasthenia gravis. Bae, JS; Go, SM; Kim, BJ, 2006)	0.64
" Patients who remained clinically stable but showed serologic evidence of an SLE flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized to receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week, and 10 mg/day for 1 week."	( The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Abramson, SB; Belmont, HM; Buyon, JP; Diamond, B; Haines, K; Ilie, V; Kim, M; Mackay, M; Marder, G; Rosenthal, P; Tseng, CE, 2006)	0.52
" Severe flares resulted in an increase in the prednisone dosage to >40 mg/day and/or the addition of an immunosuppressive agent."	( The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Abramson, SB; Belmont, HM; Buyon, JP; Diamond, B; Haines, K; Ilie, V; Kim, M; Mackay, M; Marder, G; Rosenthal, P; Tseng, CE, 2006)	0.59
" After a few dosage increases, ending with a weekly warfarin dose of 21 mg, the patient's INR values remained in the therapeutic range."	( Effects of prednisone on the International Normalized Ratio. Chock, A; Faulkner, MA; Skrabal, MZ; Stading, JA, 2006)	0.72
" We also examined how glucocorticoid dosage affected osteoporosis management in adjusted models."	( Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement. Bukowski, JF; Cabral, D; Coblyn, JS; Katz, JN; Patrick, AR; Solomon, DH, 2006)	0.33
" While the mechanism is unclear, treatment of steroid psychosis involves dosage reduction or discontinuation of prednisone."	( Steroid-induced psychosis in an adolescent: treatment and prophylaxis with risperidone. Bilge, I; Hergüner, S; Tüzün, DU; Yavuz Yilmaz, A, )	0.34
"Clinical management of warfarin therapy is complex, and dosing algorithms do not include genetic factors or interactions with other drugs for warfarin dose determinations."	( Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Bergan, S; Holmstrøm, H; Ruud, E; Wesenberg, F, 2008)	0.35
" Prednisone was reduced in dosage or discontinued in 17 dogs."	( Procarbazine as adjunctive therapy for treatment of dogs with presumptive antemortem diagnosis of granulomatous meningoencephalomyelitis: 21 cases (1998-2004). Barone, G; Coates, JR; Dewey, CW; Holloway-Azene, NM; Sessions, JK; Vitale, CL, )	1.04
"The results show that the individual pharmacokinetics of BEACOPP drugs are an important link between dosage and toxicity."	( Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. Busse, D; Diehl, V; Engert, A; Fuhr, U; Hempel, G; Jaehde, U; Jetter, A; Josting, A; Kasel, D; Klimm, B; Merkel, U; Reif, S; Rietbrock, S; Schwab, M; Wilde, S, 2007)	0.34
"Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisone are reviewed."	( Biowaiver monographs for immediate release solid oral dosage forms: prednisone. Barends, DM; Derendorf, H; Dressman, JB; Junginger, HE; Krämer, J; Midha, KK; Shah, VP; Stavchansky, S; Vogt, M, 2007)	0.77
"Aim of the study was to assess the clinical and angiographic efficacy of oral treatment with prednisone at immunosuppressive dosage after percutaneous coronary interventions (PCI) in patients with bifurcation lesions treated with elective bare metal stent (BMS) implantation in the main-branch (MB) and provisional stenting in the side-branch (SB)."	( Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study. Brunelleschi, S; Ferrero, V; Marino, P; Ribichini, F; Rognoni, A; Vassanelli, C, 2007)	0.76
"In our retrospective study we considered the mean daily dosage of steroids received by 25 patients after intestinal/multivisceral transplantation (minimal follow-up was six months)."	( Steroids in intestinal transplantation. Cescon, M; D'Errico, A; Dazzi, A; Di Simone, M; Ercolani, G; Faenza, S; Grazi, GL; Lauro, A; Lazzarotto, T; Pinna, AD; Pironi, L; Vivarelli, M; Zanfi, C, )	0.13
"This study assessed clinical and angiographic efficacies of oral treatment with prednisone at low-dose (LD) versus the previous high-dose (HD) immunosuppressive dosage used after percutaneous coronary interventions (PCIs) with bare metal stents in patients with multivessel coronary artery disease."	( Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study). Brunelleschi, S; Ferrero, V; Marino, P; Ribichini, F; Rognoni, A; Vassanelli, C, 2007)	0.8
" Secondary end points were time to first relapse, biomarkers, cumulative glucocorticosteroid dose, and the number of patients who remained relapse-free while the glucocorticosteroid dosage was tapered to 10 mg/d."	( Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Cid, MC; Hoffman, GS; Merkel, PA; Rahman, MU; Rendt-Zagar, KE; Salvarani, C; Stone, JH; Visvanathan, S; Weyand, CM; Xu, W, 2007)	0.34
" A low dosage of infliximab was used, and the prednisone dosage was rapidly tapered."	( Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Boiardi, L; Cantini, F; Catanoso, MG; Cimmino, M; Gerli, R; Hunder, GG; Klersy, C; Macchioni, P; Manganelli, P; Manzini, C; Paolazzi, G; Salvarani, C; Trotta, A, 2007)	0.94
" All consecutive patients starting long-term (> oir = 3 months), high dosage (> or = 20 mg day(-1)) prednisone therapy were enrolled."	( Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Cabane, J; Fardet, L; Flahault, A; Généreau, T; Kettaneh, A; Lebbé, C; Tiev, KP; Tolédano, C, 2007)	0.56
"7 years; giant cell arteritis 39%; mean baseline prednisone dosage 54 +/- 17 mg day(-1))."	( Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Cabane, J; Fardet, L; Flahault, A; Généreau, T; Kettaneh, A; Lebbé, C; Tiev, KP; Tolédano, C, 2007)	0.59
"The patient was treated with an increased dosage of prednisone."	( [Pulmonary and cardiac recurrence of sarcoidosis in a heart transplant recipient]. Strecker, T; Wiest, GH; Zimmermann, I, 2007)	0.59
" Once recurrence is diagnosed patients should be treated with an increased dosage of steroid in addition to standard immunosuppressives."	( [Pulmonary and cardiac recurrence of sarcoidosis in a heart transplant recipient]. Strecker, T; Wiest, GH; Zimmermann, I, 2007)	0.34
" EBV-related polymorphic PTLD was diagnosed and treated with discontinuation of cyclosporine, reduction in prednisone dosage and administration of EBV-specific cytotoxic T lymphocytes."	( Conjunctival posttransplantation lymphoproliferative disorder. Irshad, FA; Onciu, MM; Walton, RC; Wilson, TD, 2007)	0.55
"Lomustine was administered at a median starting dosage of 67 mg/m(2), PO, every 21 days until 5 doses were given or disease progression was observed."	( Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). Bannink, EO; Kaneene, JB; Mullins, MN; Obradovich, JE; Sauerbrey, ML; Van Dorp, TE, 2007)	0.7
" This analysis focused on patient characteristics, underlying disease, rituximab dosing schedule, and R-ILD characteristic-like symptoms, diagnosis, treatment, and outcomes."	( Rituximab-induced interstitial lung disease. Laber, DA; Mehta, AC; Wagner, SA, 2007)	0.34
" Adverse events observed after treatment with chloroquine or prednisone (chloroquine maculopathy,cataract, glaucoma) are related to dosage and duration of the treatment."	( [Ocular changes and general condition in lupus erythematosus (SLE)--own observation]. Brydak-Godowska, J, 2007)	0.58
"Risk for new-onset diabetes (NOD) after renal transplantation is higher with tacrolimus (Tac) than with cyclosporine (CsA), but the extent to which the diabetogenic effect of Tac is dosage dependent or steroid dependent remains uncertain."	( Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Brennan, DC; Burroughs, TE; Hardinger, K; Irish, WD; Lentine, KL; Machnicki, G; Schnitzler, MA; Swindle, J; Takemoto, SK, 2007)	0.61
" Non-steroidal anti-inflammatory drugs and colchicine are first-choice drugs, whereas corticosteroids should be considered only in patients with a frequent crisis unresponsive to non-steroidal anti-inflammatory drugs, and by using proper dosage and a careful slow tapering."	( Treatment of refractory recurrent pericarditis. Cecchi, E; Correndo, L; D'Oulx, EA; Doronzo, B; Imazio, M; Trinchero, R, 2007)	0.34
" Besides prednisone was given to all patients orally, the initiating dosage used in the treated group was lesser than that in the control group."	( [Effect of chinese herbs in enhancing prednisone for treatment of refractory rheumatoid arthritis]. Liu, W; Liu, XY; Wang, Y, 2007)	1.03
" It is concluded that sodium selenite administration at the dosage and duration chosen acts as a down regulator of Bcl-2 and improves clinical outcome."	( The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival. Asfour, IA; El-Desoky, H; Fayek, M; Hegab, HM; Moussa, MA; Raouf, S; Saleh, R; Soliman, M, 2007)	0.34
" The dosage of prednisone used was started from 20 mg/d and decreased step by step as possible after 2 weeks according to patient's condition."	( [Clinical observation on effect of modified Yanghe Decoction combined with glycocorticoid for treatment of polymyalgia rheumatica]. Fu, HZ, 2007)	0.69
"05); and the dosage of prednisone demanded in the treatment group was reduced faster than that in the control group (t = 10."	( [Clinical observation on effect of modified Yanghe Decoction combined with glycocorticoid for treatment of polymyalgia rheumatica]. Fu, HZ, 2007)	0.65
"YHD was helpful to shorten the therapeutic course for PMR, decrease the dosage of glucocorticoid used and raise the therapeutic efficacy."	( [Clinical observation on effect of modified Yanghe Decoction combined with glycocorticoid for treatment of polymyalgia rheumatica]. Fu, HZ, 2007)	0.34
"All 6 enrolled patients responded to etanercept with sustained remission (improvement of at least 70% according to European League Against Rheumatism response criteria for PMR in 4 patients and at least 50% in 2 patients) and were able to significantly reduce their median prednisone daily dosage without experiencing a disease relapse (8."	( Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Boiardi, L; Catanoso, MG; Macchioni, P; Pipitone, N; Salvarani, C, 2007)	0.52
" Proficiency testing is designed to help ensure that execution of a dissolution procedure for solid oral dosage forms adequately supports administrative and legal decisions so that measurements made at different times, by different analysts, or with different methods can be confidently compared."	( The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance. Ashley, AJ; Brown, WE; Deng, G; Eaton, JW; Glasgow, MJ; Hauck, WW; Kikwai, LC; Liddell, MR; Manning, RG; Munoz, JM; Nithyanandan, P; Stippler, E; Wahab, SZ; Williams, RL, 2008)	0.59
" In addition, the good disintegration and very good dissolution performance of the developed tablets without the addition of superdisintegrant highlighted the suitability of these formulated dosage forms."	( Development of prednisone:polyethylene glycol 6000 fast-release tablets from solid dispersions: solid-state characterization, dissolution behavior, and formulation parameters. Barrera, MG; Lamas, MC; Leonardi, D; Salomón, CJ, 2007)	0.69
"5 mg/d or less within 1 year of reaching the maximum dosage of the study drug."	( Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Albrecht, J; Chen, D; Fivenson, D; Jacobus, D; Pandya, AG; Rico, MJ; Werth, VP, 2008)	0.35
" Furthermore, patients with BP positive for IgE anti-BP180 Abs required longer duration for remission, higher dosage of prednisolone, and more intensive therapies for remission."	( Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Hara, T; Iwata, Y; Kodera, M; Komura, K; Muroi, E; Ogawa, F; Sato, S; Takenaka, M; Usuda, T; Yokoyama, Y, 2008)	0.35
" The effect of signalment, staging, CBC, and serum chemistry profile and dosage on these outcomes was examined."	( Efficacy and toxicosis of VELCAP-C treatment of lymphoma in cats. Cotter, SM; Davis, RM; Hadden, AG; Moore, AS; Morrissey, P; Rand, W, )	0.13
" For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported."	( Optimizing drug therapy in inflammatory bowel disease. Kornbluth, A; Swaminath, A, 2007)	0.34
" The dosage of prednisone was reduced by a similar amount in both groups during the open-label phase."	( A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. , 2008)	0.97
" This may be due to greater than predicted benefit from the prednisone dosage used, the short duration of the study, or the absence of any benefit of MMF in this population of patients with myasthenia gravis."	( A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. , 2008)	0.86
" Individualized dosing schedules and the emergence of non-steroidal medications are realistic expectations."	( Safety issues in the management of autoimmune hepatitis. Czaja, AJ, 2008)	0.35
" However, its optimal dosing in this subgroup has not been studied."	( Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Airee, R; Drachenberg, C; Gurk-Turner, C; Haririan, A; Kukuruga, D; Philosophe, B, 2008)	0.35
"To evaluate the effect of total rATG dosing on graft outcomes in such patients, we conducted a retrospective cohort study of 96 adult patients who received repeat transplants (85%) or had panel reactive antibody more than 40% (19%) and were maintained on tacrolimus, mycophenolate mofetil, and steroid."	( Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Airee, R; Drachenberg, C; Gurk-Turner, C; Haririan, A; Kukuruga, D; Philosophe, B, 2008)	0.35
"All consecutive patients starting long-term, high dosage corticosteroid therapy were photographed at baseline and after 3 months of therapy."	( Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy. Cabane, J; Fabre, B; Fardet, L; Flahault, A; Kettaneh, A; Tiev, KP; Tolédano, C, 2008)	0.35
" The aim of this study is to evaluate the impact of dosing time on the PK/PD of prednisolone with a simulation approach using an interactive algorithm."	( Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone. Derendorf, H; Sabarinath, SN; Winkler, J; Xu, J, 2008)	0.35
" Steroids are the standard treatment for PMR but their dosage requires adjustment depending on clinical picture, co-morbid conditions and adverse effects."	( Polymyalgia rheumatica: clinical picture and principles of treatment. Zimmermann-Górska, I, 2008)	0.35
" Afterwards the patients who responded to MMF received another 6 months MMF treatment at a dosage of 10-20 mg/kg daily."	( [A prospective multicenter clinical control trial on treatment of refractory nephrotic syndrome with mycophenolate mofetil in children]. Feng, SP; Liu, AM; Wei, MJ; Wu, XC; Wu, YB; Xu, H; Yang, Q; Yi, ZW; Yu, L; Zeng, ZF; Zhou, JH; Zhou, LJ; Zhu, GH, 2008)	0.35
" Thirty-five patients with DCHF were enrolled in the study, and prednisone (1 mg/kg/day with maximum dosage of 60 mg/day) was added to the standard treatment."	( Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Ao, YG; Deng, B; Ji, L; Ji, Z; Liu, C; Liu, G; Liu, K; Tian, L; Wang, L; Zhang, H; Zhao, Q; Zhen, Y, 2008)	2.03
" Steroid dosage was increased, and the patient exhibited right-side hearing improvement within 2 months."	( Course of auditory impairment in Cogan's syndrome. Son, HJ; Ulualp, SO, )	0.13
" Initial therapy comprises the oral administration of prednisolone in a dosage between 2-3 mg/kg/day."	( [Medical treatment of children with hemangiomas and its limitations]. Haxhija, EQ; Höllwarth, ME; Lackner, H, 2009)	0.35
" Optimal dosing for infliximab in PUK has not been established, and increasing dose frequency to every 4 weeks may be necessary."	( Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. Keystone, EC; Ma, JJ; Odorcic, S, 2009)	0.35
"The current guidelines recommend a dosage of prednisone of 60 mg/m(2) body surface area per day (BSA PRED) for the initial therapy of nephrotic syndrome (NS)."	( Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Al-Matrafi, J; Farhadi, E; Feber, J; Vaillancourt, R; Wolfish, N, 2009)	2.06
" Since survival rates for patients receiving risk-adapted programs (DAL-Hd, SPBLKH-05) were higher than in control (MOPP), relevant protocols using lower drug dosage should be recommended in groups of favorable and intermediate risk."	( [Use of risk-adapted programs of treatment of Hodgkin's disease in children and adolescents]. Kuleva, SA, 2008)	0.35
" Dosing is less frequent than many medications currently available."	( Rituximab for treatment of ocular inflammatory disease: a series of four cases. Choi, D; Kurz, PA; Rosenbaum, JT; Suhler, EB, 2009)	0.35
" However, the necessity of dosage adjustment based on renal graft function requires further studies."	( Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant. Abtahi, B; Mohammadpur, AH; Naghibi, M; Nazemian, F, 2008)	0.35
"These results suggest that the combination of ixabepilone and mitoxantrone is feasible and active in CRPC and requires dosing with pegfilgrastim."	( Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2009)	0.61
" The results of our study strongly support the use of steroids to control allergic fungal sinusitis and prevent its recurrence, and we recommend further study to identify the optimal dosage and duration of therapy."	( Management of allergic fungal sinusitis with postoperative oral and nasal steroids: a controlled study. Abbas, A; Akhtar, S; Ikram, M; Iqbal, M; Onali, MA; Suhail, A, 2009)	0.35
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( WITHDRAWN: Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Ferreira, J; Salinas, RA, 2009)	0.35
" A moderate dosage of prednisone (0."	( Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, DM; McCurdy, D; Mieszkalski, KL; Punaro, L; Reed, A; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E, 2009)	0.67
"Data were collected retrospectively for 37 patients with an established diagnosis of RFP (the diagnosis was proven by biopsy in 31 patients), all of whom met the following inclusion criteria: 1) availability of a recorded baseline ESR and/or CRP level and results of computed tomography or magnetic resonance imaging, 2) availability of followup CRP level and/or ESR with radiographic imaging 12-24 weeks after initiation of therapy, and 3) treatment with prednisone monotherapy at a starting dosage of 40-60 mg daily."	( Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Calabrese, LH; Husni, ME; Kushner, I; Magrey, MN, 2009)	0.52
" Six healthy volunteers were phototested with a xenon arc monochromator and then dosed with 30 mg of oral prednisolone or matching placebo daily for 4 days."	( Delayed ultraviolet erythema not suppressed by oral prednisolone: a randomized crossover study. Dawe, RS; Ferguson, J; Marshall, RP; McHugh, SM; Muller, FM; Murdoch, RD; Sanderson, B; Sousa, A, 2009)	0.35
" The actual CCNU dosage administered did not affect response rate or remission duration."	( Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma. Hafeman, SD; Saba, CF; Thamm, DH; Vail, DM, )	0.36
" We used ketoconazole and prednisone with dosing titrated according to serum testosterone levels to suppress sleep related erections in an attempt to prevent recurrent episodes."	( Ketoconazole and prednisone to prevent recurrent ischemic priapism. Abern, MR; Levine, LA, 2009)	0.99
" Testosterone was measured on initial presentation, and ketoconazole and prednisone dosing was titrated to approximately 200 ng/dl testosterone and based on the presence or absence of recurrent ischemic priapism episodes."	( Ketoconazole and prednisone to prevent recurrent ischemic priapism. Abern, MR; Levine, LA, 2009)	0.92
"Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized."	( Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Cartron, G; Girard, P; Hénin, E; Paintaud, G; Ternant, D; Tod, M, 2009)	0.35
" It can be used to simulate new dosing regimens of rituximab in populations of FL patients and should improve the design of future clinical trials."	( Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Cartron, G; Girard, P; Hénin, E; Paintaud, G; Ternant, D; Tod, M, 2009)	0.35
" Treatment was successful with prednisone, started at a dosage of 1 mg/kg/d, for 5 months."	( A case of linear immunoglobulin A bullous dermatosis in a patient exposed to sun and an analgesic. Caldarola, G; Cozzani, E; Parodi, A; Pellicano, R, 2009)	0.64
" It is suggested that total focal dosage used after chemotherapy be reviewed since total dosage for the entire lymph collector in excess of 30 Gy might contribute to hazards of cardiopathology."	( [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma]. Bozhenko, VK; Datsenko, PV; Ivashin, AV; Mel'nik, IuD; Pan'shin, GA; Podol'skiĭ, PN; Sotnikov, VM, 2009)	0.35
" All patients were treated with routine administration of prednisone, but to the treated group GS Capsule (50 mg) was given additionally twice every day, while to the control group placebo capsule of equal dosage was given instead."	( [Efficacy of combined therapy with ginsenosides and prednisone in treating systemic lupus erythematosus--a randomized, controlled and double-blinded trial]. Feng, YL; Ling, CQ; You, YL, 2009)	0.85
" Changes of SLEDAI and OPN, as well as the daily dosage of prednisone used were observed after 2 courses of treatment."	( [Effect of yangyin jiedu huoxue recipe on hormone withdrawal and disease activity in patients with systemic lupus erythematosus]. Fan, YS; Han, YM; Wu, GL, 2009)	0.6
" The dosage of prednisone daily used in the treated group (10."	( [Effect of yangyin jiedu huoxue recipe on hormone withdrawal and disease activity in patients with systemic lupus erythematosus]. Fan, YS; Han, YM; Wu, GL, 2009)	0.71
"Patients with active lupus nephritis (renal biopsy class III, IV, or V) were recruited for the study (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intravenous cyclophosphamide (0."	( Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Dooley, MA; Ginzler, EM; Gordon, C; Isenberg, D; Lisk, L; Wofsy, D, 2010)	0.36
" Systemic corticosteroid dosage was reduced to 10 mg of prednisone or less, while maintaining sustained control of inflammation, in 41% and 55% of patients in 6 months and 1 year respectively."	( Mycophenolate mofetil for ocular inflammation. Daniel, E; Foster, CS; Jabs, DA; Kaçmaz, RO; Kempen, JH; Levy-Clarke, GA; Newcomb, CW; Nussenblatt, RB; Pujari, SS; Rosenbaum, JT; Suhler, EB; Thorne, JE, 2010)	0.61
" In summary, modern immunosuppression today allows us to reduce the dosage of steroids and to avoid the prolonged use of cyclophosphamide."	( Induction and maintenance therapy in proliferative lupus nephritis. Glassock, RJ; Moroni, G; Ponticelli, C, )	0.13
" Tocilizumab treatment led to dosage-related decreases in the absolute neutrophil count, with a median decrease of 38% in the 4 mg/kg dosage group and 56% in the 8 mg/kg dosage group."	( Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Balow, JE; Daruwalla, J; Fleisher, T; Illei, GG; Lipsky, PE; Shirota, Y; Tackey, E; Takada, K; Yarboro, CH, 2010)	0.36
"Although neutropenia may limit the maximum dosage of tocilizumab in patients with SLE, the observed clinical and serologic responses are promising and warrant further studies to establish the optimal dosing regimen and efficacy."	( Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Balow, JE; Daruwalla, J; Fleisher, T; Illei, GG; Lipsky, PE; Shirota, Y; Tackey, E; Takada, K; Yarboro, CH, 2010)	0.36
" Remaining issues concern biology-based approaches and the guidance of therapy by PET, the definition of the optimal dosage and schedule of rituximab for DLBCL, as well as the optimal chemotherapy regimen partner for rituximab."	( Unresolved issues in diffuse large B-cell lymphomas. Murawski, N; Pfreundschuh, M; Zwick, C, 2010)	0.36
"Randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group where no therapy considered effective for this condition was administered, unless it was also given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Alvarez, G; Daly, F; Ferreira, J; Salinas, RA, 2010)	0.36
" We reviewed outcomes and prednisone dosage for all our acetylcholine-receptor (AChR)-antibody positive MG patients treated with MMF alone or with prednisone for at least 3 months."	( Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Alpers, J; Burns, TM; Conaway, MR; Hehir, MK; Sanders, DB; Sawa, M, 2010)	0.66
" It is generally agreed that dexamethasone is the steroid of choice for groups using a delayed intensification phase, but dosing schedules (intermittent versus continuous) vary."	( The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. McNeer, JL; Nachman, JB, 2010)	0.36
" This dosage is diminished very gradually according to a uniform treatment schedule during a period of 3 months, thereafter depending on the clinical course."	( [Dutch College of General Practitioner's practice guideline on polymyalgia rheumatica and temporal arteritis]. Dubbeld, P; Eizenga, WH; Geijer, RM; Goudswaard, AN; Hakvoort, L, 2010)	0.36
" Details of drug dosage history, sampling time and tacrolimus concentration in 63 patients (44 males and 19 females), 27 - 57 years old (age mean 40."	( Population pharmacokinetics of tacrolimus in kidney transplant patients. Catic-Djordjevic, A; Djordjevic, V; Jankovic, SM; Milovanovic, JR; Paunovic, G; Velickovic-Radovanovic, R, 2010)	0.36
"The derived model describes well tacrolimus clearance in terms of characteristics of Serbian kidney transplant patients, offering basis for rational individualization of tacrolimus dosing regimens."	( Population pharmacokinetics of tacrolimus in kidney transplant patients. Catic-Djordjevic, A; Djordjevic, V; Jankovic, SM; Milovanovic, JR; Paunovic, G; Velickovic-Radovanovic, R, 2010)	0.36
"De novo renal transplant patients were randomized to receive intensified dosing of MMF (1."	( The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Barama, AA; Cardella, CJ; Dandavino, R; Gourishankar, S; Houde, I; Keown, PA; Kiberd, BA; Landsberg, D; Pirc, L; Shoker, A; Wrobel, MM, 2010)	0.36
" Further studies are required to determine whether limited intensified MMF dosing can reduce acute rejection."	( The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Barama, AA; Cardella, CJ; Dandavino, R; Gourishankar, S; Houde, I; Keown, PA; Kiberd, BA; Landsberg, D; Pirc, L; Shoker, A; Wrobel, MM, 2010)	0.36
" Attempt has been made to identify clinical variables to predict patients at risk for hematologic toxicity, but an approach for individualizing drug dosing should be continued."	( Weight and body composition changes during R-CHOP chemotherapy in patients with non-Hodgkin's lymphoma and their impact on dose intensity and toxicity. Marisavljevic, DZ; Stanisavljevic, NS, )	0.13
" The drug was given by multiple intralesional injections, with the dosage calculated according to the age of the patient and size of the lesion."	( How to use bleomycin A5 for infantile maxillofacial haemangiomas: clinical evaluation of 82 consecutive cases. Luo, Q; Zhao, F, 2011)	0.37
" In this study, we calculated the area under the blood concentration-time curve (AUC) of CSA microemulsion in 15 patients with progressive IP complicating DM, and analyzed its correlation with CSA levels at blood sampling time points to investigate the optimum monitoring and dosing regimen."	( Therapeutic drug monitoring of cyclosporine microemulsion in interstitial pneumonia with dermatomyositis. Fujiki, Y; Hanafusa, T; Hata, K; Isoda, K; Kotani, T; Makino, S; Nagai, K; Shiba, H; Takeuchi, T; Yoshida, S, 2011)	0.37
" Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated."	( Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011)	0.37
" When the dosage of prednisone was reduced, symptoms returned."	( Autoimmune dysfunction and subsequent renal insufficiency in a collegiate female athlete: a case report. Colandreo, RM; Kern, A; Leone, JE; Williamson, JD, )	0.45
" This study verified that the alterations in the bone metabolism of the dogs submitted to the therapy with prednisone in a dosage of 2 mg/kg occur rapidly, which recommends a monitoring of the patients for the prevention of pathologic fractures."	( Bone demineralization in the lumbar spine of dogs submitted to prednisone therapy. Costa, FS; Costa, LA; De Oliveira, DC; Giannotti, JG; Lanis, AB; Lopes, BF, 2010)	0.81
" Results showed that administration of prednisone at a dosage of 1 mg/kg, orally, once daily for 7 days decreased total T(4) , while fT(4) was unchanged, suggesting that fT(4) may be less affected by daily prednisone administration."	( Effect of an anti-inflammatory dose of prednisone on thyroid hormone monitoring in hypothyroid dogs. Frank, LA; O'Neill, SH; Reynolds, LM, 2011)	0.91
" To evaluate the utility of preemptive warfarin dosage adjustment for preventing non-therapeutic INR following prednisone-warfarin co-administration."	( Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. Delate, T; Dowd, MB; Martinez, K; Vavra, KA; Witt, DM, 2011)	0.85
"Patients were randomized to receive either intensified dosing of mycophenolate mofetil (1."	( The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Dandavino, R; Gourishankar, S; Keown, P; Kiberd, BA; Wrobel, M, 2011)	0.37
" The dosage of glucocorticoids was higher among women than men (11."	( Glucocorticoid-related osteoporotic fractures. Al-Elq, AH; Al-Omran, AS; Al-Osail, AM; Azzam, Q; Sadat-Ali, M, 2010)	0.36
" All patients were taking prednisone (the median dosage 50 mg/day [range 30-80]) when diagnosed as having PCP."	( Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series. Kermani, TA; Warrington, KJ; Ytterberg, SR, 2011)	0.67
" A randomized phase II study is under way to further compare toxicity and efficacy of the 2 dosing schedules."	( Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z, 2011)	0.59
" GC dosing during the year before and the year after TNFi initiation were compared."	( Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis. Christensen, AF; Junker, P; Lindegaard, HM; Nilsson, AC, 2011)	0.37
" Increasing the dosage of oral steroid and minocycline resulted in relief of bullous pemphigoid, although patchy skin pigmentation remained especially in the irradiated skin."	( A case of bullous pemphigoid exacerbated by irradiation after breast conservative radiotherapy. Isohashi, F; Koizumi, M; Konishi, K; Tanei, T; Umegaki, N; Yoshioka, Y, 2011)	0.37
"Steroids are useful in alleviating the symptoms of the acute presentation of autoimmune pancreatitis, but some questions remain open such as the dosage of steroids in the acute phase and the duration of steroid therapy; finally, it should be assessed if other immunosuppressive non-steroidal drugs may become the first-line therapy in patients with AIP without jaundice and without atrophic pancreas."	( Therapeutic management and clinical outcome of autoimmune pancreatitis. Calculli, L; Cariani, G; Casadei, R; Corinaldesi, R; Morselli-Labate, AM; Pezzilli, R; Santini, D, 2011)	0.37
" In conclusion, the regular dosage and systematic albuminuria to microalbuminuria appears to be a reliable means for diagnosis of lupus glomerulonephritis in the subclinical stage to prevent renal complications that occur during the Supported Lupus erythematosus."	( [Interest of microalbuminuria in preventing kidney damage during systemic lupus erythematosus (SLE) under corticoid therapy]. Camara, C; Djessou, P; Ferdinand Djohan, Y; Koffi, G; Kouadio, LD; Monde, AA; Niamke, G; Sess, D; Tiahou, G, )	0.13
" Principal outcomes included adverse events, time from randomization to treatment failure (inability to wean off prednisone on schedule), and average prednisone dosage after week 24."	( A randomized, pilot trial of etanercept in dermatomyositis. , 2011)	0.58
" The median of the average prednisone dosage after week 24 was 29."	( A randomized, pilot trial of etanercept in dermatomyositis. , 2011)	0.67
"Mycophenolate mofetil (MMF) is now commonly used in pediatric liver transplant recipients, but no clear recommendations about the dosing regimen have been made for this population."	( Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. Barau, C; Barrail-Tran, A; Debray, D; Furlan, V; Habes, D; Hemerziu, B; Taburet, AM, 2011)	0.37
"Equivalence was met for weekend and daily dosing of prednisone for the primary outcomes of quantitative muscle testing (QMT) arm score and QMT leg score."	( Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Arrieta, A; Bertorini, TE; Clemens, PR; Cnaan, A; Connolly, AM; Day, JW; Escolar, DM; Florence, J; Hache, LP; Henricson, E; Hu, F; Kornberg, AJ; Lotze, T; Mayhew, J; McDonald, CM; Monasterio, E; Nevo, Y; Pestronk, A; Ryan, MM; Viswanathan, V; Zimmerman, A, 2011)	0.88
"Weekend dosing of prednisone is equally beneficial to the standard daily dosing of prednisone."	( Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Arrieta, A; Bertorini, TE; Clemens, PR; Cnaan, A; Connolly, AM; Day, JW; Escolar, DM; Florence, J; Hache, LP; Henricson, E; Hu, F; Kornberg, AJ; Lotze, T; Mayhew, J; McDonald, CM; Monasterio, E; Nevo, Y; Pestronk, A; Ryan, MM; Viswanathan, V; Zimmerman, A, 2011)	0.96
"This study provides Class I evidence that weekend prednisone dosing is as safe and effective as daily prednisone in preserving muscle strength and preventing body mass index increases in boys with DMD over a 12-month period."	( Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Arrieta, A; Bertorini, TE; Clemens, PR; Cnaan, A; Connolly, AM; Day, JW; Escolar, DM; Florence, J; Hache, LP; Henricson, E; Hu, F; Kornberg, AJ; Lotze, T; Mayhew, J; McDonald, CM; Monasterio, E; Nevo, Y; Pestronk, A; Ryan, MM; Viswanathan, V; Zimmerman, A, 2011)	0.88
"Although prednisone is the treatment of choice for nephrotic syndrome (NS) in childhood, the dosing regimen varies between 60 mg/m(2)/day, as recommended in early studies, to the often prescribed 2 mg/kg/day dose, which is used in common practice."	( Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference? Baracco, R; Jain, A; Kapur, G; Mattoo, TK; Saadeh, SA; Valentini, RP, 2011)	0.79
" There was no difference between the AZA- and MTX-groups in respect of prednisone dosing (apart from months 10 and 12), in quantitative MG Score improvement, proportions in sustained remission, frequencies of MG relapses, or adverse reactions and/or withdrawals."	( A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. Badri, M; Bateman, K; Heckmann, JM; Rawoot, A; Renison, R, 2011)	0.6
"Current prednisone dosing in the treatment of young patients with childhood-onset systemic lupus erythematosus (cSLE) is largely based on achieving balance between therapeutic efficacy and toxicity, with weight-based dosing a common clinical practice."	( Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Brunner, HI; Rieder, MJ; Sagcal-Gironella, AC; Sherwin, CM; Tirona, RG; Vinks, AA, 2011)	1.02
" At each visit, they assessed disease activity using a visual analog scale for physician's global assessment (VASph) and recorded whether a flare was diagnosed and/or the GC dosage was changed."	( Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. Berthelot, JM; Binard, A; Cleuziou, C; De Bandt, M; Saraux, A, 2012)	0.38
" No guidelines exist for chemotherapy dosing in the elderly population, and a clear assessment of treatment toxicity and benefits has not been previously reported."	( Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Greer, JP; Huntington, SF; Morgan, DS; Reddy, N; Talbott, MS, 2012)	0.57
" Disease severity score and prednisone dosage served as assessing measures."	( Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Barzilai, A; Baum, S; Greenberger, S; Lyakhovitsky, A; Samuelov, L; Solomon, M; Trau, H, )	0.43
" The patient worsened over the course of one week despite broad-spectrum antimicrobial therapy, but subsequently improved promptly with augmentation of prednisone dosed to 50 mg daily and addition of N-acetylcysteine."	( Acute exacerbation of pulmonary fibrosis following single lung transplantation. Bai, C; Khalil, N; Levy, RD; Wilcox, PG; Wilson, JM; Yang, D; Yee, J, )	0.33
" A significant decrease in the pemphigus severity score and the mean dosage of prednisone was observed at 3 and 6 months."	( Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Knowles, SR; Matsukura, S; Shear, NH; Walsh, S, 2012)	0.61
"73 m(2) for a total dosage of 10 g/1."	( Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial. Chen, J; Li, H; Li, X; Shen, H; Shi, X; Wang, H; Xu, G, 2012)	0.38
"In our patient, sarcoidosis developed after 3 years of continuous recombinant interferon-beta therapy, dosed 3 times a week."	( Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review. Chakravarty, SD; Crow, MK; Harris, ME; Schreiner, AM, 2012)	0.38
"Corticosteroid treatment is the standard of care in Duchenne muscular dystrophy (DMD), but the optimal age to initiate treatment and dosage pattern remain a matter of discussion."	( Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Armaroli, A; Cecconi, I; Cicognani, A; Ferlini, A; Franzoni, E; Gennari, M; Gnudi, S; Malaspina, E; Merlini, L; Talim, B, 2012)	0.38
" Prospective pharmacokinetic studies to devise a rational dosing strategy for vinblastine in patients receiving ritonavir/lopinavir are warranted."	( Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Boro, J; Cheung, MC; Ezzat, HM; Harris, M; Hicks, LK; Leitch, HA; Lima, VD; Montaner, JS, 2012)	0.38
" Blood samples were collected in four 12-hour dosing intervals during the first 3 weeks posttransplant, including samples drawn at 13 time points."	( The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. Bergan, S; Line, PD; Sæves, I, 2012)	0.64
" The results suggest that current prednisolone dosing early after liver transplantation might be too high, in particular when coadministered with methylprednisolone."	( The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. Bergan, S; Line, PD; Sæves, I, 2012)	0.64
" Both reported spectroscopic techniques can be used as fast and convenient alternatives to the standard pharmacopeial methods of prednisone and prednisolone quantification in solid dosage forms."	( Quantitative determination of prednisone in tablets by infrared attenuated total reflection and Raman spectroscopy. Mazurek, S; Szostak, R, )	0.62
" The calf pain and limited range of motion of ankle dorsiflexion subsided from day 1 on administration of oral corticosteroid at high dosage and were completely resolved by 4 months."	( Muscular polyarteritis nodosa. Cho, NS; Choi, HS; Choi, SJ; Kim, DH; Yang, SN; Yoon, ES, 2012)	0.38
" By the late 1960s, extended dosing with melphalan and prednisone tripled survival from diagnosis and became the standard of care for newly diagnosed MM."	( Evolving therapeutic paradigms for multiple myeloma: back to the future. Cherry, BM; Korde, N; Kwok, M; Landgren, O; Roschewski, M, 2013)	0.64
"We recommend monitoring MPA levels only in patients not responding to the standard 2-g/d dosage of MMF."	( Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. el-Azhary, RA; Langman, LJ; Sokumbi, O, 2013)	0.39
" Tacrolimus (FK-506) was administered at an initial dosage of 1 mg every 12 hours, and FK-506 concentration in the blood was monitored monthly."	( Tacrolimus on Kimura's disease: a case report. Bing, G; Da-Long, S; Wei, R; Xiang-Zhen, L; Xin, L; Yun-Yan, Z, 2014)	0.4
" Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel, which may enable tailored dosing in metastatic castration-resistant prostate cancer (mCRPC)."	( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012)	0.38
" Within the dosage range used in transplantation, prednisolone and prednisone exhibit concentration-dependent non-linear pharmacokinetics when parameters are measured with reference to total drug concentration."	( Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Barraclough, KA; Bergmann, TK; Lee, KJ; Staatz, CE, 2012)	0.85
" Intetumumab serum concentrations increased with repeated dosing and did not reach steady-state."	( A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c Bogdanova, N; Dawkins, F; de Boer, CJ; Dirix, L; Heidenreich, A; Rawal, SK; Schrijvers, D; Stenzl, A; Szkarlat, K; Wang, G; Welslau, M, 2013)	0.59
"Cbz at a dosage of 25mg/m(2) intravenously every 3 wk combined with 5mg of oral prednisone twice a day."	( Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M, 2013)	0.96
" There is a strong need for optimization of both specific type of glucocorticoid (eg, prednisone, vs deflazacort or others) and the dosing regimen."	( Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. Bushby, K; Connor, EM; Damsker, J; Hoffman, EP; McCall, JM; Nagaraju, K; Reeves, E, 2012)	0.6
" During the gestational period, the dosage of glucocorticoid was adjusted in one pregnancy."	( [Pregnancy outcomes of eight pregnant women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency]. Bian, XM; Hu, XY; Liu, JT; Yu, H; Zhou, Q, 2012)	0.38
" The dosage of glucocorticoid should be carefully adjusted during the pregnancy individually according to serum level of 17-OHP."	( [Pregnancy outcomes of eight pregnant women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency]. Bian, XM; Hu, XY; Liu, JT; Yu, H; Zhou, Q, 2012)	0.38
"01) and dosage of immunosuppressant."	( APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Avihingsanon, Y; Benjachat, T; Eiam-ong, S; Hirankarn, N; Kittikowit, W; Leelahavanichkul, A; Somparn, P; Tantivitayakul, P; Treamtrakanpon, W, 2012)	0.38
" Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL."	( Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. Beckers, MM; Huls, G, 2013)	0.39
" Bone loss occurs early after the initiation of corticosteroid therapy and is correlated to dosage and treatment duration."	( [Corticosteroid-induced osteoporosis]. Briot, K; Roux, C, 2013)	0.39
" Rituximab treatment reduces the steroid dosage and the need for immunosuppressive therapy in pediatric patients."	( Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Audard, V; Bouachi, K; Dahan, KY; Deschênes, G; Lang, P; Mojaat, R; Munyentwali, H; Plaisier, EM; Remy, P; Ronco, PM, 2013)	0.39
" A favourable outcome was gradually achieved after increasing the dosage of corticosteroids."	( [Infliximab-induced hepatitis during treatment of vulvar Crohn's disease]. Bouquin, R; Caussé, S; Dréno, B; Flamant, M; Joubert, M; Quéreux, G; Wylomanski, S, 2013)	0.39
" The dosage of prednisone was safely tapered using MMF, and the patient did not experience any flares or significant side effects during the course of treatment."	( Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris. Cohen, GF; Patel, NS; Vyas, N, 2013)	0.74
" However, the optimal dosing regimen and mechanism of action remain unclear."	( Therapy of relapsing minimal-change disease in adults: a new approach? Glassock, RJ, 2013)	0.39
" Findings suggest low comparative bioavailability of oral prednisone compared to prednisolone in cats and consideration of lean body mass or ideal body weight for dosing practices."	( Influence of body condition on plasma prednisolone and prednisone concentrations in clinically healthy cats after single oral dose administration. Center, SA; Randolph, JF; Rishniw, M; Simpson, KW; Warner, KL, 2013)	0.88
"Pediatric patients (4-12 years of age) with minimal change nephropathy were consecutively assigned to receive prednisone monotherapy (1-2 mg/kg/d; maximal total dose, ≤60 mg) or prednisone at the same dosage plus fluvastatin (5 mg/d if aged <5 years; 10 mg/d if aged ≥5 years), for 6 weeks."	( Effects of combined prednisone + fluvastatin on cholesterol and bilirubin in pediatric patients with minimal change nephropathy. Gong, J; Li, A; Ma, L; Song, M; Xie, Y; Yan, Y; Yang, D; Zhou, X, 2013)	0.93
" There were no adverse drug-related events and its use resulted in a significant reduction in steroid dosage during follow-up."	( Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases. Barzilai, A; Baum, S; Gilboa, S; Greenberger, S; Pavlotsky, F; Trau, H, 2013)	0.39
" Further study needs to examine rituximab dosage and scheduling as well as its place within the treatment algorithm."	( Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases. Barzilai, A; Baum, S; Gilboa, S; Greenberger, S; Pavlotsky, F; Trau, H, 2013)	0.39
" We hypothesize that these differences in dosing requirement may be due to an interethnic polymorphism in the expression of enzymes involved in tacrolimus metabolism."	( Tacrolimus therapeutic drug monitoring in Tunisian renal transplant recipients: effect of post-transplantation period. Aloui, S; Aouam, K; Ben Fredj, N; Boughattas, NA; Chaabane, A; Chadly, Z; Hammouda, M; Skhiri, H, 2013)	0.39
" The dosage was adjusted according to the severity of SLE activity index and the condition: 40 -60 mg per day for severe active stage; 20-40 mg per day for moderate active stage; 15 -20 mg per day for light active stage; and less than 15 mg per day for those in the stable stage, respectively."	( [Effects of qingyang toujie mixture in combination with prednisone tablet on Th1/Th2 cytokines in patients suffering from systemic lupus erythematosus]. Chen, YH; Duan, HY; He, YP; Huang, GH; Linag, XF; Liu, Y; Wen, XM; Xu, QY; Zeng, ZL; Zhong, JX, 2013)	0.64
" Although the patient had a relapse of the liver abscesses in association with the tapering of prednisone, the augmentation of prednisone dosage yielded a response."	( Behçet's disease complicated by multiple aseptic abscesses of the liver and spleen. Himeno, K; Inoue, M; Ishii, K; Maeshima, K; Seike, M, 2013)	0.61
" Steroid dosing may be a modifiable risk factor."	( Association between steroid dosage and death with a functioning graft after kidney transplantation. Döhler, B; Opelz, G, 2013)	0.39
"9), the mean initial CK was 4720 U/L (range, 23-38, 461; SD 6, 795), and initial mean prednisone dosage was 48 mg/d (range, 0-100, SD 22)."	( Corticosteroid Monotherapy Is Usually Insufficient Treatment for Idiopathic Inflammatory Myopathy. Block, JA; Hota, B; Manadan, AM; Mathur, T; Thiagarajan, S, )	0.35
" The dosage of prednisone and/or mizoribine was tapered according to the urinary protein-to-creatinine ratio (P/C)."	( Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria. Matsumoto, Y; Moriki, T; Nojima, Y; Shimada, Y, 2013)	1
" The changes in plasma exposures of DTG in healthy individuals as a result of prednisone dosing were not clinically significant."	( Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Borland, J; Chen, S; Peppercorn, AF; Piscitelli, S; Savina, P; Song, IH, 2013)	1.02
" Adequate glucocorticoid dosing and gradual tapering are key to treatment success."	( Polymyalgia rheumatica and giant cell arteritis: how best to approach these related diseases. Freeman, AC; Rapoport, RJ, 2013)	0.39
" There was no relation between dosage and age (p=0."	( Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM, 2013)	0.39
"During dissolution testing of solid dosage forms in the United States Pharmacopoeia (USP) Apparatus 2, samples are manually withdrawn from the medium in the vessel prior to the analysis."	( Dissolution of prednisone tablets in the presence of an arch-shaped fiber optic probe in a USP dissolution testing apparatus 2. Armenante, PM; Bredael, G; Zhang, Y, 2013)	0.74
" Due to its delayed onset of efficacy and the necessary slow titration of dosage for tolerability reasons prednisone is frequently added by clinicians to the initial prophylactic treatment of a cluster episode."	( Study protocol of Prednisone in episodic Cluster Headache (PredCH): a randomized, double-blind, placebo-controlled parallel group trial to evaluate the efficacy and safety of oral prednisone as an add-on therapy in the prophylactic treatment of episodic c Burmeister, J; Diener, HC; Holle, D; Obermann, M; Ose, C; Scherag, A, 2013)	0.94
" Low dosage of hormone replacement therapy based on their symptoms can help the patients reach a stable level of hormone within three months."	( [Pituitary functional recovery and hormone replacement therapy of patients with pituitary adenoma surgery]. Fu, XH; Jiang, S; Xue, XC; Yin, SL; Zhou, PZ, 2013)	0.39
"These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim."	( Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011)	0.66
"72 Wistar rats were randomly divided into 6 groups: blank control group, model group, prednisone group, Hedysari Radix flavonoids low, medium and high dosage group."	( [Effect of flavonoids from hedysari radix on pulmonary functions of pulmonary fibrosis rat]. Jing, M; Li, J; Li, JT; Li, XY; Lin, XY; Liu, GW; Liu, YQ; Su, Y; Sun, SB; Zhang, Y, 2013)	0.61
" To achieve these levels, AA RTRs require a significantly higher dosage of TAC compared to C patients (5."	( African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? Dayton, M; Feng, L; Kohli, R; Laftavi, MR; Nader, N; Pankewycz, O; Patel, S; Said, M, 2013)	0.39
" Standard deviation scores (SDS) of the nocturnal diastolic BP of the ABPM were positively correlated with the prednisolone dosage per kilogram (p = 0."	( Post-transplant hypertension in pediatric kidney transplant recipients. Aki, FT; Beşbaş, N; Bilginer, Y; Gülhan, B; Karabulut, E; Ozaltın, F; Topaloğlu, R, 2014)	0.4
"005) and mean daily prednisone dosage (29."	( Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Adams, A; Alperin, R; Barinstein, L; Lehman, TJ; Moorthy, N; Ramanathan, A; Singh, C, 2014)	0.73
"Israeli rheumatologists who treated AOSD with TCZ filled in questionnaires on symptoms, number of tender and swollen joints, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and dosage of prednisone at initial TCZ administration, after 6 months, and at the end of followup."	( Tocilizumab in adult-onset Still's disease: the Israeli experience. Ablin, J; Abu-Shakra, M; Caspi, D; Dranitzki, Z; Elkayam, O; Jiries, N; Kivity, S; Levy, O; Lidar, M; Padova, H; Rosner, I; Savargyl-Maman, H, 2014)	0.59
" After 6 months of treatment and at the end of followup, the number of tender and swollen joints, the ESR and CRP levels, and the prednisone dosage decreased significantly."	( Tocilizumab in adult-onset Still's disease: the Israeli experience. Ablin, J; Abu-Shakra, M; Caspi, D; Dranitzki, Z; Elkayam, O; Jiries, N; Kivity, S; Levy, O; Lidar, M; Padova, H; Rosner, I; Savargyl-Maman, H, 2014)	0.61
" These findings may assist clinicians in selecting the appropriate glucocorticoid dosage for RA patients who require these agents."	( Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Battafarano, DF; del Rincón, I; Erikson, JM; Escalante, A; Restrepo, JF, 2014)	0.4
" After 6 months, treatment response with respect to symptomatic, radiological, and laboratory improvement was comparable for the different dosage groups."	( Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Beuers, UH; Biermann, K; Brink, MA; Bruno, MJ; Buijs, J; de Buy Wenniger, LJ; Hansen, BE; Kuipers, EJ; Rauws, EA; van Buuren, HR; van Heerde, MJ; Verheij, J; Vleggaar, FP, 2014)	0.4
" When used in a dosage of 5-10 mg, most adverse effects can adequately be monitored, though accurate monitoring and awareness for infections are important."	( Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years. Bijlsma, JW; Jacobs, JW, 2014)	0.4
"Reduced dosage of G-CSF allows dose-dense chemotherapy scheduling, limits exposure to G-CSF and also represents an opportunity for cost savings."	( Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. Bonizzoni, E; Bosi, A; Fabbri, E; Kovalchuk, S; Perrone, T; Puccini, B; Rigacci, L, 2014)	0.4
"Results from 2 observational studies reported high levels of adherence to AA dosing and administration patterns consistent with prescribing information."	( Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. Ellis, L; Grittner, AM; Kozma, C; Lafeuille, MH; Lefebvre, P; McKenzie, RS; Slaton, T, 2014)	0.65
"Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules."	( Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H, 2014)	0.85
" Intermittent dosage of prednisone was administered 5 mg/kg per day on 2 consecutive days weekly for 3 months."	( Short-term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies. Fawaz, L; Ghafar, HA; Hussein, G; Mansour, L; Mostafa, FA, 2014)	0.71
" Secondary outcome measures were corticosteroid dosage during the entire hospitalization, length of stay, hospital follow-up rates, and 30-day readmission rates."	( Improving adherence for management of acute exacerbation of chronic obstructive pulmonary disease. Clark, C; Seidensticker, S; Sharma, G; Sonstein, L; Zeng, L, 2014)	0.4
" Then the dosage was reduced once daily per every other day."	( [Intervention of Shenkangling Decoction on the renal injury of primary nephrotic syndrome children patients of Shen deficiency blood stasis syndrome: a clinical observation]. Ai, S; Lu, XL; Qiu, CX; Yang, F; Zheng, J, 2014)	0.4
" There was no statistically significant difference regarding number of rituximab courses or cumulative rituximab dosage between episodes with and without infections, respectively."	( The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. Brade, J; Buchheidt, D; Hofmann, WK; Hummel, M; Kruth, J; Nissen, JC; Reinwald, M, 2014)	0.4
" Prednisone was dosed at ."	( A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, CS; Herrera, AF; Ho, VT; Jones, KT; Kim, HT; Koreth, J; Nikiforow, S; Ritz, J; Soiffer, RJ, 2014)	1.59
" It is possible that in patients treated with high-dose CS, the main objective of the clinician is to reduce dosage of CS rather than RA activity."	( Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Constant, E; Devilliers, H; Fortunet, C; Gaudin, P; Godfrin-Valnet, M; Jorgensen, C; Lambert, J; Maillefert, JF; Pers, YM; Prades, BP; Wendling, D, 2015)	0.42
" It is not known how antifolate dose and dosing frequency affect efficacy in AD, but a primary mechanism is thought to involve the antifolate-mediated accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)."	( LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. Griffin, CE; Kahn, SJ; Messinger, L; Mundell, A; Schuler, AD; Zebala, JA, 2014)	0.4
" Twice-weekly dosing negated efficacy despite having the same daily and weekly dose as effective once-weekly regimens."	( LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. Griffin, CE; Kahn, SJ; Messinger, L; Mundell, A; Schuler, AD; Zebala, JA, 2014)	0.4
" Futhermore, this is the first study to suggest a standardized starting point (CRP ≤ 4 mg/dl) and dosing schedule (oral prednisone 1 mg/kg for 7 days) for children with orbital cellulitis."	( C-Reactive Protein As a Marker for Initiating Steroid Treatment in Children With Orbital Cellulitis. Davies, BW; Durairaj, VD; Hink, EM; Smith, JM, )	0.34
"Plasma concentration monitoring is commonly used to adjust immunosuppressant dosage in transplant recipients, but adjustment is often based on clinical experience rather than rigorous quantitative indicators."	( Retrospective evaluation of the effect of mycophenolate mofetil dosage on survival of kidney grafts based on biopsy results. Chen, JS; Cheng, DP; Cheng, DR; Ji, SM; Li, X; Liu, ZH; Ni, XF; Wen, JQ; Xie, KN, 2014)	0.4
"We examined the effect of mycophenolate mofetil (MMF) dosage on graft survival by pathologic and immunologic analysis of 88 kidney recipients who were given a postoperative immunosuppressive regimen of tacrolimus (FK506), MMF, and corticosteroids."	( Retrospective evaluation of the effect of mycophenolate mofetil dosage on survival of kidney grafts based on biopsy results. Chen, JS; Cheng, DP; Cheng, DR; Ji, SM; Li, X; Liu, ZH; Ni, XF; Wen, JQ; Xie, KN, 2014)	0.4
"These results indicate the importance of using an appropriate dosage of MMF in kidney transplant recipients."	( Retrospective evaluation of the effect of mycophenolate mofetil dosage on survival of kidney grafts based on biopsy results. Chen, JS; Cheng, DP; Cheng, DR; Ji, SM; Li, X; Liu, ZH; Ni, XF; Wen, JQ; Xie, KN, 2014)	0.4
" Rescue dosage of leucovorin in variant group was higher than that in wild-type group [(312."	( [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Chen, Y; Gao, P; He, X; Li, J; Niu, C; Wang, C; Wang, Y; Zhang, H, 2014)	0.4
" These findings illustrate that the HSD11B1 genotypes are closely correlated with tacrolimus trough concentrations, suggesting that these polymorphisms may be useful for safer dosing of tacrolimus."	( Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. Fu, Q; Huang, M; Li, J; Liu, S; Liu, X; Wang, C; Wang, H; Wang, X; Zhang, Y; Zhu, C, 2015)	0.63
" Within 1 month after initiating dapsone therapy and increasing the dosage of prednisone, skin lesions promptly resolved."	( Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus. Chong, BF; Grabell, DA; Matthews, LA; Yancey, KB, 2015)	0.65
" In the phase 1 portion of the study, 24 patients received CMP at carfilzomib dosing levels of 20 mg/m(2), 27 mg/m(2), 36 mg/m(2), and 45 mg/m(2)."	( Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chaleteix, C; Chiffoleau, A; Facon, T; Fortin, J; Hulin, C; Kolb, B; Leleu, X; Mary, JY; Moreau, P; Planche, L; Roussel, M; Tiab, M; Touzeau, C, 2015)	0.67
" An attempt will be made to clarify the best and most suitable drug for treatment, and the dosage duration."	( [RS3PE syndrome: An update on its treatment using the presentation of a case]. Amodeo, MC; Poyato, M; Rodríguez, M, )	0.13
" Details regarding the natural course of this disorder, the effects of specific therapies on its progression, and the optimal therapeutic dosage and duration of prednisone are limited."	( Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients. Amato, AA; Arnold, WD; Barohn, RJ; Dimachkie, MM; Gwathmey, K; Heatwole, CR; Hebert, D; Johnson, NE; Kissel, J; McDermott, MP; McVey, AL; Pasnoor, M, 2015)	0.61
" Short-term dosing with food did not alter abiraterone acetate safety."	( Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. Acharya, M; Bernard, A; Chi, KN; Chien, C; Gonzalez, M; Griffin, TW; Jiao, J; Kheoh, T; Kollmannsberger, C; North, S; Pankras, C; Peng, L; Spratlin, J; Stieltjes, H; Tran, NP; Yu, MK, 2015)	0.42
"Dissolution testing is an in vitro procedure which is widely used in quality control (QC) of solid oral dosage forms and, given that real biorelevant test conditions are applied, can also be used as a predictive tool for the in vivo performance of such formulations."	( Impact of vibration and agitation speed on dissolution of USP prednisone tablets RS and various IR tablet formulations. Klein, S; Lange, S; Seeger, N, 2015)	0.66
" Altogether, colchicine avoided the use (n = 2) or increase in dosage (n = 5) of steroids in seven cases; the increase in steroids dosage was minimal for two patients."	( Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases. Bonjour, M; Costedoat-Chalumeau, N; Le Guern, V; Le Jeunne, C; Morel, N; Mouthon, L; Piette, JC, 2015)	0.42
"Although rabbit anti-thymocyte globulin (rATG) is commonly used as induction therapy for kidney transplantation, dosing is not standardized."	( Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients. Lee, E; Lee, S; Park, JM; Pennington, CA; Sindelar, J; Tischer, SM, 2015)	0.42
" Differences in standards of care and dosing complicate interpretation of this finding, but stratification by PRED/DFZ might be considered in clinical trials."	( Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Bello, L; Cnaan, A; Duong, T; Gordish-Dressman, H; Henricson, EK; Hoffman, EP; McDonald, CM; Morgenroth, LP, 2015)	1.86
" During omalizumab treatment, spirometry, the asthma control test (ACT) score and eosinophilia were evaluated, and prednisone dosage was recorded."	( Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. Detoraki, A; Di Capua, L; Genovese, A; Marone, G; Spadaro, G; Varricchi, G, 2016)	0.64
" The primary outcome will be measured by using the asthma control test and the secondary outcomes will be measured by using the percentage of symptom-free days, the average dosage of salbutamol aerosol and/or prednisone tablets, lung functions, daily asthma symptom scores, asthma quality of life questionnaire, and so on."	( Efficacy of acupuncture for chronic asthma: study protocol for a randomized controlled trial. Fan, L; Feng, JT; Hu, CP; Liu, YY; Shao, SJ; Wang, PY; Wang, WQ; Wang, Y; Xu, YD; Yang, YQ; Yin, LM; Zhang, TF, 2015)	0.6
" Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392)."	( A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Chae, YS; Eom, HS; Hong, J; Hong, JY; Kim, HJ; Kim, JS; Kim, SJ; Kim, WS; Lee, GW; Lee, S; Lee, SM; Oh, SY; Park, E; Park, J; Ryoo, HM; Suh, C; Won, JH; Yang, DH; Yoon, DH, 2016)	0.71
" The pemphigus disease area index (PDAI) score, direct immunofluorescence (DIF), indirect immunofluorescence (IIF), and corticosteroid dosage were evaluated before IVIG therapy, after each cycle, and at 6 and 12 months' follow up."	( IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Svecova, D, 2016)	0.43
"0 and baseline prednisone dosage was 201."	( IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Svecova, D, 2016)	0.79
" for preparation of extemporaneous dosage forms."	( Stability of Prednisone in Oral Mix Suspending Vehicle. Danopoulos, P; Friciu, M; Leclair, G; Plourde, K; Savji, T, )	0.5
" This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment."	( Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016)	0.43
" To establish safety, lenalidomide dosing in this combination was escalated in a conventional 3 + 3 design (15, 20 and 25 mg daily for 2 weeks followed by 1 week off)."	( Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. Adesunloye, BA; Arlen, PM; Beedie, SL; Chen, C; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Harold, N; Huang, X; Karzai, FH; Lee, MJ; Lee, S; Madan, RA; McLeod, DG; Ning, YM; Rosner, I; Sissung, T; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB, 2016)	0.68
" Compared with the results before MMF therapy, the steroid dosage in both groups was significantly reduced at the 6- and 12-month follow-ups."	( The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome. Du, L; Fu, H; Liu, A; Mao, J; Shen, H; Shu, Q; Tong, K, 2016)	0.43
" Growth curve comparisons and linear mixed-effects modeling, adjusted for race/ethnicity and birth year, were used to evaluate growth and steroid treatment patterns (age at initiation, dosing interval, duration, cumulative dose)."	( Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy. Ciafaloni, E; DiGuiseppi, C; James, K; Lamb, MM; Ouyang, L; Pandya, S; Weitzenkamp, D; West, NA; Yang, M, 2016)	0.43
" Daily prednisone dosing predicted lighter weight, but longer duration, and greater dosages predicted heavier weight."	( Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy. Ciafaloni, E; DiGuiseppi, C; James, K; Lamb, MM; Ouyang, L; Pandya, S; Weitzenkamp, D; West, NA; Yang, M, 2016)	0.89
" Inter- and intraindividual variability in dosing requirements conventionally use physician-guided titrated drug administration, which results in frequent deviations from the target trough ranges, particularly during the critical postoperative phase."	( Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Agopian, V; Busuttil, R; Datta, N; Eriksen, C; Farmer, D; Ho, CM; Ho, D; Kaldas, F; Kee, T; Lee, DK; Silva, A; Wang, SE; Weigle, K; Zarrinpar, A, 2016)	0.43
"We have extended the scope of this updated review to include comparisons of different corticosteroids and dosing regimens."	( Corticosteroids for the treatment of Duchenne muscular dystrophy. Brassington, R; Jichi, F; Kuntzer, T; Manzur, AY; Matthews, E, 2016)	0.43
" Cox's proportional hazards models estimated fracture risk adjusted for demographics and baseline clinical characteristics to assess dose-response relationships with current (daily) and prior (cumulative) dose, and by time since discontinuation."	( Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Adler, RA; Balasubramanian, A; Curtis, JR; Lin, CJF; Maricic, M; O'Malley, CD; Saag, K; Wade, SW, 2016)	0.43
" Adjunctive methotrexate may reduce cumulative glucocorticoid dosage by 20% to 44% and relapses by 36% to 54% in both PMR and GCA."	( Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. Buttgereit, F; Dasgupta, B; Dejaco, C; Matteson, EL, 2016)	0.43
" This study was conducted to characterize the safety and pharmacodynamic (PD) dose-response of a 7-day course of oral prednisone on biomarkers of GC receptor agonism."	( Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. Daniel, S; Fleishaker, DL; Mukherjee, A; Whaley, FS; Zeiher, BG, 2016)	0.89
"This characterization provides important and relevant information on safety and PD responses of short-term prednisone dosing over the commonly-used clinical dose range, and also provides a reference for early clinical development of dissociated agents targeting a differentiated PD profile."	( Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study. Daniel, S; Fleishaker, DL; Mukherjee, A; Whaley, FS; Zeiher, BG, 2016)	0.89
"Randomised trials and quasi-randomised trials comparing different routes of administration and dosage schemes of corticosteroid or adrenocorticotrophic hormone therapy versus a control group receiving no therapy considered effective for this condition, unless the same therapy was given in a similar way to the experimental group."	( Corticosteroids for Bell's palsy (idiopathic facial paralysis). Daly, F; Gagyor, I; Gammie, F; Madhok, VB; Somasundara, D; Sullivan, F; Sullivan, M, 2016)	0.43
"Therapeutic drug monitoring leading to individualized dosing may improve the efficacy of mycophenolate mofetil in steroid-dependent nephrotic syndrome."	( Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. Bandin, F; Bouchet, S; Brochard, K; Dallocchio, A; Decramer, S; Gandia, P; Godron, A; Guigonis, V; Harambat, J; Ichay, L; Llanas, B; Marquet, P; Morin, D; Saint-Marcoux, F; Tellier, S, 2016)	0.43
" In order to reduce the ocular side effects of the GCs there are some advisements, including a complete history, regular examination, GC should be prescribed in minimal dosage and minimal course, and as possible GC-sparing drugs should always be considered."	( Early onset steroid induced posterior subcapsular cataract in a patient with common variable immunodeficiency: case reports and review of literature. Abolhassani, H; Aghamohammadi, A; Azizi, G; Ghareje Daghi, M; Marefat, H, 2016)	0.43
" The area under the curves (AUC) of immunosuppressants was calculated by the plot of plasma trough level or dosage of each immunosuppressant versus time and was interpreted as the extent of drug exposure."	( Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy. Barratt, J; Kim, MJ; Koller, MT; Molyneux, K; Schaub, S; Stampf, S, 2016)	0.43
" Although daily glucocorticoid therapy has been shown to extend ambulatory function in DMD, less frequent dosing is often used because of side effect concerns."	( Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. Jefferies, JL; McMahon, MA; Rutter, MM; Rybalsky, I; Sawnani, H; Shellenbarger, KC; Tian, C; Wong, BL, 2017)	0.46
"Oral administration of prednisone was initiated at a dosage of 20 mg/day."	( Case report-malignant transformation in Cronkhite-Canada syndrome polyp. Ji, M; Wu, Y; Yu, L; Zhang, S; Zhao, H; Zong, Y, 2017)	0.77
" The treatment was repeated with prednisone at a dosage of 20 mg/day resulting in subsided symptoms."	( Case report-malignant transformation in Cronkhite-Canada syndrome polyp. Ji, M; Wu, Y; Yu, L; Zhang, S; Zhao, H; Zong, Y, 2017)	0.74
" The addition of methotrexate to a tapered dosage of prednisone 10 mg daily was unsuccessful, and she remains on prednisone 20 mg daily for disease control."	( Upper Airway Obstruction Requiring Emergent Tracheostomy Secondary to Laryngeal Sarcoidosis: A Case Report. Gulati, M; Herzog, EL; Homer, R; Pan, H; Ryu, C, 2017)	0.7
" Requirement of mean daily dosage of prednisone was significantly lower in RTX group [p = 0."	( Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Babu, BG; Basu, B; Roy, B, 2017)	0.73
" Although there is evidence in the literature regarding specific OCS dosing protocols, it is not known to what extent these recommendations are being followed."	( Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership. Ernst, HM; Rotenberg, BW; Rudmik, L; Scott, JR; Sowerby, LJ, 2017)	0.46
"Mammalian target of rapamycin inhibitors were neither protective nor permissive for de novo donor-specific antibody formation versus mycophenolate when used with clinically relevant tacrolimus dosing regimens."	( De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. Adebiyi, O; Cooper, JE; Gralla, J; Klem, P; Mithani, Z; Wiseman, AC, 2018)	0.48
" The dose of prednisone was modified by the clinician who was blinded to the patient's dosage of RCI."	( Repository corticotropin for Chronic Pulmonary Sarcoidosis. Baughman, RP; Birring, SS; Keijsers, R; Lower, EE; Saketkoo, LA; Shipley, R; Sweiss, N, 2017)	0.82
" On day 1 of cycle 1, seven whole-blood samples were collected for 3 h after dosing completion to obtain the maximum plasma concentration and area under the time-concentration curve during 3 h postdose (AUC0-3) in each patient."	( Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017)	0.46
" Chronic steroid use usually involves once-daily dosing, although weekly dosing in children has been suggested for its reduced side effects on behavior."	( Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. Barefield, DY; Demonbreun, AR; Earley, JU; Hadhazy, M; McNally, EM; Quattrocelli, M; Vo, AH; Warner, JL, 2017)	0.46
" Mean prednisone dosage decreased from 11."	( Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort). Benichou, J; Duquenne, C; Flipo, RM; Guillemin, F; Guillevin, L; Job-Deslandre, C; Saraux, A; Sibilia, J; Wendling, D, )	0.61
"Bullous pemphigoid is the most common autoimmune bullous disease, treated with low dosage local or systemic corticosteroids."	( [BULLOUS PEMPHIGOID RESISTANT TO CORTICOSTEROIDS]. Cohen, E; Rozenman, D; Sah, M; Ziv, M, 2016)	0.43
"The mean systemic prednisone (or equivalent) dosage significantly decreased at 3- and 6-month follow-up evaluations compared to baseline (P = 0."	( Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. Bacherini, D; Cantarini, L; Emmi, G; Fabiani, C; Favale, RA; Franceschini, R; Frediani, B; Fusco, F; Galeazzi, M; Guerriero, S; Iannone, F; Lopalco, G; Tosi, GM; Vannozzi, L; Vitale, A, 2017)	0.79
" Incidence of PIs, radiological features, patients' characteristics, underlying NHL type, rituximab/chemotherapy dosing schedules, and symptoms were recorded."	( 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics. Bairey, O; Berger, T; Cohen, YC; Eshel, L; Raanani, P; Shpilberg, O; Stern, D, 2017)	0.46
" This study examines the association between corticosteroid dosage and incidence rates of corticosteroid-related AEs."	( Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. Bao, Y; Betts, KA; Camez, A; Joshi, A; Mittal, M; Suhler, EB; Tari, S; Thorne, JE, 2017)	0.46
" Dosing of prednisone and safety were also assessed."	( Trial of Tocilizumab in Giant-Cell Arteritis. Aringer, M; Blockmans, D; Brouwer, E; Cid, MC; Collinson, N; Dasgupta, B; Dimonaco, S; Klearman, M; Rech, J; Salvarani, C; Schett, G; Schulze-Koops, H; Spiera, R; Stone, JH; Tuckwell, K; Unizony, SH, 2017)	0.84
" QMGS, MMT and MG-ADL were significantly improved and the average steroid dosage reduction was 43% (p=0."	( Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. Huang, Y; Jing, S; Lu, J; Pang, S; Quan, C; Song, J; Song, Y; Xi, J; Zhao, C; Zhou, L, 2017)	0.46
" Herein, we assessed the efficacy of steroid dosing on sarcolemmal repair, muscle function, histopathology, and the regenerative capacity of primary muscle cells."	( Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy. Demonbreun, AR; McNally, EM; Page, PG; Quattrocelli, M; Salamone, IM; Warner, JL, 2017)	0.46
" The changes in their pulmonary function for 12 months following treatment with rituximab were followed, along with other intervention performed and daily average dosing of prednisone."	( Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease. Abhyankar, S; Brownback, KR; Ganguly, S; McGuirk, JP; Streiler, C; Thomas, LA, 2017)	0.65
" The dosage of prednisone, the severity of symptoms, blood samples, the serum concentration of tacrolimus, and titers of antiacetylcholine receptor antibodies were evaluated every four weeks."	( Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone. Bu, B; Cao, Y; Gui, M; Ji, S; Li, Y; Lin, J; Liu, C, 2017)	1.04
" At the end point, the dosage of prednisone was significantly decreased (P < 0."	( Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone. Bu, B; Cao, Y; Gui, M; Ji, S; Li, Y; Lin, J; Liu, C, 2017)	0.96
"Although G-CSF is widely used to prevent or ameliorate leukopenia during cytotoxic chemotherapies, its optimal use is still under debate and depends on many therapy parameters such as dosing and timing of cytotoxic drugs and G-CSF, G-CSF pharmaceuticals used and individual risk factors of patients."	( Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. Engel, C; Loeffler, M; Loibl, S; Schirm, S; Scholz, M, 2018)	0.48
" What dosing strategy has the best balance between effect and side-effects is largely unknown."	( No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Broos, CE; Grootenboers, MJJH; Heller, R; Hoogsteden, HC; In 't Veen, JCCM; Kool, M; Looman, CWN; Poell, LHC; van den Blink, B; van den Toorn, LM; Wapenaar, M; Wijsenbeek, MS, 2018)	0.74
" All six patients in the placebo arm crossed over to the 5mg/kg dosing regimen after week 16, and two of those responded to infliximab."	( A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Cabalar, IV; Castro, C; Faghihi-Kashani, S; Garg, M; Gourley, M; Harris-Love, MO; Joe, G; Miller, FW; Plotz, PH; Pokrovnichka, A; Schiffenbauer, A; Shrader, J, 2018)	0.48
" Twelve SAE occurred within the first 3 months on prednisone (at dosage >0."	( Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis. Grutters, JC; van Es, HW; van Moorsel, CHM; van Oosterhout, MFM; Vorselaars, ADM; Wiertz, IA; Wuyts, WA, 2018)	0.73
" For the clinical study, 26 patients with NS, all prescribed the recommended dosage of prednisone (1 mg/kg/day), were randomly assigned to two groups."	( Massive Proteinuria-Induced Injury of Tubular Epithelial Cells in Nephrotic Syndrome is Not Exacerbated by Furosemide. Jing, KP; Li, JJ; Liu, HF; Liu, WJ; Pan, Q; Tang, HX; Wang, S; Wu, HL; Xu, C; Ye, L; Zou, T, 2018)	0.7
" In conclusion, prednisone-treated dogs fed ad libitum had greater glucocorticoid-induced renal effects than those dosed with fosdagrocorat."	( Renal and Hematologic Comparative Effects of Dissociated Agonist of the Glucocorticoid Receptor and Prednisone in Dogs With and Without Food Restriction. Dybowski, JA; LaBranche, T; Lettiere, DJ; Peraza, MA; Portugal, SS; Radi, ZA; Vogel, WM, )	0.69
"In real-life, belimumab is efficacious in achieving low disease activity in over 40% of unselected patients, in combination with reduction of corticosteroid dosage and number of flares."	( Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Adamichou, C; Bertsias, G; Boki, KA; Boumpas, DT; Dimopoulou, D; Elezoglou, A; Erden, A; Fanouriakis, A; Katsikas, G; Klagou, A; Konsta, S; Konstantopoulou, P; Koutsoviti, S; Liossis, SN; Mavragani, CP; Ntali, S; Panopoulos, S; Pantazi, L; Sfikakis, PP; Sidiropoulos, P; Staveri, C; Tektonidou, M; Tsalapaki, C; Vassilopoulos, D, 2018)	0.48
" Conclusion Low-dose AA (with low-fat breakfast) is noninferior to standard dosing with respect to PSA metrics."	( Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Carthon, B; Chiong, E; Figg, WD; Fishkin, P; Harvey, RD; Ibraheem, A; Karrison, T; Kozloff, MF; Martinez, E; Nabhan, C; Peer, CJ; Ratain, MJ; Stadler, WM; Szmulewitz, RZ; Yong, WP, 2018)	0.48
" Serial blood and urine samples were collected over 1 dosing interval."	( Prednisone Pharmacokinetics During Pregnancy and Lactation. Ahmed, MS; Bennett, B; Caritis, SN; Clark, S; Easterling, TR; Hays, K; Hebert, MF; Honaker, MT; Kantrowitz-Gordon, I; Ryu, RJ; Shen, DD; Thummel, KE; Umans, JG; Venkataramanan, R, 2018)	1.92
" oral dexamethasone versus oral prednisone), with consideration for dosing and pharmacokinetic properties, to better identify the optimal IM or oral corticosteroid regimens to improve patient outcomes."	( Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Campbell, S; Cross, E; Kirkland, SW; Rowe, BH; Villa-Roel, C, 2018)	0.76
" Because the dosing interval used for BV therapy was longer than that in the recommended schedule, we could not definitively attribute her recurrence to BV resistance."	( [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma]. Azuma, Y; Fujita, S; Hotta, M; Ishii, K; Ito, T; Konishi, A; Miyaji, M; Nakanishi, T; Nakaya, A; Nomura, S; Satake, A; Tsubokura, Y; Yoshimura, H, )	0.13
"Drug release testing plays a major role along all parts of the dosage form development and manufacturing process."	( Small volume method for drug release screening using ultrasonic agitation. Acevedo, AJ; Desai, D; Holt, RG; Zaman, MH, 2018)	0.48
"This study causally examined the dose-response relationship between oral corticosteroids (OCS) exposure and long-term complications among noninfectious uveitis adult patients in the United States."	( Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. Chirikov, VV; Kwon, Y; Patel, D; Shah, R, 2019)	0.51
"A moderate dose-response relationship was found between the long-term use of OCS monotherapy and the risk of developing complications in noninfectious intermediate, posterior, or panuveitis patients."	( Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. Chirikov, VV; Kwon, Y; Patel, D; Shah, R, 2019)	0.51
" The clinical efficacy during an average follow-up of 21 months (range, 14-24 months) was assessed by evaluating the changes of serum creatine kinase (CK) levels, the Medical Research Council (MRC) grading of the weakest muscle groups and dosage of oral prednisone."	( Tacrolimus combined with corticosteroids effectively improved the outcome of a cohort of patients with immune-mediated necrotising myopathy. Bu, B; Feng, F; Ji, S; Li, Y; Wang, Q, )	0.31
" In addition, the daily dosage of prednisone was statistically significantly reduced (p<0."	( Tacrolimus combined with corticosteroids effectively improved the outcome of a cohort of patients with immune-mediated necrotising myopathy. Bu, B; Feng, F; Ji, S; Li, Y; Wang, Q, )	0.41
" Thirty patients were treated with the study regimen, consisting of alemtuzumab on day 1 of a 21 day cycle with standard dosing of DA-EPOCH for 6-8 cycles."	( Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Jaffe, ES; Lucas, A; Melani, C; Pittaluga, S; Roschewski, M; Roswarski, J; Steinberg, SM; Waldmann, TA; Wilson, WH, 2019)	0.51
" The primary objective was to investigate the steroid dosage required to control brain oedema on the last day of RT in each arm."	( Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study. Carpentier, AF; Charissoux, M; Chinot, O; Cuzzubbo, S; Ducray, F; Hoang-Xuan, K; Le Rhun, E; Levy-Piedbois, C; Mandonnet, E; Portal, JJ; Psimaras, D; Quillien, V; Ricard, D; Sejalon, F; Thomas, L; Tibi, A; Ursu, R; Vicaut, E, 2019)	0.51
" No difference in the steroid dosage required to control brain oedema on the last day of RT, or one month after completion of RT, was seen between both arms."	( Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study. Carpentier, AF; Charissoux, M; Chinot, O; Cuzzubbo, S; Ducray, F; Hoang-Xuan, K; Le Rhun, E; Levy-Piedbois, C; Mandonnet, E; Portal, JJ; Psimaras, D; Quillien, V; Ricard, D; Sejalon, F; Thomas, L; Tibi, A; Ursu, R; Vicaut, E, 2019)	0.51
"3years, 48% of patients were successfully weaned from prednisone completely, and 20% were weaned to a maintenance dosage of 5-10mg/d."	( Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. Fowler, M; Guo, HH; Iagaru, A; Mittra, E; Ning, N; Witteles, R, 2019)	0.76
"Patients with GCA were randomly assigned to receive double-blind dosing with either subcutaneous tocilizumab (TCZ) 162 mg weekly plus 26-week prednisone taper (TCZ-QW + Pred-26), every-other-week TCZ plus 26-week prednisone taper (TCZ-Q2W + Pred-26), placebo plus 26-week prednisone taper (PBO + Pred-26), or placebo plus 52-week prednisone taper (PBO + Pred-52)."	( Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Aringer, M; Blockmans, D; Brouwer, E; Cid, MC; Collinson, N; Dasgupta, B; Dimonaco, S; Klearman, M; Rech, J; Salvarani, C; Schett, G; Schulze-Koops, H; Spiera, R; Stone, JH; Tuckwell, K; Unizony, SH, 2019)	0.72
" Efficacy assessment was based on incidence of FN and serious neutropenia (neutrophil count <500/μL), hospitalization days and chemotherapy dosage level."	( [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy]. Izumitani, S; Kataoka, T; Matsuo, H; Murase, T; Nishigakiuchi, R; Saeki, Y; Sakurashita, H; Taogoshi, T, 2019)	0.51
" In agreement with the gastroenterologists, patient started a new biological therapy with golimumab, and oral prednisone with slow tapering of steroid dosage following the improvement of both cutaneous and intestinal symptoms."	( Pyoderma gangrenosum successfully treated with golimumab: Case report and review of the literature. Brancorsini, D; Brisigotti, V; Campanati, A; Diotallevi, F; Molinelli, E; Offidani, A; Radi, G, 2019)	0.73
" We also conducted a dose-response meta-analysis to analyze the cumulative dosage and SONFH risk in mutation carriers."	( Association between genetic polymorphisms and osteonecrosis in steroid treatment populations: a detailed stratified and dose-response meta-analysis. Jing, M; Yang, J; Yang, X, 2019)	0.51
"5), dosing in fasted state (n = 13, DTL 12."	( Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP, 2019)	0.51
"Our cohort demonstrated high inter- and intra-patient variability in both abiraterone and D4A with fixed dosing of AA, with no effect from choice of corticosteroids, prior use of chemotherapy, or dosing in fasting state."	( Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP, 2019)	0.51
"Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the cornerstone of initial treatment for early rheumatoid arthritis (RA)."	( Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-I Bijlsma, JW; Borm, ME; de Hair, MJ; Jacobs, JW; Lafeber, FP; Linn-Rasker, SP; Pethoe-Schramm, A; Teitsma, XM; Tekstra, J; Ter Borg, EJ; van Laar, JM; Verhoeven, MM; Welsing, PM, 2019)	0.97
" The definition of remission included a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 0, prednisone daily dosage of ≤5 mg/day, and immunosuppressive drugs on maintenance dose."	( Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort. Alarcón, GS; Cucho-Venegas, JM; Elera-Fitzcarrald, C; Gamboa-Cárdenas, RV; Medina-Chinchón, M; Pastor-Asurza, CA; Perich-Campos, R; Pimentel-Quiroz, V; Reátegui-Sokolova, C; Rodríguez-Bellido, Z; Ugarte-Gil, MF; Zevallos, F, 2020)	0.77
" Also, the daily prednisone dosage was significantly decreased in 20/24 patients across all three serotype groups."	( Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. Corse, AM; Doherty, L; Roda, RH, 2019)	0.85
"Treatment of DMD patients with the corticosteroids prednisone or deflazacort remains the standard of care, and recent data shows that early treatment (as young as 5 months) with a weekend dosing regimen results in measurable improvement in motor outcomes."	( Update in Duchenne and Becker muscular dystrophy. Flanigan, KM; Waldrop, MA, 2019)	0.77
"We found that a standard dose of prednisone of 5 mg/day as recommended previously may be inadequate to achieve physiologic glucocorticoid replacement in some patients with prostate cancer while on abiraterone treatment and as a result adrenal insufficiency due to inadequate dosing might be more common than initially thought."	( Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review. Baloch, HM; Grice-Patil, ZJ; Hoang, TD; Mai, VQ; Selig, DJ; Shakir, MK, 2019)	0.8
" We observed the efficacy and safety of tocilizumab combined with methotrexate (MTX) in the treatment of refractory AOSD, and to explore the possibility of reducing the dosage of tocilizumab after disease control."	( Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article. Guo, SH; Shen, HL; Wang, CY; Wang, LP, 2019)	0.51
" Dosing of ETN was weight-based with a mean dosage over the first year of 31 mg per week."	( Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis. Jones, H; Khraishi, M; Marshall, L; Millson, B; Ruperto, N; Woolcott, J, 2019)	0.8
" A decline in both MTX and PRD use and dosage was observed and may be associated with benefits related to safety, tolerability, and overall healthcare costs."	( Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis. Jones, H; Khraishi, M; Marshall, L; Millson, B; Ruperto, N; Woolcott, J, 2019)	0.8
" Further analysis indicated that risk factors, such as skin rash, pericarditis, splenomegaly and delayed diagnosis, are highly related to the dosage of prednisone for remission."	( Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. Chen, LJ; Cheng, XB; Chi, HH; Ding, TT; Hu, QY; Ji, ZF; Jiang, LD; Lin, J; Liu, HL; Liu, S; Lu, A; Luo, CN; Shi, H; Su, YT; Sun, CY; Sun, Y; Teng, JL; Wu, LJ; Xu, J; Yang, CD; Ye, JN; Yimaiti, K; Zeng, T; Zhou, ZC, )	0.33
" In patients with skin rash, pericarditis, splenomegaly or delayed diagnosis, a higher dosage of prednisone was needed to obtain remission."	( Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. Chen, LJ; Cheng, XB; Chi, HH; Ding, TT; Hu, QY; Ji, ZF; Jiang, LD; Lin, J; Liu, HL; Liu, S; Lu, A; Luo, CN; Shi, H; Su, YT; Sun, CY; Sun, Y; Teng, JL; Wu, LJ; Xu, J; Yang, CD; Ye, JN; Yimaiti, K; Zeng, T; Zhou, ZC, )	0.35
" Intermittent steroid dosing has been proposed in Duchenne Muscular Dystrophy patients to mitigate the side effects seen with daily steroid intake."	( Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. Barish, GD; Bass, J; Demonbreun, AR; Haldar, SM; Jiang, Z; Kuntz, NL; McNally, EM; Peek, CB; Quattrocelli, M; Zelikovich, AS, 2019)	0.51
" Survey items evaluated PCP preferred oral glucocorticoid and dosing regimen for children with acute asthma exacerbations, provider- and patient-level factors contributing to glucocorticoid preferences, and perception of glucocorticoid regimens in terms of treatment failure, resolution of symptoms and adherence."	( Primary care provider preferences for glucocorticoid management of acute asthma exacerbations in children. Hoch, H; Mistry, RD; Moran, E; Navanandan, N; Smith, H, 2021)	0.62
" The attributes included efficacy and withdrawals due to adverse events, as well as dosing and other rare risks of treatment."	( Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. Bombardier, C; Deardon, R; Hazlewood, GS; Kaplan, GG; Ma, C; Marshall, DA; Panaccione, R; Pokharel, G; Seow, CH; Tomlinson, G, 2020)	0.56
" No organ-oriented toxicity increased with tazemetostat dosage escalation (severity and incidence)."	( A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Cullières-Dartigues, P; Dubois, R; Dubois, S; Herbaux, C; Jardin, F; Karlin, L; Le Gouill, S; Michot, JM; Molina, T; Morschhauser, F; Picquenot, JM; Ribrag, V; Salles, G; Sarkozy, C; Suttle, B; Tilly, H, 2020)	0.56
" Secondary objectives are to describe variation in practice between different specialties and to identify the commonly used dosing and frequency for dexamethasone."	( Dexamethasone Versus Prednisone for Pediatric Acute Asthma Exacerbations: Specialists' Practice Patterns. Peterson, R; Young, KD, 2021)	0.94
"To determine whether a dose-response relationship exists between short-term oral prednisone administration and common clinicopathologic variables, cardiovascular biomarkers, and systolic arterial blood pressure (SAP) in healthy dogs."	( Evaluation of dose-response effects of short-term oral prednisone administration on clinicopathologic and hemodynamic variables in healthy dogs. Mahaffey, AL; Mochel, JP; Murphy, SD; Seo, YJ; Tinklenberg, RL; Ward, JL; Yan, Y, 2020)	1.03
" The phase III VISTA trial established the bortezomib dosing schedule for VMP."	( Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Cavo, M; Deraedt, W; Dimopoulos, MA; He, J; Jakubowiak, A; Kampfenkel, T; Lam, A; Mateos, MV; Qi, M; San-Miguel, J, 2020)	0.81
"The SLEDAI-2KG provides a novel concept for the assessment of lupus disease activity while accounting for glucocorticoids dosage to reflect on disease activity overall at a particular visit."	( Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. Anderson, N; Gladman, DD; Su, J; Touma, Z; Urowitz, MB; Zandy, M, 2021)	0.62
"A questionnaire was developed to evaluate practices and beliefs around steroid dosing in a simplified case of uncomplicated AECOPD."	( Provider perceptions on steroid dosing in AECOPD: Laying the groundwork for steroid stewardship. Cole, JL; Smith, S, 2020)	0.56
"Initial dosing ranged from 40 to 625 mg/day with only four responders (13%) selecting 40 mg/day."	( Provider perceptions on steroid dosing in AECOPD: Laying the groundwork for steroid stewardship. Cole, JL; Smith, S, 2020)	0.56
" Only systemic corticosteroids have consistently proven successful in suppressing the rash; however, the response is often only partial, and symptoms tend to recur as the dosage is tapered."	( Eosinophilic dermatosis of hematologic malignancy effectively controlled with omalizumab maintenance therapy. Gates, G; Lor, M; Yu, Y, 2020)	0.56
"07, and no difference in prednisone dosing between the 2 groups."	( Effect of Initial Prednisone Dosing on Ocular Myasthenia Gravis Control. Carey, AR; Henderson, AD; Shah, YS, 2021)	1.26
" An abbreviated profile within the first 4 hours after PL dosing provides a good prediction of PL exposure in renal Tx recipients."	( Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. Andersen, AM; Åsberg, A; Bergan, S; Bjerre, A; Gustavsen, MT; Midtvedt, K; Skauby, RH; Vethe, NT, 2021)	0.96
" A highest daily dosage of prednisone of 40 mg or higher, even when administered for a month or less, significantly increased the risk of ON."	( Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study. Kallas, R; Li, J; Petri, M, 2022)	1.02
" Four trials included European cohorts using dosing schedules according to the regimens studied."	( Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis. Dorresteijn, EM; Schijvens, AM; Schreuder, MF; Teeninga, N; Teerenstra, S; Webb, NJ, 2021)	0.62
"A human mechanistic physiology-based pharmacokinetic (PBPK) model of vincristine following intravenous dosing was developed to predict potential DDI interactions with combination therapy."	( Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. Chen, B; Fretland, AJ; McGinnity, DF; Pilla Reddy, V; Sharma, S; Vishwanathan, K; Ware, JA; Xu, Y; Zhou, D, 2021)	0.62
" A patient presented with acute onset encephalopathy, mainly characterized by agitation and confusion, rapidly responsive to high dosage steroid therapy and complete remission within 3 days from onset."	( Hyperacute reversible encephalopathy related to cytokine storm following COVID-19 vaccine. Amore, G; Baldelli, L; Cortelli, P; D'Angelo, R; Guarino, M; Montini, A; Panzera, I; Rinaldi, R; Rossi, S, 2021)	0.62
" More aggressive dosing initiation of NPH based on steroid dose may allow for earlier achievement of euglycemia without a difference in hypoglycemia."	( Insulin NPH for steroid-induced hyperglycemia: Predictors for success. Dungan, K; Gaborcik, JW; Stone, AC, 2021)	0.62
"028) and prednisone dosage during pregnancy ≥12."	( Good pregnancy outcomes in lupus nephritis patients with complete renal remission. Chen, D; Chen, Y; Hu, W; Li, K; Liu, Z; Yang, L; Zhang, H, 2022)	1.14
" Age, anti-C1q and anti-phospholipid antibodies, and prednisone dosage during pregnancy were risk factors for adverse pregnancy outcomes."	( Good pregnancy outcomes in lupus nephritis patients with complete renal remission. Chen, D; Chen, Y; Hu, W; Li, K; Liu, Z; Yang, L; Zhang, H, 2022)	0.97
" The primary efficacy results evaluated were hospitalization rate related to HES, morbidity (new or worsening), relapses/failure, treatment-related adverse effects, prednisone dosage ≤10 mg/day for ≥8 weeks, and eosinophil count <600/μL for ≥8 weeks."	( Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis. Alves Júnior, JM; Bernardo, WM; Bley, F; Prota, FE; Villagelin, D, 2021)	0.82
" In this setting, the personalization of steroid dosage might prevent an over exposure to the drug, but this strategy is not available yet."	( [Steroidi tra necessità e tossicità]. Affatato, S; Lucca, B; Sandrini, S, 2021)	0.62
" However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs every-other-week dosing has not been evaluated."	( New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Aringer, M; Bao, M; Blockmans, D; Brouwer, E; Cid, MC; Dasgupta, B; Rech, J; Salvarani, C; Spiera, R; Spotswood, H; Stone, JH; Unizony, SH, 2022)	0.72
"A multifaceted stewardship intervention significantly reduced steroid dosing in hospitalized AECOPD patients."	( A multifaceted stewardship intervention helps curb steroid overprescribing in hospitalized patients with acute exacerbations of COPD. Cole, JL; Smith, SE, 2022)	0.72
" Five hundred and seventy-two patients were excluded due to insufficient documentation of oral corticosteroid dosage, no radiographic evidence supporting the diagnosis of AVN, insufficient data confirming the temporal relationship between oral corticosteroids and AVN, and/or a cumulative dosing of >10,000 mg prednisone."	( Oral corticosteroid use and the risk of developing avascular necrosis: A large retrospective review. Campbell, DA; Grond, SE; Little, RE; Loehrl, TA; Poetker, DM, 2022)	0.9
"2%) were subject to dosing adjustments."	( The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma. Brown, AB; Carty, SA; Kaminski, MS; Phillips, TJ; Runge, JS; Wilcox, RA, 2023)	0.91
" One month of once-weekly glucocorticoid dosing improved muscle specific force in both males and females."	( Intermittent glucocorticoid treatment enhances skeletal muscle performance through sexually dimorphic mechanisms. Barefield, DY; Hadhazy, M; McNally, EM; Page, PG; Quattrocelli, M; Salamone, IM; Tahtah, I; Tomar, G, 2022)	0.72
" Here, we investigated whether dosage time affected prednisone effects on muscle bioenergetics."	( Muscle mitochondrial remodeling by intermittent glucocorticoid drugs requires an intact circadian clock and muscle PGC1α. Bass, J; Levine, DC; McNally, EM; Miz, K; Peek, CB; Quattrocelli, M; Wintzinger, M, 2022)	0.97
"Immunosuppressive dosing of corticosteroids at the start of treatment impairs immune checkpoint inhibitor (ICI) efficacy in advanced non-small cell lung cancer (NSCLC)."	( Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study. Berrios, JRG; Fabbri, A; Giannarelli, D; Marrucci, E; Nelli, F; Ruggeri, EM; Virtuoso, A, 2022)	0.72
" A prednisone equivalent threshold of 700 mg defined low (LCD) or high (HCD) cumulative dosing during the 90 days before starting ICIs."	( Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study. Berrios, JRG; Fabbri, A; Giannarelli, D; Marrucci, E; Nelli, F; Ruggeri, EM; Virtuoso, A, 2022)	1.34
"These findings imply that immunosuppressive corticosteroid dosing before ICIs, even of short duration, might affect survival."	( Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study. Berrios, JRG; Fabbri, A; Giannarelli, D; Marrucci, E; Nelli, F; Ruggeri, EM; Virtuoso, A, 2022)	0.72
"Initial algorithm-based dosing appears to be effective in predicting tacrolimus dose requirement."	( Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation Trial. Andrews, LM; de Winter, BCM; Francke, MI; Hesselink, DA; Keizer, RJ; van Gelder, T, 2022)	0.72
" For every measured tacrolimus predose concentration (C 0,obs ), model-based dosing advice was simulated using the InsightRX software."	( Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation Trial. Andrews, LM; de Winter, BCM; Francke, MI; Hesselink, DA; Keizer, RJ; van Gelder, T, 2022)	0.72
"The combination of an algorithm-based tacrolimus starting dose with model-based follow-up dosing has the potential to minimize under- and overexposure to tacrolimus in the early posttransplant phase, although the additional effect of model-based follow-up dosing on initial algorithm-based dosing seems small."	( Model-Based Tacrolimus Follow-up Dosing in Adult Renal Transplant Recipients: A Simulation Trial. Andrews, LM; de Winter, BCM; Francke, MI; Hesselink, DA; Keizer, RJ; van Gelder, T, 2022)	0.72
" The protective effect of HCQ was dosage related."	( Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. Deng, X; Gao, D; Geng, Y; Hao, Y; Huang, H; Ji, L; Wang, Y; Zhang, Z, 2022)	0.72
"Variation in dose and duration of corticosteroids for childhood-onset steroid-sensitive nephrotic syndrome occurs worldwide, likely reflecting the evolving evidence on optimal dosing and variable severity of the disease observed between patients."	( Characteristics Associated with Variation in Corticosteroid Exposure in Children with Steroid-Sensitive Nephrotic Syndrome: Results from a Canadian Longitudinal Study. Brobbey, A; Chanchlani, R; Dart, AB; Lapeyraque, AL; Morgan, CJ; Nettel-Aguirre, A; Perinpanayagam, MA; Rodriguez-Lopez, S; Samuel, S; Tee, JB, 2021)	0.62
" Furthermore, incremental increases in the dosage of SCs were associated with a greater risk for these outcomes."	( Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database. Acharya, NR; Akpandak, I; Arnold, BF; Chen, EM; Miller, DC; Sun, Y, 2022)	0.72
" Glucocorticoids regulate the circadian cycle of energy metabolism, but little is known about how circadian timing of exogenous glucocorticoid dosing directly regulates heart metabolism through cardiomyocyte-autonomous mechanisms."	( Impact of circadian time of dosing on cardiomyocyte-autonomous effects of glucocorticoids. Bass, J; Durumutla, HB; Miz, K; Molkentin, JD; Panta, M; Peek, CB; Prabakaran, AD; Quattrocelli, M; Sargent, M; Wintzinger, M, 2022)	0.72
"Our study identifies cardiac-autonomous mechanisms through which circadian-specific intermittent dosing reconverts glucocorticoid drugs to metabolic boosters for the heart."	( Impact of circadian time of dosing on cardiomyocyte-autonomous effects of glucocorticoids. Bass, J; Durumutla, HB; Miz, K; Molkentin, JD; Panta, M; Peek, CB; Prabakaran, AD; Quattrocelli, M; Sargent, M; Wintzinger, M, 2022)	0.72
" The prednisone dosage played no role in CH incidence in patients with HL."	( Does transitory steroid-induced central hypothyroidism in children treated for haematological malignancies warrant clinical intervention? Grizelj, A; Kranjčec, I; Matijašić, N; Oletić, L; Štromar, L, 2022)	1.24
" Clinical response in short-term follow-up was independent of prednisone dosage and underlying etiology."	( Cohort study of infantile epileptic spasms syndrome: etiological analysis and treatment of corticosteroids. Cheng, M; Hong, S; Jiang, L; Jiang, Y; Li, T; Liang, X; Liao, S; Luo, Y; Zhong, M; Zou, N, 2022)	0.96
" The dosage of pyridostigmine bromide was reduced for 69."	( Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis. Caifeng, S; Haiou, P; Jingsheng, Z; Wenjun, Q; Xueshi, H; Yi, L; Zhanyou, W, 2022)	0.93
" The results from this study suggest that dosing ipatasertib after an evening meal followed by overnight fasting can be an effective strategy for managing increased glucose levels."	( Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications. Agarwal, P; Gallo, JD; Hinton, H; Huang, KC; Miles, DR; Rasuo, G; Rotmensch, J; Sane, RS; Sutaria, DS, 2022)	0.72
" However, the optimal protocol and dosage of rituximab combined with first-line therapy for NSAbs-associated AE remains unclear so far."	( Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies. Du, Y; Hao, Y; Li, C; Li, L; Liu, J; Si, H; Yan, Q; Yao, D; Zhang, W; Zhao, C; Zhao, Y, 2022)	0.72
" While changes of mRS, MMSE and NPI scores, as secondary endpoint, were all markedly accelerating improvement between baseline and each visit, as well as both oral prednisone dosage and relapse were also greatly reduced during follow-up."	( Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies. Du, Y; Hao, Y; Li, C; Li, L; Liu, J; Si, H; Yan, Q; Yao, D; Zhang, W; Zhao, C; Zhao, Y, 2022)	0.92
"Our simplified regimen of combined low-dose rituximab firstly showed significantly accelerating short-term recovery and long-term improvement for AE with NSAbs, in parallel with markedly reduced prednisone dosage and clinical relapses."	( Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies. Du, Y; Hao, Y; Li, C; Li, L; Liu, J; Si, H; Yan, Q; Yao, D; Zhang, W; Zhao, C; Zhao, Y, 2022)	0.91
" In the past, attempts to reduce the dosage of glucocorticoids were made using cyclophosphamide, cyclosporin A, mofetil mycophenolate, and their combinations."	( [Efficacy of rituximab in minimal change disease, an atypical renal manifestation of antiphospholipid syndrome]. Długosz, G; Masajtis-Zagajewska, A; Nowicki, M, 2022)	0.72
" Heterogeneous dosing practices were observed."	( A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. Cerdeña, S; Cortese, MJ; Grover, NS; Haverkos, B; Hill, BT; Hughes, ME; Jodon, G; Kahl, BS; Kaiser, J; Kamdar, M; Landsburg, DJ; Namoglu, E; Olson, M; Orellana-Noia, V; Portell, C; Rainey, M; Rudoni, J; Snow, A; Sohail, M; Voorhees, T; Watkins, MP; Wei, W, 2023)	0.91
"The potential effects of glucocorticoid administration on rivaroxaban's anticoagulant bioactivity in dogs, and an appropriate rivaroxaban dosage regimen for dogs receiving glucocorticoid therapy are unknown."	( Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs. Brooks, MB; Hafner, PM; Mackin, AJ; Thomason, JM; Wills, RW, 2022)	0.99
" Prednisone administration had no apparent influence on the anticoagulant effects of rivaroxaban in healthy dogs, suggesting that combined therapy will not require dosage adjustments."	( Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs. Brooks, MB; Hafner, PM; Mackin, AJ; Thomason, JM; Wills, RW, 2022)	1.9
" In unfit older patients, a dynamic dosing strategy is often applied."	( How I treat older patients with DLBCL in the frontline setting. Lugtenburg, PJ; Mutsaers, PGNJ, 2023)	0.91
" The primary outcome was to evaluate cumulative prednisone dosage at 12 and 24 months of follow-up in the two groups."	( Treatment of idiopathic nephrotic syndrome at onset: a comparison between 8- and 12-week regimens in everyday clinical practice. Emma, F; Gatto, A; Gianviti, A; Lucchetti, L; Massella, L; Vivarelli, M, 2023)	1.17
" However, when the dosage of prednisone was tapered and finally stopped, the eosinophil count increased and the infiltrative shadow returned."	( [A CASE OF ALLERGIC BRONCHOPULMONARY MYCOSIS WITH NONTUBERCULOUS MYCOBACTERIOSIS SUCCESSFULLY TREATED WITH BENRALIZUMAB FOR STEROID WITHDRAWAL]. Fukunishi, Y; Kajiwara, K; Kikuchi, T; Makino, H; Nagai, A; Yamamoto, H, 2022)	1.01
" Longitudinal changes in outcomes, progression to key disease milestones, and dosing and body composition metrics were analyzed descriptively and in multivariate models."	( Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1. Frean, M; Freimark, J; Goemans, N; Henricson, EK; Hor, KN; Koladicz, K; Lane, H; Marden, JR; Mayer, OH; McDonald, CM; Miller, D; Signorovitch, J; Trifillis, P; Zhang, A, 2023)	0.91
"9) and higher baseline prednisone dosage (RR = 1."	( Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica. Bartoloni, E; Bogdanos, D; Bursi, R; Cafaro, G; Fiumicelli, E; Gerli, R; Perricone, C; Riccucci, I, 2023)	1.22
" However, the relationship between prednisone dosage and infection risk is ill-defined."	( Does Prednisone Dose Affect Rates of Periprosthetic Joint Infection Following Primary Total Hip and Total Knee Arthroplasty? Christ, AB; Heckmann, ND; Kebaish, KJ; Lieberman, JR; Mills, ES; Oakes, DA; Piple, AS; Wang, JC, 2023)	1.7
" Univariate and multivariate regression analyses were performed to assess the 90-day risk of infectious complications based on prednisone dosage as follows: 0 to 5, 6 to 10, 11 to 20, 21 to 30, and >30 milligrams."	( Does Prednisone Dose Affect Rates of Periprosthetic Joint Infection Following Primary Total Hip and Total Knee Arthroplasty? Christ, AB; Heckmann, ND; Kebaish, KJ; Lieberman, JR; Mills, ES; Oakes, DA; Piple, AS; Wang, JC, 2023)	1.63
"Glucocorticoids are associated with serious side effects related to dosing and time of use."	( Development of a web tool to calculate the cumulative dose of glucocorticoids. Díaz-González, F; Guerra-Rodríguez, M; Loricera, J; Montero-Pastor, N; Moriano, C; Sánchez-Alonso, F; Sánchez-Costa, JT, 2023)	0.91
" We designed a therapy combining a gradual reduction of prednisone with a long-term, stable dosage of sirolimus."	( Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Gao, H; Liu, S; Luo, C; Mai, Y; Pan, C; Wang, Y; Zhang, X; Zheng, S, 2023)	1.48
" However, pediatric clinical trials to identify the correct dosage and tolerability of TRF-budesonide are urgently needed."	( A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide. Antonucci, L; Colucci, M; Emma, F; Vivarelli, M, 2023)	0.91
"Dissolution is used to determine the rate and extent of drug release from the dosage form into a dissolution medium, which allow to assess the batch-to-batch variability."	( Measurement uncertainty arising from sampling and analytical steps of dissolution test of prednisone tablets. Lourenço, FR; Sano, AY, 2023)	1.13
" Adverse events were noted regardless of starting dosage or regimen."	( Perception and usage of short-term prednisone and prednisolone in dogs. Gober, M; Hillier, A, 2023)	1.19
"For children with OMG, the addition of various immunosuppressants can reduce the dosage of GC and adverse reactions."	( [Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis]. Chen, H; Chen, Y; Huang, ZX; Wang, RY; Zhong, JM, 2023)	0.91
" Optimizing prednisone (and prednisolone) dosing by measuring their concentrations and calculating their pharmacokinetic parameters will allow for personalized treatments for patients, producing more effective and safer treatments for GVHD."	( Simultaneous Determination of Prednisone and Prednisolone in Serum by Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry. Carlow, DC; Schofield, RC; Scordo, M; Shah, G, 2024)	2.11